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Thesis abstract 
Objectives – The research aimed to a) determine the feasibility of conducting a study of 
exhaled breath biomarkers in the acute asthma setting; and b) determine whether a 
positive bronchial challenge test results in detectable changes in exhaled volatile organic 
compounds (VOC).  
Methods – The Exhaled Breath Biomarkers in Acute Asthma feasibility study was 
undertaken to compare two different approaches to capturing acute asthma data. In the 
first, participants attending secondary care for treatment of an acute asthma attack 
were recruited; in the second participants who were at high risk of experiencing an 
attack were recruited and asked to contact the researcher should such an event occur. 
The Bronchial Challenge Testing in Asthma study was undertaken to determine the effect 
of mannitol dry powder inhalation on VOC in exhaled breath. 
In addition to the above studies, systematic reviews of the literature on 8-isoprostane 
in exhaled breath condensate and exhaled breath VOC in adult asthma were conducted. 
Findings – The literature reviews found insufficient evidence to confirm that EBC 8-
isoprostane levels were raised in the presence of asthma or acute asthma attack; a 
number of exhaled VOC were found to be associated with asthma but with a high level 
of inter-study variation.  
Breath capture studies in acute asthma proved feasible - both approaches were 
successful in recruiting participants and capturing breath samples, and the acceptability 
of breath sampling devices was similar to that of existing clinical devices. Obtaining 
breath samples before systemic corticosteroids were administered and identifying 
infectious triggers of exacerbation proved difficult. The effect of bronchial challenge on 
exhaled VOC was detectable but further development of methods is required to produce 
reliable results.  
Conclusion – Designing a phase II biomarker study with the aim of validating previous 
studies and estimating the accuracy of predictive models appears feasible but further 
methodological refinement is required.  
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Asthma Breath Biomarker Assessment study 
Asthma Bronchial Challenge study 
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AE Adverse event 
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ANOVA Analysis of variance 
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Chapter 1 - Background and introduction 
1.1 Overview 
Asthma is a chronic disorder of the airways affecting an estimated 339 million people 
worldwide (1). In the UK 5.4 million people are receiving treatment for asthma, 
generating a health service spend of approximately £1 billion per annum (2).  
The Global Initiative for Asthma provide a disease definition, the length and 
descriptive nature of which reflects the complexity of the disease. 
A heterogeneous disease, usually characterised by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness, and cough that vary over 
time and in intensity, together with variable airflow limitation. (3) 
Management of the condition is informed chiefly by symptoms and measures of 
airway calibre such as peak expiratory flow. There is currently no singe gold-standard 
test for the diagnosis of asthma. With no definitive cure available, the mainstay of 
treatment is inhaled β2 adrenergic receptor agonists and corticosteroids, which serve 
to relax smooth muscle in airways and reduce inflammation respectively. 
1.2 History 
1.2.1 Historical descriptions and definitions 
Reference to asthma-like symptoms can be found going back several thousand years; 
sources include the Ebers Papyrus (Egypt, 1550 BC), the Neu Ching (China, 1,000 
BC), the Susruta Samahita (India, 450 BC) and Homer’s Iliad (Greece, 800 BC) (4). 
To take just one example, the Neu Ching describes a wheezing condition which varies 
with the seasons (5). 
The word asthma is a Greek noun derived from the verb aazeein meaning to exhale 
with open mouth or pant (6); while the earliest recorded use of the word is in the 
Iliad (5, 7)  Aretaeus of Cappadocia (Greece circa 100 AD) was perhaps the first to 
use the term to describe what today would be called an asthma attack (4, 8). 
In terms of disease understanding and therapy there was little documented progress 
between these early references to asthma and the 1600s when descriptions started 
to resemble those of our current understanding and bronchial constriction was first 
linked to expiratory difficulty (4).  




In the 18th century descriptions included the paroxysmal nature of the condition, the  
excessive use of respiratory muscles, the absence of fever, and the presence of 
symptoms such as wheeze, cough, and phlegm (4). 
The 19th century saw the identification of smooth muscle in the airways and thus a 
mechanism for bronchial constriction; an important step in the understanding of 
asthma pathophysiology. Dr Henry Salter is one of the key figures of this period; he 
described a “paroxysmal dyspnoea of a peculiar character with intervals of healthy 
respiration between attacks” (7) which is commonly cited as a key point in the 
refinement of the term asthma (9). He linked airway narrowing with smooth muscle 
contraction and also identified a characteristic cellular appearance to asthmatic 
sputum. In 1868 he posited the involvement of both neural and vascular elements, 
suggesting that inflammation of airway mucosa led to the neural stimulation of 
smooth muscle contraction (10). Later that century Paul Ehrlich identified the 
eosinophil, an inflammatory cell subsequently found to be associated with asthma. 
Another key figure in the history of asthma is Sir William Osler, often referred to as 
the Father of Modern Medicine (9); he identified familial and allergic elements to the 
disease as well as focussing on the role of smooth muscle in airways (7). His 
description of asthma issued in 1892 is largely unchanged from those today, namely 
spasm of the bronchial muscles; swelling on bronchial mucous membranes; 
inflammation of bronchioles; resemblance to hay fever; a hereditary element; 
commonly a childhood onset; and a variety of causes of exacerbation, including 
infection (9).  
Allusions to allergy are prevalent throughout the history of asthma with links being 
drawn to occupation (Hippocrates (7)), feathers (Cardano (4)), old mattresses 
(Ramazinni (4)) and pollen (5, 7). However, the first clear description of seasonal 
asthma is reported to be that of John Bostock in 1819 (4). In the late 18th and early 
19th century studies with pollen showed it was possible to provoke a local allergic 
reaction but the term allergy was not used until Clement von Pirquet in 1906 (4). In 
1911 skin allergy testing was developed and the role of histamine in anaphylaxis was 
shown in 1911 (10).  The identification of IgE (9) and the links between house dust 
mite allergy and asthma led to a reconceptualization of asthma as not only a condition 
of bronchoconstriction but also of inflammation and allergy. 
Although bronchoconstriction and the role of smooth muscle had already been 
identified, bronchial hyper-responsiveness in asthma was first described by Curry in 
1946 (10); work which led to the subsequent development of the histamine challenge 
as a diagnostic test in asthma.  




In addition to inflammation and bronchoconstriction, structural changes may occur 
in the airways, particularly in those with more severe disease (9). In the early 20th 
century morbid anatomical examinations revealed mucous impaction, airway wall 
thickening, smooth muscle hypertrophy, submucosal oedema, and infiltration by 
eosinophil and neutrophils; mucosal denudation and basement membrane thickening 
were later identified (10). It is likely that these changes in the epithelium affect the 
barrier function of the airways; coupled with changes in the cellular immunity this is 
posited to make those with asthma more vulnerable to respiratory virus infection (9). 
More recent pathophysiological developments have been biochemical in nature, 
examining the immunology and biochemical mediators of inflammation in increasing 
depth; the clinical application of which can be seen in the latest drug therapies (see 
section 1.5). 
The emphasis placed upon the different elements of asthma has varied over time 
likely influenced by a combination of both physiological understanding and available 
treatments. Asthma definitions have been described as swinging from a focus on 
bronchoconstriction in the 1960s, to inflammation in the 1990s, and back to a more 
balanced appreciation of both in the 2000s (11).  In the 2010’s the discussion has 
centred on disease heterogeneity and the extent to which a single umbrella term 
such as asthma is useful at all (11-13). 
1.2.2 Historical prevalence and incidence 
The UK has had a charity dedicated to researching the cause and cure of asthma 
since 1927 when Asthma UK (originally the Asthma Research Council) was founded 
(14). It is noted by McFadden (10) that although associated with a high morbidity, 
historically asthma had a relatively low mortality. Indeed, Siegel (15) reports that in 
the 19th century asthma deaths were considered rare and mortality rates in the young 
remained stable throughout the early 20th century up until the beginning of an asthma 
‘epidemic’ in the 1960s. While arguments have been posited for an increase in the 
incidence of asthma – including westernisation, urbanisation, pollution, the hygiene 
theory (13) and improved diagnosis / reporting – it is frequently argued that the 
1960s epidemic of asthma deaths may have, at least in part, been due to the 
effectiveness of bronchodilator treatment in improving symptomology leading to an 
over-reliance on bronchodilators. Not only might these have masked worsening 
underlying disease and delayed help-seeking (16) but their cardiotoxic effects were 
underappreciated and may have contributed to mortality (9).  
 




More respiratory-selective β2-agonists were subsequently developed while at the 
same time trials were showing the positive effect of corticosteroids on asthma 
management; results which led to increasing awareness and uptake of preventative 
inhalers in the 80s. 
1.2.3 The development of respiratory function tests and asthma monitoring 
The spirometer was invented by John Hutchison in 1846 and entered more 
widespread clinical use in the 1950s in the form of the vitalograph (4). Performing 
and interpreting spirometry is a specialised skill; in the UK accreditation with the 
Association for Respiratory Technology and Physiology (ARTP) is recommended. 
Spirometry therefore tends not to be conducted on a regular basis in primary care 
but rather at annual asthma reviews or specialist secondary care centres.  
A cheaper, more portable means of measuring lung function was developed after 
world war two in the form of the peak expiratory flow (PEF) meter (10); this entered 
common usage in the 1960s and 70s. PEF meters allowed regular home monitoring, 
making variable airflow obstruction easier to detect.  
Personalised asthma action plans designed to empower patients in the management 
of their own asthma were first introduced in 1990 (17); these are now a key part of 
asthma management guidelines and can be used with either symptoms or peak 
expiratory flow readings to guide patient action. 
Assessment of inflammation by sputum differential cell count (specifically the 
percentage of eosinophils) has been used widely in research (18) and is well 
established as a marker of airway inflammation (19) and disease activity (20). 
Directing clinical management (for example titration of steroid treatment) according 
to the percentage of sputum eosinophils has been found to improve outcomes (21-
24) and BTS/SIGN guidelines recommend considering this in the management of 
patients with difficult asthma. The technique of inducing sputum is however time 
consuming, semi-invasive and requires laboratory facilities; perhaps because of this 
its uptake in clinical practice has been limited (25).   
Exhaled breath gas analysis is another means of non-invasive airway assessment 
containing, as it does, a number of molecules indicative of inflammation. Exhaled 
breath gas markers including nitrite, nitrate and volatile organic compounds (VOC) 
have been the target of much research, but only one compound - Nitric oxide (NO) 
– has made the leap into clinical use. The fraction of exhaled nitric oxide (FeNO) is - 
alongside sputum eosinophils - one of the best established markers for disease (20).  




It is recommended by the National Institute for Clinical Health Excellence (NICE) for 
the diagnosis and monitoring of patients with asthma whose symptoms are 
unresponsive to corticosteroids. Although widely used in research its clinical use has 
been inconsistently recommended by asthma guidelines (26).  
1.2.4 The history of drug therapies 
McFadden describes the modern pharmacologic era for asthma as starting in the 
1920s (10). Prior to this a variety of treatments were employed; as with early 
treatments for many diseases some of the ingredients are likely to have been 
deleterious to health while others may have been of benefit. Some of the inhalants 
used for asthma included smooth muscle relaxants, mucolytics, vasoconstrictors and 
cough suppressants.  
Anticholinergics were present in some of the herbs of the 19th century (4); these 
inhibit the parasympathetic nervous system by blocking the cholinergic nerve activity 
which contributes to smooth muscle contraction and airway narrowing (27). 
Ipratropium is a modern anticholinergic which may be prescribed as a pressurised 
metered dose inhaler (pMDI) or used in a nebuliser. 
Adrenergics were first used in asthma in 1900 and adrenalin was first used via an 
inhaler in 1929 (4). Modification of the drugs occurred with analogues being 
developed (rather than extracted directly from the adrenal gland). The pMDI was 
subsequently invented and in 1956 was used to deliver an adrenalin analogue 
isoproterenol (a β-adrenoreceptor agonist)(10). These had unfortunate cardiotoxic 
effects which – as previously stated - may have contributed to the 1960s asthma 
death epidemic. Less cardiotoxic, respiratory selective, and longer acting β2 agonists 
were developed, including the still widely used salmeterol and formoterol. Trials of 
dry powder inhalers were first carried out in 1967 (28). 
Methyl xanthines are present in coffee, recommended as a treatment for asthma by 
William Withering in 1786 (4). In 1921 the bronchodilator effect of methyl xanthines 
was demonstrated, with theophylline being used for asthma the following year and 
aminophylline in 1944. Cromones are another group or medications derived from a 
plant which had been used traditionally as an antispasmodic. Cromoglycate and 








The treatments mentioned so far focus on tackling bronchoconstriction and were 
initially used to treated acute episodes; as longer acting formulations were developed 
and asthma better understood, regular use began in an attempt to prevent asthma 
attacks from starting (10); there was, however, no treatment to tackle the 
inflammatory pathophysiology which characterised many asthmas until the advent of 
glucocorticoids.  
Corticosone was first extracted from the adrenal gland in 1936 with successful trials 
in asthma in the 1950s and its first use as an aerosol the following year (4). Oral 
corticosteroids were used for asthma in 1956. Aerosolised steroids (beclomethasone 
and betamethasone) followed in the 1970s (10) transforming the management of 
asthma (29).  
More recent pharmacologic developments include leukotriene receptor antagonists. 
These gained a licence for use in asthma in the 1990s and work by blocking the action 
of leukotrienes - an inflammatory mediator in the immune pathway involved in 
allergy.   
The newest class of drugs are the monoclonal antibodies or ‘biologics’ which include 
omalizumab, mepolizumab, benralizumab reslizumab, dupilumab and 
tezepelumab. Omalizumab binds to IgE preventing its action on immune cells 
thereby retarding allergic reactions; the others all target interleukins or cytokines - 
chemical mediators involved in the inflammatory cascade (commonly in the 
production of eosinophils). Omalizumab (Xolair) was approved for use in the UK in 
2005, and mepolizumab (Nucala) in 2015. 
1.3 Epidemiology and disease burden 
1.3.1 Prevalence and incidence 
Asthma is one of the most common non-communicable diseases; it affects an 
estimated 339 million people worldwide (8); and morbidity and mortality are high 
despite treatment that is effective in the majority of patients (13). Prevalence in the 
UK is thought to be between 7% and 9% (30) placing it amongst the highest in 
Europe. Asthma UK estimate that in excess of 5 million people in the UK currently 
receive treatment for asthma (30); of these, 200,000 are thought to have severe 
asthma, responding poorly to a combination of bronchodilators and steroids. The 
British Lung Foundation (BLF) report that in 2012 incidence of asthma was 36% 
higher and prevalence 11% higher in the most deprived communities when compared 
to the least deprived. They suggest damp housing, fungal spores, pollution and 
second-hand smoke may be contributing factors (31). 




1.3.1 Disease burden 
The NHS spend on asthma is estimated at  £1 billion per annum (32). A large 
proportion of costs are likely to come from acute secondary care – Rodrigo et al (33) 
report that only 20% of asthma patients in the U.S. have ever been admitted to 
hospital with an acute exacerbation, yet these patients account for over 80% of the 
asthma healthcare costs. In the UK for the year 2016/17 there were a reported 
77,124 hospital admissions for asthma (30). While the mortality rate from asthma 
exacerbations has declined since the 1960’s, there has been relatively little progress 
in the last 10 years (34).   
With the advent of social media, blogging, and vlogging - and with the activities of 
asthma charities - it is very easy to find personal accounts of the lived experience of 
asthma. There is a body of work on long term conditions and their effect on the 
individual, conducted from a number of perspectives – physiological, psychosocial, 
and socioeconomic. Similarly, a great deal of research has been conducted into 
disease management and the design of medical care systems for long term 
conditions. People are living longer but are increasingly likely to have multiple long-
term conditions; acknowledgement of this is one of the key drivers of the NHS Long 
term Plan (35) which includes personalised and digitally enabled care. It is worth 
noting that relapsing-and-remitting diseases may pose their own distinct difficulties, 
for example in terms of medication adherence and psychology. Moreover, unlike 
some other long term conditions such as diabetes, asthma does not attract free 
prescriptions in the UK. The Global Asthma Network reported 23.7 million disability 
adjusted life years (DALYs) globally as a result of asthma in 2016 and state that this 
has not changed since 1990 (8). They ranked asthma 16th in the leading causes of 
years lived with disability (YLD) globally.  
1.4 Asthma definitions and diagnosis 
1.4.1 Defining asthma 
“What is this thing called love? – or, defining asthma”  Gross (36) 
Defining a disease with multiple endophenotypes creates difficulty. The above 
editorial title by Gross (cited by Sakula (4)) suggests that – as with love – clinicians 
and patients know what asthma is, but find it hard to provide a definition that reflects 
the multitude of possible forms in which it exists. In slightly less prosaic terms The 
Lancet describes it as “one of the most elusive of all common chronic disorders”(13). 
It is increasingly recognised that the term asthma represents a heterogenous set of 
clinical conditions (37); definitions of athma are thus frequently wide ranging and 
descriptive in nature. 




The National Institure of Health use the following definition - “a chronic inflammatory 
disorder… that is complex  and  characterised by variable and recurring symptoms, 
airflow obstruction, bronchial hyperresponsiveness and an underlying inflammation” 
(38). Many of the earliest definitions centred on bronchoconstriction; however as the 
importance of inflammation and eosinophils were established, the focus came to rest 
more on inflammation as the defining characteristic, as exemplified by the NIH 
definition. As discussed in section 1.2.1 the most recent asthma definitions have 
swung back to a more balanced view of both bronchoconstriction and inflammation 
(11) such as this from the Global Initiative for Asthma (GINA): 
A heterogeneous disease, usually characterised by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness, and cough that vary over 
time and in intensity, together with variable airflow limitation. (3) 
The fact that it is usually characterised by inflammation reflects the existence of 
variable airflow obstruction in the absence of active inflammatory processes. The fact 
that what was once thought to be a defining disease characteristic is not ubiquitous 
has added impetus to the argument that the label ‘asthma’ might better 
conceptualised as an umbrella term or perhaps abandoned entirely having outlived 
its utility (12).  
1.4.2 Clinical features of asthma and diagnosis 
BTS/SIGN guidelines (39) identify the following clinical features, the presence of 
which increase the probability of an asthma diagnosis: 
- History of recurrent episodes 
- Variable peak flow when symptomatic and asymptomatic 
- Symptoms of wheeze, cough, breathlessness and/or chest tightness 
- Personal or family history of atopic conditions 
The guidelines recommend undertaking a structured clinical assessment of asthma 
probability based on the above clinical features; spirometry; and the comparison of 
diagnostic tests undertaken when symptomatic and asymptomatic (in order to assess 
variability).  
A number of tests may be conducted including reversibility testing (where lung 
function is assessed before and after a nebulised SABA), bronchial challenge testing, 
FeNO, blood eosinophil count, allergy testing and IgE level. Positive results increase 
the likelihood of an asthma diagnosis being appropriate but none are diagnostic or 
definitive when taken in isolation. 




1.4.3 Acute asthma 
Such is the level of variability that the notion of a ‘mild’ exacerbation has been 
deemed unworkable; most definitions of such fall within normal levels of symptom 
variation (40). The BTS/SIGN guidelines use the categories moderate, severe and life 
threatening based on a number of physiological signs including PEF, respiratory rate, 
ability to complete sentences and blood gases. A strong argument has been made 
for the abandonment of the term asthma exacerbation in favour of lung attack (12); 
with authors arguing that this would reverse the trivialisation of the condition and 
more accurately convey the potentially fatal consequence of the event.  
Acute asthma exacerbations or asthma attacks have three main types of trigger - 
viruses, bacteria or allergens (41), although exercise, irritant exposure or a change 
in weather conditions can also trigger variability in symptoms (3). Lower respiratory 
tract infections are more commonly viral but these are clinically indistinguishable 
from those of a bacterial origin (42) creating the potential for overuse of antibiotics 
in the management of acute asthma. Each trigger may act through a different 
mechanisms but with a final common pathway – that of inflammation and/or 
bronchoconstriction (43).  
1.4.4 Pathophysiology of asthma and aetiology 
Pathophysiology 
Much of the pathophysiology of asthma has been discussed in section 1.2.1 (the 
history of the disease). It is characterised by three inter-related elements – those of 
inflammation, bronchial hyperreactivity or hyperresponsiveness (BHR), and airway 
remodelling.  
BHR is defined by Joos et al as an abnormal increase in airflow limitation due to 
smooth muscle contraction following exposure to non-allergic stimulus (44).  
Bronchial inflammation may be characterised by a variety of inflammatory cells 
including, eosinophils, mast cells, lymphocytes and neutrophils, which may infiltrate 
any or all layers of the bronchial wall (45); the predominant inflammatory cell may 
vary with neutrophilic, eosinophilic and paucigranulocytic as possible endotypes.  
Eosinophilic inflammation is a result of type 2 helper T-cells (Th2) producing 
inflammatory cytokines; Th2 cytokines include those interleukins responsible for the 
production of IgE and eosinophils in both atopic reactions and inflamation. Mucous 
hypersecretion may also be a feature. However, non-eosinophilic asthma has also 
been identified; Th2-low, it has instead been linked to activation of Th1 and Th17 
cells (46). 




Bronchial remodelling is characterised by stuctural changes in elements of the airway 
wall such as basement membrane thickening and smooth muscle hypertrophy or 
fibrosis. It is associated with longer standing disease but can be present early on and 
sometimes in the absence of inflammation (47). Mutiple pathways may be involved 
in each of these processes but it is the chemical mediators of inflammation and allergy 
which have received the greatest attention with drugs being developed to target 
different parts of the allergic pathway and/or inflammatory cascade.  
The aetiology of asthma has not been entirely elucidated but increasingly it is 
considered - like many other conditions – to be a result of gene-environment 
interactions (47). A large hereditabe component has been evidenced by twin studies 
but the rapid increase in asthma prevalence suggests environmental factors (48). 
Amongst the environmental factors posited are diet, allergen exposure and the 
hygiene hypothesis. The latter is supported by evidence of a negative association 
between childhood infections and allergic disease later in life; exposure to microbial 
products such as endotoxins having a positive effect on the development of the 
immune system. Similarly allergen exposure in early life may have a protective effect 
(49). However, microbial agents have been posited to have negative effects also, 
with infection of the airways being implicated in the subsequent development of 
asthma (48). In recent years there has been a growth in research into the microbiome 
and the role this may play in both the development and maintenance of a healthy 
immune system. Genetic studies have reported a large number of genes to be 
associated with asthma (multiple interacting genes, some with protective 
associations, some causative (50)) but relatively few have been replicated (51); 
genome-wide association studies have however pointed to potentially new aspects of 
disease pathogenesis such as epithelial barrier function. It has been suggested that 
therapeutics should focus on increasing airway resistance to the inhaled environment 
/ environmental insults rather than continuing to focus on inflammation (52).  At 
present there is no unifying theory to explain the aetiology (49). 
Phenotypes 
A phenotype is an observable and measurable disease characteristic – for example 
airway eosinophilia; whereas endotype referes to a sub-specification of disease based 
on underlying pathophysiological mechanism (53).  
Deliu points out that the same observable features of a disease can be produced by 
differing underlying mechanisms, thus differing endotypes may have the same 
phenotype; alternatively different observable features can be the result of a single 
underlying pathophysiological process after it has been mediated via different 
individuals’ unique biological systems.  




The endo-phenotype schema perhaps most commonly used is based upon Th2 status 
(see figure 1) (46). 
 
Figure 1 – A commonly used asthma phenotyping schema based on the presence 
or absence of helper T cells.  
The Th2-high classification is a broad umbrella category capturing several different 
conditions including (but not limited to) atopic asthma, non-atopic asthma, exercise 
induced asthma, aspirin exacerbated respiratory disease, and late onset eosinophilic 
asthma. There is no definite consensus on conditions that clearly fall within the Th2-
low group, but it is thought to potentially include neutrophilic, paucigranulocytic, 
mixed granulocytic, smoking associated, and obesity associated asthma. 
This system of categorisation has yet to be integrated into national clinical guidelines. 
GINA state that although recognisable clusters based on demographic features or 
clinical characteristics exist, with the exception of severe asthma and the new biologic 
drugs there has been little evidence to establish a strong relationship between these 
clinical patterns and underlying pathophysiological processes (endotypes). They 
currently recognise the following phenotypes: 
 Allergic asthma – typically of childhood onset with a family history of allergic 
disease / atopy; typically eosinophilic and responsive to steroids. 
 Non-allergic asthma – No associated allergies; airway inflammatory profile 
may be eosinophilic, neutrophilic or paucigranulocytic; may be less responsive 
to steroids.  
 Adult onset asthma – More common in women, tending to be non-allergic and 
responding less well to steroids.  
 Asthma with persistent airflow limitation – non-reversible airflow limitation 
likely due to airway wall remodelling in long-standing asthma 
 Asthma with obesity – highly symptomatic but with low levels of airway 
inflammation. 
Th2 high










 Occupational asthma – response to an inhaled irritant at work to which a 
patient is sensitive or has become sensitised. 
1.5 Treatment 
There are numerous guidelines for the pharmacological management of asthma 
including both the Global Initiative for Asthma (GINA) and the American Thoracic 
Society (ATS). In the UK there are the BTS/SIGN guidelines and the guidelines 
published by the National Institute for Health and Care Excellence (NICE); 
occasionally these guidelines deviate from one another (54). 
BTS/SIGN guidelines recommend a stepped approach to asthma management (as 
shown in figure 2); increasing or reducing treatment according to control. BTS/SIGN 
define control as an absence of symptoms, normal lung function and no limitation to 
normal activities.   
It is worth noting Haldar et al (21) identified a group of patients with high risk of 
asthma attack but low symptom expression.  
Amongst such at-risk patients, BTS/SIGN recommendations may not be sufficient to 
identify disease control; the use of a biomarker such as FeNO may be of benefit. 







Figure 2 – BTS/SIGN treatment guidelines. Adapted from the 2019 guidelines. 
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At the top level of treatment, BTS/SIGN guidelines suggest consideration of other 
steroid-sparing drugs; the new wave of ‘biologic’ medicines would fall under this 
category.  
There are other treatments not covered in the algorithm: 
 Bronchial thermoplasty, used to treat bronchial wall thickening. 
Radiofrequency pulses are used to reduce smooth muscle mass in the 
bronchial wall and also to target nerve endings and neuroendocrine epithelial 
cells (55); although this may reduce severe exacerbations and hospital 
admissions for up to five years (39) there is an increased risk of exacerbation 
immediately after treatment (55) and it is recommended for the treatment of 
non-responsive asthma only (39). 
 Azithromycin – a macrolide antibiotic thought to have possible anti-
inflammatory effects. Previously limited in use to those with a non-type 2 
inflammation (for example paucigranulocytic or neutrophilic), there has been 
some suggestion that it may have wider applications (16). 
 Magnesium sulphate – used in the acute setting where exacerbation has been 
refractory to treatment. Magnesium acts as a smooth muscle relaxant / 
bronchodilator. Ramsahai et al report little benefit from nebulised magnesium 
(16) but cite a Cochrane systematic review reporting a small improvement in 
lung function and reduced hospital admissions where IV magnesium sulphate 
is used. 
Other aspects of disease management include assessment of therapy adherence, 
trigger avoidance advice, and personalised asthma action plans to empower self-
management. 
Patients are concerned about the long term effects of treatments, particularly inhaled 
bronchodilators and corticosteroids. This is evident from the results of a Priority 
Setting Partnership on Asthma (56) which ranked information on the adverse effects 













1.6 Biomarkers  
1.6.1 An Overview 
A biomarker may be defined as a “characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (57). Applications include 
diagnosis; indicating clinical prognosis; and/or predicting or monitoring response to 
therapy.  
The SIGN/BTS clinical guidelines (25) recommend that diagnosis of asthma be based 
on symptoms and spirometry while peak expiratory flow readings should be used for 
ongoing disease monitoring. These are measures of airway calibre however, not 
measures of underlying pathophysiological change or activity. The ability to directly 
assess disease activity may improve diagnostic certainty, facilitate phenotyping and 
inform treatment algorithms used in the management and prevention of acute 
asthma exacerbations thereby reducing disease burden. 
Inflammation can be assessed directly by analysis of lung biopsy or broncho-alveolar 
lavage. Both of these are undertaken via bronchoscopy which is expensive and 
invasive, and therefore unsuited to the purpose of regular clinical monitoring. As 
discussed in section 1.2.3, assessment of inflammation by induced sputum 
differential cell count is well established as a marker of airway inflammation (19) and 
disease activity (20) and directing clinical management according to percentage of 
sputum eosinophils has been found to improve outcomes (21-24). The technique is 
however time consuming and semi-invasive, and its uptake in clinical practice has 
been limited (25).  The need to quantify inflammation by less invasive means has 
been pursued through a number of avenues including the analysis of sputum, exhaled 
breath condensate (EBC), exhaled breath gases, blood, plasma and urine. 
Blood tests offer a more standardised approach than some of the emerging 
technologies currently do - for example serum proteins such as eosinophilic cationic 
protein or leptin use existing, reproducible laboratory technologies - however it is 
argued that they are less sensitive and slower to respond to changes within the 
airways (47) than an exhaled breath sample; moreover they are more vulnerable to 
being affected by systemic conditions.  In contrast, circulating levels of epithelial 
proteinases may act as an early warning for exacerbation; however the application 
would need to be less invasive if it were to be used for routine self-management.  
 




Urinary leukotrienes have been used in their ratio with FeNO to identify a subset of 
patients more responsive to LTRA (58), while urinary markers of lipid peroxidation 
and eosinophil-oxidised oxidation were found by another study to be associated with 
asthma (59). These studies used nuclear magnetic resonance (NMR) analysis which 
is not widely available and - as with serum – urinary metabolites may be less 
responsive to airway change and vulnerable to systemic confounders. 
Other non-invasive airways assessments using EBC or exhaled breath gases as the 
sample medium are not yet part of standard clinical practice. There are a number of 
reasons for this including practical issues (the time and facilities required for some 
tests), a lack of studies (in the case of emerging technologies) and conflicting 
evidence of benefit.  
1.6.2 Exhaled Breath Gas 
Exhaled breath is a mixture of air from the alveoli – the site of gaseous exchange – 
and air from the anatomical “dead-space” where there is no such exchange; the ratio 
being approximately 350ml/150ml respectively (60). Amongst the breath tests which 
have made the leap into clinical use are C-urea for helicobacter pylori infection and 
nitric oxide for airways inflammation in asthma (60). The fraction of exhaled nitric 
oxide (FeNO) is measurable using commercially developed equipment and has 
become widely used; alongside sputum eosinophils it is one of the best established 
markers for disease (20). However, FeNO monitoring equipment requires controlled 
breathing which may prove an obstacle for some patients; in one study (61) only 
70% of participants experiencing an acute exacerbation of COPD or asthma were able 
to successfully complete the FeNO test (compared with 100% using an EBC collection 
device). FeNO is a single biomarker reflecting a single pathological process (47); it is 
argued by some that its use as an inflammatory marker in non-atopic asthma is 
limited because it is associated primarily with allergic and eosinophilic inflammation 
(62); it is not yet recommended in all guidelines; it is not recommended for use in 
the care of acute asthma; nor is it of use in non-eosinophilic phenotypes; and 
systematic reviews conducted on studies of FeNO guided asthma treatment have had 
conflicting results (63-68). Other exhaled breath gas markers including nitrite, nitrate 
and volatile organic compounds (VOC) have been the target of research. Due to the 
complex aetiology of asthma and multiple possible phenotypes an argument can be 
made that a single biomarker or exhaled gas may be limited in its utility.  
Recent developments in monitoring have led to the development of equipment which 
is able to produce a profile of multiple VOC in exhaled breath and their relative 
concentrations (69); a ‘breath-print’ which has been used in the identification of 
disease phenotypes.  




Studies suggest that VOC may be able to differentiate asthma from other airways 
diseases (70-72) and guide asthma treatment; in one study (73) it outperformed 
both FeNO and sputum eosinophil count in predicting steroid responsiveness. This 
field is still in its infancy and no study has yet considered this measure during an 
acute exacerbation of asthma.  
1.6.2 Exhaled Breath Condensate (EBC) 
In addition to gases, exhaled breath contains aerolised airway lining fluid which in 
turn contains a number of molecules indicative of inflammation (74). Exhaled breath 
may be collected and condensed, and – importantly - this can be undertaken during 
normal tidal breathing; it is therefore not dependent on patient effort and can be 
undertaken in the acute setting. EBC has been analysed for its acidity (pH) and the 
presence of leukotrienes, prostaglandins, hydrogen peroxide and other markers of 
inflammation and oxidative stress. A recent review of EBC pH (75) suggests acidity 
is a good but non-specific marker of numerous diseases, not limited to respiratory.  
Oxidative stress is known to play an important role in the pathogenesis of asthma 
(76) and markers of oxidative stress can be found in both exhaled breath gas and 
EBC. Oxidative stress is defined as “a disturbance in the prooxidant-antioxidant 
balance in favour of the former, leading to potential damage” (77)(pxc-xvi). The 
damage caused by oxidants may result in apoptosis or cellular necrosis; oxidants can 
induce mucous secretion or alter remodelling of extracellular matrix and they can 
cause smooth muscle contraction and bronchoconstriction (78, 79). All of the above  
may contribute to asthma exacerbations or death.  
Amongst the many markers of oxidative stress the compound 8-isoprostane has the 
advantage of being relatively stable and suitable for batch analysis. It is a 
prostaglandin-F2-like compound formed by the peroxidation of arachidonic acid (80)  
in cell membrane phospholipids. This non-enzymatic reaction is catalysed by free 
radicals and is thus a potential marker of oxidative status. It has been shown to be 
higher in asthmatics than non-asthmatics (80-82); higher in severe asthma than in 
moderate asthma (83); higher in moderate asthma than in mild asthma (84, 85); 
able to predict asthma severity (84); and responsive to treatment with corticosteroid 
therapy (86, 87). Others have, however, reported contradictory findings (88, 89) and 
the majority of these studies are cross-sectional in design making it difficult to draw 
inferences about causation. The results do however suggest that 8-isoprostane has 
potential as a biomarker in that it may be capable of both indicating an abnormal 
process and response to treatment.  




1.6.3 Markers of Infection 
The results of bacterial cultures take too long to guide initial therapy so there is a 
clinical need to develop methods of phenotyping attacks in order to facilitate 
appropriate tailoring of treatment (including safely withholding antibiotic therapy).  
Point of care tests for the identification of viral or bacterial pathogens are in 
development with the most rapid using nucleic acid amplification techniques, 
however, these have not yet entered clinical use due to issues relating to 
interpretation, sensitivity and specificity (90, 91). 
Examination of VOC within exhaled breath gas has the potential to inform this 
subject. VOC profiles can classify the dominant sputum inflammatory profile in 
asthma (70) and were found to be associated with the presence of lower respiratory 
tract bacterial infection (LRTI) in ventilated patients (69). Inflammatory mediators 
dissolved within EBC may also inform this subject; soluble triggering receptor 
expressed on myeloid cells 1 (sTREM-1) - a neutrophil cell signalling receptor (92) - 
can be used to identify the presence of bacterial infection (93). It has been found to 
be elevated in serum and to correlate with blood neutrophil numbers during asthma 
attacks (94). It has not yet been measured in EBC but is significantly higher in the 
exhaled ventilator condensate of patients with ventilator acquired pneumonia, when 
compared to those without (95). Interleukins have previously been measured in EBC; 
Interleukin-33 is a non-specific pro-inflammatory cytokine that has recently been 
implicated in rhinovirus induced asthma attacks (96). This has been identified in BALF 
but not yet studied in EBC. These are both promising biomarkers for use in acute 
asthma management. Furthermore the engagement of toll-like receptor cells by 
lipopolysaccharides produced by gram-negative bacteria have been shown to alter 
the production of VOC offering potential markers of infection (97). 
1.6.4 Beyond single markers 
Coumou & Bel (98) note that the varying strength of correlation between surrogate 
airway-eosinophilia markers and sputum eosinophil count may be due to the 
populations studied and the fact that there are multiple pathways resulting in 
eosinophilia. It is argued that a panel of biomarkers is likely needed to capture the 
variance in underlying disease pathophysiology and enable categorisation into 
endophenotypes (47). Wadsworth et al argue that these might include a wider array 
of markers; moving away from those purely focussed on inflammation to encompass 
other disease components such as structural epithelial changes, mucous hyperplasia 
and myofibroblast proliferation (47).  




Ramsahai et al (16) suggest that heterogeneity exists not only in the underlying 
disease but also in acute exacerbation and argues for the expansion of precision 
medicine in asthma to enter the treatment of exacerbations; for example using 
macrolide antibiotics in those exacerbations associated with neutrophilic asthma and 
evidence of bacterial infection.  
It is hoped that exhaled breath analysis capable of identifying and quantifying a range 
of markers reflective of multiple pathophysiological pathways might address this as 
yet unmet clinical need.  
1.7 Patient priorities for research 
 
In a mixed-methods asthma study Caron-Flinterman et al (99) reported medication 
side-effects to be the number one patient concern, while more knowledge on the 
origins of asthma was their number one research priority. Similarly, a James Lind 
Alliance Priority Setting Partnership (100) reported the adverse effects of medication 
to be the number one priority, while number two and three were questions about the 
most effective ways to manage asthma.  
Biomarker research is directly relevant to disease management and – through 
accurate monitoring and medication titration - relevant to patient’s medication 
concerns, precision medicine being one potential route by which non-beneficial 
medications can be eliminated from a patient’s treatment regimen.  
The European asthma research innovation partnership (EARIP) (101) gathered 
stakeholders (including patients, health professionals, researchers and industry 
representatives) to discuss research priorities. They reported that exploring the value 
of VOC to phenotype asthma and predict clinical outcomes (such as asthma attack or 
response to treatment) would be of great interest. Masefield et al (102) published 15 
key research priorities identified by EARIP in a roadmap for asthma research and 
development. Number one was to identify, understand and better classify the 
different forms of asthma, and their effect on airway inflammation. Number six was 
to develop tools for quick, accurate and low-cost diagnosis to distinguish asthma from 
other causes of breathlessness, cough and wheeze. Numbers eight and nine were to 
evaluate new ways of measuring airway inflammation in monitoring asthma; to 
identify biomarkers for exacerbations, and to understand the interactions between 
biomarkers, risk and comorbidities.  
 




1.8 Overview of thesis and rationale  
 
Asthma is a chronic disease with potentially life threatening exacerbations or attacks; 
the majority of patients have disease that responds well to conventional therapy but 
a significant minority have severe or refractory disease. It is a heterogeneous disease 
with multiple endophenotypes which have not been fully elucidated and no gold 
standard for diagnosis.  
Moreover, during acute attack standard assessment methods such as spirometry and 
biomarker assessment such as FeNO are challenging for patients to perform (103). 
After very little change in the mainstay of treatment a number of new ‘biologic’ drugs 
have been developed targeting specific elements within immuno-inflammatory 
pathways. Set against this background, the need for biomarkers to diagnose, 
phenotype and direct treatment is apparent. Input from PPI groups suggests that 
patient priorities for research are well aligned with these clinical needs. To be adopted 
in a clinical context, simple methods of assessment which are relatively non-time 
consuming at the point of care are required, with non-invasive methods being 
preferable. Exhaled breath collection is non-invasive and – in the case of FeNO – has 
already entered into clinical use in a way that the more invasive, time-consuming 
sputum eosinophil count has not achieved. Metabolomic analysis holds great promise 
in heterogeneous disease due to the ability to apply an inductive, non-targeted 
approach to biomarker identification. 
Acute exacerbations of asthma may be triggered through a number of mechanisms 
including infection. It is thought that bacteria are responsible for relatively few 
exacerbations nonetheless many patients receive antibiotics as bedside tests to 
determine the presence and type of infective agents (or other trigger) are lacking. 
Exhaled VOC and compounds within EBC hold promise for use in phenotyping 
exacerbations, with potential application in both the acute and non-acute settings.  
Ransohoff (104) in work based on Sullivan et al (2001) suggests five phases to 
biomarker research (in a parallel to the three phase approach used for drug studies). 
Phase one is a pre-clinical exploratory study designed to identify promising directions, 
the primary aims of which are 1) to identify leads for potentially useful biomarkers, 
and 2) to prioritise the identified leads. Phase two is clinical assay and validation –
the primary aim of this stage is to estimate the true and false positive rates, or ROC 
curves for subjects with and without a condition.  
 
 




This thesis aims to: 
1) Summarise the literature on promising methods of exhaled breath analysis in 
asthma. 
2) Assess the feasibility of conducting phase one or two exhaled breath 
biomarker studies of asthma in the acute setting. A secondary objective was 
to collect data on exploratory outcomes including the ability of biomarkers to 
distinguish between controlled and exacerbated states.   
 
3) Determine the ability of exhaled breath VOC sampling and analysis to detect 
those changes induced by bronchial challenge testing (namely the release of 
inflammatory mediators triggered by bronchial challenge using mannitol dry 
powder). 
Summary 
The ability to directly assess inflammatory state may improve diagnostic certainty, 
facilitate phenotyping and inform treatment algorithms used in the management and 
prevention of acute asthma exacerbations thereby reducing disease burden. The 
development of a non-invasive, easy-to-use test measuring airway inflammation 
and/or infection, and its validation in clinical practice would provide potential 
opportunities for more effective management of exacerbations, reduced medication 
usage, and reduced hospital admissions. This could lower healthcare costs and 
enhance the lives of patients living with asthma. The two studies comprising this 
thesis fall within the phase one stage of biomarker research - establishing the 
feasibility of an acute study and identifying leads for potentially useful biomarkers. 
Service users have confirmed that they believe the research topic of the PhD is 
worthwhile. They aided the design to make it more acceptable to patients and 




This chapter has provided a disease description, outlined clinical questions which 
need addressing and provided an overview of the current state of research into 
exhaled breath biomarkers. Chapter two examines EBC as a sample medium and 
8-isoprostane as a potential asthma biomarker within this. It presents a systematic 
review of the EBC 8-isoprostane literature in adults with asthma.  Chapter three is 
comprised of a systematic review of the literature on exhaled breath gases – 
specifically VOC – in adult asthma.  




The review reports on both the results of such studies and the methods used 
(including a summary of both sample processing and statistical methods). The later 
chapters of this thesis present two studies of exhaled breath analysis in acute asthma 
which were conducted by the author at the Norfolk & Norwich University Hospital 
Trust. Chapter four describes the development of the breath sampling and analytical 
methods used within these studies. In Chapter five the protocol and methods used 
for the two studies are presented. First the feasibility study Exhaled Breath 
Biomarkers in Acute Asthma (ABBA); this study aimed to determine the feasibility of 
conducting exhaled breath analysis in the acute setting and compares two different 
recruitment and assessment methods. Second Bronchial Challenge Testing in 
Asthma: The Effect of Mannitol Dry Powder Inhalation on Volatile Organic Compounds 
in Exhaled Breath (ABC). This study aimed to determine whether inflammatory 
changes induced by bronchial challenge testing can be detected using exhaled breath 
samples and the analysis of volatile organic compounds. Chapter six presents the 
results from the ABC study while chapter seven present the results of the ABBA 
study. Chapter eight concludes the thesis with a discussion of both studies, the 
experimental results and study limitations. 




Chapter 2 – Exhaled breath condensate and 8-
isoprostane 
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2.1 Introduction  
 
The previous chapter provided an overview of exhaled breath assessments, covering 
the variety of methods currently employed for this task, and highlighting the 
multitude of biomarkers and sample mediums which have been investigated.  
This chapter focusses more narrowly on exhaled breath condensate as the medium 
and 8-isoprostane as the biomarker. A systematic review, this chapter has been 
published as Peel, AM, Crossman-Barnes, CJ, Tang, J. Fowler, SJ, Wilson, AM, Loke, 
YK. Biomarkers in Adult Asthma: A Systematic Review of 8-isoprostane in Exhaled 
Breath Condensate (2017) Journal of Breath Research, Vol 11, Number 1.  It has also 
been presented under the same title at the British Thoracic Society Winter Conference 
2016 and under the title 8-Isoprostane in Exhaled Breath Condensate: A Systematic 
Review in Adult Asthma at the Asthma UK Centre for Applied Research Annual 
Scientific Meeting 2016. 
 




Collecting and analysing the condensate from exhaled breath (EBC) as a non-invasive  
measure of disease activity, has been studied since the early 1980’s (105). Several 
different commercial devices are available and this methodology has been adopted 
in a number of studies looking at an ever growing number of potential biomarkers.  
Oxidative stress is thought to play an important role in asthma as both a causative 
factor and a result of inflammation (76, 106). It results from the action of reactive 
oxygen species (ROS), formed through the addition of an electron/s to oxygen. These 
ROS - also known as free radicals - are so named because they react easily with other 
molecules, such as the phospholipids in cell membranes, with damaging effects. The 
presence of ROS is not abnormal; their production is a part of common metabolic 
activity and there are physiological levels at which ROS may play a role in cell 
signalling (79). Oxidative stress occurs where there is a failure of homeostasis due 
either to an excess of ROS (such as may occur during inflammation) or to a lack of 
antioxidants; this can cause cellular damage, proinflammatory mediator release, 
mucous secretion, remodelling of extracellular matrix, smooth muscle contraction 
and bronchoconstriction (78, 79, 106).  
The reaction of ROS with other molecules is so rapid that their direct measurement 
is difficult; however, end products of ROS ‘attack’ are more stable and may be useful 
as surrogate markers for oxidative stress. Arachidonic acid within the phospholipids 
of cell membranes is converted, through the action of oxidants, into isoprostanes – 
prostaglandin-like compounds. 8-isoprostane was first identified in 1990 (107) and 
is a prostaglandin-F2-like compound specific to oxidative stress, stable, and 
measurable in EBC (108-110). Paediatric studies of EBC 8-isoprostane have been the 
subject of a systematic review (111) which found the majority of studies reported a 
significant association between 8-isoprostane and asthma, however, as biomarker 
thresholds vary with age (112), there is a need to review the adult literature. A 
systematic approach was selected in order to view the evidence as whole, and to 
identify common themes as well as inconsistencies that may only become apparent 
through evaluation of the entire dataset. The review aimed to assess the evidence 
regarding the efficacy of EBC 8-isoprostane as a biomarker – its ability to identify 











The study protocol was registered with the International Prospective Register of 
Systematic Reviews (PROSPERO) (registration number CRD42016027312).  The 
primary objective of the review was to assess the ability of 8-isoprostane to identify 
and distinguish between a) those with asthma and healthy controls b) levels of 
asthma severity, and c) response to treatment. A secondary objective was to 
determine possible thresholds appropriate to a diagnosis of asthma or classification 
of severity. 
Search Strategy 
A search strategy was developed using terms relating to asthma, exhaled breath 
condensate and 8-isoprostane (see table 3).   
 
Table 3 – Search terms for 8-isoprostane in exhaled breath condensate 
Terms relating to the condition of interest -
asthma  
Asthma* OR “Bronch* hyperreactivity” 
 
Terms relating to the collection method - 
exhaled breath condensate. 
“Exhaled breath condensate” OR “Breath test*” OR 
“Lung function test*” OR “Expired air” 
Terms relating to the biomarker of interest -  
8-isoprostane 
*isoprostane* OR Dinoprost* OR *prost* OR “Lipid 
peroxid*” OR *prostaglandin* 
 
Master search string 
(adapted for use in individual databases as 
required) 
 
(Asthma* OR “Bronch* hyperreactivity”) AND  
(“Exhaled breath condensate” OR “Breath test*” OR 
“Lung function test*” OR “Expired air”) AND 
(*isoprostane* OR Dinoprost* OR *prost* OR “Lipid 
peroxid*” OR *prostaglandin*) 
 
 
The strategy was modified as required for individual databases and implemented in 
the following online databases: Cochrane, Embase, PubMed, Lilacs, Scopus, 
ClinicalTrials.gov, Open Grey and ProQuest. 
Two reviewers (AMP & CJCB) screened titles and abstracts for inclusion, resolving 
discrepancies through discussion with a third reviewer (YKL). The screening and 
selection process is described in a PRISMA flow chart (see figure 3).  
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database searching 
























Additional records identified 
through other sources 
(n = 5) 
Records after duplicates removed 
(n =  768) 
Records screened 
(n = 768) 
Records excluded 
(n = 727) 
Full-text articles assessed 
for eligibility 
(n = 41) 
Full-text articles excluded, 
with reasons (n =21) 
 
Not EBC 8-isoprostane 
(n=4) 
Exhaled breath 
condensate not collected 
(n=2) 
Smokers included (n=2) 
Study not completed (n=1) 
Unable to measure 8-
isoprostane (n=3) 
Abstract only; further 
information not 
forthcoming (n = 1) 
Inadequate or poorly 
described diagnosis (n=4) 
EBC device poorly 




Studies included in 
qualitative synthesis 
(n = 20) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 4) 
Figure 3 – PRISMA flow diagram: 8-isoprostane in exhaled breath condensate. 
Steps taken in the identification of studies for inclusion in review. 





Inclusion / exclusion criteria are described in table 4 below. 
 
Table 4 – 8-isoprostane in EBC: inclusion & exclusion criteria 
Inclusion criteria Exclusion criteria 
Abstract in English 
Primary data 
Quantitative data 
Diagnosis of asthma according to 
recognised guidelines 
EBC 8-isoprostane measured 
Human subjects 
Adult participants (aged 18+) 
Review articles 
Studies including paediatric patients 
Studies of occupational asthma 
Studies of current smokers  
In vitro studies 
Use of a custom EBC device with insufficient 
description or which fails to meet ATS/ERS 
guideline recommendations (113). 
Studies published as comment / letters will 
have a request for further information made; 
they will be excluded if further detail is not 
forthcoming. 
 
Studies were excluded if the EBC collection device failed to meet ATS/ERS 
construction guidelines (114) (or was described insufficiently to determine this), or if 
the method of asthma diagnosis failed to meet recognised guidelines or was 
incompletely described.  An exception to this was the use of nose-clips; although this 
was recommended, the guidelines state that there were no data underpinning this 
recommendation. A study by Vass et al (115) published since the guidelines found 
no significant difference between samples collected with or without nose-clips 
(although 8-isoprostane was not one of the mediators studied).  
During the initial screening process several conference abstracts were found. On 
contacting the authors it was confirmed that the results had not been published more 
fully elsewhere but insufficient information was forthcoming to determine suitability 
for inclusion. In order to avoid selective dissemination bias an analysis of these 









Data extraction and quality assessment was conducted by two reviewers 
independently (AMP and CJCB). Data were extracted directly into SPSS (116); papers 
were assessed for quality and risk of bias (117); and the overall strength of evidence 
was assessed (118, 119). Discrepancies between the two reviewers were resolved 
through discussion with a third (YKL). 
Statistical methods 
The objective was to produce a quantitative synthesis using methods appropriate to 
the data extracted and to assess statistical heterogeneity using the I2 statistic. Open-
Meta Analyst was used to conduct a random effects meta-analysis of mean difference 
(between asthma and control groups) for those studies reporting continuous data 
with a mean and standard deviation (SD). Where the SD was not reported it was 
calculated from confidence intervals or standard error (except where data had been 
transformed). In studies with multiple arms data was combined. Papers which 
presented their results as a median and range could not be included.  
2.3 Results 
The number of papers identified through the database search was 1,045; a further 
five were identified through reference searches (see PRISMA diagram, figure 3). This 
was reduced to 768 on removal of duplicates. Title and abstract screening resulted 
in 41 papers which was reduced to 20 after screening full texts. Study characteristics 
are summarised in table 5.  
 





Table 5 – 8-isoprostane in EBC: study characteristics and results 
Author Publication 
type 
Country N = 
 
EBC device Method 
of 
analysis 













Battaglia et al (2005) Journal Netherlands 31 EcoScreen ELISA Small airway 
function 
Mild - - 
Brussino et al (2010) Journal Italy 32 RTube ELISA Allergen 
challenge 
Mild p<0.001 - 
Carpagnano et al (2006) Journal Italy 26 EcoScreen ELISA + 
GC-MS 
GORD Mild persistent - - 
Fritscher et al (2012) Journal Canada 67 RTube LC-
MSMS 
COPD & asthma Mild persistent  NS - 
Gratziou et al (2008) Journal Greece 28 EcoScreen ELISA Seasonal allergic 




Head & Mickleborough 
(2013) 
Journal USA 7 EcoScreen LC-MS  Supplements Mild-to-
moderate 
- - 
Komakula et al (2007) Journal USA 114 RTube ELISA BMI Moderate-to-
severe 
NS - 
Kostikas et al (2002) Journal Greece 50 Custom 
device  
ELISA pH Mild + 
moderate 
- - 
Mastalerz et al (2011) Journal Poland 21 EcoScreen GC-MS Aspirin sensitivity Mild-to-
moderate 
- - 
Mastalerz et al (2015) 
 
Journal Poland 53 EcoScreen GC-MS Aspirin sensitivity Moderate - - 
Mickleborough et al 
(2013) 
Journal USA 20 EcoScreen ELISA Supplements Mild-to-
moderate 
- - 
Piotrowski et al (2011) Journal Poland 52 EcoScreen ELISA Asthma severity Severe + never 
treated 
NS  NS 




Samitas et al (2009) Journal Greece 62 EcoScreen ELISA Asthma severity Mild + 
moderate + 
severe 
p<0.001 p< 0.01 
Shimizu et al (2007) 
 
Journal Japan 62 EcoScreen ELISA GORD Moderate p<0.05 - 
Sood et al (2013) 
 
Journal USA 14 RTube ELISA  Allergen Mild atopic NS - 
Zhao et al (2008) 
 
Journal Japan 64 EcoScreen ELISA GORD Mild p= 0.034 - 
  
 




Gemicioglu et al (2014) Conference 
abstract 




Newly diagnosed - - 










Sedlak et al (2013) Conference 
abstract 
Czech Republic 61 EcoScreen LC-MS Inflammatory 
phenotype 
Severe refractory  p<0.001 - 
Sedlak et al (2012) Conference 
abstract 
Czech Republic 20 No info LC-MS Oral steroids Difficult-to-
control 
p<0.001 - 
p<  = a significant relationship reported       ELISA = Enzyme-linked immunosorbent assay 
NS  = a non-significant relationship reported      GC-MS = Gas chromatography mass spectrometry 
 -    = not analysed or not reported          LC-MS  = Liquid chromatography mass spectrometry 
N  = number of participants in asthma and healthy control groups eligible for inclusion          GORD = Gastro-oesophageal reflux disease




2.3.1 Quality assessment  
Results of the Quadas-2 quality assessment can be found in table 6. It was not 
possible to assess the risk of bias arising from patient selection methods or from 
the conduction of the index test (EBC collection); in all but one paper description of 
patient sampling and/or recruitment methods was absent, and in only one paper 
was it clear whether the laboratory analysis of EBC was conducted by someone 
blinded to the participants’ asthma status.  The time between reference and index 
standards was not clearly stated in five of the papers. The larger the interval the 
greater the risk of a change in condition between the two assessments and potential 
misclassification of asthma severity; asthma assessment within 1 week of EBC 
collection was deemed to be acceptable. Participant drop-out occurred in very few 
studies... 
Table 6 – 8-isoprostane in EBC: QUADAS-2 quality assessment 















1. Battaglia 2005 ? ?      
2. Brussino 2010 ? ?      
3. Carpagnano 2006  ?      
4. Fritscher 2012 ? ?  ?    
5. Gratziou 2008      ? ?      
6. Head 2013 ? ?   ?   
7. Komakula 2007 ? ?      
8. Kostikas 2002 ? ?      
9. Mastalerz 2011 ? ?      
10. Mastalerz 2015 ? ?   ?   
11. Mickelborough 2013 ? ?  ? ?   
12. Piotrowski 2011 ? ?      
13. Samitas 2009 ? ?   ?   
14. Shimizu 2007 ? ?  ?    
15. Sood 2013 ?   ?    




16. Zhao 2008 ? ?  ?    
Potentially eligible studies  
(conference abstract/review excerpt) 
a. Gemicioglu 2014   ? ?    ?  
b. Holguin 2009         ? ? ? ?  ? ? 
c. Sedlak 2013     ? ? ? ? ?  ? 
d. Sedlak 2012    ? ? ? ? ? ? ? 
 
2.3.1.1 Variability: Pre-analytical 
One study (Samitas et al (83)) coated the condenser surface of their EBC collection 
device in Tween-20 (a non-ionic surfactant) to reduce eicosanoid adherence. They 
report 8-isoprostane concentrations which are towards the higher end of results 
within this review. The extent to which this was due to the use of Tween-20 is 
unclear; Sood et al (120) examined this method and found no significant difference 
in 8-isoprostane between samples collected with or without Tween. 
Three studies (Battaglia et al (121), Fritscher et al (122) and Sood et al (120)) 
undertook or cited 8-isoprostane recovery rates obtained from spiking tests; all 
were over 90%. Sood et al found that concentrating their samples by lyophilisation 
had no effect on recovery rates, whereas Battaglia et al found lower rates when 
they used an immunoaffinity sorbent and lyophilisation. 
Kostikas et al (123) cooled their condensing surface to minus 10oC whereas other 
studies used minus 20oC. This study was included as it does not contravene 
ATS/ERS recommendations and evidence on the effect of temperature on EBC 8-
isoprostane collection is conflicting (124-126).  
Not mentioned in the ATS/ERS guidelines but specified by Cayman in their enzyme-
linked immunosorbent assay (ELISA) information (127) is the use of an anti-oxidant 
- butylated hydroxytoluene (BHT) - for EBC samples which are being frozen and 
stored for later analysis.  
Key 
 = high risk / high level of concern regarding applicability 
 ? = unclear risk / unclear level of concern regarding applicability 
 = high risk / high level of concern regarding applicability 
 




This is to prevent further (in vitro) oxidative formation of 8-isoprostane. The 
majority of studies using ELISA kits stored their samples for later analysis but none 
reported the use of BHT.  
Relatively few studies reported the length of time samples were stored for but 
Samitas et al evaluated the stability of 8-isoprostane at -80oC and found no 
significant difference in samples tested at one, four and eight weeks (although an 
upward trend could be noted).  
2.3.1.2 Variability: Analytical 
For their ELISA, Cayman cited a sensitivity of 3pg/ml and inter-assay variation rates 
of 10-24% however this validation was not undertaken in EBC. Sood et al (120) 
found the intra-assay CV in EBC to be 37.7% compared to 6% in buffer diluent. 
They concluded that interference from the EBC matrix was possible; the extent to 
which this might be a confounder in other studies is unclear as Sood et al’s analysis 
was conducted on a lyophilised, concentrated EBC sample. The majority of studies 
in this review cite intra-assay and inter-assay CV <10%.  
Several studies utilised mass spectrometry techniques as their method of analysis 
– GCMS and LC-MS/MS methods offer improved sensitivity and selectivity over 
immunoassays, hence they are often regarded as the superior method for 
measurement of isoprostanes (128-130). Fritscher et al (122) report the limit of 
detection with LC-MS to be 0.05-0.1pg; while Mastalerz et al (131) report that of 
GC-MS to be between 0.17 and 0.89pg/ml. The results found by studies using mass-
spectrometry frequently fell below the lower detection limit of immunoassays. Two 
papers compared the results produced by ELISA methods with a) GC-MS 
(Carpagnano et al) and b) radioimmunoassay (Sood et al). Sood et al report 
discordance between methods while Carpagnano do not.  
The absence of prime certified standard reference materials (SRM) produced by 
accredited bodies (such as NIST) for the production of calibration curves is a further 
source of potential inaccuracy and inter-laboratory variation. 
2.3.1.3 Grade Assessment 
A GRADE assessment was completed (using GradePro GDT (132)) for the 12 studies 
reporting on both asthma and control groups (see table 7). The strength of the 
evidence pertaining to the differentiation of disease status was judged to be very 
low due to the inconsistency and imprecision of results. 
  






Table 7 – 8-isoprostane in EBC: GRADE evidence profile 
Setting: Adult non-smokers in any clinical setting.  
Bibliography: Battaglia, Hertog, Timmers et al (2005); Brussino, Badiu, Sciascia et al (2010); Carpagnano, Resta, Ventura et al (2006); Fritscher, Post, 
Rodrigues et al (2012); Gratziou, Rovina, Makris et al (2008); Komakula, Khatri, Mermis et al (2007); Kostikas, Papatheodorou, Ganas (2002); Piotrowski, 
Majewski, Marczak et al (2011); Samitas, Chorianopoulos, et al (2009); Shimizu, Dobashi, Zhao et al (2007); Sood, Qualls, Seagrave et al (2013); Zhao, 
Shimizu, Dobashi et al (2008).  
Quality assessment 






Inconsistency Indirectness Imprecision Other considerations 
Is exhaled breath condensate 8-isoprostane capable of differentiating between healthy controls and those with asthma? 







Very serious 1 Not serious  Very 
serious 2 
Publication bias strongly 
suspected; 
all plausible residual 
confounding would reduce 
the demonstrated effect 3 
Cases (asthma) 353; controls 229.  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
1. Significant unexplained variability in results; I-squared test for statistical heterogeneity = 94 
2. Large variance in study data   
3. Probable publication bias 
Very low quality – Little confidence in the effect estimate; the true effect is likely to be substantially difference from the estimate of the effect.




2.3.1.4 Quality assessment summary 
For the majority of included papers there are no concerns over applicability to the 
review question but the risk of bias in the studies is largely unclear and there are 
unresolved methodological questions. Overall assessment of the evidence grade is 
very low.  
2.3.2 Quantitative synthesis  
 
2.3.2.1 Prediction of asthma attack or treatment response 
There were no studies examining the strength of association between 8-isoprostane 
concentration and frequency of asthma attack, nor studies examining the ability of 
8-isoprostane to predict the risk of attack or response to treatment.  
2.3.2.2 Differentiation of disease status  
There was a large degree of clinical heterogeneity; studies examined different asthma 
phenotypes and severities, and utilised different interventions (including provocation 
tests and treatments). Given the broad study question being addressed, studies were 
considered sufficiently homogenous for meta-analysis despite these differences.  
Using Open Meta Analyst (133) a random effects meta-analysis of mean difference 
between groups (see figure 4) was performed. The estimated mean difference was 
+21.62 pg/ml in those with asthma (standard error 5.21). The p-value of <0.001 
suggests statistical significance, and the lower bound of the meta-analytical point 
estimate - 11.4pg/ml – is above the detection limit for the ELISA (2.8 to 7pg/ml). 
However, the I2 test result - 94 - suggests a considerable degree of statistical 
heterogeneity, and the estimated mean difference (21.62pg/ml) should be viewed in 
light of the overall range of averages for EBC 8-isoprostane which varied from 
0.25pg/ml to 78.10pg/ml.  




















Figure 4 – Random effects meta-analysis showing a significant mean between-group difference in 8-isoprostane levels (asthma versus 
controls). Weighted mean difference of 8-isoprostance levels between asthma and control groups showing significantly higher levels (+21.62 
pg/ml (SE 5.21, p<0.001)) in asthma patients, but with considerable heterogeneity I2 = 94.46%. 
 




2.3.3 Qualitative synthesis   
Ten papers (n = 419) reported average 8-isoprostane levels to be higher in asthma 
than in healthy controls, while five papers (n = 389) reported averages to be the 
same or higher in controls.   
Of the ten studies reporting higher concentrations in asthma, only seven (n=329) 
reported the difference to be statistically significant. However, of the three which 
were excluded, two (123, 134) simply omitted to report the significance level, while 
the third study – Sood et al (120) - was not powered to detect a between-group 
difference in 8-isoprostane concentration. 
With the exclusion of conference abstracts, five papers (n=248) report a significant 
difference, and five papers (n=278) report either no significant difference or higher 
concentrations amongst controls.  All papers scored similarly in their quality 
assessment.  























Table 8 – 8-isoprostane in EBC study results: averages & variance 
   Average EBC 8-isoprostane 
level 















(1.6 - 2.7)  
3.6 
(2.9 - 7.6) 







(19.92 - 23.35) 
16.43 
(15.50 - 17.41) 
Carpagnano, Resta, 




(8.9 - 23.8) 
6.9 
(5.6 – 9.7) 





(0.4 - 2.0) 
0.9 
(0.2 - 1.7) 




Interquartile range 39.0 
(4.0 - 125) 
18.5 
(4 - 37) 
Head & Mickleborough pg/µl 
(mean) 
Standard error 3.08 
(+/- 1.5) 
_ 




95% CI 11.0 
(9.6 - 12.4) 
11.0 

















Kaszuba et al 
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Shei et al 
pg/ml 
(mean) 




Marczak et al 
    Severe asthma 
              &  
Never treated asthma 
(two groups within study) 
pg/ml 
(median) 
Interquartile range  
3.8  
(2.5 – 10.73) 
 
4.67 








et al  
pg/ml 
(mean) 




















Zhao, Shimizu, Dobashi et 
al 
pg/ml 
(median)   
Interquartile range 16.20 
(11.7 – 19.1) 
3.5 
(2.6 – 7.9) 
 
* Log transformed data 


























Potentially eligible studies 
(conference abstracts) 
Gemicioglu, Duman, 
Akdeniz et al 
No units given 
(mean) 
Standard deviation 135.72 
(+/- 38.85) 
 









Sedlak, Cap, Kacer et al No units given 
(?) 





Sedlak, Cap, Kacer et al pg/ml 
(?) 









Results from those papers reporting a median and those reporting a mean are 
displayed in figures 5 and 6 respectively. Even when looking only at those studies 
reporting a significant between-groups difference, there is a considerable overlap of 
results between studies - the range of values for controls in one study being similar 
to those for asthma in another. This degree of statistical heterogeneity precludes the 
determination of threshold values. 
 
Figure 5 – Median levels of 8-isoprostane in asthma and control groups; between study 
overlap in the two groups is apparent. The values for controls in one study falls within 
those for asthma in another; statistical heterogeneity which prevents the  determination 










Figure 6 – Mean levels of 8-isoprostane in asthma and control groups; between study 
overlap in the two groups is apparent. The values for controls in one study falls within 
those for asthma in another; statistical heterogeneity which prevents the determination 









There was a large degree of overlap in 8-isoprostane concentration between 
severities of asthma. This may be attributable to between-study methodological 
differences, however, three studies (83, 88, 122) made within-study comparisons of 
severity. Samitas et al (83) report a significant difference between the severe and 
milder asthma groups, whereas Piotrowski et al (88) report a small, non-significant 
difference (0.87 pg/ml). Kostikas et al (135) report a difference of 15 pg/ml but do 
not comment on its statistical significance. 
Both Brussino et al (136) and Sood et al (120) investigated the effect of allergen 
challenge on EBC 8-isoprostane concentration. Brussino et al reported a statistically 
significant increase while Sood et al reported no such change.  
Gratziou (137) studied patients with seasonal allergic rhinitis and concurrent asthma, 
reporting significantly higher levels of 8-isoprostane during pollen season, and a 
significant decrease after treatment with nasal corticosteroids. Mastalerz et al (131, 
138) conducted a pair of studies in which patients with aspirin intolerant asthma 
(AIA) or aspirin exacerbated respiratory disease (AERD) were subjected to an aspirin 
challenge; they found no significant difference in 8-isoprostane after challenge. 
Baseline measures of pulmonary function (spirometry) were commonly reported in 
order to characterise study populations; their relation to EBC 8-isoprostane was less 
commonly examined. Eight studies conducted such an analysis, of which only two 
reported a significant (negative) correlation. Similarly, baseline blood eosinophil 
count was reported by five papers but analysed in relation to 8-isoprostane by only 
one (reporting no correlation). FeNO was measured by six studies; four assessed the 
degree of correlation with EBC 8-isoprostane only one of which yielded a statistically 
significant (positive) association. Two papers undertook sputum analysis; one 
reported on the relationship with EBC 8-isoprostane - no significant association was 
found.  
2.3.4 Subgroup analysis 
Methodological heterogeneity has been suggested as one of the factors inhibiting 
clinical use of EBC (114). Those papers included in the meta-analysis all used ELISA 
as their method of analysis but represent a mixture of asthma severities and EBC 
collection devices. A sub-group analysis of EBC collection and analytical methods was 
used as a means of exploring this heterogeneity.  
Five of the seven studies using the EcoScreen reported a positive difference between 
asthma and control groups; four were statistically significant, the fifth was not 
reported upon. Of the four studies using the RTube, two reported a positive difference 
between groups of which one was statistically significant.  




The condensing surface of the RTube is polypropylene while on the EcoScreen it is 
teflon. Several papers have looked at the possible impact of device and condensing 
surface upon EBC results (124-126, 139-143). Czebe et al (125) compared the RTube 
and EcoScreen and concluded that both temperature and condenser surface had an 
impact on biomarker levels. Soyer et al (124) found similar results although neither 
study examined 8-isoprostane. Rosias et al (126) did study 8-isoprostane and 
concluded that condenser surface did have an effect but that there was no difference 
between polypropylene and teflon. Moreover they concluded that temperature 
difference between the two did not appear to have a significant effect on 8-
isoprostane collection. Based on current studies of methodology it is not possible to 
be certain that choice of device explains any of the heterogeneity in the results. 
Regarding analytic method, if the outlier generated by the inclusion of conference 
abstracts (Sedlak et al (144)) is excluded, the results from mass spectrometry exhibit 
a smaller range and are considerably lower than the majority of results from ELISA. 
However, Carpagnano et al (134) – the only study to confirm their ELISA results 
using gas chromatograph-mass spectrometry - report no discrepancy between the 
two measures; this is in line with previous studies (80). That analytical method is 
responsible for a degree of heterogeneity in the results is plausible but cannot be 
stated with certainty. 
The inclusion of papers studying mild or intermittent asthma - in which there may be 
little or no oxidative stress – might explain the lack of consistently observed 
difference between asthma and control groups.  
A sub-group analysis comparing moderate-to-severe asthma with controls was 
conducted to explore this possibility (see table 9). Results were inconclusive; of the 
eight included papers (83, 88, 123, 144-148) five reported a between-groups 
difference (four of which were statistically significant) while three reported no 
difference.  
Table 9 – 8-isoprostane in EBC sub-group analysis: moderate or severe asthma 
 8-isoprostane concentration levels 
 Asthma > controls Controls > asthma 
All papers 5 studies 
(n = 253) 
3 studies 













This review highlights a lack of comparability between studies, as well as evidence 
gaps which create difficulties in determining 8-isoprostane thresholds for diagnosis 
or severity classification of asthma. The clinical value of EBC 8-isoprostane as a 
quantitative assessment of oxidative stress in asthma remains unclear due to 
variability in results and inadequate standardization. 
The previously published paediatric review (111) reported more consistent findings - 
five of the six identified studies found a significant difference between asthma and 
healthy control groups. However, the studies exhibited a similarly large degree of 
variance in their results (ranging between 4.2 – 56.4pg/ml for asthma and 2.6 – 
34.2pg/ml for control groups). 
The ATS / ERS taskforce of 2005 (113) was set-up to address variability in EBC results 
and lack of standardisation in methods. They suggested two likely contributors to 
variability - varying EBC dilution levels and biomarkers being at the lower end of 
assay sensitivity. That there exists a large degree of variance in 8-isoprostane 
concentration levels even where studies have used the same EBC collection method 
would support these assertions.  
Ahmadzai et al in 2013 (149) discuss three possible methods of calculating a dilution 
factor, none of which has established itself as a gold standard and none of which 
were used in the studies comprising this review. Only one study (131) used a dilution 
factor, giving their results in both pg/ml and parts per million of palmitic acid. It 
remains to be seen whether this improves reproducibility.  
It has been suggested that lyophilisation may be useful for reducing variability by 
concentrating samples thereby raising biomarkers away from the lower end of assay 
sensitivity. There are a lack of studies examining the reliability and reproducibility of 
this method (149). Unfortunately the only studies in this review to have used this 
approach (Battaglia et al (121) and Sood et al (120)) concentrated their samples to 
differing levels (threefold and fourteenfold respectively). Furthermore, Sood et al 
reported an intra-assay CV of 37.7% and an inter-day CV of 71.6% when using this 
method.  
The validity of any assessment of diagnostic test accuracy rests upon the accuracy 
of the reference standard to which it is compared; studies where diagnosis was 
conducted according to recognised guidelines were included.  
 




A large number of exclusions were due to lack of diagnostic clarity; many undertook 
spirometry as a study measure rather than a diagnostic assessment and - unless 
reviewed by a physician and judged against a clearly described standard - can’t be 
accepted as diagnostic confirmation. Furthermore, guidelines stress the importance 
of variable airflow obstruction to diagnosis; this cannot be assessed by a single 
spirometry measurement thereby complicating the process for any study wishing to 
have a rigorous diagnosis as the basis for inclusion.  
Of concern were studies where it was neither explicitly stated that smokers were 
excluded, nor was smoking status featured in the participant description. There were 
six studies in which this occurred and over which there must be some concern that 
data might include that from smoking participants. This would be a potential 
confounder; there is evidence that EBC 8-isoprostane is significantly higher in 
smokers compared to healthy controls (150) and may increase in an acute smoking 
response (151).  
Another potential confounder is the effect of food and drink; 16 of the studies did not 
mention fasting prior to tests. The ATS/ERS guidelines (114) state that eating and 
drinking do not affect the non-volatile components of EBC as far as is known, but 
Ahmadzai (149) point out that food & drink may elevate levels of oxidants in body 
fluids and has the potential to influence oxidant concentrations in EBC (although they 
identify no studies describing any such effect on 8-isoprostane). The extent to which 
this might constitute a confounder is unknown.  
Several authors confirmed they were unable to measure 8-isoprostane in a majority 
of their samples (152-154). Of those studies in this review which reported 
undetectable samples the percentage ranged from 16% (Komakula et al) to 50% 
(Piotrowski et al). Not all papers made clear the cause of missing data (whether an 
inability to obtain EBC samples or an inability to detect 8-isoprostane) nor how this 
was handled in the analysis. Gratziou et al (137) gave non-detectable levels of 8-
isoprostane a value of 3.9pg/ml (the lower limit of assay detection) while Sood et al 
ascribed undetectable levels a value half the lower detection limit; neither state how 
many cases this applied to. If these samples came predominantly from healthy 
controls, raising them might obfuscate any difference between asthma and controls.  
In chapter four of this thesis the researchers own experiences with detecting 8-
isoprostane in EBC are detailed; in a study of patients with idiopathic pulmonary 
fibrosis, 8-isoprostane was detectable in only four out of 49 samples, with none 
yielding results that were above the lower limit of quantification for the enzyme-
linked immunosorbent assay (ELISA) used. 




The absence of oxidative stress is a potential explanation of inability to detect 8-
isoprostane. This might be the case for studies of mild or intermittent asthma. The 
use of provocation tests or the study of moderate-to-severe asthma is one potential 
approach to this problem but the results of such studies were no less conflicted. 
Although not one of the primary study objectives, factors for which an association 
with 8-isoprostane was reported were examined. The majority of studies which 
assessed GORD and BMI reported a significant association with 8-isoprostane. It is 
possible that these are important confounders which may need to be controlled for 
in future studies. 
2.4.1 Limitations 
By employing rigorous inclusion criteria for asthma diagnosis and EBC methodology 
several ‘key’ papers were excluded, including that of Montuschi et al (80) frequently 
cited by others as justification for their methodology. These exclusions are justified 
as the use of rigorous inclusion criteria are crucial for a review of diagnostic test 
accuracy.  
Inability to assess the risk of bias in key domains of the QUADAS-2 quality 
assessment tool makes any conclusions from this review necessarily tentative. 
Furthermore, it was possible to conduct meta-analysis of only four studies due to the 
frequent use of median, range, and log-transformed data.  
The increasing ability to examine several biomarkers - for example Sedlak et al (144, 
145) – creates a risk that non-significant findings may go unreported unless high 
reporting standards are adhered to. Hussain et al mention EBC 8-isoprostane in the 
methods section of a conference abstract (155) but not in the results, nor anywhere 
in the full published paper (156); suggesting that 8-isoprostane was either 
undetectable or the results were non-significant. Although these may constitute a 
publication bias, the under-representation of negative findings makes the lack of 
positive findings in this review more robust.  
2.4.2 Occupational asthma 
Writing, registering and following a protocol is an important tool for limiting the risk 
of bias in systematic reviews. In the protocol for this review occupational asthma 
(OA) formed part of the exclusion criteria, being deemed sufficiently atypical to 
warrant separate consideration.  However, an argument can be made that excluding 
an asthma phenotype as ‘atypical’ makes little sense given the heterogeneity of the 
condition and absence of a ‘typical’ asthma.  
 




Furthermore, studies of occupational asthma using a specific inhalation challenge 
(SIC) - where the putative causative agent is used in a broncho-provocation test - 
might offer greater assurance of oxidative stress in the airways of the participant at 
the time of assessment. In light of these considerations the results of the initial 
literature search were subsequently revisited and studies of occupational asthma 
identified. A single reviewer (AMP) conducted a literature search (6th September 
2016) using the same databases and search terms as the original study with the 
addition of ‘OR occupation*’ in the asthma part of the search string. Twenty six 
papers were identified. Sixteen were excluded on the basis that they studied healthy 
participants (with occupational exposure to potentially sensitising agents, as opposed 
to formally diagnosed occupational asthma); four were reviews; three did not study 
EBC 8-isoprostane, and one was not available in an English translation. Two papers 
were suitable for inclusion (157, 158). In the study by Klusackova et al (2008) only 
six participants had a positive SIC, thus the study was underpowered to draw any 
significant conclusions. In Pelclova et al (2014) 8-isoprostane levels were raised in 
those with occupational asthma as compared to controls.   
2.5 Conclusion 
There is a trend towards higher EBC 8-isoprostane concentrations in subjects with 
asthma compared to controls. Twice as many studies reported higher levels amongst 
those with asthma than did not. However the strength of this evidence is weak and 
the number of studies reporting a significant difference was the same as that 
reporting none. A random effects meta-analysis found a significant difference 
between groups however its rigour is compromised by the small number of studies 
and substantial statistical heterogeneity.  
Concentrating EBC samples may address some of the variability and difficulty arising 
from the use of ELISA. However, the central issue of calculating EBC dilution cuts 
across analytical methods and a gold standard is still to be determined. It will be 
essential to develop accurate, reliable and standardised methods of both EBC 
collection and 8-isoprostane analysis if its use as a biomarker in asthma is to be 
properly evaluated. 
While research into EBC continues, interest in exhaled breath gases (volatile organic 
compounds) is growing. A search conducted on the 14th September 2019 using 
Google Scholar and limited to publications in 2019 returned 807 hits for “exhaled 
breath condensate” compared to 1,530 for “exhaled volatile organic compounds”. In 
the next chapter (chapter 3) the literature on exhaled volatile organic compounds 
is examined in relation to adult asthma. 





Chapter 3 – Asthma Breathomics 
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The previous chapter reviewed current evidence for the use of 8-isoprostane in 
exhaled breath condensate (EBC) in adult asthma. While results suggested there may 
be a difference in EBC 8-isoprostane levels between those with asthma and healthy 
controls, the evidence is currently too weak to reach a firm conclusion and true tests 
of diagnostic test accuracy in an undiagnosed population have not yet been 
conducted.  
This chapter reviews those studies which have applied an analysis of exhaled breath 
VOC to adults with asthma. A systematic review, it has been published in Respiratory 
Medicine as Peel, A. Sinha, A. Fowler, S. Loke, Y. Wilkinson, M. Wilson, A. (2020) 
Volatile organic compounds associated with diagnosis and disease characteristics in 
asthma. It has also been presented as a poster at the British Thoracic Society Winter 
Meeting (2019) under the title Asthma breathomics – a systematic review of exhaled 
volatile organic compounds associated with diagnosis and disease characteristics.   
 





A review of paediatric asthma breathomics was published in 2017 (159) however this 
was not based on a systematic literature search and it limited itself to publications 
from the preceding ten years. A systematic search was conducted in order to 
determine whether the published review had identified all relevant studies. This is 
presented within this chapter and was published as Peel, AM. Loke, YK. Wilson, AM. 
(2018) Asthma Breathomics – Promising Biomarkers in Need of Validation (letter to 
Editor). Pediatric Pulmonology, 2018; 1-3. DOI: 10.1002/ppul.23941 
The identification and or quantification of metabolites offers an alternative route to 
diagnosis and disease management. Metabolites are low molecular weight (typically 
defined as <1500 amu1) organic and inorganic chemicals produced by cellular 
processes (including pathophysiological processes). The term ‘metabolome’ refers to 
the entire set of metabolites associated with a biological system (160). Change in the 
metabolome reflects change in underlying cellular activity (161) - disease 
pathophysiology can alter the relative concentrations of metabolites produced, or 
produce metabolites which are absent in health (162) - metabolomics is thus gaining 
traction as a means of biomarker discovery in disease (163). 
Volatile organic compounds (VOC) are carbon-based, low molecular weight 
compounds, volatile at room temperature. The study of endogenous VOC generated 
by metabolic processes within the body and exhaled on the breath is commonly 
referred to as breathomics (164). Such studies produce data on a large number of 
compounds permitting inductive, hypothesis-generating approaches in which data 
are interrogated in order to identify disease-induced metabolomic permutations 
(165) without the prior identification of a candidate marker. This approach has been 
applied to many diseases including asthma. 
Rufo et al (166) conducted a systematic review of the asthma breathomic literature 
in 2014, identifying 18 studies which reported on diagnostic accuracy. In a meta-
analysis of six studies they calculated a pooled area-under-the-curve (AUC) value of 
0.94. This figure needs to be interpreted with caution however as all but one of the 
included studies compared established-treated disease with non-disease (rather than 
testing diagnostic accuracy in those with a suspicion of disease) and the meta-
analysis pooled diagnostic models which were comprised of differing VOC. In addition, 
a mixture of adult and paediatric studies were included; age has since been identified 
as a factor which should be controlled for (167).  
 
1 AMU = atomic mass unit 





Interest in the field has continued to grow and a number of breathomic asthma 
studies have since been published. Neerincx et al (159) reviewed paediatric asthma 
breathomics, to which a systematic search has been appended (168); and recent 
reviews have provided an overview of metabolomics in exhaled breath (169) and 
across different biomediums (170, 171).  
The aim of this study was to systematically review the literature on adult asthma 
breathomics - including studies of diagnosis and of disease characteristics - providing 
a comprehensive list of significant VOC identified to-date.  
3.2. Methods  
 
A study protocol was developed in line with Prisma-P guidelines and registered with 
the International Prospective Register of Systematic Reviews (PROSPERO) 
(registration number CRD42017082727).  The primary objective of the review was 
to ascertain the classification accuracy of VOC models for asthma diagnosis, 
phenotyping, and disease control. The secondary objectives were to identify the study 
methods used and to compile a list of those VOC identified by studies as significant 
for use in future validation efforts. The search strategy used to identify relevant 


















Table 10 – Asthma breathomics: search strategy 
SEARCH TERMS 
The following key words and MeSH terms were used - metabolomics, breathomics, 
exhaled breath, breath test, volatile organic compound* and asthma. The search 
string was optimised for each database. Below - as an example – is the search string 
as used in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 
 
(("Breath Tests"[Mesh] OR "Exhalation"[Mesh] OR "exhaled"[All Fields] OR 
breath[All Fields]) AND ("Asthma"[Mesh] OR "asthma"[All Fields] OR "asthmatic"[All 
Fields]) AND ("Volatile Organic Compounds"[Mesh] OR "Volatile Organic 
Compound*"[All Fields])) OR (("asthma"[MeSH Terms] OR "asthma"[All Fields] OR 
"asthmatic"[All Fields]) AND (Breathomic*[All Fields] OR ("metabolomics"[MeSH 
Terms] AND ("exhalation"[MeSH Terms] OR "exhalation"[All Fields] OR "exhaled"[All 
Fields] OR breath[All Fields] OR "breath tests"[MeSH Terms])))) 
Limits applied to results - ‘humans’. 
 
SEARCH STRATEGY 
Inclusion criteria – Physician diagnosed asthma or asthma diagnosis according to 
recognised guidelines; clinical studies published in full; primary data; VOC in 
exhaled breath studied (by any collection or analytical method). 
Exclusion – Reviews; editorial; secondary data; studies of exhaled breath 
condensate; non-asthma studies; studies published in abstract form only. 
 
SEARCHES 
PubMed; Medline (including Embase and OVID medline) 
In addition, the references from Rufo et al’s review; from the researchers’ own 
reference libraries; and from the reference lists of included articles were searched. 
Researchers working in the field were asked to highlight papers they were aware 
of.  The searches were conducted independently by two reviewers (AS and AP) on 










Two reviewers (AP & AS) screened titles and abstracts for inclusion, resolving 
discrepancies through discussion with a third reviewer (MW). In total 290 records 
were identified; this was reduced to 266 after removing duplicates. On screening 
abstracts and/or full texts, 48 citations of adult asthma breathomic studies were 
identified, of which 28 were abstracts and 20 full journal articles. A PRISMA diagram 
(figure 7) describes the screening and selection process. Quality assessment was 
undertaken using the CASP diagnostic checklist (172) (see table 15). Data extraction 















Figure 7 – PRISMA flow diagram: asthma breathomics review. Steps taken in the 
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database searching 























n Additional records identified 
through other sources 
(n = 8) 
Records after duplicates removed 
(n = 266) 
Records screened 
(n = 266) 
Records excluded 





Reasons for exclusion – 
disease other than 
asthma, not primary data, 
EBC not VOCs 
Abstracts or full-text 
articles assessed for 
eligibility 
(n = 78) 
Articles excluded  
(n = 30) 
 
Paediatric asthma (n=17) 
EBC not VOCs (n=5) 
In vitro study (n=1) 
Not asthma (n=1) 
Mixed asthma/COPD 
population (n=1) 
Mixed age population 
(n=2) 
No VOC results presented 
(n=3) 
Adult asthma breathomic 
references identified 
(n = 48) 
Studies published in full 
(n = 20) 
Abstracts  
(n = 28) 







Twenty journal articles met the criteria for inclusion (table 11). Fifteen of these 
compared VOC in asthma and healthy controls (70, 73, 173-184), of which ten 
reported diagnostic accuracy (70, 73, 174, 175, 177, 178, 181-184). Four studies 
reported on the ability to differentiate between asthma and COPD, one lung cancer 
and one allergic rhinitis (71, 175, 182-184). Seven studies examined the ability to 
discriminate between phenotypes (70, 71, 73, 174, 185-187) (two were cluster 
analyses), while three reported on levels of disease control or activity (70, 179, 185).  
One paper was included (188) which failed to meet Rufo et al’s inclusion criteria (due 
to the absence of a comparator group) and one was excluded (189) due to the use 
of exhaled breath condensate as its sample medium. One paper reporting on volatile 
organosulfides was included (173) while another was excluded due to including both 
adults and adolescents (190, 191). 
Results were typically given as accuracy rates for the correct classification of samples 
- the area under the curve for receiver operator characteristics (AUROC), cross-
validation values (CVV) or correlation coefficients. Tables 11 and 12 display the list 
of full publications along with results; Table 13 summarises study design and breath 
sampling methods; while Table 14 details the data processing and statistical methods 
used. There was heterogeneity in all aspects of study methodology, from sample 
collection through to statistical analysis. The majority of GC-MS studies used principal 
component analysis (PCA) in their statistical analysis however approaches to data 
pre-processing, discriminatory analysis and cross-validation varied. Given the 
methodological heterogeneity and variety of compounds upon which breathomic 
models were based, meta-analysis was deemed inappropriate; instead a narrative 
synthesis of study findings is presented. 
 





Table 11 – Asthma breathomics: included studies and results 
Study Country Year Population Result 
Awano et al  
(173) 
Japan 2011 Asthma = 7 
Non-asthma = 386 
(both groups age range 60-65) 
Asthma and the presence of dimethyl sulphide > 1.0nmol L-1   in mouth air 
Crude OR 7.4 (95%CI 1.4-39.0); Adjusted OR 6.9 (95% CI 1.1-44.2) 
Brinkman et 
al (185)  
Netherlands 2017 Asthma (partly controlled, mild-
moderate) = 23 
Baseline vs loss of control: eNose classification accuracy - 95%, GC-MS 68% 
Loss of control vs recovery: eNose classification accuracy - 86%, GC-MS 77% 
Significant association between exhaled metabolites and sputum eosinophils: 
Pearson r>0.46, p<0.01 
Dragonieri 
et al (174) 
Netherlands 
 
2007 Asthma (mild-severe)  
= 20 
Controls = 20 
Asthma vs controls:  CVV 90-100%; M-distance 2.77-5.32. 
Mild vs severe asthma: CVV 65%; M-distance, 1.23. 
Dragonieri 
et al (184) 
Italy 2018 Asthma & allergic rhinitis (AAR): 
training set = 14; validation set = 7. 
Allergic rhinitis only (AR) and 
healthy controls (HC) as above 
Training set  
AAR vs AR: CVA=86%, p<0.01; AUROC 0.93  
AR vs HC: CVA=82%, p<0.01; AUROC 0.92 
AAR vs HC: CVA=75% ,p<0.05; AUROC 0.87  
Validation set 
AAR vs AR: CVA=83%, p<0.01; AUROC 0.92  
AR vs HC: CVA=77%, p<0.01; AUROC 0.87 
AAR vs HC: CVA=67 , p<0.05; AUROC 0.77 
Fens et al 
(175)  
Netherlands 2009 Asthma (mild-severe, persistent) = 
20 
COPD = 30 
Controls = 40 
Asthma vs COPD: accuracy 96%; p< 0.001 
Asthma vs controls: accuracy 93 – 95%; p< 0.001 
Fens et al 
(71)       
Netherlands 2011 Asthma (stable) = 60  
(21 w/ fixed airways) 
COPD = 40 
Asthma vs COPD: accuracy 83-88%; p<0.001 
AUROC 0.93-95 (95% CI 0.84–1.00); sensitivity 85-91%, specificity 90% 
Fixed asthma vs classic asthma: accuracy 58%; p=0.23; AUROC 0.68 (95% CI 0.50-
0.85); sensitivity 60%, specificity 67%. 






al  (70) 
UK 2011 Asthma (mild-moderate) = 35 
(sputum for phenotyping n=18) 
Controls = 23 
 
Asthma vs controls: accuracy = 86% (PPV 0.85, NPV 0.89) 
Sputum eosinophilia: AUROC 0.98 (95% CI = 0.91-1.00; sensitivity = 0.75, specificity 
= 0.90). 
Sputum neutrophilia: AUROC 0.90 (95% CI = 0.76-1.00; sensitivity = 0.80, specificity 
= 0.75). 
Uncontrolled asthma: AUROC 0.97 (95% CI = 0.93-1.00; sensitivity = 0.89, specificity 
= 0.88). 
Larstad et al 
(176) 
Sweden 2007 Asthma (stable) = 13 
Controls = 14 
Baseline isoprene lower in asthmatic subjects (113 ppb vs 143; p = 0.03) 
No significant difference in baseline ethane, pentane, or nitric oxide. 




2010 Asthma (stable) = 10 Reduction in airway calibre was not associated with an altered eNose breath profile 
Meyer et al 
(177) 
Switzerland 2014 Asthma (mixed severity) = 195 
Controls = 40 
Asthma vs controls: accuracy 99% (sensitivity 100%, specificity 91%) 
Inter-cluster or cluster vs control accuracy: 82% – 95% 
Linear discriminant analysis (LDA) for correct classification of all clusters and controls 
= 43%. 
Montuschi 
et al (178) 
Italy 2010 Asthma (mild, intermittent) = 27 
Controls = 24 
Asthma vs controls: diagnostic accuracy 88% 
 
Olopade et 
al (179)  
USA 1997 Asthma (acute exacerbation) = 12 
Stable asthma  = 11 
Controls = 17 
Significantly higher exhaled pentane levels during acute exacerbation (p < 0.05). No 
significant difference in exhaled pentane levels between stable/controlled asthma 
and healthy controls (p>0.05). 
Paredi et al 
(180) 
UK 2000 Asthma (steroid naive) = 14 
Asthma (steroid treated) = 12 
Controls = 14 
Ethane in untreated asthmatics > healthy controls or ICS treated asthma (p<0.05) 
In untreated asthma, exhaled ethane correlated with levels of nitric oxide exhalation 
(p<0.05); those with FEV1 <60% predicted had higher levels of ethane than those 
>60% (p<0.05). 
Plaza et al  
(186) 
Spain 2015 Asthma (persistent) = 52 Eosinophilic vs neutrophilic: accuracy 73%; P=0.008; AUROC 0.92 
Eosinophilic vs paucigranulocytic: accuracy 74%; p=0.004; AUROC 0.79 
Neutrophilic vs paucigranulocytic: accuracy 89%; P=0.001; AUROC 0.88 
Reynolds et 
al (188)  
UK 2014 Asthma & controls = 17 
 
Discriminant analysis of asthma vs controls not reported 










2013 Asthma (mild-moderate) = 25  
Controls = 20 
Asthma vs controls: AUROC 0.77 (95%CI = + 0.14;p = 0.002) 
Steroid responsiveness: AUROC = 0.88 (95% CI = + 0.16; p = 0.008) 
van der 
Schee et al 
(181) 
Europe 2013 Asthma (U-BIOPRED, severity not 
specified) = 10 
Controls = 10 
Asthma vs control:  
eNose AUROC = 0.77 (95% CI = 0.22), p = 0.050 




Australia 2012 Asthma (GINA step 1-3) = 20 
COPD = 17 
Controls = 7 
Asthma vs controls: eNose accuracy 70%, p=0.047 
Asthma vs COPD: eNose accuracy 70%, p=0.019 
de Vries et 
al (183) 
Netherlands 2015 Asthma (mild to severe) = 37 
Controls = 45 
COPD = 31 
Lung cancer = 31 
Asthma vs COPD: accuracy 81%, AUROC 0.81 (95%CI + 0.09), p=0.001 
Asthma vs controls: accuracy 87%, AUROC 0.94 (95%CI + 0.15), p<0.001 
Asthma vs lung cancer: accuracy 68%, AUROC 0.71 (95%CI + 0.09), p=0.045 
 
de Vries et 
al (187) 
Netherlands 2018 Asthma (mild to severe)= 278  
COPD = 157. 
Training set=321; validation set 
114. 
Training set 
Clusters differing in ethnicity (p=0.01); systemic eosinophilia (p=0.02); neutrophilia 
(p=0.03); BMI (p=0.04); FeNO (p<0.01), atopy (p<0.01); exacerbation rate (p<0.01). 
Regression models predictive of eosinophilia (R2=0.58); neutrophilia (R2=0.41)  
Validation set 








AUROC – area under the curve for receiver operator characteristics 
CVA – cross-validation accuracy 
CVV – cross-validation value 
LDA – linear discriminant analysis 
NPV – negative predictive value (percentage of true negatives)                                 
PPV – positive predictive value (percentage of true positives) 
SD – standard deviation 






Studies published only in abstract form were excluded due to the inability to fully assess inclusion criteria, study quality and risk of bias. 
However, the exclusion of such publications creates a vulnerability to selective dissemination bias; their results are summarised in table 12.  
Table 12 – Asthma breathomics: results from abstracts 




al (193)  
2014 Electronic noses capture severe asthma 





n = 77 
 
Significant between-cluster differences in 




2013 Unbiased cluster analysis of severe 
asthma based on metabolomics by the U-






n = 57 
p -values for between-cluster differences in 
clinical characteristics 0.001 – 0.02 
Brinkman et 
al (195) 
2015 Unbiased clustering of severe asthma 





Severe asthma n= 35 
 
p -values for between-cluster differences in 
clinical characteristics and eNose profiles 
p = 0.02-0.04 
Brinkman et 
al (196) 
2015 Exhaled breath volatile organic 
compounds can classify asthma patients 





n = 27 
Identifying sputum eosinophilia; 
AUROC 0.94  (95% CI, 0.85-1) 
Brinkman et 
al (197) 
2015 Longitudinal changes in exhaled breath 
GC/MS profiles during loss of asthma 







Subsequently published in full (185) 
(see table 1) 
Brinkman et 
al (198) 
2016 Identification of exhaled volatile organic 












2016 Identifying biomarkers of loss of 







2018 Exhaled volatile organic compounds as 
markers for medication use in asthma 





n = 108  
 
Identification of urinary oral 
corticosteroids (baseline, replication and 
validation) AUROCs 67 - 91; identification 
of urinary salbutamol AUROCs 70 – 82. 
Capuano et 
al (201) 
2012 Classification ability of two eletronic 




Severe asthma n = 10 
COPD n = 9 
Healthy controls n = 6 
Classification asthma vs COPD: 
Cyranose 320 = 92%, Ten2010 = 86% 
Classification disease vs controls: 
Cyranose 320 = 88%, Ten2010 = 88% 
Crespo et al 
(202)  
2013 Discrimination of bronchial inflammatory 
phenotype of asthmatic patients by using 




Asthma n = 44 
(eosinophilic = 16  
neutrophilic = 8  
paucigranulocytic = 20) 
Eosinophilic vs neutrophilic = 100% 
Eosinophilic vs paucigranulocytic = 100% 










An 'omics' study to investigate the 






Moderate atopic asthma = 
10 
Healthy control = 10 
Significant diurnal variability in 7 VOC 
including 2-undecanal (p=0.03) found in 
those with asthma but not controls. 
Fens et al 
(204) 
2011 Exhaled molecular patterns change after 




Mild intermittent n = 9 
Healthy controls = 14 
Before and after RV16 inoculation 
Significant change in principal components 
in asthmatics p=0.01 p=0.015. 
No change in controls 
Fens et al 
(205) 
2015 Volatile organic compounds (VOC) in 
exhaled breath of asthma patients differ 
between loss of control and stable phase 
American Thoracic 
Society Conference 




2013 An electronic nose can distinguish 




Eosinophilic = 9 
Non-eosinophilic = 11 
Controls = 10 
Eosinophilic vs non-eosinophilic p < 0.0001 
AUROC 1.0 (95% CI – 0.96 – 1.0); CVV 
59.1% 





Ibrahim et al 
(207) 
2010 Metabolomics of breath volatile organic 
compounds for the diagnosis and 





Subsequently published in full (70) 
(see table 11) 
Meyer et al 
(208) 
2012 Defining adult asthma endophenotypes 
by clinical features and patterns of 
volatile organic compounds in exhaled air 
European Academy 




Subsequently published in full (177)  
(see table 11) 
Montuschi 
et al (209) 
2010 Diagnostic performance of an electronic 
nose, fractional exhaled nitric oxide and 
lung function testing 
American Thoracic 
Society Conference 
Subsequently published in full (178) 
(see table 11) 
Pelit et al 
(210) 
2016 Breath print of severe allergic asthma 
with SPME-GC-MS analysis of exhaled air 




Severe allergic asthma = 27  
Healthy controls = 42 
 
Asthma vs controls: classification accuracy 
88.6% (sensitivity 95.6%, specificity 95.8%) 
Santini et al 
(211) 
2014 Discrimination between oral 
corticosteroid-treated and oral 
corticosteroid-non-treated severe asthma 





Severe asthma (adult) = 73 
OCS vs no OCS: accuracy 71% 
 
Santini et al 
(212) 
2015 Breathomics can differentiate between 






Severe = 39 
Omalizumab vs non-use 
eNose: accuracy 0.85 
GCMS: accuracy 0.83 
van der 
Schee et al 
(213) 
2012 Predicting steroid responsiveness in 




Subsequently published in full (73) 
(see table 11)  
Schleich et 
al (214) 
2015 Do volatile organic compounds (VOC) 
discriminate between eosinophilic and 




Asthma n= 276 
(eosinophilic = 122                 
neutrophilic = 50                                 
paucigranulocytic = 90) 
Identification of good discriminatory VOC 
reported.  
Identity of VOC and accuracy results not 
reported. 
de Vries et 
al (215) 
2016 Exhaled breath analysis for identifying 




Subsequently published in full (187) 
(see table 11) 





inflammation in a mixed population of 
patients with asthma or COPD 
De Vries et 
al (216) 
2017 Inflammatory phenotyping of chronic 
airway disease (including both Asthma 
and COPD) by breathomics 
American Thoracic 
Society 
Subsequently published in full (187) 
(see table 11) 
Wagener et 
al (217) 
2012 Exhaled air volatile organic compounds 






n = 36 
Mod-to-severe 
 
Correlation coefficients -  
VOC & sputum eosinophilia (>3%): 0.42-
0.47  
VOC & sputum eosinophilia (excl. 
participants on OCS): 0.49-0.62 
Wagener et 
al (218) 
2013 Exhaled breath profiling and eosinophilic 
airway inflammation in asthma – results 




N = 27 
(25 severe) 
Eosinophilic vs non-eosinophilic  
Accuracy = 85%. AUROC 99% (95% CI 0.97-
1.0). 
Zanella et al 
(219) 
2018 Breath print for asthma phenotyping ? n = 245 
 
Eosinophilic, neutrophilic, 
paucigranulocytic, mixed granulocytic. 
AUROC classification 0.68-0.71. 
 
Mixed age population (adolescents) 
Couto et al  
Abstract 
(190)  









Oxidative stress in asthmatic and non-
asthmatic adolescent swimmers - A 
breathomics approach 
Paediatric Allergy & 
Immunology 
 
Congress of the 
European Academy 
of Allergy and 
Clinical Immunology 
 No separate clustering of groups on PCA 
analysis 
Controls demonstrated a more varied 
response to exercise; exhibiting a more 
pronounced decrease in the studied 
metabolites post-exercise. 
 
It should be noted that nine of the abstracts and one full paper were produced from a single large European programme of study - U-BIOPRED. 
These all analysed cohort sub-groups; it is not clear whether the same patients might feature as cases in more than one of these publications.  
 





Table 13 – Research methods in asthma breathomic studies: breath sampling 


















al  (173) 
2011 Correlations between health 
status and OralChromaTM-
determined volatile sulfide 

















et al (185)  
2017 Exhaled Breath Profiles in the 
Monitoring of Loss of Control 
and Clinical Recovery in Asthma 
N 
 








et al (174) 
2007 An electronic nose in the 
discrimination of patients 
with asthma and controls 
Y Y Tedlar bag 
 




2018 Exhaled breath profiling by 
electronic nose enabled 
discrimination of allergic 
rhinitis and extrinsic asthma 
N Y Tedlar bag 
 
N Y Y eNose 
Fens et al 
(175)  
2009 Exhaled breath profiling 
enables discrimination of 
chronic obstructive 
pulmonary disease and 
asthma 
  Y Y  Tedlar bag N   Y X eNose 
Fens et al 
(71)       
2011 External validation of exhaled 
breath profiling using an 
electronic nose in the 
discrimination of asthma with 
fixed airways obstruction and 
chronic obstructive 
pulmonary disease. 
Y Y Tedlar bag N Y Y eNose 






al  (70) 
2011 Non-invasive phenotyping 
using exhaled volatile organic 
compounds in asthma 
N Y X Y Y X GC-MS 
Larstad et 
al (176) 
2007 Determination of ethan, 
pentane and isporene in 
exhaled air – effects of 
breath-holding, flow rate and 
purified air. 
Y Y Tedlar bag Y X X GC 
Lazar et al 
(192) 
2010 Electronic Nose Breathprints 
are independent of acute 
changes in airway caliber in 
asthma 
Y Y Tedlar bag N X X eNose 
Meyer et 
al (177) 
2014 Defining adult asthma 
endotypes by clinical features 
and patterns of volatile 
organic compounds in exhaled 
air. 
N N Tedlar bag Y X X GC-MS 
Montuschi 
et al (178) 
2010 Diagnostic performance of an 
electronic nose, fractional 
exhaled nitric oxide, and lung 
function testing in asthma. 






al (179)  
1997 Exhaled pentane levels in 
acute asthma 
 
Y N Tedlar bag N X X GC 
Paredi et al 
(180) 
2000 Elevation of Exhaled Ethane 
Concentration in Asthma 
Y N Tedlar bag N X X GC 
Plaza et al  
(186) 
2015 Inflammatory asthma 
phenotype discrimination 
using an electronic nose 
breath analyzer 
N Y Tedlar bag N Y X eNose 
Reynolds 
et al (188)  
2014 Analysis of human breath 
samples using a modified 
? Y ? Y X X TD-SESI-MS 










Schee et al 
(73)  
2013 Predicting steroid 
responsiveness in patients 
with asthma using exhaled 
breath profiling. Clinical And 
Experimental Allergy 
N Y Tedlar bag N Y X eNose 
van der 
Schee et al 
(181) 
2012 Effect of transportation and 
storage using sorbent tubes of 
exhaled breath samples on 
diagnostic accuracy of 
electronic nose analysis 






2012 Detection of gastro-
oesophageal reflux disease 
(GORD in patients with 
obstructive lung disease using 
exhaled breath profiling. 
N N Tedlar bag N Y X eNose 
de Vries et 
al (183) 
2015 Integration of electronic nose 
technology with spirometry: 
validation of a new approach 
for exhaled breath analysis 
Y N X N Y X eNose 
de Vries et 
al (187) 
2018 Clinical and inflammatory 
phenotyping by breathomics 
in chronic airway diseases 
irrespective of the diagnostic 
label 
Y N X N Y Y eNose 



































- 3 studies 
 
GC-MS / GC /  
TD-SESI-MS = 7 
eNose = 9 




GC-MS: Gas chromatography-mass spectrometry 

















Table 14 – Research methods in asthma breathomics studies: statistical analysis 





Validation of gas chromatograms. In-house Univariate analysis chi-square and ANOVA; multivariate logistic regression. 
Brinkman 
et al (185) 
De-noising, peak detection & alignment, using 
XCMS. PCA, BoxCox power transformation, 
normalisation. 
NIST Univariate analysis; ANCOVA and Pearson correlation tests; FDR correction and 
standardised QR decomposition used. Multivariate analysis by PCA. t-test. 
Dragonieri 
et al (174) 
Savitzky-Golay filtering & baseline correction NA 
 
PCA & double cross-validatory implementation of linear canonical discriminant 
analysis. Pattern recognition algorithm & cross-validation estimate of error made. 
Dragonieri 
et al (184) 
?  NA PCA, independent t-test, CDA, leave-one-out cross-validation, ROC-curve 
Fens et al 
(175) 




Linear canonical discriminant analysis & ROC. Cross-validation by leave one out 
method. Altman analysis with Bonferroni correction. Intra-class correlation 
coefficients.  
Fens et al 
(71) 
eNose sensor data reduced by PCA NA 
  






? Univariate logistic regression analysis, PCA, multivariate logistic regression. 
Discriminant function analysis with leave-one-out cross validation. 
Larstad et 
al (176) 
? In-house  Kruskal-wallis, Wilcoxon signed rank test. 
Lazar et al 
(192) 
Savitzky-Golay filtering and baseline correction, 
sensor data reduced by PCA 
NA 
 
Mixed model analysis, paired t-test.  
Meyer et 
al (177) 
Baseline correction, peak detection, normalisation 
of retention times, global normalisation. 
? Unsupervised hierarchical 2-step cluster analysis. Linear discriminant analysis. 
Montuschi 
et al (178) 
? ? eNose sensor data reduced by PCA. Feed-forward neural network. Unpaired t-test, 
Mann Whitney U test, Pearson coefficient. 
Olopade et 
al  (179) 
? ? Wilcoxon signed rank test. 
Paredi et 
al (180) 
? ? One-way ANOVA with Bonferroni correction. 





Plaza et al 
(186) 
? NA PCA, univariate ANOVA, post-hoc least significant difference test. Linear canonical 
discriminant analysis. Leave-one-out validation. AUROC. 
Reynolds 
et al (188) 
Noise reduction, normalisation ? Qualitative analysis of spectograms 
Van der 
Schee et al 
(73)  
eNose sensor data reduced by PCA 
 
NA Unpaired T-test, canonical discriminant analysis, cross validation by boot strapping. 
ROC and AUC. Pearson correlation coefficients. 
Van der 
Schee et al 
(181) 
Deconvolution, peak determination & peak 
alignment, background subtraction.  
NIST Principal component reduction, unpaired t-test, leave-one-out cross-validated linear 





 eNose sensor data reduced by PCA NA Canonical modelling. Cross-validation, interclass Mahalanobis distance.  
 
de Vries et 
al (183) 
Corrected for ambient VOC; normalized NA PCA, univariate ANOVA, internal validation by bootstrapping, linear canonical 
discriminant analysis, AUROC. 
De Vries et 
al (187) 
Corrected for ambient VOC (based on alveolar 
gradient), data normalised. 
NA PCA, unsupervised hierarchical clustering using Euclidean distance and ward linkage. 
Similarity profile analysis. 10x algorithm repetition upon sub-sets. Between-cluster 
comparisons by ANOVA, Kruskal-Wallis or Chi-squared tests. Validated using 
independent data set. Supervised analysis by multiple linear regression, Regression 
model validated using independent data set. 
 
 
  ? = not reported             ANOVA: analysis of variance 
  AUC: area under curve        AUROC: Area under a receiver operating characteristic curve 
  COW: Correlation optimized warping       GC x GCMS: 2 dimensional gas chromatography mass spectrometry 
  HP-SPME/GC-qMS: Headspace solid-phase extraction, gas chromatography quadrupole mass spectrometry MCCV – Monte Carlo Cross Validation      
  NIST: National Institute of Standards and Technology      PCA: Principal component analysis      
  PLSDA: partial least squares discriminant analysis      ROC: Receiver operator characteristics                                                     
  SPLS: sparse partial least square discriminant analysis      SPME: Solid phase microextraction                                      
  TD-SESI-ToFMS: thermal desorption / secondary electrospray ionisation / time-of-flight mass spectrometry TIC: Total Ion Chromatogram                                                   
  ToFMS: Time-of-flight mass spectrometry       WEKA: a suite of machine learning software / algorithms hosted by the University of Waika 





3.3.1 Quality assessment 
Twenty studies were published in full and their quality assessed using the Critical appraisal skills programme (CASP) checklist (see table 
15). 
Table 15 – Asthma breathomics: CASP quality assessment 


















standard?                                                                     
. 


























8. How sure are 
we about the 
results? 
Consequences 
and costs of 
alternatives 
performed? 















would be the 
impact of using 
this test on 




     
 
      
Brinkman 
(185) 




   
Dragonieri 
2007 (174) 
      
 
    
Dragonieri 
2018 (184) 
           
Fens 2009 
(175) 
       
 
   
Fens 2011 
(71) 
           
Ibrahim (70)          
   
Larstad 
(176) 
       
 
    







           
Meyer (177) 
 
           
Montuschi 
(178) 














































    
 




        
 
   
de Vries 
2015 (183) 
       
 
   
de Vries 
2018 (187) 






Note: CASP checklist question 10 “Can the test be applied to your patient or population of interest?” was omitted. This question refers to resource and opportunity costs for test implementation not 
appropriate to the field of research as it currently stands. Similarly, question 12 was answered in the negative due to the hypothesis-generating, proof-of-concept stage of the research.  





Examining predictive models for their diagnostic test accuracy in asthma, there is no 
single valid and reliable test against which the new diagnostic can be measured. In 
a recent study of patients with a primary care diagnosis of asthma (220) the diagnosis 
could not be supported in 33% of cases; furthermore this is not a novel finding (221-
223). The matter is further complicated by the heterogeneous nature of the disease; 
inflammation is not an essential component of the disease, thereby limiting the use 
of existing inflammatory biomarkers. Studies with diagnoses made by a physician or 
according to recognised clinical guidelines were included while accepting that, as a 
reference standard, this is likely to fall short of the assumed 100% accuracy. One 
study recruited from a severe asthma clinic with physician diagnosis inferred rather 
than explicitly stated (188).  
Studies of diagnostic test accuracy should ideally examine the population in which 
the test would be employed - those with a clinical suspicion of disease or diagnostic 
uncertainty. The majority of studies compared healthy controls against participants 
with an existing asthma diagnosis (and commonly receiving treatment); such results 
are likely to over-estimate diagnostic accuracy and might perhaps better be 
characterised as hypothesis-generating or proof-of concept studies. In the majority 
of studies it was not clear that a random or continuous sample of patients had been 
used; where there is selection of participants there is risk of inclusion bias leading to 
over-estimation of test accuracy.  
For those studies reporting on symptoms or loss of asthma control, the time between 
symptom reporting and VOC-sampling is important due to the potential for symptoms 
to vary; delay between the two could lead to inaccuracy or obfuscate a relationship. 
Timing in studies was frequently implied rather than explicitly stated. 
In the majority of studies it was not possible to say that index tests were conducted 
and interpreted without knowledge of the reference standard; blinding was rarely 
mentioned. Nonetheless the risk of bias is low; analytical methods such as gas 
chromatography-mass spectrometry, and statistical methods such as PCA are hard 
to corrupt. Some risk nevertheless exists as storage time and conditions prior to 
processing have the potential to influence outcomes; in addition statistical methods 
for discriminant analysis are prone to over-fitting and require validation 
Study participants were generally well described with the exception of body mass 
index (BMI) and ethnicity. BMI may affect markers of oxidative stress (224) and VOC 
(167, 187); and evidence exists of ethnic differences in both pulmonary function 
(225, 226) and breath profiles (187, 227).  





3.3.1.1 Technical validity  
 
Breath sampling 
There are two key methodological issues relating to sample collection a) that of how 
to best deal with ambient VOC; and b) how to collect and store samples prior to 
analysis. 
Ambient VOC 
A consensus method for dealing with ambient, environmental VOC has been outlined 
by European Respiratory Society (ERS) technical standards (228). This recommends 
1) parallel sampling of ambient air for background correction using alveolar 
concentration gradients, and 2) the use of VOC-filtered air. More detailed discussion 
of these issues can be found within the technical standards themselves (229). Of the 
included studies, ten measured ambient air VOC; the way these data were utilised 
varied. 
Exogenous VOC in breath can be minimised through the use of filtered air but inhaled 
VOC may be retained for some time and wash-out periods vary depending on the 
VOC in question. Wallace et al (230) estimate that some retention times may be as 
long as 3 days; and breathing synthetic air for 30 minutes was found to reduce but 
not eliminate ambient VOC (231). If VOC analysis is to be clinically useful the period 
of time for which filtered air is breathed prior to assessment needs to be practicable; 
complete elimination of the ‘exposome’ is unlikely. Furthermore, ambient VOC may 
be absorbed trans dermally. In the case of some semi-volatile or aerosolised 
compounds, dermal uptake may be up to four times higher than inhalation (232, 
233) however the relationship between dermally absorbed VOC and their exhalation 
is largely unstudied. Current recommendations offer a pragmatic rather than a 
perfect solution; 12 of the included studies used filtered air.   
Sampling methods 
Two main approaches have been taken to the collection of samples prior to analysis 
– 1) the use of impermeable bags, 2) the use of sorbent materials. 
Numerous studies have examined the properties of gas sampling bags (234-238). 
Beauchamp et al (237) summarise the drawbacks of this method which include 
material emissions, diffusion of VOC (into or out of the bag), adsorption effects, 
reactive chemistry and the production of artefacts. While VOC losses have been 
described as within acceptable levels (236, 237) this could nonetheless result in those 
VOC present at very low concentrations becoming undetectable; moreover the 
differential decay rates reported across VOC could change relative concentrations 
over time.  





Breath samples collected in impermeable bags can be concentrated using stainless 
steel tubes packed with adsorbent material. These may be stored (239, 240) before 
desorption and analysis; studies suggest storage at room temperature for 14 days or 
less results in acceptable sample retention (181). Direct sampling onto sorbents is 
also possible. In both cases a decision has to be made as to which adsorbent(s) to 
use. Tenax – a porous polymer - is used in many of the studies; its hydrophobicity is 
suited to humid breath samples and it can adsorb a wide range of VOC (241). Its 
ability to capture low mass VOC is however limited and compound breakthrough may 
be an issue. Dual-bed sorbents are an attempt to combat these issues while also 
limiting the quantity of water adsorbed. If a deductive approach is used - looking for 
specific compounds - the appropriate sorbent(s) need to be selected. For inductive 
approaches there must be recognition that sorbent selection limits the range of VOC 
collected; disease-related VOC permutations may go undetected if outside of this 
range. The stability of adsorbed samples is time and temperature dependant (242) ; 
of the six studies concentrating samples on sorbent tubes, two did not report the 
duration of storage, and three either did not report the temperature or stored 
samples at room temperature.  
In addition to the storage of samples there is also variation in the nature of the 
sample. The majority of included studies using Tedlar bags collected mixed expiratory 
air by way of single or multiple exhalations. However, if the lung metabolome is the 
exclusive target of investigation there will be sample contamination from the upper 
respiratory tract. The importance of breath fraction to asthma breathomics is yet to 
be established.  
Ibrahim et al (70) used a novel device with a facemask and pressure sensor to 
selectively sample air from the lower respiratory tract directly onto sorbent tubes. 
This approach has since been commercialised in a device from Owlstone (Cambridge, 
UK). Fifteen of the studies used a collapsible reservoir (Tedlar or Nalophan bag) while 
one used a syringe.  
Sample analysis  
A range of methods have been applied to the analysis of breath samples including 
various forms of mass spectrometry; some offline - such as gas chromatography-
mass spectrometry (GC-MS) - and others online - such as ion mobility spectrometry 
(IMS), proton transfer mass spectrometry (PTR-MS), selected ion flow tube mass 
spectrometry (SIFT-MS) and  field asymmetric ion mobility spectrometry (FAIMS). 
A full review of these methods may be found in Beale et al (241) and elsewhere. 
 





Due to its sensitivity and selectivity, GC-MS has become the standard method by 
which to characterise the human metabolome (243), including that detectable via 
the breath  (although alternatives such as FAIMS may be equally efficacious (244)). 
This approach has been complemented by the electronic nose (eNose); chemical 
cross-reactive sensor arrays (245) over which breath samples may be passed 
inducing detectable changes in the sensor material, thereby characterising the 
relative concentrations of VOC present (246). eNoses lack the ability of MS to identify 
VOC; thereby precluding their use for biomarker discovery but their ability to 
produce real-time data holds promise in point-of-care diagnostics. Of the studies in 
this review, nine used an eNose; seven mass spectrometry; and four a combination 
of the two.  
 
3.3.1.2 Statistical validity 
A range of statistical techniques may be used in the identification of disease-induced 
metabolomic permutations; these have been comprehensively reviewed elsewhere 
(164, 169, 241). Although strategies for avoiding false discoveries (247) and 
minimum reporting standards for data analysis in metabolomics (248) have been 
published, and applied to breathomics (228, 249) there is no standard statistical 
framework for analyses (250); the ERS technical standards are not prescriptive in 
this respect. As shown in table 14, approaches to data processing and pre-processing 
varied, both in the techniques used and the extent to which they were reported.  
The majority of papers undertook inductive / untargeted analyses in which there was 
no a priori identification of compounds. Such analyses when applied to large data 
sets are prone to over-fitting and the resultant VOC models require validation; 
without this the performance of the model cannot purport to be accurate. Internal 
cross-validation is one of the methods commonly applied however the rigour this 
imparts may be limited by the small sample size of many of the included studies. Ten 
studies describe undertaking some form of internal validation such as leave one out 
cross-validation or boot strapping; only three studies used an external validation set 
(71, 184, 187). 
Five studies (173, 176, 179-181) conducted targeted analyses based on compounds 
previous identified as associated with asthma or inflammation; a deductive approach 
not associated with the aforementioned statistical challenges. Although these findings 
provide support for the utility of certain VOC in asthma breathomics, they were not 
an attempt to provide external validation to any one specific model.  





Furthermore, although Awano et al (173) specified compounds of interest a priori, 
their relationship with clinical variables (including asthma) was examined by way of 
post-hoc analyses and vulnerable to the risk of false discovery.  
In studies other than those using an eNose, compound identification is possible. 
There are a number of databases which may be used including the Pacific Northwest 
National Laboratory (PNNL), the National Institute for Standards and Technology 
(NIST), Metlin, or in-house custom libraries constructed using reference standards. 
The extent to which use of different libraries might limit comparability is unclear; 
however, Sharpe et al (251) compared PNNL with NIST and reported that for all but 
one of the 12 compounds they compared, there was agreement between databases 
to within the level of experimental uncertainty. Few papers reported the libraries used 
for compound identification and none the match-percentages for compound 
identification. The chemical analysis working group metabolomics standards initiative 
(MSI) published proposed minimum reporting standards which include both data pre-
processing and metabolite identification (252). Implementation of such reporting 
standards would allow identification of studies at risk of spurious candidate marker 
identification.  
3.3.1.3 Clinical validity 
Two potential confounders were common across studies – medication and study 
location. Participants with asthma were frequently taking medication such as inhaled 
corticosteroids (ICS) or β2-agonists which healthy controls were not; any observed 
between-group difference in exhaled VOC might be due to medication metabolites 
rather than disease-related changes in biochemical pathways. The extent to which 
this was addressed in studies varied, likely due to the emergent nature of this field 
of research and the inclusion of small-scale, proof-of-concept studies. Evidence 
regarding the extent to which medication might act as a confounder is unclear (73, 
174, 205, 224) but exhaled VOC have been reported to be capable of identifying 
those asthma patients in which oral corticosteroid and salbutamol urinary metabolites 
were present (200).  
The second potential confounder was background bias. In many studies the site of 
recruitment differed between controls and those with asthma but it was unclear 
where breath sampling took place. de Vries et al (183) report no significant difference 
between samples from different medical sites (p=0.89); however the ambient VOC 
profile of hospitals may differ greatly from other locations (253) and a systematic 
difference in location could be the cause of sample differentiation, rather than disease 
metabolites.  





The application of background air subtraction and use of filtered air constitute an 
attempt to negate this but as discussed in section 3.1.2.1 there are limitations.  Other 
potential confounders such as smoking history, age, and gender (224) were not 
always well matched between groups. Asthma severity was frequently stated but 
where it was not, medication-use was rarely reported with sufficient detail to make 
an assessment of severity. Many studies contained a mixture of asthma severities; 
and while spirometry results were commonly presented measures of asthma control 
were not. 
3.3.2 Qualitative synthesis 
3.3.2.1 Asthma Diagnosis   
The ability of breathomics to differentiate between those with asthma and healthy 
controls was examined by 15 studies. These models reported moderate-to-excellent 
discriminative ability, citing CVVs of 90-100% (174), classification accuracies of 
86%(70) to 99%(177), and AUROCs of between 0.70 (182) and 0.94 (183). It should 
be emphasised that these accuracy rates are based on populations with diagnosed 
disease; the studies were examining the difference in VOC profiles between healthy 
controls and those with established, treated, and frequently long-standing asthma. 
The diagnostic performance of VOC models in a real clinical population with 
undiagnosed, untreated respiratory symptoms of relatively recent onset may be very 
different.  
In many studies the risk of sampling bias was unclear; and in some studies there was 
a risk of confounding, for example large differences in the average age of groups (73, 
183). While studies with physician diagnosed asthma were included, the standard to 
which this was reported and conducted varied between studies. It is also worth noting 
that several studies used populations of mixed asthma severity; it is unlikely that 
breathomic models would be applied homogenously across such a population. 
Five studies conducted a targeted analysis of compounds. In the case of pentane, 
Olopade et al (179) report significantly higher levels during acute asthma attack but 
both Olopade and Larstad et al (176) report no significant difference between 
controlled-asthma and healthy controls. Paredi et al (180) report significantly higher 
levels of ethane in untreated asthma compared with treated disease or healthy 
controls. They do not comment on treated-asthma versus healthy controls but 
Larstad et al (176) found no significant difference (in ethane levels) between a largely 
steroid-treated controlled asthma group and healthy controls.  Larstad et al do 
however report a significantly lower level of isoprene in those with asthma.  





Awano et al cite an adjusted odds ratio of 6.9 (95% CI 1.1-44.2; p<0.05) for asthma 
in the presence of dimethyl sulphide; while van der Schee report AUCs of 0.79-0.84 
(p<0.05) for the differentiation of asthma from controls using a five-compound 
model.  
Ten studies performed untargeted analyses producing diagnostic models for the 
differentiation of asthma from healthy controls. Fewer studies aimed to differentiate 
between asthma and other respiratory diseases; four examined COPD and asthma 
reporting classification accuracies of between 70% and 96% (71, 175, 182, 183); 
one  differentiated between asthma and allergic rhinitis reporting an AUROC of 93% 
(184); while another examined lung cancer and asthma, reporting a classification 
accuracy 68% (183). In all but the allergic rhinitis study there was a large difference 
in average age between the asthma and the other respiratory disease group. 
3.3.2.2 Asthma Phenotypes   
Eight studies examined asthma phenotypes including sputum cell type, steroid 
responsiveness, disease severity and airway reversibility. 
Both Plaza et al (186) and Ibrahim et al (70) constructed models differentiating 
between eosinophilic, neutrophilic and paucigranulocytic phenotypes, with 
classification accuracies of 73% to 74% (186), and AUROCs of 0.79 (186) to 0.98 
(70). Differentiation was likely not due to differences in ICS use (which were similar 
between groups in Plaza et al), but it was not reported whether there were other 
systematic between-group differences in treatment regime. Brinkman et al report 
two VOC significantly correlated with sputum eosinophilia (correlation coefficients of 
r>0.46 & 0.47 (P<0.01)) but did not find any such correlations for sputum 
neutrophilia (185). 
de Vries et al (187) examined a combined asthma and COPD population in a large 
multi-centre study. They identified clusters differing in eosinophilia (p=0.02), 
neutrophilia (p=0.03), atopy (p<0.01) and exacerbation rate (p<0.01). Further 
clusters based on ethnicity (p=0.01) and exhaled nitric oxide (p<0.01) were 
identified.  
Van der Schee et al (73) examined eNose results for the prediction of steroid 
responsiveness, reporting an AUROC of 0.88 and greater accuracy than either sputum 
eosinophil count or FeNO. For the differentiation of mild from severe asthma 
Dragoneiri et al (174) report a CVV of only 65% (M-distance, 1.23). Similarly Fens 
et al (71) report an accuracy of just 58% (AUROC 0.68) for the differentiation of fixed 
and classic asthma.  





Meyer et al conducted a cluster analysis of both VOC data and clinical parameters. 
While VOC profiles were able to differentiate between some clinical clusters with good 
levels of accuracy, they also reported distinct clinical clusters with similar VOC 
profiles, and distinct VOC clusters with similar clinical characteristics.  
3.3.2.3 Loss of asthma control 
Four of the included studies examined some aspect of asthma control. Brinkman et 
al (185) conducted a prospective medication-withdrawal study. Classification 
accuracy for baseline versus loss of control - as measured by the asthma control 
questionnaire (ACQ) - was 95% using an eNose and 68% by GC-MS; loss of control 
versus recovery was 86% (eNose) and 77% (GC-MS). Ibrahim et al (70) using GC-
MS report an AUROC of 0.96 for the identification of loss of control; and Olopade et 
al (179) report significantly higher levels of pentane during exacerbation compared 
to recovery. It is unlikely that the observed differences in breath profiles are due to 
changes in airway calibre - Lazar et al (192) undertook bronchial challenge testing 
on participants with stable asthma and reported no changes associated with 
bronchoconstriction. 
3.3.2.4 Discriminant compounds 
Nine of the included studies report on compound identities (presented in table 16). A 
total of 76 compounds were cited as significant. Of these, nine were reported in more 
than one paper - 2,4-dimethylheptane; 2,6,10-trimethyldodecane; 2,6,11-
trimethyldodecane; acetone; benzene; ethane; isoprene; phenol; and toluene - and 
two – acetone and isoprene - were reported by three studies. The models constructed 
by any given study were thus comprised of compounds largely or entirely absent 
from the models presented by other studies. Moreover, it was not always clear in 
which direction the compounds differed. In the case of isoprene, Dallinga et al and 
van der Schee (174, 181) found it to be elevated in asthma, while Larstad et al (176) 
report it to be lowered. Despite the lack of concordance between studies, where 
attempts have been made to validate previous models the results have been positive. 
van der Schee (181) used five compounds previously linked to asthma (acetone, 
isoprene, carbon disulphide, toluene and 1-propanol) and report an AUC of 0.79-0.84 
(p<0.05). Where compounds have not been identified but validation has been 
undertaken results have been similarly positive. Fens et al (71) report a phenotyping 
accuracy of 83-88% in an external validation exercise; Montuschi et al validated their 
data in a distinct test set, reporting a diagnostic accuracy of 87.5%; de Vries et al 
(187) found the majority of clusters identified in their training set to be confirmed in 
an independent validation set; and Dragonieri (184) report diagnostic AUCs of 77- 
92% in an external validation exercise.   





Table 16 – Asthma breathomics: volatile organic compounds identified 
Study Discriminant compounds 
identified 
Compound type Direction of difference 
in asthma group          
(if appropriate) 
Differentiated groups Differences between 
case and control 
groups 
Awano et al 
(173) 
Dimethyl sulphide  Sulfur and nitrogen 
compounds 
+ Asthma vs non-asthma Not reported 
Brinkman et 
al (185) 
Acetonitrile   
Methanol  
Bicyclo[2.2.2]octan-1-ol.4-methyl  

























Acetic acid  
























Asthma vs controls Attempts to match 
age and gender and 
disease severity. 
Differences in FEV1 % 
predicted and FVC % 
predicted. 
Ibrahim et al 
(70) 
2,6,10-trimethyldodecane  
2,6,11-trimethyldodecane   
Benzyl alcohol  
3,4-Dihydroxybenzonitrile  
2-methyldecane   
1-methyl-4-(1-
methylethylidene)cyclohexene   
Butanoic acid,2,2-dimethyl-3-oxo-









Acids & esters 
 
Ketone 
+                                             
+   








Asthma vs controls 
 
Closely matched in 
age, gender, and BMI.  
Differences in FEV1, 
FVC & and FEV1/FVC. 





Allyl methyl sulphide  
 
4-nitroso ethylester benzoic ac  
2-butyl-cyclohexanol   
5,5-Dibutylnonane   




Sulfur and nitrogen 
 
















Camphene   
1,1-Dimethylpropyl 2-
Ethylhexanoate   
2,6,10-trimethyldodecane   
7a-Isopropenyl-4,5-
dimethyloctahydroinden-4-yl) 




Cyclohexene-4-methylene   
Terpenoids 





















Eosinophilic vs non-eosinophilic Closely matched in 
age. Differences in 
FEV1 % predicted, FVC 
% predicted, and in 
FEV1/FVC 
Cyclopentene,1,3-dimethyl-2-(1-
methylethyl)   
2,7-dimethyl naphthalene   
3,5-dimethyl Cyclohexanol  

















Differences in age, 
FEV1 % predicted and 
FEV1/FVC 
Benzene   
Pentadecane, 1-methoxy-13-
methyl   
Heptanoic ac   
Bicyclo[3.1.0]hex-2-ene, 4-













Control vs loss of control Differences in age, 
FEV1 % predicted, FVC 
% predicted, and in 
FEV1/FVC. 






methyl/butanal, 2-methyl  
















Larstad et al 
(176) 






Asthma vs controls Differences in gender, 
weight, FEV1 % 
predicted and FVC % 
predicted. 
Meyer et al 
(177) 




1,3-dione, 4-phenyl-  
Dodecane  
Phenol   
Quinoline decahydro-  
2-Propionyloxypentadecane  




5-hexenoic acid  
Alcohol 
Aromatic 
Acids & esters 




Sulfur & nitrogen 
Acids & esters 



















Asthma vs controls Not reported 
Olopade et al  
(179) 
Pentane  Alkane + 
 
Controlled vs loss of control 
(acute) 
NA – longitudinal 
study 
Paredi et al 
(180) 
Ethane Alkane + 
(in untreated asthma) 
Steroid treated vs non-steroid 
treated & healthy controls 
Closely matched in 
age. 
Differences in gender, 
FEV1 % predicted and 
RV/TLC % predicted 





van der Schee 
et al (181) 
Acetone    
Isoprene       
Carbon disulphide    












Asthma vs controls 
 
Differences in age, 



















Not reported Control vs loss of 
control  
NA – longitudinal study 
Brinkman 
et al (198) 
Pantolactone,5                                   
Methylacetate,32                                
Methylcyclohexane,22                        
Cyclohexane-D12,50                     
Pinene,22                                       
Eucalyptol,74                          
furan 2-methyl,70              
Isopropyl alcohol              
Acids & esters 


















et al (203) 
2-Undecanal Aldehyde Diurnal variation in asthma which is not present 
in healthy controls 
Closely matched in age.  
Difference in FEV1  
Mixed age group 
Couto et al 
(190, 254).  
Nonane   
2,2,4,6,6-pentamethylheptane      
Decane,     
Dodecane 
Tetradecane 











 Asthmatic vs non-
asthmatic adolescent 
swimmers.  
No significant differences 
reported. 





The majority of abstracts did not publish details on compounds of interest, only 
Brinkman et al (76), Couto et al (38), Durrington et al (203) & Fens et al (73). The 
abstract by Fens et al was not subsequently published in full. The study by Couto et 
al was, however they included study participants under the age of 18. They report 
that samples from asthma and healthy controls could not be separated based on 
distinct metabolites. Brinkman et al present a list of compounds found to correlate 
with clinical variables; this was a univariate analysis without the more sophisticated 
methods such as Bonferonni correction which would normally be applied to a large 
dataset; moreover the validity of compound identification is hard to determine. While 
the compounds of interest for these four abstracts are presented it is not possible to 
assess study quality, risk of bias, and full methodology. 
 
3.4 Paediatric asthma 
 
A review of the paediatric asthma breathomic literature was published by Neerincx 
et al (159) in 2017. The results were encouraging, suggesting good predictive 
accuracy for VOC profiles in asthma diagnosis. However, the authors reported on only 
those studies which they were aware of and limit their scope to the last 10 years. 
Given that the first study of an exhaled VOC in asthma may well have been Olopade 
et al in 1997 (179) it is possible that studies may have been omitted leaving the 
review potentially vulnerable to bias. The results of the literature search used for this 
chapter was screened for paediatric studies (these searches had been conducted with 
no date limits). 
The number of references to paediatric asthma breathomic studies was 17. Six were 
abstracts, of which three were not published in full elsewhere (255-257); two 
presented identical data - early findings from a study by the review authors which is 
yet to be published (258, 259); and one has since been published in full (260). The 
list of full studies identified by this search was similar but not identical to that of 
Neerincx et al. Neerincx et al included two papers (261, 262) examining pre-school 
wheeze (not asthma) but excluded a paper published more than 10 years ago (263); 
this was a longitudinal study of asthmatic children living in a high pollution area 
(n=26). This study reported largely non-significant results, with the exception of 
exhaled benzene which exhibited a moderate positive association with bothersome / 
severe asthma symptoms. The study was limited by the small number of breath 
samples obtained on symptom-free days (n=6).  
An absence of significant findings is of course one reason why abstracts might not 
progress to full publication.  





While there are good reasons for excluding abstracts from a review – including the 
inability to assess the quality of studies and risk of bias – this does have the potential 
to give an unbalanced viewpoint; one which emphasises positive associations and 
downplays null findings. Of the abstracts not subsequently published in full - 
Gahleitner et al (256) did not report any results; while Brinkman et al (255) report a 
cluster analysis which identified groups that differed significantly in clinical 
parameters. Wang et al (257) found a correlation with night waking but not with 
asthma control test scores; whereas Vijverberg et al (258, 259) reported an area 
under the curve of between 0.71 and 0.97 for the identification of disease control. 
It would seem then that the review by Neerincx et al (159) succeeded in capturing 
the majority of relevant literature; the additionally identified study adds little to their 
findings. The abstracts identified by this search present results largely relating to the 
ability of VOC to differentiate between states of disease control, the results of which 
were conflicting. Overall little was found to either challenge or expand the findings of 
their review. 
3.5 Discussion  
 
The accuracy of classification achieved by breathomic models suggests VOC-profiling 
in exhaled breath has potential for use in asthma diagnosis and management. The 
ability to discriminate between those with asthma and healthy controls has been 
consistently demonstrated but, to be of clinical use, these findings need to be 
validated in independent prospective cohort-studies undertaken in populations with 
only a clinical suspicion of asthma; this would enable the determination of diagnostic 
test accuracy. Given the high incidence of asthma misdiagnosis, development of such 
a test could be clinically significant and of benefit in the presence of diagnostic 
uncertainty.  
Sputum eosinophil count has long been considered the definitive method for 
assessing lung inflammation, and when used to guide treatment has been shown to 
improve asthma outcomes (264). However, FeNO has been found to predict steroid 
responsiveness (265) and has now been integrated into national asthma guidelines 
for both management and diagnosis (266, 267).  
The ease of use and rapidity of results with FeNO measuring devices has led to more 
widespread clinical uptake than that achieved by sputum eosinophil count.  
 





However, VOC profiling has the potential for wider application than either including 
the identification of alternative sputum profiles (such as neutrophilic or 
paucigranulocytic); monitoring of control in non-eosinophilic phenotypes; 
identification of treatable traits; and the differentiation of transient pre-school 
wheeze and asthma.  
A clinically-meaningful threshold has been determined for both sputum eosinophilia 
and FeNO and the reproducibility of measurements established. This is not yet the 
case for breathomic models. While VOC-measurements within-individuals may be 
reproducible and breath profiling may display good levels of accuracy, relatively few 
results have been replicated or externally validated. It is important to note that, in a 
heterogeneous disease such as asthma, findings based upon asthma populations 
defined by one ‘gold standard’ (such as sputum eosinophils) will not be accurately 
validated in a population based on an alternative diagnostic standard (e.g. physician 
diagnosed asthma) which may be composed of other or multiple phenotypes.  
 
The inter-study variability reported in this review may in part be due to instrument 
variability. Between-laboratory comparisons for GC-MS data can be challenging due 
to the dynamic nature of the measuring equipment. However, this may be improved 
through the implementation of the MSI reporting standards coupled with comparative 
analysis of laboratory data quality. eNoses have demonstrated variability, both 
between manufacturers (258) and between devices of the same model (268), and 
sensor ‘drift’ can be difficult to detect. This may be, to some extent, a self-limiting 
problem; as potential markers are identified, study methodology may shift from 
inductive to deductive. With targeted studies it is possible to address calibration 
issues from the outset giving increased confidence in results. 
Causes of inter-study variability do not lie exclusively with the instrumentation; 
metabolomics involves substantial inter-subject variation (241). This is not 
necessarily simply a result of comparing different asthma severities or phenotypes. 
A number of variables may have an effect on VOC profiles including the exposome 
(269), respiratory rate (270) and breathing route (271). In a study of healthy 
volunteers Philips et al (272) report the mean number of VOC per breath sample to 
be <350 but the number of different compounds across their studies as a whole to 
be >3,400. Moreover, of the total compounds identified in their study only 27 were 
found in the samples of all participants. However, both Fens (175) and de Vries et al 
(183) report a high correlation coefficient for within-day repeatability and between-
day repeatability for participants.  





It would seem then that breath prints are relatively stable within- but vary 
considerably between-individuals (229). Sterk argues that while complicating the 
independent validation of results this variation offers hope in terms of individual 
phenotyping (273) including the identification of treatable traits and implementation 
of personalized medicine.  
 
Recent work in other diseases has shown that diet and lifestyle are important 
confounders in breath VOC analysis (274). While this may apply to many of the 
smaller studies included within this review, with sufficiently large patient cohorts this 
may not be the case. In a study of 494 participants, variables thought to be highly 
confounding – including age and smoking - appeared not to effect the ability of a 
diagnostic model to distinguish gastric cancer from healthy controls (275).  
 
In common with other emergent fields of study (113) there is a conflict between 
innovation and standardisation. Due to its potential for both inductive and deductive 
approaches, and for both offline and online analysis, breathomics is likely to remain 
more heterogeneous in its methodology than some other fields. However, the arrival 
of technical standards for exhaled biomarkers (228), minimum reporting standards 
(252) and CE-marked, production-line breath capture devices, goes a long way 
towards addressing some of the potential sources of confounding and variation. 
Despite the publication of such standards there is still considerable leeway in how 
samples may be processed and analysed; these decisions are crucial given that the 
clinical relevance and wider acceptance of results hinges on the correct selection and 
application of these techniques. The quality of analysis amongst the included papers 
is inconsistent and hampered by the low numbers of participants in many of the early 
studies. Internal validation of results does seem however to be becoming the norm, 
and as participant cohorts continue to grow the risk of overfitting diagnostic models 
will further reduce. Whilst the determination of which features within a dataset should 
be included in diagnostic models has improved, compound identification remains 
relatively poor with few of the studies checking the putative identifications against 
chemical standards. Better identification will allow the biological origins of exhaled 
VOC to be determined; the first step in linking breathomics to other ‘omics in a 












Breathomics is well suited to the age of personalised medicine; the large data sets 
typically produced are highly individualised and reflect a multitude of metabolomic 
pathways; a feature which is particularly attractive for the study of complex 
heterogeneous diseases such as asthma.  
The potential exists not only for diagnostics, phenotyping and the identification of 
treatable traits but – when coupled with other ‘omics – the linking of phenotypes to 
endotypes. Results to-date are promising but validation in independent prospective 
cohorts is needed; this may be challenging given the high levels of inter-individual 
variation. However, addressing inter-study variation through the identification of 
important confounders, increasing study size, and methodological and analytical 
standardisation will facilitate these efforts. Identification of a limited number of 
compounds with strong discriminative ability may decrease processing time and aid 
the development of point of care testing; crucial if breathomics is to make the leap 
into clinical application.  
Chapter two presented a synthesis of the literature on exhaled breath condensate 
and a single potential asthma biomarker – 8-isoprostane. This chapter (chapter 
three) presented the literature on exhaled breath gases in asthma; an approach 
capable of capturing data on multiple potential biomarkers. Subsequent chapters 
present the methods used in the two studies of exhaled breath biomarkers in asthma 
which comprise this thesis (chapter five); and their results (chapters six and 
seven). The next chapter (chapter four) outlines work conducted in the 









Chapter 4 – Developing Methods: exhaled breath 
sampling and assessing patient acceptability 
 
4.1 Introduction 
In the first chapter, the heterogeneity of asthma was described and the need for 
clinically applicable biomarkers was outlined. Chapters two and three reviewed the 
literature regarding two methods of breath analysis – EBC and exhaled VOC - and 
their application to asthma. Later chapters presents the findings of two studies using 
these methods:  
 Exhaled breath biomarkers in acute asthma: a feasibility study (chapter six).  
 Bronchial Challenge Testing in Asthma (chapter seven).  
This chapter provides a background to the methods used in capturing and processing 
breath samples and the development of a questionnaire used to assess these 
methods.  
4.2 Exhaled breath condensate and 8-isoprostane 
4.2.1 Background 
Oxidative stress is thought to play an important role in the pathogenesis of asthma 
(76) and markers of oxidative stress can be found in both exhaled breath gas and 
EBC condensate. Amongst the many markers of oxidative stress 8-isoprostane has 
the advantage of being relatively stable and suitable for batch analysis. Studies have 
reported it to be higher in asthmatics than non-asthmatics (80-82); able to predict 
asthma severity (84); and responsive to treatment with corticosteroid therapy (86, 
87). The results of the review presented in chapter 2 suggest that although 8-
isoprostane has potential as a biomarker (in that it may be capable of both indicating 
an abnormal process and its response to treatment) further studies need to be 
undertaken to establish this. Of particular interest was the number of authors who 
reported an inability to measure 8-isoprostane in the majority of their samples. 
4.2.2. Exhaled breath condensate study methods 
Exhaled breath condensate sampling was conducted in accordance with ERS 
guidelines (228) using the RTube from Respiratory Research (Texas, USA)(see figure 
8). This is a single use device with a one way valve which meets guideline 
recommendations. It works by forcing exhaled breath through a tube which is cooled 
through the application of a chilled metal sleeve.  





As breath travels through the tube exhalate condenses on the cooled surface. The 
metal cooling sleeve was stored in a -80oC freezer and removed immediately prior to 
use.  
Figure 8 – The RTube: stock image of the device in use (withour noseclips).  
                        
Participants were asked to wear nose clips and - using tidal breathing - breathe 
through the RTube for a period of ten minutes. Respiratory rate, time taken to collect 
sample and volume of condensate collected were recorded; it was not possible to 
record volume of breath exhaled as recommended by guidelines. Time from sampling 
to freezing was recorded; samples were frozen in a -80 freezer. Time-to-freezer and 
duration of storage prior to analysis may be important depending on the stability of 
the biomarker in question.  
4.2.3. Methodological Issues 
As alluded to in chapter 2 there are as yet unresolved methodological issues with the 
measurement of biomarkers in EBC and with 8-isoprostane specifically.  
Ashnish Sinha – a student (Masters in Research) at the UEA - conducted a study in 
which he recruited patients with idiopathic pulmonary fibrosis and obtained two EBC 
samples of approximately 500-1,000µL from each participant. The researcher 
assisted in sample collection and together with members of the Norwich Medical 
School (Isabelle Piec and Jonathan Tang) a protocol was developed for the processing 
and analysis of samples. EBC was pipetted into eppendorfs containing a 0.005% 
solution of BHT in ethanol, an antioxidant to prevent further in-vitro formation of 8-
isoprostane.  Samples were frozen within 5 minutes of acquisition and assayed within 
3 months of collection using an express ELISA kit from Cayman Chemicals to measure 
8-isoprostane.  





Of 49 samples only four had detectable 8-isoprostane levels, of which only two were 
above the lower limit of detection (10 pg/ml); none were above the lower limit of 
quantification (30pg/ml).  The remaining EBC sample volume (that which was not 
used in the ELISA) was frozen to -80oC. 
Effros et al (276, 277) published a methodology – since used in several studies (278-
281) - to concentrate EBC samples through lyophilisation and calculate the relative 
concentration of water and airway lining fluid (ALF) within EBC samples by measuring 
conductivity. Effros et al suggest that, in the absence of any significant kidney 
dysfunction, respiratory secretions have the same osmolarity as plasma. Total ionic 
content as indicated by sample conductivity of EBC cannot be used to indicate how 
much of the sample volume is ionic-ALF and how much is water due to the presence 
of ammonia from the upper airways. Lyophilisation has the effect of removing 
ammonia thereby making this calculation possible. Using an average figure for 
plasma osmolarity in the healthy individual, sample conductivity can thus be used to 
calculate dilution rates.  
This methodology was applied to the collected samples. First the conductivity of 
reverse osmosis (RO) water (produced ‘in house’ at the UEA biomedical facility) and 
high performance liquid chromatography (HPLC) water (deionised water 
commercially available from Fisher Chemical, UK) were tested. Both returned results 
of < 2 µS; RO water was used for all following steps. 
Using a VirTis Wizard 2.0 (Genevac, UK) samples were lyophilised to 80 millitorr at 
minus 80oC over a period of approximately 24 hours and returned to storage at minus 
80oC. Lyophilised samples were then defrosted and reconstituted in 200µL of reverse 
osmosis water (within 6 months of original sample collection). Due to the variety in 
the pre-lyophilisation volumes, reconstitution to a set volume of 200µl resulted in 
varying degrees of sample concentration. The concentration factor was calculated by 
dividing the post-ELISA, pre-lyophilisation sample weight by 200. 
The reconstituted samples were placed in a heater and maintained within 1o of 25oC. 
A Jenway conductivity meter and micro-conductivity probe calibrated to a lower limit 
of 150µL of fluid volume was used to measure sample conductivity. The conductivity 
reading was corrected by the degree to which the sample had been concentrated.  
Based on a molecular weight of 58.44g/mol, 438mg of NaCl in 50mL of RO water was 
used in order to produce a 150mmol/L solution of NaCl. Serial dilutions of this solution 
were used to produce a conductivity-concentration calibration curve.  In constructing 
the calibration curve, the conductivity of solutions was measured in eppendorfs using 
a volume of 400µL. Eppendorfs containing the solution were then weighed and frozen.  





The intention was to lyophilise these, reconstitute them in 200µL of RO water and 
measure their conductivity in order to assess the validity of conductivity measures in 
lyophilised and concentrated samples.  
After testing the conductivity of reconstituted EBC samples, an overnight Cayman 
Chemicals ELISA with an 18 hour incubation period and detection limit of 2.7pg/ml 
was used to measure 8-isoprostane. It was hoped that concentrating the samples 
would raise 8-isoprostane away from the lower limit of detection thereby improving 
the reliability of the results; however despite these measures 8-isoprostane was 
universally undetectable.  
Development of a liquid chromatography mass spectrometry method was posited. 
The conductivity measurement undertaken on the first aliquot of EBC would have 
allowed the approximate ratio of ALF to water within sample to be calculated. 
However, there was insufficient sample remaining to both set up and develop the LC-
MS analysis of EBC 8-isoprostane and reserve sufficient volume for lyophilisation and 
conductivity testing. 
Alternative methods of dilution calculation have been suggested. Plasma proteins are 
reported to be present in airway lining fluid in proportion to those levels in the serum. 
One simpler method of EBC dilution is to measure serum albumin or total protein 
within serum and compare this to the levels present in EBC. Unfortunately 
contemporaneous phlebotomy had not been conducted and so this option was not 
available; however this should be a consideration in future studies. 
4.3 Volatile organic compounds  
4.3.1 Assessing contaminants – VOC within the medical gas supply system 
The ReCIVA (Owlstone, Cambridge, UK) was used to collect VOC samples (282)(see 
figure 9). This is a CE-marked device connected to a laptop computer; a single use 
mask with integral bacterial filter is used and it requires minimum patient effort 
(normal tidal breathing). 





Figure 9 – The ReCIVA: stock image of the device. When in use the device would be 
connected via tubing to an air supply and attached to the participant using adjustable 
straps. 
                                     
Air needs to be supplied at approximately 40 litres a minute to drive the device; less 
than this and the patient may experience resistance when breathing. Initially it was 
planned to use the hospital’s medical air supply in conjunction with a high-rate 
flowmeter to achieve this. At the time of writing the study protocol the ERS technical 
standards for conducting exhaled breath studies (228) had not been published.  As 
discussed in chapter 3 supplying patients with air contaminated with VOC might 
impact upon results; particularly if the contaminants present - and their 
concentration levels - vary. Background levels of contaminants might be taken into 
account by obtaining a sample of the gas supply contemporaneous with patient 
sampling; contaminants might then be accounted for by way of an alveolar 
concentration gradient; an approach which has been used by other research groups.  
Samples from both the hospital medical air and oxygen supply were tested at a 
number of different locations.  Samples were taken from those sites most likely to be 
used for patient sampling during the study, but also from the sites nearest and 
furthest from the source. Unlike the medical air which is manufactured (filtered) on-
site, medical oxygen is obtained in compressed form from an external supplier (BOC). 
Results of this initial testing revealed large but consistent contaminants to be present 
































Samples were taken by running food grade tygon tubing between the hospital gas 
flow meter and Markes dual-bed (carbograph-5 / carbograph-2) sorbent tubes. Flow 
rate was set at the lowest possible calibrated level (0.5L/min) in order not to exceed 
the flow capacity of the sorbent tubes. Tygon tubing is used for patient sampling by 
the Manchester Institute of Biotechnology (MIB) breath research group in line with 
ReCIVA manufacturer’s instructions; although it may emit VOC, levels are low and 
believed to have negligible impact on the chromatogram resulting from patient 
samples. In order to determine the source of contamination the tests were repeated 
with PTFE tubing. This is inflexible and not suited to patient sampling in the clinical 
environment but is non-emitting of VOC. In order to obtain a more consistent flow 
rate the following set-up was used – tubing was run between the hospital flow meter 
and a PTFE Y-join. To one arm a further length of PTFE tubing was attached, freely 
venting to the immediate environment. To the other arm of the Y-join was attached 
a length of PTFE tubing attached to a Markes sorbent tube.  





The tube was inserted into the ReCIVA device which was set to continuous sampling 
at a rate of 200ml/min. A second sorbent tube was inserted into the ReCIVA and used 
to sample ambient air. Samples were obtained in the same fashion using Tygon 
tubing instead of PTFE tubing. The process was repeated on two separate occasions. 
On analysis of the results there was, again, a high level of contaminants in the 
samples obtained using tygon tubing but low levels when PTFE tubing was used. 
There was no apparent difference in contaminants between the oxygen samples 
taken using PTFE tubing on the two separate occasions. This would suggest that 
levels of contaminants in the hospital oxygen system are both low and consistent 
over time.  
PTFE tubing is not practicable for sampling in the clinical situation – it is relatively 
inflexible and non-malleable making it difficult to attach to the Y-join and to the wall 
supply / flow meter. Tygon tubing is convenient, flexible, and suitable for use in the 
often times limited space available in a busy clinical environment. Moreover, tygon 
is being used by Owlstone and the MIB breathomics group; in order to make results 
comparable it is important to standardise procedures where as possible. The flow rate 
when using the tubing to supply the ReCIVA device for patient sampling is 
approximately 40L/min (the device then draws the supplied air through the sorbent 
tubes at a maximum flow rate of 0.5L/min). The rate of flow likely reduces the degree 
of contamination from the tubing. Given the discrepancy between flow rates used to 
power the ReCIVA and that which were used for sampling the hospital air, a sampling 
procedure was established in which oxygen was supplied to the ReCIVA at a high flow 
rate – in excess of 15 L/min. The high flow oxygen was directed through tygon tubing 
to the ReCIVA face mask which was fitted to a glass dummy-head (3D Display Ltd, 
Faversham, UK). The face mask had been baked at 100 degrees centigrade for 2 
hours in order to remove surface VOC. Sampling was undertaken using tygon tubing 
which had been baked at 60 oC for 2 hours and PTFE tubing. All tubing was purged 
with high flow medical air (10L/min) for 10 mins prior to use. Samples were also 
taken at 3 different locations within the hospital using PTFE. One final set of samples 
was taken using the raw (unbaked) tygon). The difference between raw tygon, baked 
tygon and PTFE using this delivery system was minimal. This difference between 
oxygen samples taken at different locations using PTFE was similarly negligible.  
The conclusion reached was that contaminants originating from the tygon tubing were 
minimised when flow rates were increased to those used in patient sampling using 
the ReCIVA.  
 





Given the publication of ERS technical standards specifying a clean air supply should 
be used, and in light of the fact that the emergency department within the NNUH 
contained no supply of medical air, a CASPER clean air filter (Owlstone Medical, 
Cambridge) was purchased. This draws ambient air through a chamber of activated 
carbon pellets, scrubbing it of VOC before supplying it to the ReCIVA at the required 
flow rate. 
It was anticipated that a proportion of those patients being treated in acute secondary 
care would be given supplementary oxygen as part of their initial care. In order to 
be most useful in informing treatment decisions at the point of care it might be 
necessary to undertake breath sampling while patients are in receipt of oxygen; this 
requires the ability to supply oxygen to the mask. Enquiries were made to the 
manufacturer as to the possibility of introducing oxygen to the CASPER prior to the 
air scrubber. The manufacturer responded that the CASPER unit was not rated to 
handle medical gases, it was thus able to supply VOC-scrubbed ambient air but not 
VOC-scrubbed medical oxygen. For those patients in receipt of supplementary oxygen 
NNUH oxygen was to be mixed at a rate of 15L/min with VOC-scrubbed air via the 
CASPER by way of a PTFE Y-join and the mixture delivered to patients via the ReCIVA. 
A sample of this mixture could be obtained prior to obtaining patient samples in order 
to allow the calculation of alveolar gradients.  
4.3.2 Sample processing  
VOC samples on sorbent tubes were stored in a cold room at 4-7oC for a maximum 
of 14 days before being couriered to the MIB laboratory for dry purging, thermal 
desorption and GC-MS. In a study by van der Schee et al (239), 15 compounds (either 
common to breath samples or known to be related to asthma) were sampled, stored 
and transported prior to analysis by both eNose and GC-MS. They concluded that 
compounds were adequately stable for storage over a period of 14 days. Although 
stored in a cold environment, samples were shipped under normal carriage conditions 
(unrefrigerated); studies suggest storage at room temperature for 14 days results in 
acceptable sample retention (181, 240).  
Sorbent tubes were dry purged with tubes weighed pre- and post-purge in order to 
calculate the quantity of water removed. In the most humid of samples this did not 
fully dry the tubes (6.8mg reduced to 2.3mg) but GC-MS results appeared to have 
been unaffected.  
Gas chromatography is a method used to separate compounds within a sample 
utilising the differing rates at which they travel through a carrier medium.  





An inert gas is used through which compounds travel; the larger the molecule the 
slower the rate of travel, thereby leading to separate of compounds based on mass. 
Mass spectrometry can then be used to determine the mass or particles and 
composition of molecules. Compounds are ionised in order to generate and separate 
charged molecule fragments whose mass-to-charge ratio can then be determined; 
compounds can be quantified by measuring daughter ions and a large proportion 
identified by their fragmentation pattern (60). 
After analysis tubes were conditioned at MIB for 1 hour at 330oC in VOC-scrubbed 
dry nitrogen before they were capped, packaged and couriering to Norwich for use. 
The process of analysis was as follows: 
- 100µL of a calibration standard (1 ppmv, 4-Bromofluorobenzene in nitrogen, 
Thames Restek, UK) was loaded onto tubes as an internal standard. 
- Tubes were pre-purged for 2 minutes in 50 mL min-1 He carrier gas to ensure 
the removal of any air or moisture.  
- Tubes were desorbed at 320°C in 50 mL min-1 He carrier gas using a TD-100 
(Markes International) onto a general purpose hydrophobic trap (Markes 
International) for cryo-focussing.  
- VOC were desorbed at 330°C into the GC column capillary gas chromatograph 
(7890B GC, Agilent, SantaClara, CA, USA) fitted with a DB-5 ms Ultra Inert 
column (length 30 m × internal diameter  0.25 mm, film thickness  25 µm, 
(5%-Phenyl)-methylpolysiloxane, Agilent) using a temperature ramp:  40°C 
hold 0 min, ramp 6°C min-1 to 170°C, hold 0 min, ramp 15°C min-1 to 190°C. 
The total time was 23 minutes with an He carrier gas flow of 1.3 mL min-1.  
- For mass spectrometry, a triple-quadrupole mass spectrometer (7010, 
Agilent) was used in electron ionization mode at 70 eV, with a scan range of 












4.3.3 Sample analysis 
 
4.3.3.1 Pre-processing 
All files were converted to the open mzXML format prior to pre-processing.  
 
Targeted analysis 
Masshunter Quantitative analysis (Agilent, SantaClara, CA, USA) was used for the 
targeted analysis. MW at the MIB manually inspected chromatograms; selecting 
peaks for which a reasonably confident identification could be made. This process 
was repeated until continued inspection yielded no new compounds.  
A target list of compounds was compiled based on those which were identified with 
the exclusion of known exogenous contaminants. One strength of this approach is 
the selection of peaks with confident identifications; unidentified compounds being of 
limited use to a phase one exploratory biomarker study. This target list was then 
used for the deconvolution of chromatograms.  
 
Untargeted analysis 
Chromatograms were screened for inclusion in the final dataset by manual appraisal 
and all samples deconvolved and aligned using eRah (283). This performs automated 
compound deconvolution and alignment across samples in GC-MS metabolomics; 
producing a table with the integrated area of the compound for each sample. Volatile 
organic compounds were identified by comparison of mass spectra and retention 
indices using the national institute of standards and technology (NIST) database. The 
results generated by this pre-processing method were then sent to the study author 
for analysis. 
4.3.3.1 Data analysis 
The internal standard – p-bromofluorobenzene – was used to normalise the data by 
dividing each of the columns (representing compound volume) by the internal 
standard value. A further data refinement was to normalise the compound intensities 
by the sample volume.  
 
Correcting for exogenous compounds is a contentious issue. ERS technical standards 
(228) recommend calculation of an alveolar gradient – the difference between the 









However, Cao and Dung (60) argue that although this provides an indication of 
whether a VOC is endogenous or exogenous the matter is far from straight forward, 
being affected by the ratio of alveolar to dead space ventilation; breathing pattern; 
the ventilation/perfusion ratio in the lung; and on the alveolar concentration 
gradients of the compounds in question. They argue that these complex 
interdependencies cannot be accounted for through an alveolar gradient (60). 
Schubert et al (284) in a study of mechanically ventilated patients measured venous, 
ambient air and exhaled breath concentrations. They reported that concentrations in 
blood and exhaled breath correlated well only for those compounds where the 
inspired concentration was less than 5% of the expired concentration. They advocate 
using uncorrected data but with the exclusion of any compound in which the inspired 
concentration is greater than 5% of the expired concentration. Another approach is 
to calculate the retention coefficient for individual VOC and then apply these in an 
effort to correct values according to inspiration concentrations (285). This approach 
might be useful once a panel of biomarkers have been identified but is impractical 
for use with large target lists or untargeted analysis where the retention coefficient 
for many compounds may not yet have been established. The data analysis plan was 
to follow ERS recommendations and undertake a background correction using 
alveolar gradients while acknowledging that this may be an imperfect solution. 
 
4.4 Developing a questionnaire to assess patient acceptability   
 
4.4.1 Defining Acceptability  
Acceptability - 
“the perception among implementation stakeholders that a given 
treatment, service, practice, or innovation is agreeable, palatable, or 
satisfactory” p.67, (286). 
Kaltenthaler et al (287) state that patient acceptability is a key component to consider 
when evaluating new technology, arguing that there is an ethical obligation to 
understand what treatments are most acceptable. They point out that acceptability 
can have important ramifications for research; if patients find a particular procedure 
less acceptable than others recruitment may be impacted. Moreover results may be 
skewed - drop-out rates may vary according to procedure received or device used; 
or alternatively only certain (potentially unrepresentative) patients might be willing 
to participate. The effect of acceptability may extend beyond research into clinical 
effectiveness - adherence and attendance are likely to be affected by acceptability of 
the procedures undertaken or devices used (287).  





Proctor et al (286) published a useful review of implementation outcome taxonomy 
from which the above definition is taken.   They differentiate ‘patient satisfaction’ 
from ‘patient acceptability’ suggesting that acceptability refers to a specific 
treatment/device, whereas satisfaction refers to the service as a whole. They also 
discuss the concept of appropriateness; they describe this as being similar to 
acceptability but defined as the perceived fit, relevance, or compatibility of the 
innovation for a given practice setting or to the addressing of a particular issue or 
problem. 
4.4.2 Patient Reported Outcome Measures 
Having determined that patient acceptability of devices is important and defined the 
terms it was necessary to find a PROM tool to capture this. The Medical Outcomes 
Study Visit Rating Questionnaire, or modifications of it, have been used to assess 
acceptability and satisfaction in the past (288, 289), however this questionnaire 
includes elements which were not pertinent such as length of time waiting for an 
appointment, and convenience of getting to the office/clinic. Specialism-specific 
clinical questionnaires have been developed in other areas of medicine (290, 291) 
but none were found assessing patient acceptability in respiratory medicine. Using 
the following search terms in pubmed - “acceptability AND diagnostic test AND 
(respiratory OR asthma OR COPD)” – two papers assessing patient acceptability were 
identified; one examined the acceptability of bronchial hyper-responsiveness testing 
and the other a new inhaler (292, 293) but neither used a validated questionnaire 
suitable for generic respiratory use. Treatment acceptability questionnaires have 
been in use for some time (294) however these tend to look at multiple areas (in 
addition to acceptability) such as ethics, effectiveness, side-effects, clinicians 
knowledge and trustworthiness (295). 
Due to the lack of existing, suitable, and validated questionnaires for assessing 
acceptability a respiratory-specific questionnaire was developed with reference to the 
aforementioned existing questionnaires and in line with the NHS Health Technology 
Assessment guidelines (296). Questions were designed to examine the acceptability 
of clinical assessment methods or tools. 
To be of maximum practical use the AAQ was designed to assess both acceptability 
and appropriateness. Five domains were identified from the literature; three relating 
to acceptability (appeal; comfort & ease of use; and concerns) and two to 
appropriateness (appropriateness to setting, appropriateness to patient/condition 
severity). Through feedback from members of the research team and clinical 
specialists an initial list was reduced to eight questions covering five domains (see 
table 18). 





A visual analogue scale (VAS) for overall acceptability was added at the end of the 
questionnaire. This was to ensure that acceptability was captured not only by this 
non-validated questionnaire but by a second more widely used metric. This would 
allow the internal consistency of the test to be calculated by comparing the overall 
score from questionnaire with the result from this question.  
 
  








Table 18 – Patient reported outcome measures: acceptability - domains & questions 
 Domains 
 






















How willing would 
you be to have your 
asthma monitored 
using this device in 
the future? 
 
How easy / difficult did 
you find it to use the 
device? 
 
How comfortable / 
uncomfortable did you 
find the test? 
 
How bothered / 
embarrassed were you 
during the test? 
 
How likely do you 
think it is that using 




How believable is it 













This device would be appropriate 
for use in the following situations – 










4.4.3 Patient and Public Involvement  
The Asthma UK Centre for Applied Research (AUKCAR) patient and public 
involvement (PPI) group were contacted and their feedback sought on draft versions 
of the questionnaire. Through this it was hoped to assess the face validity of the 
questions; their appropriateness; and the acceptability of the questionnaire. The 
AUKCAR PPI liaison officer (research follow Melissa Goodbourn) offered initial 
feedback on the AAQ-R and advice on the letter of invitation to the PPI group. The 
PPI group were then sent a letter of invitation to collaborate (this included a 
description of the study and pictures of the study devices); a draft copy of the AAQ-
R upon which to comment; and a feedback sheet (see appendix 4). Four PPI group 
members offered to engage with the process and offered their feedback. 
The feedback sheet attempted to gain input on the following three factors: 
 
- Validity & appropriateness 
o Attempting to elicit how the participant would decide between 
devices; how they would weigh up a device’s acceptability and by 
doing this determine whether the AAQ-R would capture this 
 
- Acceptability 
o Determining whether the questionnaire is acceptable to the user and 
whether it makes sense to them 
 
- Precision 
o Whether the options for responding are appropriate and give 
sufficient scope 
 
The group reported that they found none of the questions difficult to understand, 
distressing or pointless, and felt that no key questions were missing. Via the feedback 
sheet, the group were asked ‘if several similar breathing devices were available for 
monitoring asthma, what sort of things would you use to decide between them?’ The 
answers received can be summarized as – ease of use, ability to understand the 
results, and suitability to the acute setting. These were all covered by questions 
already included in the AAQ-R. Asked for potential concerns about any new device, 
the group answered – the speed of getting results; confidence in the results; impact 
of the test on breathing; physician reliance on results; and the time taken to use the 
device. With the exception of time, these concerns were all covered by questions 
already included. The time taken to receive results was deemed not applicable – the 
ReCIVA and RTube being research tools currently rather than point of care devices. 
The acceptability of the time taken to undertake the test could be expressed by 
participants through the ‘ease of use’ question or captured in the free text box at the 
end of the questionnaire.  





Given that one participant had expressed the opinion that the questionnaire was 
overly long it was decided not to add a question to assess the acceptability of time 
directly (see chapter seven for further discussion). 
In framing and scoring the questions it was decided to use a five-point scale, as used 
by the majority of questionnaires found (Evidence-based Practice Attitude Scale; 
Behaviour Intervention Rating Scale; Patient Visit Rating Questionnaire; and the 
Patient Satisfaction Survey). Fitzpatrick et al (296) discuss the merits of Likert and 
visual analogue scales (VAS). They suggest that there is little empirical evidence that 
VAS are superior to Likert scales despite the apparent precision and range of 
responses possible with the VAS. Moreover, they cite concerns over the lower 
acceptability of VAS as a task. One of the PPI group suggested fewer responses could 
be used to simplify the questionnaire, however, a 3-point Likert scale would give a 
reduced amount of information and not allow for any gradation in response. The other 
three respondents were satisfied that the amount of choice presented in the 
questionnaire was about right. 
In order to provide a measure to which the AAQ-R results could be compared a VAS 
relating to overall acceptability was included. One of the respondents suggested 
adding numeric gradations to this. Both Hawker et al (297) and Ferreira et al (298) 
when comparing pain scales found a numeric rating scale for pain to be preferable to 
a VAS without any gradations. Crichton (299) states that an argument can be made 
the VAS scales are “an attempt to produce interval/ratio data out of subjective values 
that are at best ordinal”.  However, in light of the feedback received and these 
comments, it was decided to change the VAS to a numerical scale. 
Another suggestion from the PPI group was to add a free text box after each question. 
Given that another participant said they felt the questionnaire was rather long and 
could be simplified, this suggestion (regarding multiple text boxes) was not 
implemented.  However, one was added to the end of the questionnaire.  
To summarise the PPI feedback; all the questions were easily understandable, 
nothing was missing and all the criteria which they would use to choose between 










4.4.5 Assessment of Acceptability Questionnaire – Respiratory (AAQ-R) 
A copy of the AAQ-R as used in the ABBA study can be found in appendix 4 
 
4.4.6 Criteria for developing a patient reported outcome measure (PROM)  
The following criteria - suggested by Fitzpatrick et al (296) and taken from the 
Oxford University Patient Reported Outcomes Measurement group (300) - are 
recommended for consideration when developing a patient reported outcome 
measure (PROM): appropriateness; acceptability; feasibility; interpretability; 
precision; reliability; validity; and responsiveness. Table 19 outlines the Oxford 
University PROM recommendations and how these were to be assessed in the ABBA 
study. 
 
Table 19 – Assessment of patient reported outcome measures 
Criteria Explanation Assessor Method of assessment 











Feedback from the AUKCAR 
PPI group and members of 
the respiratory research 
team on draft versions of 
questionnaire. 





Feedback from the AUKCAR 
PPI group on draft versions 
of questionnaire. Missing 
data frequency and time 
taken to complete 
questionnaire.  






Assessed throughout the 
course of study via feedback 
from the research team. 
Interpretability How 
interpretable are 
the scores of the 
instrument? 
Researcher Does the questionnaire result 
in usable data that can be 
statistically analysed with 
meaningful outcomes?  
Precision How precise are 





Without a gold standard to 
compare against evaluating 
this is challenging. Scores 
can be compared with the 
opinions expressed by focus 
group participants 














Correlation between the 
answers on questions 
assessing similar aspects of 
acceptability (internally 
consistent) and the degree of 
concordance in results when 
the questionnaire is repeated 
in similar circumstances 
(reproducible). Internal 
consistency coefficients. 
Validity Does the 
instrument 






Face validity can be assessed 
by members of the AUKCAR 
PPI groups, researchers and 
clinicians. Questionnaires can 
be compared against focus 
group transcripts. Drop-out 
rates and reasons for drop-
out can be compared with 
questionnaire results. 
Responsiveness Does the 
instrument 
detect changes 





Descriptive and inferential 
statistical analysis can be 
used to examine the 
differences in questionnaire 
scores for the different 
assessment methods used 
(e.g. PEF, EBC, FeNO) and 
circumstances of use (e.g. 














   






While the RTube is a commercially available, CE marked device, it can be used for a 
number of different purposes and a defined methodology for the biomarker of choice 
needs to be established. The equivocal results from the systematic literature review 
of asthma and 8-isoprostane (see chapter 2) coupled with a lack of success in 
measuring 8-isoprostane in early attempts led to the abandonment of this aspect of 
the study. EBC samples would still be collected in order to answer the feasibility 
questions; with future analysis of samples dependant on the identification of a 
suitable target marker. 
The ReCIVA is another CE-marked commercially available device, its use is more 
circumscribed but choices still need to be made – from the circumstances of use and 
choice of sorbent through to the approach to sample analysis and data processing.  
Assessment of device acceptability is an area which has received relatively little 
attention; this chapter outlines the steps taken in developing a tool to assess this.  
The next chapter (chapter 5) describes how these and other methods were used in 
the two studies which make up this thesis - Exhaled breath biomarkers in acute 
asthma: a feasibility study (ABBA); and the Asthma Bronchial Challenge study (ABC). 
Chapter six presents the results of the ABC study, while chapter seven presents 
the results of the ABBA study.   





Chapter 5 – Study methods 
 
In the first chapter, disease heterogeneity was described and the need for clinically 
applicable biomarkers outlined. Chapters two and three reviewed the literature 
regarding two methods of breath analysis and their application to asthma. Chapter 
four presented some of the preliminary work which was undertaken in order to ready 
these breath capture methods for use in studies at the NNUH. This chapter presents 
the methods used in the two studies which comprise this thesis - Exhaled breath 
biomarkers in acute asthma: a feasibility study (ABBA); and Bronchial Challenge Testing 
in Asthma: The Effect of Mannitol Dry Powder Inhalation on Volatile Organic Compounds in 
Exhaled Breath (ABC).  
5.1 Common Methods 
 
Equipment and methods of assessment which were used in both studies are here 
described; the specific context of their use within the studies is detailed in sections 
5.2 and 5.3.  
5.1.1 Assessments   
Fraction of Exhaled Nitric Oxide  
The fraction of exhaled nitric oxide (FeNO) was measured using a Niox Vero nitric 
oxide analyser (Aerocrine, Chicago, USA) (see figure 10), with an expiratory flow rate 
of 50ml/sec. Measurement was conducted according to the manufacturer’s 
instruction and National Institute for Health and Care Excellence guidelines (267, 
301).  
Figure 10 - The Niox Vero: stock image of the device. 
 





Volatile Organic Compounds 
Exhaled breath VOC were captured using a ReCIVA sampling device used in 
conjunction with a CASPER clean air filter (282) (as described in chapter four; see 
also fig. 8) and Markes Tenax-GR inert-coated sorbent tubes (Markes International, 
Pontyclun, UK).  
Breath collection was gated using factory settings targeting exhalate from the lower 
airways. Duplicate patient-breath samples were taken in addition to a sample of the 
filtered air supply. Filtered air was sampled by attaching the CASPER filtered air 
outflow to the ReCIVA and mask which were fitted to a glass head.  
Oxygen saturation level, respiratory rate and patient comfort were monitored 
throughout the sampling process and the test was ceased if oxygen saturation rates 
dropped below 92%; if respiratory rate increased markedly; or if the patient became 
uncomfortable, distressed or requested to stop. 
Samples (adsorbed to sorbent tubes) were pseudonymised and stored securely in a 
cold room (5-7oC) at the University of East Anglia before being shipped to the MIB 
and dry purged within 2 weeks; tubes were then analysed by gas chromatography-
mass spectrometry. In general, VOC within breath samples are found in the mid 
parts-per-trillion by volume (pptV) to high parts-per-billion by volume (ppbV) range 
in breath. Results were supplied by the MIB - after undertaking data pre-processing 
- in the form of intensity counts without unit measurements. Samples consisted of 
patient breath replicates and CASPER filtered air samples. The geometric mean of 
replicate samples was calculated. Where missing values constituted one of a pair of 
replicates, the single present value was used in lieu of a geometric mean. Where 
missing values existed after this process, half the smallest value for that compound 
was substituted. 
 
In the ABBA study participants wore the ReCIVA device and breath sampling was 
started immediately (due to the acute medical setting); whereas in the ABC study 
participants breathed filtered air for a period of 5 minutes in order to reduce 
inhalation of exogenous compounds; although background subtraction may not be 
accurate for all VOC - varying as it does according to factors relating to both the 
compound itself, duration and intensity of exposure, and the individual concerned 
(BMI specifically) (302) – a background subtraction was undertaken in order to 
generate an alveolar gradient; the results of which were then compared to those of 
a non-corrected analysis.  
 






The American Thoracic Society (ATS) / European Respiratory Society (ERS) 
recommends using a composite score for the assessment of asthma control (40). The 
Asthma Control Questionnaire (ACQ) is a patient-based tool for assessing asthma 
control based on a seven day recall (303). Recognised by the American Thoracic 
Society and NICE and widely used in research, the ACQ is available from 
http://www.qoltech.co.uk/index.htm.  
Phlebotomy  
Phlebotomy was undertaken by a suitably qualified person. Where a full blood count 
was requested as part of usual care the results were obtained and the eosinophil 
count noted. 
General 
Phlebotomy (blood eosinophil count) and FeNO were conducted in order to both 
characterise the study population and monitor for carry-over effect in the ABC study. 
Calibration and servicing of all equipment was carried out in accordance with the 
manufacturers’ recommendations.  
5.1.2 Safety assessment 
In conducting the asthma breathomic literature review (see chapter 3) the author 
noted no adverse events reported by previous studies using VOC capture equipment; 
furthermore the ReCIVA is currently in use in a large European asthma study 
(UBIOPRED: STRATA). Adverse events (AEs) and serious adverse events (SAEs) were 
recorded and reported according to NNUH Foundation Trust Protocols. Definitions of 
harm were taken from EU directive 2001/20/EC article 2 as operationalised in NNUH 
standard Operating Procedures (SOP) 206. All AEs and SAEs were considered for 
severity, seriousness, causality and expectedness and noted on the care report form 
(CRF). A serious adverse event was defined as that which results in death, is life-
threatening, requires hospitalisation or prolongation of hospitalisation, results in 
persistent or significant disability or incapacity, or is otherwise considered medically 
significant by the investigator.  
SAEs were noted on the CRF; entered in the SAE log; the study supervisor informed 
within 24 hours and the REC informed within 15 days. Participants experiencing an 
SAE were followed up until resolution and documented throughout; and their primary 
care practice informed in order that the SAE might be added to their medical record.  





AEs were recorded on case report forms, patient notes and compiled in an end of 
study report. Unexpected AEs were also communicated to the participants’ primary 
care practitioner.   
5.1.3 Data management 
Demographic data and clinical data were collected and recorded on a CRF. In order 
to maintain confidentiality, participant data was anonymised using a participant 
identification number (PIN); personal data linked to the PIN was stored securely as 
was data generated by the study. Paper CRFs were identified using this PIN number 
and locked securely; paper documents linking participant identity to the PIN number 
were stored separately to all CRFs and locked securely. VOC samples were securely 
stored at UEA laboratory facilities and pseudonymised before being transported to 
MIB for analysis. All data was stored securely on either the NNUH or UEA central 
storage server with access, security and back-up controls in place as per SOP 805. 
The study team then analysed study data in line with the protocol objectives and 
following the data analysis plans.  
5.1.4 Data Analysis 
After GC-MS analysis and the completion of all patient facing study activity, VOC data 
was examined according to the protocol developed by authors at the MIB breath 
research group (304), in line with minimum reporting standards for metabolomics 
(248). As described in chapter 4, VOC data underwent a pre-processing phase 
consisting of deconvolution, baseline correction and centring.  Following this a target 
list of compounds for use in asthma metabolomics analysis was developed.  Targeted 
analysis of VOC samples was undertaken using MassHunter (Agilent, Santa Clara, 
USA). This initial stage of data pre-processing was conducted by MW at MIB.  
 
The results of this analysis were sent to the UEA as a comma separated values (CSV) 
excel file. Using Excel (Microsoft Office, 2016, v16.0.4954.1000), SPSS (116) (IBM, 
v.25) and R-Studio (version 1.2.1335) the following analytical plan was undertaken: 
- Data normalisation (using the internal standard and sample volume)  
- Calculation of skew and kurtosis for each compound 
- Histograms of sample distribution for each compound 
- Correlation plot to identify possible batch effects 
- Intra-class correlation coefficient and standard deviations to assess reliability 
- Background corrections and calculation of alveolar gradient 
- Box plots and Mann Whitney or Wilcoxon Signed Rank test (according to the 
outcome being assessed) 
- Multiple regression analyses: logistic regression analysis 





Where background correction produced a negative values, a constant of 10 was 
added to the data-set before log transformation.   
PCA is commonly used as the multiple regression test of choice for metabolomics 
however given the low numbers of samples relative to the large number of 

































5.2 Exhaled Breath Biomarkers in Acute Asthma: A Feasibility Study 
 
Full title: Exhaled Breath Biomarkers in Acute Asthma: A Feasibility Study 
Study abbreviation: Asthma Breath Biomarker Assessment: The ABBA Study 
Registered with clinicaltrials.gov Registry number NCT03084016 
Research Ethics Committee (REC) Approval gained REC reference 16/LO/0639 
 
5.2.1 Background 
Asthma is a chronic disease of the airways, defined by variation in both expiratory 
airflow limitation and symptoms. The mainstay of asthma diagnosis and monitoring 
remains the assessment of these two disease aspects - symptoms through clinical 
history and/or validated tools such as the Asthma Control Questionnaire; and airflow 
limitation via spirometry or peak flow readings (305). However, as discussed in 
previous chapters the utility of such measures are limited by the variable nature of 
the disease and its heterogeneity. Non-invasive measures of assessing airway 
pathophysiology have been the subject of study for several decades and CE marked 
devices for capturing both EBC and exhaled VOC are now commercially available. 
The study of exhaled VOC is still in its infancy and relatively little research has been 
conducted on such technology in the context of acute asthma attack. The capture 
and analysis of multiple VOC has the advantage of being suited to inductive analyses. 
Using such an approach to identify those VOC which are associated with acute asthma 
exacerbation could identify markers for use in identifying loss of control; while 
phenotyping asthma exacerbations by identifying the trigger or underlying disease 
phenotype might help guide treatment in the acute setting.  
Before attempting to conduct any definitive study to answer such questions, it is first 
necessary to address issues of feasibility. These include patient toleration of breath 
capture devices and the acceptability of using such devices during an acute asthma 
attack. There are also issues of participant retention and follow-up, specifically 
whether the ‘usual-care’ post-admission follow-up appointment stipulated in UK 
guidelines (305) offers a suitable sampling opportunity for controlled disease, and – 
when targeting an acute population - what proportion of those recruited return to a 
controlled state during the study duration.  





If attempting to phenotype exacerbations, any future study would have to establish 
whether the methods chosen were capable of identifying the presence or absence of 
common triggers; including viral and bacterial infection. 
The aim of this feasibility study was to assess two alternative methods of recruiting 
patients and capturing exhaled breath samples during acute asthma attack. This was 
undertaken with a view to determining the best approach for a definitive study 
evaluating biomarkers in acute asthma (including but not limited to inflammatory 
markers and potential markers of infection). In addition to assessing the feasibility 
of such a study it was planned to collect data on exploratory outcomes including the 
ability of biomarkers to distinguish between controlled and exacerbated states and 
their ability to identify triggers of exacerbation.            
5.2.2 Objectives 
 
5.2.2.1 Primary objective 
To determine the feasibility of a study to evaluate the utility of exhaled breath 
biomarkers in patients with acute asthma. This includes answering the following 
feasibility questions:  
 What is the best method of recruiting patients into a definitive study?  
 
 Are patients both prepared and able to provide exhaled breath condensate, 
exhaled breath gas and other samples in the acute asthma setting? Are 
patients prepared to perform repeated measures / multiple assessments? 
 
 Are outpatients both willing and able to contact the research team and return 
for assessment when experiencing an exacerbation? 
Previous studies suggest that recent severe exacerbation is a strong 
predictor of future exacerbation (306-308); however, it is not known 
what percentage of such patients would contact the research team 
and attend a study visit during such an exacerbation.  
 Are researchers able to perform the initial assessment of hospital patients 
early during acute exacerbation?  
In a previous study (61) patients were recruited within 24 hours of 
admission to hospital, however, when biomarker assessment was 
conducted relative to commencing systemic corticosteroid therapy is 
not known. 
 Is it possible to assess patients who are in receipt of supplementary oxygen?  
 
 How does collection of EBC & VOC compare with more established 
measurements (such as FeNO) in terms of acceptability to patients? 
 





 Is it possible to obtain exploratory data comparing controlled and 
exacerbated states to power a definitive study? 
 
 What percentage of patients experiencing an acute exacerbation have a 
bacterial trigger?  
Studies have found between 3 and 50% (309); further studies are 
required to narrow this range and to power a definitive study. 
 
5.2.2.2 Secondary objectives  
 To explore whether biomarkers are able to distinguish between stable and 
acutely exacerbated states 
 
 To explore whether biomarkers have any predictive value in the event of an 
exacerbation 
o Do markers predict hospital attendance or admittance? 
 
 To explore whether biomarkers are able to distinguish between viral, 
bacterial and allergen triggered exacerbations 
  
5.2.3 Methods 
5.2.3.1 Study design 
This was a single centre, longitudinal observational study with the primary aim of 
assessing the feasibility of research using breath sampling devices during acute 
asthma attack. The ability to capture information during such an attack was assessed 
using two different approaches: 
1) Acute arm: recruiting patients in secondary care during an acute exacerbation 
of their asthma; re-assessing them once their asthma was stable and 
controlled.  
 
2) Outpatient arm: recruiting clinically stable outpatients at increased risk of 
having an exacerbation (by virtue of having had an acute exacerbation within 
the previous 12 months (307, 308)). These participants were to be followed 
for a period of up to 12 months and asked to contact the research team for 
assessment in the event of an exacerbation. Should they do this and undergo 
an acute assessment they would be invited to provide a further sample at a 
later date when controlled. 
A recruitment target of 100 participants experiencing - or at risk of experiencing - an 
asthma exacerbation was set. The study included a participant focus group to obtain 
in-depth feedback on the breath capture devices and the study methods used.   





5.2.3.2 Study setting 
The study was conducted at the Norfolk and Norwich University Hospital (NNUH) 
(Norwich, Norfolk, UK); a regional tertiary centre for patients with difficult to control 
asthma. All study activities took place at the NNUH. In the year preceding study-
commencement this site saw approximately 800 patients with asthma. A pragmatic 
/ convenience sample method was used recruiting from the NNUH respiratory 
outpatient department; accident and emergency department (A&E); acute medical 
unit (AMU); and inpatient wards.  
5.2.3.3 Sample size 
The recruitment target of 100 participants was based on the assumption that that 
20-40% of participants would experience an attack within the 12 month follow-up 
period (307, 310, 311) and that approximately 30% of these participants would 
appropriately contact the research team for assessment during an exacerbation. This 
would permit an estimate of the rate of individuals experiencing an exacerbation to 
within +/- 7.8 to 9.6% of a 95% confidence interval; and to estimate the rate at 
which those who experience an exacerbation attend for an assessment to within 4.7 
to 6.4% of a 95% confidence interval (312). It was anticipated that recruitment in 
the acute study arm (during hospital attendance for acute exacerbation) would be 
challenging; within the overall aim of recruiting 100 participants, a target of 12 was 
set for recruitment in the acute arm in order to assess the feasibility of this approach 
(313).   
Regarding the exploratory outcomes, van der Schee et al state that the inflammatory 
processes underlying asthma are known to provide sufficiently different VOC-based 
breath profiles at sample sizes of between 10-20 participants per comparator group 
(174, 314).  
5.2.3.4 Eligibility criteria 
The following inclusion criteria were applied: 
1. Male or female 
2. Aged 18 or above  
3. Able to provide informed consent 
4. A confirmed asthma diagnosis requiring treatment with inhaled bronchodilator 
therapy +/- inhaled corticosteroids. 
5. Non-smoker (or ex-smoker of 6 months or more with a less than 10 pack year 
history). 
6. Current exacerbation or exacerbation within the previous 12 months. 
7. Within 24 hours of having presented to acute secondary care (applicable to 
the acute study arm only) 





With no gold standard test available for the diagnosis of asthma the majority of 
research uses either a physician diagnosis, a diagnosis made according to recognised 
guidelines, or diagnosis accompanied by a measure of airway reversibility. Patients 
were eligible for inclusion in the acute arm if they received a diagnosis of asthma 
exacerbation from the acute secondary care physician assessing them. This 
pragmatic definition of asthma (and exacerbation) was adopted because full 
diagnostic evidence (such as reversibility) might not be available for all patients at 
the time of exacerbation. Diagnosis for all participants was confirmed retrospectively 
through a review of secondary care records ascertaining whether the participant’s 
diagnosis met BTS/SIGN diagnostic guidelines.  
That smoking may affect exhaled breath biomarkers is well established (315), 
however the extent and duration of this effect on the markers under consideration in 
this study is not. In line with other studies, current smokers and ex-smokers with a 
greater than 10 pack year history or with less than 6 months non-smoking were 
excluded.  
Exclusion criteria: 
1. Major chronic cardiorespiratory disease other than asthma 
2. Significant comorbid condition 
3. Receiving maintenance oral corticosteroid therapy or other 
immunosuppressant or immunomodulatory therapy (including biologics) 
4. Pregnant 
5. Participating in a clinical trial of an investigational medicinal product (CTIMP). 
6. Unable to speak English. 
 
Patients with a major chronic cardiorespiratory disease other than asthma or 
significant comorbid condition were excluded. Defining a ‘significant comorbid 
condition’ is problematic (316) however for the purposes of this study guidelines were 
developed by physician members of the research team to be used by the researcher 
in classifying comorbidities (see table 20). In the event of medical conditions not 
covered by this guidance, the opinion of the patients’ acute care or respiratory 
physician was sought and noted. Patients receiving maintenance oral corticosteroid 
therapy (or other immunosuppressant therapy) or those unable to provide informed 
consent were also excluded. Patients found to be ineligible on screening were not 
entered into the trial, however reasons for ineligibility were recorded. Patients with 
an acute non-respiratory infection were excluded.   





Patients with acute respiratory infection were included in order to capture data on 
infectious triggers of asthma, however patients with pneumonia were excluded. 
Patients who were pregnant were excluded - pregnancy increases metabolic activity 
and oxidative stress, and has been shown to alter exhaled breath VOC (317).  
The eligibility criteria were applied as follows during the screening process: 
a. Diagnosis of acute asthma exacerbation (currently or within previous 12 
months). 
b. Patient meets inclusion criteria 
c. Patient does not meet any of the exclusion criteria. 
 
 
Table 20 – Study exclusion criteria: comorbidities 
1. Major chronic cardiorespiratory disease other than asthma 
- COPD 
- Bronchiectasis 
- Interstitial lung disease (including sarcoidosis, pulmonary fibrosis) 
- Pneumoconiosis 
- Lung cancer 
- Cystic fibrosis 
- Heart failure 
- Pulmonary oedema. 
 
2. Significant comorbid condition 
If the comorbid condition is not listed as the primary diagnosis / presenting 
complaint then it will not be deemed a significant comorbidity unless it is one of 
the following:  
- Pneumonia 
- Pleural effusion 
- Pneumothorax 
- Acute infection (other than respiratory) 
- Septicaemia 
- Any cancer 
 
Examples 
- An asthma attack and coexistent acute urinary tract or kidney infection 
would be excluded 
- An asthma attack with lower respiratory tract infection would be included 
















Standard care for patients who attend secondary care with an asthma attack is to be 
invited to an outpatient appointment with an asthma specialist nurse 4-8 weeks later 
(as per BTS/SIGN guidelines(305)). In addition, outpatient clinics are populated by 
patients referred from primary care with difficult to control asthma who may have 
experienced an attack within the previous 12 months. Such clinics thus provide an 
opportunity to invite ‘at risk’ outpatients to participate. Recruitment of outpatients 
was undertaken by screening clinic records and sending invitations; through 
invitation at asthma clinic appointments; and through advertising within the NNUH 
and on a respiratory research microsite hosted on the NNUH website’s Research and 
Development pages. 
Acute arm: 
Recruitment in acute secondary care took place at the Norfolk & Norwich University 
Hospital (NNUH); a number of avenues were available for patient identification. 
Posters were placed in accident and emergency (A&E) and the acute medical unit 
(AMU) asking staff to contact the research team if they had a patient they believed 
might be suitable for inclusion and who expressed an interest in participation. Names 
and presenting complaints of all patients entering A&E and AMU are logged on the 
hospital information technology system – Symphony - which can be used to identify 
potential patients for screening. In addition, the Early Supported Discharge Service 
(ESDS) compile a triage list each morning; this is reviewed daily by the asthma 
specialist nurse team who identify any patients with asthma. This team were asked 
to offer information to potentially suitable patients, contacting the researcher for 














Having identified a patient as potentially suitable for inclusion their notes were viewed 
and/or their clinician consulted to determine whether they were sufficiently stable to 
approach regarding participation. Those meeting any of the following criteria were 
deemed unstable and not suitable for approach: 
- Transfer to intensive care (ITU), the high dependency unit (HDU) or intubation 
being considered. 
- O2 saturation below 94% despite receiving supplementary oxygen 
- Unable to complete even short sentences 
- Obvious distress and inability to complete the consent process. 
 
If a patient was deemed insufficiently stable they were reviewed again after a period 
of time; if stable enough to approach they were presented with a participant 
information sheet. If they wanted to be considered for entry to the study they were 
given the opportunity to ask further questions of the researcher and time to consider 
their participation. Informed consent was then sought and the patient screened for 
eligibility.  
Outpatient arm: 
Potentially suitable patients were sent or given a letter of invitation and participant 
information sheet. If they contacted the research team and expressed interest, the 
researcher answered questions, outlined the eligibility criteria, and invited the person 
to a study visit. For those with an outpatient appointment, on arrival the patient was 
asked if they had received the information and whether they would like to be 
considered for entry to the study. This was undertaken in a location and manner 
which both preserved the patients’ privacy and afforded them the opportunity to 
decline participation without pressure. Patients who wished to be considered for study 
inclusion were given the opportunity to ask further questions; informed consent was 
sought and the patient screened for eligibility.  
Participant consent 
The study was conducted in accordance with Good Clinical Practice (GCP) guidelines 
and according to the guiding principles of the Declaration of Helsinki. Consent to 
participate in the study was sought and obtained by an appropriately trained 
individual and conducted according to GCP guidelines.   





Potential participants were given sufficient time to consider their inclusion into the 
study; informed that they were free to withdraw from the study at any time without 
giving a reason and that this would have no impact upon the quality of their current 
or future treatment; and were informed that all data collected in the study would be 
held confidentially. It was also explained that in the event of their withdrawal data 
collected up to that point could not be erased and would be used in the final analyses 
where appropriate. At every follow-up call and assessment it was established whether 





The GINA definition of asthma exacerbation (318) covers a broad range of severities; 
for this study the BTS/SIGN guidelines were used to classify the severity of 




















Table 21 – BTS/SIGN asthma guidelines: classification of severity 
Moderate asthma Increasing symptoms 
PEF > 50-75% best or predicted 
No features of acute severe asthma 
Acute severe asthma Any one of: 
- PEF 33-50% best or predicted 
- Respiratory rate > 25/min 
- Heart rate > 110/min 
- Inability to complete sentences in one breath 
Life threatening asthma Any one of the following in a patient with acute severe asthma: 
Clinical Signs Measurements 






- Silent chest 
- Poor respiratory 
pressure 
- PEF < 33% best or 
predicted 
 
- SpO2 < 92% 
 
- PaO2 < 8 kPa 
 
- Normal PaCO2  
(4.6-6.0 kPa) 
Near fatal asthma Raised PaCO2, and/or requiring mechanical ventilation with 
raised inflation pressures.  
 
Asthma exacerbation or attack was defined according to the ATS/ERS 
recommendations (40) as operationalised by Virchow (319):  
 nocturnal awakenings due to asthma requiring short-acting beta-agonist 
medication (SABA) for 2 consecutive nights 
 increase in occasions of SABA use on 2 consecutive days (minimum increase 
of 4 puffs per day) 
 a decrease in PEF of 20% or more on two consecutive days or 30% at any 
time 
 the need to increase inhaled steroids 
 the need to commence oral or parenteral corticosteroid therapy or the need 
to access acute medical care (e.g. accident and emergency).  





This was explained to study participants in the recruitment process; it was detailed 
on the participant information sheet; participants were given a wallet sized reminder 
card as well as a leaflet detailing the above threshold and giving the research teams 
contact details. Two members of the AUCAR PPI group reviewed the PIS and provided 
comments.    
Demographic Data and clinical information 
Contact details, general demographic information and clinical details were taken from 
medical notes and by direct patient enquiry.  
Peak Expiratory Flow (PEF) 
PEF readings taken by hospital staff were retrieved from the hospital notes and 
recorded. A study specific PEF was taken using a mini wright peak flow meter in order 
to ensure consistency and contemporaneousness with other study assessments.  
Sputum 
Spontaneously expectorated sputum (SES) is described by Holz et al (320) as simple, 
economic and non-invasive. Holz et al report that - in asthmatic subjects not 
experiencing acute exacerbation - approximately 75% were able to produce adequate 
samples. Spontaneously expectorated sputum samples were collected from patients 
in the acute asthma setting. For those patients producing a sample in the acute 
setting, a further (spontaneous) sputum sample was obtained at the time of their 
follow-up clinic appointment. Samples were send to the NNUH pathology laboratory 
for bacterial culturing. 
Fraction of Exhaled Nitric Oxide  
Performed as described in section 5.1.1 
Exhaled Breath Condensate (EBC) 
Exhaled breath condensate was collected using an RTube - a commercially available 
handheld device (Respiratory Research, Austin, USA). As per the manufacturer’s 
instructions, patients were asked to breathe into the device using normal tidal 
breathing for a period of 10 minutes. This was conducted in the seated position. 
Samples were pipetted into an eppendorf, anonymized and stored securely at a 
temperature of -80oC. Nose clips were used as per ATS/ERS guidelines (114, 321) 
where tolerated by the participant. Delivery of supplementary oxygen would prevent 
the use of nose clips for EBC, moreover it has been found to increase markers of 
oxidative stress in healthy volunteers (322) and those with COPD (323).  





EBC assessment was not conducted until such a time as participants had their oxygen 
removed or were considered stable enough to do so. The planned analysis of EBC 
samples from the ABBA study was not undertaken due to the equivocal findings of 
the systematic review of EBC 8-isoprostane and an inability to detect 8-isoprostane 
using a commercially available ELISA kit (a result which the review findings suggest 
is perhaps not uncommon (see chapter 2)). The samples remain in storage at -80oC 
pending the establishment of a reliable and sensitive method of 8-isoprostane 
detection or selection of alternative biomarker.  An alternative method of sample 
dilution calculation (such as serum albumin) would need to be used unless it were to 
be established that there is little inter-and intra-individual variation in EBC dilution. 
Volatile Organic Compounds 
VOC sampling was conducted as describe in section 5.1.1. For those patients 
receiving supplementary oxygen, the patients’ oxygen mask / nasal cannulae were 
substituted with the ReCIVA device; this was used to supply an air-oxygen mixture 
for a period of less than 10 minutes, before returning them to their original oxygen 
supply (see chapter four). Patients in receipt of > 50% oxygen or saturating at less 
than 94% were not assessed. 
Nasal swabs 
Nasal swabs were taken from patients experiencing an exacerbation and underwent 
PCR analysis for viral DNA at the NNUH pathology laboratory.  
Assessment Acceptability Questionnaire – Respiratory (AAQ-R) 
After use of each of breath assessment / capture device – RTube, ReCIVA, Niox Vero 
- patients were asked to complete the AAQ-R questionnaire investigating its 
acceptability.  
A global rating of change (GRC) 
A GRC measure was used to capture the change in asthma symptoms between 
exacerbation and follow-up. Kamper et al (2009) in their review suggest that GRC’s 
are high in face validity and correlate well with other self-report measures (e.g. 
disability or pain scales) and clinician rated measures of change. Kamper et al 
recommend a scale of 7-9 points suggesting that this offers the best compromise 
between patient preference, adequate discriminative ability and test-retest reliability.  
 
 





Figure 11 – The Global Rating of Change scale as used in the ABBA study. 
The following GRC was used for this study: 
 
 
With respect to your asthma symptoms, how would you rate yourself now 
compared to when I/we last saw you?   
 
Very much worse                Unchanged                         Very much 
better 
      





Phlebotomy was performed as detailed in section 5.1.1.  An additional vacutainer was 
taken for study purposes; permitting future analysis of samples once a marker of 
interest has been identified. Samples were left for 30-60 minutes to clot, centrifuged 
at 2,000 revolutions per minute for ten minutes at room temp (21oC) before being 
transferred to eppendorfs, pseudonymised and placed in a -80oC freezer. 
 





Asthma severity assessment Physiological signs & symptoms 
Wrights Mini Peak Flow  Respiratory function - expiratory airflow obstruction 
RTube – Exhaled breath 
condensate 
Analysed for 8-isoprostane (+/- other novel 
markers) 




Bacterial culturing  
Phlebotomy Blood eosinophils 
Serum stored for potential analysis of other markers 
Nasal swab Viral DNA 
 





Qualitative Assessments of Feasibility 
A focus group was undertaken in order to obtain more in depth, qualitative data on 
the study methods used, and for the purpose of assessing the validity and utility of 
the AAQ-R. Views on the acceptability of trial methods including recruitment strategy 
and assessment procedures/devices were captured. The Krueger & Casey (324) 
approach to running a focus group was used, with the discussion scheduled for 
approximately one hour. A bank of questions / prompts for use in facilitating the 
discussion was compiled (see appendix 2). Prompts were designed to move from the 
general to the more specific, although participants were encouraged to discuss the 
issues that are/were important to them rather than following a pre-determined 
schema. The discussions were recorded on a digital tape recorder, and the recording 
transcribed and pseudonymised. 
5.2.3.7 Safety assessment 
The protocols regarding adverse events are documented in section 5.1.1. Only 
procedure-related adverse events (AEs) and procedure-related serious adverse 
events (SAEs) were recorded in the ABBA study. Participants experiencing a 
procedure-related SAE were to be followed up until resolution and documented 
throughout. An annual report was submitted to the REC detailing any SAEs. 
 
5.2.3.8 Schedule 
Participants who were recruited in the acute arm were asked if they wished to 
continue in the outpatient study arm (and contact the research team in the event of 
experiencing another asthma attack). By combining the two study arms, five possible 
stages of assessment were created.  
Those patients recruited during acute exacerbation (stage one) whose asthma was 
not controlled at the time of their follow-up outpatient appointment (stage two) were 
invited back for a study-specific assessment at a later date, thereby allowing more 
time to regain asthma control (stage three). Those patients enrolled in the outpatient 
study arm who contacted the study team and attended for assessment during an 
asthma attack (stage four) were invited back for a further assessment once they had 
regained asthma control (stage 5). The flow of participants through the study is 
outlined in figure 12. 
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Figure 12 - Participant flow in the ABBA study 
 




In the acute arm patients underwent study assessment after completing the 
recruitment and consent processes. Following discharge, information on tests, 
therapies received and duration of hospital stay was extracted from patient notes 
and/or hospital IT systems. Upon their follow-up outpatient appointment being 
booked the researcher contacted the participants asking them if they consented to 
continued participation and arranging a study visit. In addition to those tests 
performed as standard care for outpatient appointments (such as spirometry) a 
repeat set of study assessments was conducted. A measure of global record of change 
(GRC) was recorded in addition to ACQ. Those participants not meeting the ACQ 
threshold for disease control (1.5 in the case of the study) were invited to return for 
a further assessment at a later date. 
Those participants in the outpatient arm who contacted the researcher in the event 
of an exacerbation were asked to attend the NNUH for a full study assessment. 
Participants were contacted every three months to remind them about study 
participation and to ask for details of any unreported exacerbations; this contact was 
by telephone or mail. Those outpatients who were admitted to hospital for an 
exacerbation were approached as inpatients and asked if they were happy to undergo 
a study assessment. All those outpatients who underwent assessment were invited 
to attend a follow-up appointment at a later date when symptom control had been 
achieved.  
Participants were withdrawn from the study for any of the following reasons: 
a. Removal of consent - participant choosing to withdraw. 
b. Diagnosis of major cardiorespiratory condition other than asthma. 
c. Development of a significant comorbidity. 
 
Study participants all received standard care in both the secondary and primary 
healthcare settings. Participants in the outpatient arm were followed up for a period 













5.2.4.1 Feasibility outcomes 
Primary outcomes were chosen to provide feasibility data informing the design of 
future acute asthma studies using exhaled breath capture devices. 
 
Table 23 – ABBA study feasibility outcomes 
Feasibility – recruitment 
Recruitment rate (participants 
recruited/time)  
Time required to recruit to study 
Number of invited patients that agree 
to participate. 
How many patients with asthma are 
willing to participate 
Number of participants excluded on 
screening 
How many patients with asthma are 
eligible 
Numbers recruited and in which arm  Which recruitment method results in 
the greatest number of assessments 
Reasons for exclusion Are the eligibility criteria appropriate 
Acceptability of recruitment process  Is the recruitment process appropriate 
Number of patients recruited in the 
acute arm who fail to attend their 
outpatient follow-up appointment? 
Is the usual-care outpatient 
appointment a suitable opportunity for 
capturing follow-up data? 
Number of participants who are lost to 
follow-up or withdraw consent  
Sample size calculation - how many 
patients will be required to account for 
the study drop-out rate. 
Number of patients recruited in the 
outpatient arm that experience an 
exacerbation 
Planning future study 
Number of patients experiencing an 
exacerbation, appropriately contacting 
the research team and attending for 
assessment 
Planning future study 
Severity of exacerbations captured in 
outpatient and acute study arms 
Are a range of attack severities 
captured by both study arms? 
Number of potentially eligible patients 
in the acute arm that were approached  
Staffing resources 
Number of acute-arm participants who 
were controlled at their follow-up 
outpatient appointment 
Does the follow-up outpatient clinic 
appointment provide an opportunity for 
assessing clinically stable patients? 




Number of outpatient arm participants 
who were controlled at their follow-up 
appointment 
Planning future study – how many 
participants are required to obtain a 
sufficiently large number of controlled 
samples? 
 
Feasibility – assessment 
Time taken to collect samples and/or 
complete tests. 
Planning of future study 
Sample size / volume Determining future sampling 
methodology appropriate to biomarker 
chosen and required analysis. 
The number of patients able to produce 
spontaneously expectorated sputum 
sample 
Planning of future study methods 
The number of participants completing 
tests successfully (yielding a sample 
sufficient for use). 
Sample size calculation – how many 
participants are required to obtain the 
required number of samples 
Reasons for incomplete tests  Planning of future study methods 
Reasons for unusable samples Planning of future study methods 
Number of patients who successfully 
complete all tests at all visits. 
Future study design – delivering on 
target recruitment numbers 
Acceptability of collection processes - 
obtaining sample, timing of sampling, 
time taken to obtain sample, 
acceptability of devices used. 
Future study design  
Adverse events – number, nature, 
context, severity, action taken. 
Future study design 
Time between study assessment and: 
- Admission to hospital 
- Commencement of systemic 
corticosteroids. 
Future study design 
Ability to obtain data on exacerbation 
from patient  
Feasibility 
Acceptability of study methods to 
participants  
Patient perception of study; do any 
design features deter participation 
 
 




5.2.4.2 Secondary outcomes 
In addition to the feasibility outcomes described above, an exploratory analysis of 
exhaled breath biomarkers was planned.  
Exploratory data 
Is there a significant difference in VOC concentration levels between exacerbated and 
stable states? 
Are there distinct breath profiles associated with exacerbated and stable states? 
What are the ranges for inflammatory markers in the acute state and in the stable 
state?  
What is the variability of the difference in inflammatory marker levels between the 
acute and stable state? 
Do exhaled breath biomarkers predict hospital admission? 
Does the questionnaire developed to capture patient acceptability of clinical 
assessment devices have validity & reliability? 
 
5.2.5 Data analysis  
5.2.5.1 Primary outcomes 
Primary Outcome: To collect sufficient data to determine whether a larger trial 
investigating biomarkers in acute asthma is feasible to undertake.  
Measures used to determine this outcome include: 
- Screening and recruitment rates, drop-out rate, and exacerbation rate.  
- Summary data on the use of time and patient feedback will also be produced.  
A screening log was kept in order to record reasons for exclusion. The analysis of 
primary outcomes was conducted using SPSS version 23.0 (116). Analysis of 
qualitative data was to be undertaken using framework analysis supported by use of 
NVivo software with the credibility of thematic analysis checked by a second reader. 
Results were to be presented both quantitatively (e.g. keyword frequency) and 
qualitatively (e.g. vignette’s or anonymised quotations).  
Both qualitative and quantitative data on recruitment and assessment methods were 
to be used to assess study feasibility. 
5.2.5.2 Secondary outcomes 
Exploratory outcomes were to be assessed by comparing acute VOC data with that 
obtained when controlled; with analysis conducted according to the protocol 
developed by authors at the MIB breath research group (304) and outlined in section 
5.1.4. 




Data from all stages of the study was to be summarised; differences between 
stages/groups estimated; the ability of biomarkers to differentiate exacerbated from 
controlled asthma; infective from non-infective triggers; and their ability to predict 
clinical outcomes (such as severity of exacerbation and therapy dose/duration) 
estimated. The degree of concordance between novel biomarkers and existing 
asthma markers (such as FeNO, blood eosinophils) and respiratory function tests was 
also to be evaluated. 
5.2.6 Study approvals 
The ABBA study was registered with the clinicaltrials.gov database (registration 
number NCT03084016). Research ethics committee (REC) approval was gained from 
London-Fulham REC on 1st July 2016 (reference number 16/LO/0639). The study was 
registered with the NIHR clinical research network portfolio (central portfolio 
management system ID 33202).The study was approved for adoption to the NIHR 
portfolio on 2nd March 2017. 
5.2.7 Study amendments 
Amendment 1 (protocol v1.2) 
During the course of the study it became apparent (see chapter 4, developing a 
methodology) that it would be possible to deliver oxygen to patients via the ReCIVA. 
This meant that, contrary to the original protocol, patients would not need to wait 
until they were stable enough to be removed from oxygen before undergoing breath 
capture with the ReCIVA. In light of this a request was made to assess patients while 
still in receipt of supplementary oxygen and then to add a further additional 
assessment visits for these patients in which the effect of supplementary oxygen on 
exhaled VOC could be assessed.  
An offer was made to the researcher to conduct genomic analysis (16S rRNA and/or 
whole genome shotgun analysis) on any sputum samples obtained. In light of this a 
request was made to undertake induced-sputum sampling at the follow-up 
appointment for those participants who were able to provide a sample in the acute 
setting. Amendment 1 was approved by London-Fulham REC on the 1st September 
2016 and by the HRA on the 3rd November 2016. 
Amendment 2 (protocol v1.3) 
A number of patients booked into outpatient clinics did not have any electronic letters 
available to view nor notes available for screening. As a result it was challenging for 
the researcher to screen and ascertain whether to send a study invitation. In light of 
this a request was made for permission to approach patients who had not received 
advance information, providing this at their clinic appointment. Other requests in this 
amendment were to push the study end date back to July 2018.  




Due to difficulties in obtaining appropriate training in sputum laboratory processing 
techniques and ongoing quality assessment, the analysis of sputum was limited to 
bacterial culturing at the NNUH pathology laboratory (for spontaneously generated 
sputum samples only). The addition of butylated hydroxytoluene (BHT) solution to 
EBC samples was removed; the originally proposed EBC analyte – 8-isoprostane – 
had been shown to be an unreliable measure of oxidative stress using current 
methods. Tests for alternative markers in EBC could be adversely affected by the 
presence of BHT, thus storage without this additive is preferable. While an ACQ score 
of 1 was selected for asthma control, initial screening revealed that many patients 
attending the asthma outpatient clinic had an ACQ consistently > 1. This population 
with largely moderate-to-severe or difficult-to-control asthma may rarely score < 1. 
As a result a cut point of 1.5 was proposed, the threshold recommended by the ACQ 
authors for use in clinical trials.  
Both pneumonia and acute infection were listed as ‘significant comorbid condition’s 
which would result in study exclusion. It was realised that this guidance was not 
sufficiently specific; patients who presented to secondary care with both acute 
asthma attack and respiratory infection were proposed for inclusion. Any other type 
of acute infection would continue to be excluded. This would allow data capture for 
participants presenting to secondary care with an asthma exacerbation triggered by 
bacterial or viral infection. Patients with a physician diagnosis of pneumonia or 
septicaemia would be excluded. A CASPER clean air supply pump for the ReCIVA was 
purchased from Owlstone Medical Ltd (Cambridge, UK); use of this rather than 
hospital air was proposed. Amendment number 2 (protocol v1.3) was approved by 
London-Fulham REC on 24th April 2017. 
Amendment 3 (non-substantial) (protocol v1.4) 
After the REC approved protocol 1.3, HRA requested minor changes leading to 
amendment 3 (protocol 1.4). This was comprised of minor changes to some study 
documents; it was deemed to be a non-substantial amendment and did not require 
REC approval. Amendment number 3 (protocol v1.4) received HRA approval on the 
3rd July 2017.  
Amendment 4 (non-substantial) (protocol v1.5) 
A fourth amendment request was submitted requesting a number of small changes - 
permission to advertise the study on a study specific website hosted by NNUH or 
UEA; permission to take an additional vacutainer of blood; permission to recruit a 
PIC site if required to boost recruitment; and permission to issue participants a 
universal container for collection of a sputum sample. Amendment number 4 (v1.5) 
was approved by the HRA on the 3rd October 2017. 




Amendment 5 (protocol v1.6) 
Due to slower than anticipated recruitment a request was made to extend the study 
end date to the 31st December 2018; with participants being followed up for a period 
of 12 months or until December 2018, whichever came first.  
In the original study protocol a follow-up assessment for a small cohort of participants 
was suggested in order to assess the effect of oxygen therapy on exhaled breath 
profiles. Given a lack of participants assessed while in receipt of oxygen the need for 
this assessment was obviated. An exit questionnaire was drafted to collect data on 
unreported / unassessed exacerbations; the degree of control attained; and whether 
any exclusion criteria had developed during the study period. 
Amendment number 5 – was approved by London–Fulham REC on the 20th July 2018 























5.3 Bronchial Challenge Testing in Asthma: The Effect of Mannitol Dry Powder 
Inhalation on Volatile Organic Compounds in Exhaled Breath 
 
Study Abbreviation - Asthma Bronchial Challenge: The ABC Study 
Registered with clinicaltrials.gov - Registry number NCT03575663  
Research Ethics Committee (REC) Approval gained - REC reference 17/EE/0430 
 
5.3.1 Background 
As discussed in previous chapters, asthma is defined by variation in both expiratory 
airflow limitation and symptoms. Bronchial hyperresponsiveness (BHR) - as a cause 
of airflow limitation - is a key pathophysiological feature of asthma; although the 
extent to which its presence depends on the inflammatory phenotype is debated 
(325, 326). BHR is defined by Joos et al as an abnormal increase in airflow limitation 
following exposure to non-allergic stimulus (44). Bronchial challenge testing attempts 
to identify BHR through the inhalation of a stimulus at doses which cause no 
significant reaction in healthy subjects but provokes bronchoconstriction in those with 
hyperresponsiveness. It is recommended as one possible method of assessing airflow 
variability for asthma diagnosis (39, 327).  
Bronchial challenge tests can be classified as direct or indirect. Direct testing with an 
agent such as histamine or methacholine stimulates the smooth muscle of airway 
walls thereby causing bronchoconstriction.  
Indirect testing works by provoking inflammatory cells (chiefly mast cells and 
eosinophils) to cause the release of inflammatory mediators including prostaglandins, 
leukotrienes, and histamine (328); mannitol achieves this through its osmotic effect, 
dehydrating the airway lining. These inflammatory mediators act upon airway smooth 
muscle to cause bronchoconstriction. Indirect testing should only generate this 
response if inflammatory cells are present in the airways; a notion supported by its 
strong correlation with other measures of inflammation such as the fraction of 
exhaled nitric oxide (FeNO) (329, 330) and sputum eosinophils (331). This may be 
the reason for its greater specificity - as an asthma diagnostic - than methacholine 
(332, 333), but it may also limit the test’s utility to the Th2 inflammatory phenotype 
- those with eosinophilic asthma have the strongest response to mannitol (334) and 
those with neutrophilic asthma the lowest (326). 
 




Whether bronchial challenge testing has a role outside of diagnosis remains to be 
seen; the STAMINA trial (335) compared management according to a standard 
strategy (involving symptoms and lung function tests) with a strategy based on dose-
response to mannitol. The group whose inhaled corticosteroids (ICS) was titrated 
according to mannitol remained on a greater dose of ICS but had fewer mild 
exacerbations, and there were significant differences in the fraction of exhaled nitric 
oxide (FeNO), reliever inhaler use and BHR (as measured by methacholine 
challenge). Overall the results were equivocal and the mainstay of disease monitoring 
remains the assessment of symptoms and airflow limitation (305).  
The pathology of asthma exacerbation or attack is still insufficiently understood (12). 
Investigating changes in VOC profiles occurring during acute asthma attack may help 
elucidate mechanisms at work; moreover, statistical associations with clinical 
outcomes offer a potential route for disease monitoring and/or treatment guidance 
even when the pathophysiological pathway responsible for the given metabolite 
remains unclear. Conducting research into acute asthma is, however, challenging 
(see chapter 7). This is particularly the case for breathomic studies which may be 
confounded by exogenous VOC in the hospital environment and elsewhere (the 
exposome) and by treatment. Prospective medication withdrawal-studies constitute 
a valid approach but given the effect of medication metabolites on VOC profiles (336), 
differences in medication status needs to be accounted for; as does the 
environmental confounding which may result from the time between sampling points 
(baseline and loss of control).  
Lazar et al (192) studied the effect of direct bronchial challenge (methacholine) on 
exhaled breath using an electronic nose (eNose). Lazar et al (192) concluded that 
acute bronchoconstriction in response to methacholine did not affect exhaled breath 
profiles as measured by the eNose. However the challenge procedure itself – 
irrespective of whether methacholine or sham - altered the VOC profile relative to 
baseline. The use of the eNose precluded the ability to identify individual analytes; 
while the use of direct bronchial challenge assessed the metabolomics of airway 









The study aimed to determine the effect of indirect bronchial challenge testing upon 
volatile organic compounds (VOC) in the exhaled breath of adults with well-
controlled, mild-to-moderate asthma.  
5.2.3.1 Primary objective  
To determine the effect of indirect bronchial challenge testing on VOC profiles in 
patients with asthma.  
a. The effect of indirect bronchial challenge testing with mannitol dry 
powder 
b. The effect of a sham indirect bronchial challenge test 
5.2.3.2 Secondary objectives 
a. To explore the variability of biomarkers in patients with asthma 
i. What is the inter-individual and intra-individual variability in 
exhaled breath VOC in a cohort of patients with asthma 
 
b. To explore whether biomarkers are able to predict outcomes 
i. Are VOC profiles able to predict response to bronchial challenge 
testing?  
 
5.3.3 Methods  
5.3.3.1 Study design 
This was a placebo-controlled study of exhaled breath metabolomics. Participants 
underwent sampling of exhaled breath VOC before and after undertaking an indirect 
bronchial challenge test using mannitol dry powder (MDP). Those participants 
exhibiting a positive mannitol challenge response returned for a sham bronchial 
challenge and further breath sampling.  
The release of inflammatory mediators was provoked through the use of a mannitol 
challenge; taking breath samples before and after the bronchial challenge offers a 
route by which changes in exhaled VOC may be assessed while minimising potential 
confounders such as time, medication and the exposome. 
The study was conducted over one consent visit and one-to-two assessment visits. 
At each assessment visit a breath sample was obtained before and after undertaking 
either an indirect bronchial challenge test or a sham challenge. The bronchial 
challenge test used Osmohale (Pharmaxis, Sydney, Australia), a MDP inhalation. This 
has an elimination half-life of 4.7 hours. The sham challenge consisted of performing 
the required inspiratory effort through the Osmohale delivery device using a 0mg 
capsule (containing no mannitol).  




The study assessments occurred at intervals of no sooner than two weeks from the 
previous assessment, in order to permit post-challenge normalisation of airways.  
Only those who exhibited a positive bronchial challenge result at the first visit were 
invited for a second, sham-challenge visit. Where possible the two assessment visits 
were completed within one month (with a two week tolerance) in order to minimise 
the potential for dropout or changes in disease activity. Study visits were postponed 
for participants reporting a recent asthma exacerbation, respiratory tract infection 
(RTI), change in treatment or significant change in either asthma control, FeNO or 
FEV1 within the previous four weeks. A ‘significant change’ was defined as the 
minimum clinically important difference in the parameters of interest – for asthma 
control this was a change of 0.5 in ACQ score (337); for spirometry a decline in FEV1 
of greater than 0.25L (338); and for FeNO an increase of 10 parts per billion. This 
was to ensure that results are not influenced by a carry-over effect from the first visit 
or a change in the underlying disease activity or treatment.  
At the study visit participants undertook breath capture and VOC sampling using a 
ReCIVA device to selectively sample late phase expiratory breath. The laboratory 
staff undertaking the analysis of breath samples were blinded through use of a 
randomly generated sample number. It was not possible to blind the researcher or 
the participant as it became apparent during the testing process whether the 
mannitol capsules were full or empty.  
5.3.3.2 Study setting 
All study assessments were conducted within the Respiratory Outpatients Clinic at 
the Norfolk & Norwich University Hospital (NNUH). Test results for all participants not 
under the care of the respiratory department at the NNUH were communicated to 
their GP in order that they form part of their primary care record.   
The risk of participant drop-out was minimised by conducting the study over a 
relatively short (one month) period for each participant. Lazar et al (192) used a two 
visit cross-over study design; they recruited 18 participants in total and reported no 
drop-outs. 
5.3.3.3 Sample size 
A formal power calculation was not possible due to a lack of information on the 
number of VOC which might be of interest and the degree of variance which might 
occur. However, van der Schee et al state that “The inflammatory process underlying 
this disease is known to provide a sufficiently differential VOC-based breath profile 
at the current sample size” and they reference two studies (174, 314) with sample 
sizes of between 10 and 20 participants in each group. 




An approximate number was calculated using MetSizeR, a publicly available 
application constructed by statisticians at University College Dublin for Principal 
Component Analysis (PCA) sample size calculations in metabolomics. For an 
untargeted analysis using nuclear magnetic resonance (NMR) spectroscopy - and 
based on 300 spectral bins of which an assumed 0.1 were significant and a target 
false discovery rate (FDR) of 0.05 - a sample size of 38 was required (19 in each 
group).  This is roughly in agreement with those sample numbers used by previous 
breathomic studies (70, 192).  
The study aimed to obtain pre- and post-MDP challenge samples from 20 participants 
with positive mannitol challenge results. Both Porsbjerg et al (339) and Brannan et 
al (340) report MDP challenge to have a sensitivity of approximately 60% for the 
identification of those with asthma. However, it should be noted that the sensitivity 
of bronchial challenge tests may be lower in populations of asymptomatic participants 
(341); hyper-responsiveness may be attenuated by treatment (342) with some 
patients becoming as non-responsive as non-asthmatics (343). In contrast, Leuppi 
et al (342) report negative mannitol challenges in only 16% of asthmatics assessed 
at their clinic (the majority of which had FEV1 >80% predicted). If a positive bronchial 
challenge result in 38% of participants is assumed, a total participant number of 55 
would yield 20 participants with a positive response upon which pre- and post-test 
analysis could be performed.  
The end of the study was deemed to have been reached once 60 participants had 
been recruited; once 20 participants had a positive bronchial challenge result (and 
sham follow-up), or by the 28th February 2019.  
5.3.3.4 Eligibility criteria 
 
Inclusion criteria 
 Male or female 
 Aged 18 or over 
 Able to provide informed consent 
 Self-report of asthma diagnosis from health professional 
o Diagnostic confirmation meeting BTS guidelines will be sought from 
primary care 
o Suspected asthma being investigated by way of mannitol challenge 
 Non-smokers; or ex-smokers of at least two years duration with less than a 
ten pack year history 
 Asthma treated according to level-1 to level-4 of BTS treatment guidelines 
 
 





 Respiratory tract infection, asthma exacerbation or change in treatment step 
within the previous four weeks 
 Major chronic cardiorespiratory disease other than asthma  
 Significant comorbid condition  
 Condition that may be compromised by repeated spirometry manoeuvres or 
induced bronchospasm (see appendix, eligibility guidelines) 
 Asthma treated at level 5 of the treatment guidelines or higher 
 Pregnant or nursing mothers 
 Current smokers or ‘vapers’ 
 Ex-smokers of < 2 years duration or > 10 pack years. 
 Participating in a clinical trial of an investigational medicinal product (CTIMP). 
 Unable to speak English. 
 Low baseline lung function (FEV1 <1.50 litres or < 70% predicted value) 
 Known hypersensitivity to mannitol, gelatin or strong anaphylactic response 
in the past.  
 
Patients with asthma treated at level-one to level-four of the BTS/SIGN treatment 
guidelines were assessed. This excluded any patients receiving oral corticosteroids 
or biologic drugs (such as omalizumab or mepolizumab). 
Patients were eligible for inclusion if they reported a diagnosis of asthma from their 
primary care physician; from their secondary care physician, or if they were being 
investigated (by way of mannitol challenge) in secondary care for possible asthma. 
If the participant was recruited from primary care, diagnostic confirmation - meeting 
BTS standards - was be sought from their primary care practice. This included a 
clinical history suggestive of asthma and diagnostic tests confirming variability in 
airflow over time (such as spirometry or reversibility testing).  
Participants were all never smokers or non-smokers of at least 2 years duration with 
less than a 10 pack year history. Participants had no other serious cardiorespiratory 
disease or significant comorbidities, and had not experienced an asthma attack, chest 
infection or changed their asthma medication within the preceding 4 weeks.  Those 
with conditions which might be compromised by repeated spirometry manoeuvres, 
or low baseline lung function (FEV1 <1.50 litres or < 70% predicted value) were 
excluded. A questionnaire was sent to the general practice of all participants to 
establish the extent to which their diagnosis could be supported (with respect to 
BTS/SIGN guidelines). For those recruited from the NNUH this information was 
extracted from their outpatient records. 
 




All participants gave their written informed consent. The study was approved by the 
Cambridge South NHS Ethics Committee and registered with ClinicalTrial.org under 
the identifier NCT03575663. 
5.3.3.5 Participant identification, recruitment and retention 
The study was conducted in accordance with Good Clinical Practice guidelines and 
according to the guiding principles of the Declaration of Helsinki; the researcher 
maintained all relevant participant privacy requirements; ensured that participant 
consent was fully informed and that potential participants had sufficient time to 
consider their inclusion in the study. All participants were informed that they were 
able to withdraw from the study at any point in time should they choose to, and that 
this would not prejudice the quality of their current or future treatment. Participants 
were reassured that all data collected in the study would be held confidentially.  
In order to maintain confidentiality, participants’ data was anonymised using a case 
reference number; personal data linked to the case reference number was be stored 
securely as was data generated by the study.  
 
Two urban general practices were recruited to act as participant identification 
centres; their patient registers screened; and those with a diagnosis of asthma who 
had been prescribed a short-acting β2-agonist and/or low dose of inhaled 
corticosteroids were sent a study invitation. All those who contacted the study centre 
(Norfolk & Norwich University Hospital Foundation Trust (NNUH)) were invited to 
attend a screening / consent visit; those who passed the inclusion criteria were 
recruited.  In addition, electronic letters from NNUH outpatient asthma clinics were 
screened and invitations sent to patients with diagnosed asthma, treated at or below 
level 4 of the British Thoracic Society asthma guidelines; advertisements were also 
placed at the NNUH and local university (University of East Anglia). Recruitment 
ceased on 28th February 2019. 
 
A flexible recruitment strategy was employed  
Advertising (poster, leaflet or electronic) 
o Advertisements in secondary care services (including respiratory outpatient 
clinics) at the NNUH 
o Advertisements on the UEA and NNUH intranet (noticeboard and email 
bulletins), and print advertisements on the UEA campus. 
o Advertisement on a respiratory research microsite within the NNUH website’s 
Research and Development pages. 




o Screening of NNUH asthma clinic lists, clinic letters, physiology laboratory 
records and/or the NNUH respiratory research database. 
o The study was accepted onto the National Institute of Health Research 
(NIHR) portfolio and two local GP surgeries agreed to act as Participant 
Identification Centres. Participating surgeries searched their clinical 
management systems and invite potentially suitable patients to contact the 
study team. A patient information sheet was sent by the GP surgery along 
with the letter of invitation. 
o Patients being referred for a mannitol challenge test as part of usual 
investigatory care or clinical indication were also eligible for study 
participation.  
 
Advertisements featured contact details for the respiratory research team. Upon 
contact from a potential participant an information sheet and letter of invitation was 
sent and a follow-up phone call made to ensure the potential participant has received 
the information.  
Those who were given study information in face-to-face contact received a participant 
information sheet and letter of invitation; they were given an explanation of the study 
and the inclusion criteria, and time to ask questions. Those who wished to offer their 
consent on the spot this were accepted only after confirming that they had fully 
understood the study. They were encouraged to take the information away, to think 
about it and discuss it with others, and contact to us with any further questions before 
deciding if they wished to participate.  
For those who were sent the study information (either in the post or electronically) a 
follow-up phone call was made in order to confirm they have received the requested 
information. If at this time the recipient expressed an interest in participation, or if 
they subsequently contact the research team and expressed interest, the researcher 
answered any questions they had, outlined the eligibility criteria, and invited the 
person to a study visit. In line with good clinical practice full, formal assessment of 
inclusion/exclusion criteria was not undertaken prior to obtaining informed consent, 
however, in order to avoid ineligible members of the public attending a study 
appointment (and thereby wasting their time) the researcher outlined the inclusion 
criteria to all potential participants before inviting them to a study visit. 
Informed consent was undertaken at the first study appointment, after which the 
participant was assessed as to whether they met the study eligibility criteria.  




Figure 13 - Participant assessments in the ABC study 
Participants or potential participants scoring >1.25 on the ACQ were encouraged to 
refer to their personalised asthma management plan and consider making an 
appointment with their care team should they feel they need help in achieving greater 
control. Assessment of patients was grouped into study assessment days in order to 
maximise time efficiency and patients sent appointment reminders by mail, email or 
phone.  
For those participants who had not taken any of the restricted medications it was 
possible to undertake the first bronchial challenge assessment at their initial consent 
visit. For example, patients using only a short-acting bronchodilator (SABA) and who 
had not used it in the prior 8 hours. Participants who had taken one of the restricted 
medications were invited back for the first study assessment at a future date when 
they had sufficient time to withhold their medications.  Communication with 
participants in order to arrange and remind about upcoming study assessments 
included contact by telephone, text, email and/or letter. 
As a thank you for participation, participants received a voucher to the value of £20 
for each assessment visit (excluding the consent visit if this was on a separate 
occasion).  
Patients who were found to be ineligible at the recruitment / consent visit were invited 
to return in the future if the reason for ineligibility was subject to change – for 
example if they had experienced a chest infection in the last few weeks. 
5.3.3.6 Assessments 
Study visits consisted of capturing demographic details, clinical history, degree of 
asthma control (using the ACQ), and asthma severity. Disease severity was based 
on the level of treatment required to achieve symptom control according to the 
BTS/SIGN guidelines. Following this, assessments were conducted sequentially as 










3. Bronchial challenge 










Those with a positive bronchial challenge response were invited for a second visit 
with a sham bronchial challenge. 
Participants’ asthma diagnoses were categorised as being of high, intermediate or 
low probability according to BTS/SIGN guidelines. For those recruited from GP 
surgeries, if the GP questionnaire was not returned and there was a negative 
bronchial challenge test, normal FeNO and no evidence of airway obstruction, the 
likelihood of asthma was graded as low.  
Mannitol & placebo challenges 
Bronchial challenge tests are recommended by both BTS/SIGN and GINA guidelines 
as a method for confirming variability in airflow limitation. Tests were undertaken by 
trained staff according to both manufacturer and clinical guidelines. This included 
post-test monitoring for 15 minutes and ensuring that the FEV1 had returned to within 
5% of pre-challenge level. Testing took place in the NNUH hospital with appropriate 
access to staff, medication and resuscitation equipment as per guidelines. Challenges 
were undertaken using an Osmohale test kit containing mannitol dry powder. 
Doubling doses of mannitol dry powder (MDP) were inhaled with two FEV1 
measurements between each dose. The MDP used was Osmohale (Pharmaxis, 
Sydney, Australia). Manufacturer guidelines suggest a single, between-dose fall in 
FEV1 of 10%, or a cumulative fall of 15% (relative to baseline) constitutes a positive 
test result. Sham challenges using empty capsules were performed in an identical 
manner with the same number of inhalations and spirometric manoeuvres as during 
the participant’s MDP challenge. As per the manufacturer guidelines patients withheld 
medications for a period of time prior to assessment, including short-acting beta-2 
agonists (8 hours), inhaled corticosteroids (12 hours), long acting beta-agonists (24 
hours), antihistamines (72 hours), leukotriene-receptor antagonists (4 days). It was 
not possible to blind the researcher or participant due to the ease of detecting the 
presence of absence of mannitol during the test procedure. 
Exhaled breath collection  
VOC were captured in a non-invasive test using the ReCIVA (see section 5.1.1.). 
Patients were asked to refrain from vigorous exercise for 24 hours and caffeine on 
the morning of the test. Diet, last alcohol intake, use of mouthwash, and home 
location were recorded to look for potential confounding factors. Participants 
breathed filtered air for 5 minutes before sampling commenced; the aim of this five 
minute period was to normalise the exhaled breath milieu post spirometry and to 
washout out VOC inhaled from the hospital environment as much as was practicably 
possible. In addition to duplicate patient-breath samples and a filtered air sample; a 
sample of room air was also obtained.  




For this the ReCIVA unit was set to collect 500mls of room air and the unit left running 
(without a mask attached) in the area in which patient sampling was to take place 
Asthma Control Questionnaire (ACQ)  
Performed as described in section 5.1.1 
Fraction of Exhaled Nitric Oxide  
Performed as described in section 5.1.1 
Phlebotomy 
Performed as described in section 5.1.1 
Spirometry 
Spirometry was undertaken according to best practice guidelines (344) which 
included spirometry both before and after the bronchial challenge test, and 
measurements of FEV1 during the test as per guidelines (345). 
5.3.3.7 Safety assessment 
Adverse events were recorded as described in section 5.1.1.  The risk of adverse 
events was deemed to be low. The study included only those with well controlled, 
mild-to-moderate asthma and satisfactory baseline lung function; using methods 
recommended by international guidelines (GINA & BTS/SIGN) and a CE-marked 
collection device already used in other clinical trials.  
 
It was anticipated that undertaking the tests had the potential to cause anxiety; 
participants were continually accompanied by staff and advised that they might 
withdraw consent at any time without their care being compromised. The aim of 
bronchoprovocation testing is to cause a bronchoconstriction reaction, this carries 
with it a known risk of bronchospasm. This risk was managed by following guidelines 
for test administration which include the exclusion of anyone with a condition that 
may be aggravated by bronchoprovocation; a step-wise increase in provocation 
dosage; close monitoring of spirometry; delivery of a post-test bronchodilator, and 
post-procedural monitoring for a minimum of 15 minutes. Undertaking the post-test 
VOC sampling delayed the administration of the post-test bronchodilator by up to 10-
15 minutes, however in doing so it also had the effect of extending the overall post-
test observation period. Tests were conducted within the NNUH, in an area where a 
physician trained to treat acute bronchospasm was available; and where nebulised 
bronchodilators, oxygen, subcutaneous adrenalin, and resuscitation equipment were 
also available. Participants were advised to take their post-test salbutamol prior to 
the post-challenge VOC capture if they felt a clinical need to do so.  
 
 




As part of the preparation for the test, participants were required to withhold certain 
medications, including asthma medications, for between six hours and four days (as 
per guidelines). Inhaled corticosteroids were withheld for 12 hours; a full list of 
medications and the times required for withholding can be found in the appendix. 
This forms part of the guidelines for this procedure (346) and is considered 
appropriate for a population of participants with asthma. Patients were advised to 
take their medication should they experience any symptoms; to prioritise their care 
over study participation and to follow their existing personalised asthma action plan 
(as agreed with their GP, nurse or respiratory clinician). It was also suggested that if 
they have any concerns over this they may wish to have someone with them for the 
period during which they are withholding medications. The safety profile for 
Osmohale  (available from 
http://www.aridol.info/assets/pdf/20151014_Osmohale_spc_uk.pdf) states that in a 
study of 1,046 subjects - which included both healthy individuals and those with 
asthma - no serious adverse effects were reported and most adverse events were 
mild and transient. 
 
5.3.3.8 Schedule 
This was a two to three visit study depending on - a) whether the first bronchial 
challenge could be conducted at the time of consent and, b) whether the participant 
exhibited a positive bronchial challenge result. Participants received an indirect (MDP) 
bronchial challenge test first. Those exhibiting a positive response were invited back 
for a second study visit at which they received a sham MDP challenge. The two 
bronchial challenge visits occurred within 4 weeks of one another (with a two week 
tolerance either way).  
While there is an extensive discussion of exhaled breath confounders in chapters 2 
and 3, it is worth here mentioning physiological determinants of exhaled breath VOC 
profiles outside of disease processes. It is likely that the expiratory manoeuvres 
undertaken in spirometry and as part of the FeNO and bronchial challenge tests would 
impact on exhaled VOC. Use of a sham mannitol challenge permits this to be assessed 
and differentiate these effects from those of the physiological response to mannitol. 
In a trio of papers by Sukul et al (347-349), breath holding, forced expiratory 
manoeuvres and body positioning were investigated for their effect on VOC. All were 
found to have an effect on breath VOC profiles however they returned to baseline 
within 10-20 seconds in the case of breath holding. The authors conclude that 
reliability of breath profiles is dependent upon the avoidance of forced breathing. 
However, it was essential to conduct spirometry in order to ascertain a baseline FEV1 
against which to judge airway response to the bronchial challenge.  






5.3.4.1 Primary outcomes 
To determine the effect of indirect bronchial challenge testing on VOC profiles in 
patients with asthma.  
1. Is there a significant difference in VOC levels between breath samples taken before 
and after an indirect bronchial challenge using mannitol dry powder? 
2. Is there a significant difference in VOC levels between breath samples taken before 
and after a sham mannitol challenge? 
3. Are there any compounds which differ significantly before and after a mannitol 
challenge which do not also differ before and after a sham bronchial challenge? 
 
5.3.4.2 Secondary outcomes 
 
What is the inter-individual and intra-individual variability in exhaled breath VOC in a 
cohort of patients with mild-to-moderate asthma? 
Is there a significant difference in VOC concentrations at baseline between those who 
have a positive mannitol challenge and those who have a negative result? 
 
5.3.4 Data Analysis 
 
5.3.4.1 Data management 
Data was managed as described previously (section 5.1.3). In addition, after 
pseudonymisation VOC samples were labelled with a randomly generated sample ID 
number before being securely transported to MIB for analysis. Those laboratory staff 
processing the sorbent tubes were blinded as to the nature of the sample until all 
samples had been processed. 
5.3.4.2 Data analysis 
Data analysis followed the plan outlined in section 5.1.4. 
Primary outcomes 
Data analysis was conducted in order to assess whether a significant difference in the 
concentration of exhaled VOC exists between pre- and post- positive mannitol 
challenge samples; between pre- and post- negative mannitol challenge samples; 
and between pre- and post- sham challenge samples. Those compounds identified as 
significantly differing across pre- and post- samples were then compared to 
determine if any were unique to the positive mannitol challenge group. 





Inter and intra-individual variability was characterised by standard deviation and by 
calculating the intraclass correlation coefficient  
Baseline samples were divided into those belonging to those with a positive bronchial 
challenge and those with a negative bronchial challenge and compound intensities 
tested for significant difference. 
5.3.5 Study approvals 
 
The ABC study was registered with the clinicaltrials.gov database (registration 
number NCT03575663). Research ethics committee (REC) approval was gained from 
Cambridge South REC on 12th December 2017 (reference number 17/EE/0430) and 
from the Health Research Authority (HRA) on the 21st December 2017. The study 
was registered with the NIHR clinical research network portfolio (central portfolio 
management system ID 35754). 
Amendment number one (protocol version 1.2; 10th May 2018) was approved by 
Cambridge South REC on the 8th June 2018 and by the HRA on 16th June 2018. 
Amendment number two (protocol version 1.3; 5th November 2018) was approved 
by Cambridge South REC on 30th November 2018 and by HRA on 3rd December 2018. 
5.3.6 Amendments 
 
Amendment One (protocol version 1.2) 
On initial application, the REC requested the exclusion of those with moderate 
disease, limiting recruits to those with mild disease (British Thoracic Society 
treatment levels 1-2).  However, a limited response was received to the mailshot 
from the first PIC. It is possible that those with very mild disease may be less 
motivated to participate in research and that recruitment in this patient population 
may therefore be challenging. Furthermore, those participants with well controlled, 
mild asthma are less likely to experience a positive mannitol challenge response 
pushing up the overall number of participants required in order to achieve 20 positive 
responses (the number required by the sample calculation).  
A request was made seeking permission for the recruitment of those treated at up to 
level 4 of the British Thoracic Society guidelines without a threshold Asthma Control 
Questionnaire score. Such patients may be more motivated to participate in research 
and are more likely to exhibit a positive bronchial challenge result.  




This treatment level includes those on a high dose of inhaled steroids and/or 
additional treatment such as an oral medication; but excludes those on oral steroids 
or biologics.  
The initial study protocol specified a randomised cross-over study design. Given that 
it was possible to blind neither the research participant nor the researcher, a cross-
over design was used solely to account for any carry-over effect from the bronchial 
challenge. However, given the short half-life of Mannitol (4.7 hours) and one-month 
interval between study visits it was anticipated this washout period would obviate the 
need for randomisation. Furthermore, washout was assessed using measures of 
pulmonary function and asthma control including spirometry, the ACQ, and FeNO. 
Conducting the real mannitol challenge first for all patients would allow the researcher 
to invite only those participants exhibiting a positive response to return for a sham 
challenge; thereby reducing the study burden on those participants with negative 
bronchial challenge results.  
Amendment Two (protocol version 1.3) 
Initially a recruitment target of 40 participants had been set. The literature regarding 
the number of participants likely to have a bronchial hyperreactivity (BHR) response 
to the mannitol challenge was varied and an estimate of 55% was made. After 
recruiting 40 participants and conducting 29 bronchial challenges it became apparent 
that this was an over-estimate; there was a BHR response rate of 38% at this 
juncture. The researcher requested the recruitment ceiling be increased to a 
maximum of 60. In order to facilitate the recruitment and assessment of these 
additional participants the study end-date was pushed back to the 28th February 
2019. As per the original protocol, recruitment would cease once 20 positive 















Several elements of the ABBA study were omitted at the sample and data analysis 
stages; table 24 details these omissions and their reasons. 
Table 24 – ABBA study omissions 
EBC analysis The systematic review of EBC 8-isoprostane (chapter two) threw 
doubt on the utility of 8-isoprostane as an asthma biomarker; and 
methodological issues (detailed in chapter 4) dissuaded us from 
pursuing this analysis. Samples were stored for analysis pending 
identification of a suitable marker and methodology for its 
analysis.  
VOC data The results of ABC data analysis (detailed in the following chapter) 
revealed methodological issues which undermined the reliability of 
the data analysis. Furthermore, difficulty in deconvolving the data 
at the pre-processing stage meant the supplied data were not of 






Due to a limited number of participants in the focus group 
insufficient data was generated for a thematic analysis. Data 
instead was used for illustrative vignettes and in an assessment of 




The identification or confirmation of markers of disease activity may provide 
opportunities for more effective asthma management, while alternative tests for 
airway hyper-reactivity would have the potential to save time and patient discomfort. 
Biomarkers appropriate for disease monitoring, phenotyping and stratification are 
key in the development of personalised medicine and targeted therapeutics and have 
the potential to create more effective management of exacerbations, reduced 
medication usage (21-24), and reduced hospital admissions. In this chapter the 
methods and rationale for both the ABBA and ABC studies have been described, and 
the history of amendments recorded to make clear those changes which took place 
over the course of the study.  




Assessing the feasibility of such research in the acute setting is an important part of 
the translational pipeline in which basic science research finds a real-world clinical 
application. Findings from these studies may aid in the identification of asthma 
biomarkers and inform the design of future studies. The studies have been peer 
reviewed and deemed by members of the AUKCAR to meet the aims of their Core 
Research Programme. The next chapter (six) presents the results of the ABC study; 
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Chapter 6 - Bronchial Challenge Testing in Asthma: The Effect of 
Mannitol Dry Powder Inhalation on Volatile Organic Compounds 
in Exhaled Breath 
 
The study aimed to determine the effect of indirect bronchial challenge testing upon 
VOC in the exhaled breath of adults with well-controlled, mild-to-moderate asthma. 
The release of inflammatory mediators was provoked through the use of a mannitol 
challenge; breath samples were obtained before and after the challenge and analysed 
by GC-MS (as described in chapter 5). 
6.1 Participants 
6.1.1 Recruitment 
Forty six adult participants with mild-to-moderate asthma were recruited, treated at 
level-one to level-four of the BTS/SIGN treatment guidelines(39). Two different 
recruitment strategies were used. In the first, two urban general practices were 
selected to act as participant identification centres; their patient registers screened; 
and those with a diagnosis of asthma who had been prescribed a short-acting β2-
agonist and/or low dose of inhaled corticosteroids were sent a study invitation. All 
those who contacted the study centre (NNUH) were invited to attend a screening / 
consent visit; of these 25 passed the inclusion criteria and were recruited.  In the 
second recruitment strategy, electronic letters from NNUH outpatient asthma clinics 
were screened and invitations sent to patients with diagnosed asthma, treated at or 
below level 4 of the British Thoracic Society asthma guidelines; advertisements were 
also placed at the NNUH and local university (University of East Anglia). A further 21 
participants were recruited via this route.  
 
6.1.2 Participation 
All patients attended a baseline visit at which they provided a breath sample before 
and after a bronchial challenge using mannitol dry powder. Those participants (n = 
16) who exhibited a BHR response (a decrease in FEV1 of > 15%) were invited to 
return and give further breath samples before and after a sham bronchial challenge. 
15 participants undertook a follow-up placebo challenge; one participant with a 
positive bronchial challenge was excluded due to asthma exacerbation in the 
intervening period.  Follow-up sham-challenges occurred no sooner than two weeks 
from the bronchial challenge in order to permit post-challenge normalisation of 
airways. 
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Baseline characteristics of participants are described in table 25. The mean age was 
52; 61% of participants were female; 11% were on the lowest level of treatment, 
prescribed only a SABA inhaler; mean baseline FEV1 was 2.98 litres; and the mean 
ACQ score was 0.52 (indicating good control). 
 
Between group difference was tested using the Chi-squared and independent-t tests; 
where ordinal data was skewed the Mann-Whitney test was used. The FEV1% 
predicted was significantly lower in those with a positive mannitol challenge (93.3% 
+16.5) when compared to those with a negative challenge (102% + 12.1), 
t(44)=2.04, p=0.047. The number of participants who - when classified according to 
BTS/SIGN diagnostic guidelines - had a high likelihood of asthma, was significantly 
larger in the positive mannitol challenge group (p=0.005). There were no other 
significant between-group differences in participant baseline characteristics. 
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Table 25 – ABC study: participant baseline characteristics 













Age years  

























 p=0.74  
Ethnicity; 
identifying as white 
British  
n (%)  
      40  









rural    n (%)  




















p=0.56   
Pack years  

































p=0.64   
Years since 
diagnosis  






+ 19.2  
  p=0.09 
Personal or 

























































p=0.33   
ACQ score  







  p=0.22 
 








  p=0.40 
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p=0.42   
Leukotriene 
receptor 




     1 
     (2%) 
8 
(17%) 




































































p=0.85   
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Change in disease activity and carry-over effect is presented in table 26; the mean 
time between visits was 36 days and there were no significant differences in 
participants between the two study visits in respect of spirometry, FeNO, ACQ and 
blood markers. Normally distributed data was analysed by the paired t-test, while for 
non-normally distributed data the Wilcoxon signed rank test was used. 
 












Days between challenge 
and placebo; days.  
Mean (range) 
36 (106)   
Blood eosinophils 





z = -0.18 
p = 0.86 
 
Blood eosinophilia 





z  = 0.00 
p = 1.0 
 
Blood neutrophils 





z = -0.39 
p = 0.70 
 
Blood neutrophilia 





z = 0.00 
p = 1.0 
 






z = -0.71 








z = -1.65 















z = -0.16 
p = 0.88 
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6.2 GC-MS results – targeted approach 
6.2.1 Data analysis – target list 
 
Chromatograms were inspected and compounds identified; this process was repeated 
with subsequent chromatograms to a point of saturation. This list was then reduced 
by excluding common exogenous contaminants, resulting in 58 compounds. Using 
this target list the remaining chromatograms were deconvolved in Masshunter 
Quantitative (Agilent, Santa Clara, USA). Data processing resulted in a data set 
consisting of 381 samples with a result for each of 58 VOC. 
 
Table 27 – List of VOC for targeted analysis 
1. Sulfur dioxide 
2. Acetone 
3. Isoprene 
4. Dimethyl selenide 
5. Ammonium acetate 
6. Furan, 2-methyl 
7. 1,3,5-trifluorobenzene 
8. Benzene 
9. Propanoic acid 
10. Heptane 
11. Trichloroethylene 








19. Maleic anhydride 
20. Ethylbenzene 
21. Benzene, 1,3-dimethyl- 
22. Phenylethyne 
23. Oxime-, methoxy-phenyl- 
24. Styrene 
25. Heptanal 


















41. 1,2-butanediol, 1-phenyl- 
42. Benzenemethanamine, N,N-
dimethyl- 
43. Benzene, (methoxymethyl)- 




47. Benzene, (bromomethyl)- 
48. Nonanal 
49. Benzoic acid 
50. 1-decen-3-one 
51. Decanal 
52. Ethanol, 2-phenoxy- 




56. Phenylmaleic anhydride 
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This target list includes acetone and isoprene; the two compounds which the 
systematic review of asthma breathomics (chapter four) found to have been reported 
as significant in three or more publications. From the list of nine compounds to have 
featured in two publications (chapter four), two - toluene and benzene – also feature 
in the above target list.  
6.2.2 Technical consistency and baseline characterisation 
 
6.2.2.1 Skew & kurtosis  
Patient sample data was log-transformed and the skew and kurtosis calculated. 
Despite transforming the data, many of the compounds exhibited high levels of skew 
and kurtosis. This is can be seen in the histograms of sample distribution (fig 14).   
This is relatively common in breathomic data which is typically heavy tailed. Of note 
is the apparently bimodal distribution of dimethyl selenide; ammonium acetate; 
heptane, 2,2,4,6,6-pentamethyl-; and nonanal, which could reflect differing levels of 
the compound in pre- and post-bronchial challenge samples.  
The results of skew and kurtosis calculations were divided by their own standard 
error; using a threshold of 1.96 to indicate normal distribution, 25 of the compounds 
were found to be normally distributed while 33 were above this threshold. These 
results are presented in table 28. Those compounds without high levels of skew 
and/or kurtosis are highlighted. Of the compounds reported to be of interest by 
previous studies, isoprene, acetone and benzene were skewed and kurtosed.
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Table 28 – ABC study VOC results: skew and kurtosis 








-0.879 0.223 1.062 0.442 N Log sulfur dioxide 
-1.227 0.223 2.927 0.442 N Log acetone 
-1.367 0.223 1.963 0.442 N Log isoprene 
-0.610 0.223 -1.438 0.442 N Log dimethyl selenide 
0.082 0.223 -0.571 0.442 Y Log ammonium acetate 
-1.291 0.223 2.672 0.442 N Log furan, 2-methyl 
-1.008 0.223 4.272 0.442 N Log 1,3,5-trifluorobenzene 
-0.979 0.223 2.675 0.442 N Log benzene 
-0.134 0.223 -0.703 0.442 Y Log propanoic acid 
0.404 0.223 0.947 0.442 N Log heptane 
0.027 0.223 0.017 0.442 Y Log trichloroethylene 
-0.083 0.223 -0.210 0.442 Y Log urea, ethyl- 
-0.973 0.223 1.124 0.442 N Log 3,5-dihydroxybenzamide 
0.308 0.223 0.835 0.442 Y Log toluene 
0.272 0.223 0.001 0.442 Y Log hexanal 
2.231 0.223 6.399 0.442 N Log tetrachloroethylene 
-0.851 0.223 0.742 0.442 N Log ß-Methylhistamine 
-1.040 0.223 1.887 0.442 N Log dimethylsulfoxonium formylmethylide 
-0.839 0.223 0.156 0.442 N Log maleic anhydride 
1.815 0.223 5.747 0.442 N Log ethylbenzene 
2.226 0.223 6.261 0.442 N Log benzene, 1,3-dimethyl- 
-0.710 0.223 1.338 0.442 N Log phenylethyne 
-0.783 0.223 0.155 0.442 N Log oxime-, methoxy-phenyl- 
-0.698 0.223 -0.208 0.442 N Log styrene 
0.056 0.223 0.170 0.442 Y Log heptanal 
-2.282 0.223 8.753 0.442 N Log methanesulfonylacetic acid 
-0.275 0.223 0.374 0.442 Y Log tricyclo[2.2.1.0(2,6)]heptane, 1,3,3-
trimethyl- 
-0.935 0.223 0.589 0.442 N Log benzaldehyde 
-0.119 0.223 -0.389 0.442 Y Log pentanoic acid 
-0.239 0.223 1.305 0.442 N Log 2-vinylfuran 
-1.388 0.223 3.752 0.442 N Log benzonitrile 
-0.696 0.223 -0.540 0.442 N Log heptane, 2,2,4,6,6-pentamethyl- 
-0.634 0.223 -0.368 0.442 N Log benzofuran 
-0.468 0.223 0.643 0.442 N Log decane 
-0.148 0.223 -0.533 0.442 Y Log octanal 
-0.212 0.223 -0.494 0.442 Y Log 3-Carene 
-0.231 0.223 -0.493 0.442 Y Log benzyl chloride 
0.419 0.223 -0.177 0.442 Y Log o-Cymene 
-0.020 0.223 -0.089 0.442 Y Log 2,2,4,4-tetramethyloctane 
0.100 0.223 -0.204 0.442 Y Log d-Limonene 
-0.211 0.223 -0.158 0.442 Y Log 1,2-butanediol, 1-phenyl- 
-0.361 0.223 -0.462 0.442 Y Log benzenemethanamine, N,N-dimethyl- 
-0.698 0.223 0.201 0.442 N Log benzene, (methoxymethyl)- 
-0.579 0.223 -0.151 0.442 N Log octane, 2,6,6-trimethyl- 
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-0.971 0.223 0.525 0.442 N Log acetophenone 
-0.571 0.223 1.167 0.442 N Log benzene, 4-ethenyl-1,2-dimethyl- 
-0.714 0.223 0.630 0.442 N Log benzene, (bromomethyl)- 
0.221 0.223 -0.655 0.442 Y Log nonanal 
0.161 0.223 1.494 0.442 N Log benzoic acid 
0.273 0.223 0.353 0.442 Y Log 1-decen-3-one 
0.295 0.223 -0.459 0.442 Y Log decanal 
0.258 0.223 -0.144 0.442 Y Log ethanol, 2-phenoxy- 
-1.553 0.223 3.882 0.442 N Log phthalic anhydride 
-0.094 0.223 0.346 0.442 Y Log tetradecane 
-0.216 0.223 0.407 0.442 Y Log  5,9-undecadien-2-one, 6,10-dimethyl-, 
(E)- 
-0.590 0.223 -0.720 0.442 N Log phenylmaleic anhydride 
0.022 0.223 0.399 0.442 Y Log pentanoic acid, 2,2,4-trimethyl-3-
carboxyisopropyl, isobutyl ester 







The results of skew and kurtosis calculations were divided by their own standard error using a 
threshold of 1.96 to indicate normal distribution; those compounds without high levels of skew 
and/or kurtosis are highlighted in grey. 
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9.2.2.2 Sample distribution  
Figure 14 – ABC study: VOC distribution histograms showing a range of skew and 
kurtosis and a bimodal distribution in some compounds. These histograms 
present the combined data from pre- and post-challenge breath samples, in both 
mannitol and sham challenges. In many cases data transformation has not 
resulted in a normal distribution. 
 
 




Key: Distribution histograms were produced using the log-transformed geometric mean of replicate 
patient samples. Raw data for compounds were in the form of intensity counts; a semi-quantitative 
method that provides relative quantification without a unit of measurement represented on the X-axis. 
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Figure 14 – ABC study: VOC distribution histograms showing a range of skew and 
kurtosis and a bimodal distribution in some compounds. These histograms 
present the combined data in pre- and post-challenge breath samples, from both 
mannitol and sham challenges. In many cases data transformation has not 







Key: Distribution histograms were produced using the log-transformed geometric mean of replicate 
patient samples. Raw data for compounds were in the form of intensity counts; a semi-quantitative 
method that provides relative quantification without a unit of measurement represented on the X-axis. 
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9.2.2.3 Correlation plot 
Non-biological variation between sample analyses in GC-MS is possible due to 
differences in the analytical equipment and instrumentation over time  – the so 
called ‘batch effect’ (350). Batch effects lead to increased variability and decreased 
power to detect significant differences (351). Attempts to remove non-biological 
variation are made by normalising data; in this study by normalising VOC data 
against an internal standard. In order to screen for correlations between compounds 
which might indicate the persistence of a batch effect despite data normalisation, a 
correlation plot was produced (see figure 15). The lack of highly correlated results 
between compounds suggests such an effect is unlikely. 
Chapter 6 – Bronchial challenge testing in asthma: the effect of mannitol dry powder 




Figure 15 – ABC study: VOC correlation plot showing few highly correlated compounds. This is 
























Key  Correlation coefficients are colour coded according to the degree of positive or negative correlation, with darker / 
stronger colours indicating an increasing degree of correlation. VOC are numbered as follows: 
1. Sulfur dioxide 
2. Acetone 
3. Isoprene 
4. Dimethyl selenide 
5. Ammonium acetate 
6. Furan, 2-methyl 
7. 1,3,5-trifluorobenzene 
8. Benzene 
9. Propanoic acid 
10. Heptane 
11. Trichloroethylene 








19. Maleic anhydride 
20. Ethylbenzene 
21. Benzene, 1,3-dimethyl- 
 
22. Phenylethyne 
23. Oxime-, methoxy-phenyl- 
24. Styrene 
25. Heptanal 

















41. 1,2-butanediol, 1-phenyl- 
42. Benzenemethanamine, N,N-
dimethyl- 
43. Benzene, (methoxymethyl)- 




47. Benzene, (bromomethyl)- 
48. Nonanal 
49. Benzoic acid 
50. 1-decen-3-one 
51. Decanal 
52. Ethanol, 2-phenoxy- 




56. Phenylmaleic anhydride 









Reliability of results can be assessed by calculating the intraclass correlation coefficient for compounds (352); this describes the degree of 
correlation for a given VOC between replicate samples.  In addition - using the geometric mean of replicates – the standard deviation of 
VOC values was calculated; this represents the degree of variation between participants. This was compared with the standard deviation 
within participants (between replicate samples). Results are present in table 29 below. Those compounds exhibiting a greater variation 
between-replicates than between-participants (suggesting unreliability) have been highlighted in grey. Similarly, intraclass correlation 
coefficients of less than 0.7 suggest unreliability; these compounds have also been highlighted.  
 
Table 29 – ABC study VOC results: intraclass correlation coefficient and standard deviation in baseline (pre-challenge) samples 
Compound Standard deviation Intraclass correlation 
coefficient Between participants  Within participant  
(between replicates) 
Data used:  
Baseline (pre-challenge) samples only; 
geometric mean of replicates, log-
transformed.  
Data used:  
all samples; log-transformed.  
 
Log sulfur dioxide 0.35 0.18 0.92 
Log acetone 0.25 0.09 0.95 
Log isoprene 0.39 0.11 0.97 
Log dimethyl selenide 1.14 0.26 0.99 
Log ammonium acetate 0.88 0.10 1.00 
Log furan, 2-methyl 0.30 0.17 0.90 
Log 1,3,5-trifluorobenzene 0.13 0.08 0.91 
Log benzene 0.17 0.10 0.92 
Log propanoic acid 0.44 0.56 0.53 
Log heptane 0.29 0.18 0.90 
Log trichloroethylene 0.12 0.04 0.98 
Log urea, ethyl- 0.84 0.17 0.99 




Log 3,5-dihydroxybenzamide 0.56 0.16 0.98 
Log toluene 0.22 0.15 0.86 
Log hexanal 0.27 0.18 0.88 
Log tetrachloroethylene 0.28 0.06 0.99 
Log ß-Methylhistamine 0.34 0.14 0.94 
Log dimethylsulfoxonium formylmethylide 1.11 0.34 0.96 
Log maleic anhydride 0.26 0.10 0.96 
Log ethylbenzene 0.29 0.16 0.92 
Log benzene, 1,3-dimethyl- 0.33 0.18 0.91 
Log phenylethyne 0.18 0.08 0.95 
Log oxime-, methoxy-phenyl- 0.78 0.30 0.96 
Log styrene 0.27 0.13 0.93 
Log heptanal 0.34 0.15 0.95 
Log methanesulfonylacetic acid 0.44 0.24 0.89 
Log tricyclo[2.2.1.0(2,6)]heptane, 1,3,3-trimethyl- 0.37 0.29 0.82 
Log benzaldehyde 0.16 0.08 0.94 
Log pentanoic acid 0.43 0.26 0.89 
Log 2-vinylfuran 0.21 0.10 0.94 
Log benzonitrile 0.24 0.12 0.91 
Log heptane, 2,2,4,6,6-pentamethyl- 0.68 0.50 0.85 
Log benzofuran 0.21 0.07 0.97 
Log decane 0.35 0.20 0.91 
Log octanal 0.34 0.20 0.90 
Log 3-Carene 0.43 0.23 0.92 
Log benzyl chloride 0.63 0.75 0.58 
Log o-Cymene 0.40 0.11 0.98 
Log 2,2,4,4-tetramethyloctane 0.29 0.33 0.67 
Log d-Limonene 0.47 0.12 0.98 
Log 1,2-butanediol, 1-phenyl- 0.42 0.44 0.68 
Log benzenemethanamine, N,N-dimethyl- 0.88 0.73 0.83 
Log benzene, (methoxymethyl)- 0.30 0.20 0.87 
Log octane, 2,6,6-trimethyl- 0.48 0.49 0.74 
Log acetophenone 0.28 0.08 0.98 




Log benzene, 4-ethenyl-1,2-dimethyl- 0.32 0.14 0.95 
Log benzene, (bromomethyl)- 0.61 0.59 0.70 
Log nonanal 0.37 0.21 0.91 
Log benzoic acid 1.25 0.98 0.87 
Log 1-decen-3-one 0.55 0.42 0.83 
Log decanal 0.38 0.30 0.82 
Log ethanol, 2-phenoxy- 0.54 0.56 0.69 
Log phthalic anhydride 0.32 0.18 0.88 
Log tetradecane 0.43 0.26 0.90 
Log  5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 0.52 0.45 0.81 
Log phenylmaleic anhydride 0.45 0.14 0.97 
Log pentanoic acid, 2,2,4-trimethyl-3-
carboxyisopropyl, isobutyl ester 
0.35 0.40 0.66 








Compounds highlighted in grey have a greater variation between-replicates than between-participants and/or intraclass correlation coefficients of less than 
0.7 suggestive of unreliability.  
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9.2.2.5 Correcting for exogenous VOC 
Correcting for exogenous compounds has been a contentious issue and a number of 
different approaches have historically been used (see chapter 3). A consensus 
method was outlined by the ERS in their technical standards for exhaled breath 
analysis (228). These recommend a) parallel sampling of ambient air for background 
correction using alveolar concentration gradients, and b) the use of VOC-filtered air. 
Calculating an alveolar gradient through background subtraction may not be accurate 
for all VOC, varying as it does according to factors relating to both the compound 
itself, duration and intensity of exposure, and the individual concerned (for example 
BMI) (302). It is possible to calculate the retention coefficient for individual VOC and 
then apply these in an effort to correct values according to inspiration concentrations 
(285). This approach might be useful once a panel of biomarkers have been identified 
however the retention coefficient for the 58 compounds making up the target list 
have not yet been established.  
Following the ERS’ technical standards study participants breathed VOC-scrubbed air 
for a period of 5min in order to reduce inhalation of exogenous compounds and an 
alveolar gradient was calculated. Using normalised data, the geometric mean of 
replicate background air samples was subtracted from the geometric mean of patient 
samples. While the majority of samples yielded a positive result after this calculation 
was performed (i.e. in the majority of cases the patient exhaled VOC in greater 
quantities than were present in the air), for a significant minority of samples this 
produced a negative value (concentrations in the air were higher than those in the 
patient breath sample). There was no VOC for which all values were positive after 
performing this calculation. Overall, after background correction 71% of values were 
positive. 
The calculation was repeated subtracting the value obtained from a sample of the 
CASPER filtered air. Again a sizeable number of negatives were present; for only one 
compound – isoprene – were negative values entirely absent. Overall 64% of values 
were positive. 
An argument can be made against background subtraction (284) but in order to 
maintain rigour it is recommended that any compound occurring in background 
samples at greater than 5% of the level found in breath samples should be excluded.  
(302, 353). Were such a rigorous approach to be applied the majority of the data set 
would be excluded; only 33 of the 58 compounds had any background samples where 
VOC levels were less than 5% of that found in the patient samples; and there were 
no compounds where this was the case for all of the samples.  
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The percentage of samples in which background VOC were found to be less than 5% 
of patient VOC ranged from 0% to 66% of samples for any given VOC.  
An alternative approach to background contaminants was trialled in which the mean 
level of each VOC in background samples was calculated; the mean plus three 
standard deviations was set as a threshold for inclusion. There were no VOC for which 
all values were above this threshold, indeed the majority of samples were below this 
threshold. Only one compound had greater than 75% of results above this threshold 
(acetone, 85%); and only two compounds had 50% of results above this threshold 
(acetone and isoprene).  
It is possible that levels of some compounds might be equal or higher in the 
background air than in the patient samples, particularly if this exogenous VOC was 
metabolised in the lungs, reducing the quantity exhaled; furthermore some 
compounds may be at the lower limit of detection, affecting reliability of the results.  
Filtered air samples were compared directly to the background air samples; when 
subtracting the filtered air values from those of the background air the results were 
frequently negative indicating that VOC / contaminants existed at higher levels in the 
filtered air than in the background air. The percentage of positive results for each 
VOC ranged from 2 to 84% with a mean of 53%.  
Given that participants underwent a five minute washout period in which they were 
breathing filtered air this was deemed the most appropriate data to use for 
background subtraction. The background calculations were undertaken on all patient 
samples – both pre and post-challenge. It is possible that some VOC might be present 
at equal or greater levels in background air (producing a negative value) when 
sampled at baseline but present at lower levels (producing a positive value) in post-
challenge patient samples due to the test procedure or inflammatory response. For 
this reason 50% was selected as the negative value threshold for compound 
exclusion.   
9.2.2.6 Exclusions 
Those compounds with negative values in greater than 50% of samples after 
background subtraction had been conducted were excluded from further analysis; as 
were those compounds with poor reliability (as indicated by a low ICC and a within-
participant SD greater than between participants). This resulted in a compound list 
of 38 VOC. Compounds excluded and the reasons are summarised in table 30. 
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Table 30 – ABC study VOC results: excluded compounds 
COMPOUND REASON FOR EXCLUSION 
1,3,5-TRIFLUOROBENZENE BG>PT 







BENZENE, 1,3-DIMETHYL- BG>PT 
PHENYLETHYNE BG>PT 
HEPTANE, 2,2,4,6,6-PENTAMETHYL- BG>PT 
DECANE BG>PT 






1,2-BUTANEDIOL, 1-PHENYL- WP>BP 
ICC <0.7 
BENZENE, (METHOXYMETHYL)- BG>PT 
OCTANE, 2,6,6-TRIMETHYL- WP>BP 
BG>PT 
BENZENE, (BROMOMETHYL)- BG>PT 
NONANAL BG>PT 
DECANAL BG>PT 















WP>BP = within-participant standard deviation greater than between-participant  
ICC<0.7 = intraclass correlation coefficient less than 0.7 
BG>PT = VOC present in background air in greater quantity than in patient breath sample in 
more than 50% of cases  
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6.2.3 Comparative data – the association of VOC with patient status 
 
The geometric mean of patient replicate samples, corrected by the values obtained 
from filtered air samples were used. Given that up to 50% of these values were 
negative, in order to log transform the data a constant of 10 was added to the values 
before transformation. R Studio was used for log transformation and production of 
boxplots. Excel was used for the constant addition and log transformation prior to 
conducting Mann Whitney and Wilcoxon-signed rank tests in SPSS. 
6.2.3.1 Baseline VOC associations with mannitol challenge outcome 
6.2.3.1.1 Boxplots 
Baseline (pre-challenge bronchial challenge) samples were categorised into those 
who had a positive response to mannitol challenge and those who had a negative 
response. Box plots were produced for each VOC (fig. 16) and a Mann Whitney test 
conducted (table 31).  
Some results were widely spread with a large inter-quartile range (IQR) and range 
(for example benzene); whereas others were closely grouped with only a small 
degree of variance (for example tetrachloroethylene). 
In the case of ammonium acetate and benzoic acid, results exhibited a large range 
in the baseline positive samples but a far smaller range in the baseline negative 
samples. Conversely, for both isoprene, furan,2-methyl and 3-carene results were 
more tightly grouped in the baseline positive and more widely spread in the baseline 
negative samples. 
While the degree of variance in the results appears to differ between baseline positive 
and negative samples, with the exception of furan, 2-methyl there is not an obvious 
difference in the median compound level between the two patient groups.  




Figure 16 – ABC study boxplots: a comparison of baseline samples categorised according to subsequent mannitol challenge result (positive vs negative). 
While some differences in distribution are apparent there is little obvious bertween-group difference in median VOC levels  
Key 
Baseline (pre-challenge) samples 
categorised according to their subsequent 
bronchial challenge result   
Positive mannitol challenge 
Negative mannitol challenge 





Baseline (pre-challenge) samples 
categorised according to their subsequent 
bronchial challenge result   
Positive mannitol challenge 
Negative mannitol challenge 
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9.2.3.1.2 Mann Whitney test  
Table 31 – ABC study: baseline association with mannitol challenge outcome 
(Mann Whitney test) 
Compound p-value 
Sulfur dioxide 0.580 
Acetone 0.393 
Isoprene 0.612 
Dimethyl selenide 0.310 
Ammonium acetate 0.836 
Furan, 2-methyl 0.032 
Benzene 0.747 
Heptane 0.393 




Dimethylsulfoxonium formylmethylide 0.800 
Maleic anhydride 0.963 
Oxime-, methoxy-phenyl- 0.628 
Styrene 0.747 
Heptanal 0.549 













Benzenemethanamine, N,N-dimethyl- 0.181 
Acetophenone 0.420 
Benzene, 4-ethenyl-1,2-dimethyl- 0.982 
Benzoic acid 0.926 
1-decen-3-one 0.645 





Phenylmaleic anhydride 0.504 
Benzophenone 0.678 
 
For only one compound was there a significant difference at baseline between 
those who went on to have a positive bronchial challenge test and those who had 
a negative one – Furan, 2-methyl. This was found to be higher in those who went 
on to have a positive challenge. Using a p-value of 0.05 is likely to result in false 
discoveries given that 38 compounds were being investigated. A Benjamini-
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Hochberg false discovery rate (FDR) calculation was conducted in Excel with a 
threshold of 0.05; all results were found non-significant.  
9.2.3.1.3 Logistic regression analysis 
 
A logistic regression was performed to ascertain the effect of VOC levels on the 
likelihood of a positive or negative challenge. Sulfur dioxide and acetone 
contributed the most to the model with significance values of 0.290 and 0.251 
respectively; nether meeting the 0.05 threshold for significance. The model 
explained 10.2% (Nagelkerke R2) of the variance in mannitol challenge result. It 
correctly classified 71.7% of cases but with an accuracy of 25% in classifying 
positive challenges; producing a very large number of false negatives. 
 
















4 12 25.0 
Negative 
challenge 
1 29 96.7 
Overall 
percentage 
  71.7 
(cut value = 0.500) 
 
 
6.2.3.2 Differentiating between pre and post-challenge samples (positive challenges only) 
6.2.3.3.1 Boxplots 
Pre-challenge and post-challenge samples were compared for those participants 
who experienced a positive mannitol challenge. The resultant box plots (figure 17) 
show no marked differences between the two sets of samples with median results 
appearing quite similar. Unlike the previous comparison there appears to be 
relatively little difference between groups in the degree of variance. However, on 
conducting a Wilcoxon-signed ranks test three compounds exhibited a significant 
difference between baseline and post-challenge – isoprene; urea ethyl; and 5,9-
undecadien-2-one, 6,10-dimethyl-, (E)-. 
  


























Paired sample analysis: pre-positive and 
post-positive bronchial challenge. 
Pre-challenge 
Post-challenge 
Figure 17 – ABC study boxplots: paired sample analysis of participants with a positive mannitol challenge – pre- vs post-challenge samples. 
For the majority of compounds there is little apparent difference in median VOC levels or distribution across the two groups.  


















Paired sample analysis: pre-positive and 
post-positive bronchial challenge. 
Pre-challenge 
Post-challenge 
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6.2.3.3.2 Wilcoxon-Signed Rank test 
 
Table 33 – ABC study VOC results: pre- vs post- positive mannitol challenge 
Compound p-value 
Sulfur dioxide 0.605 
Acetone 0.605 
Isoprene 0.017 
Dimethyl selenide 0.134 
Ammonium acetate 0.079 
Furan, 2-methyl 0.605 
Benzene 1.000 
Heptane 1.000 




Dimethylsulfoxonium formylmethylide 0.234 
Maleic anhydride 0.326 
Oxime-, methoxy-phenyl- 0.109 
Styrene 0.679 
Heptanal 0.796 













Benzenemethanamine, N,N-dimethyl- 0.063 
Acetophenone 0.301 
Benzene, 4-ethenyl-1,2-dimethyl- 0.079 
Benzoic acid 0.221 
1-decen-3-one 0.179 
Phthalic anhydride 0.088 
Tetradecane 0.642 
5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 0.039 
Phenylmaleic anhydride 0.326 
Benzophenone 0.756 
 
On conducting a Benjamini-Hochberg FDR calculation (with a threshold of 0.05) all 
results were found non-significant. In order to determine if these changes (the 
statistical significance of which were not verified after FDR) were likely to have 
occurred due to the release of inflammatory mediators caused by the mannitol 
challenge or whether these were changes induced by the testing process – repeated 
spirometry - a Wilcoxon-signed rank test was performed.  
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This was conducted on the pre- and post- challenge data from the negative mannitol 
and sham mannitol challenges (see table 34). 
Table 34 – ABC study VOC results: pre- vs post- sham & negative challenges 
Compound Wilcoxon-signed rank test 
p-value 






Sulfur dioxide 0.441 0.875 
Acetone 0.006 0.008 
Isoprene 0.614 0.583 
Dimethyl selenide 0.063 1.000 
Ammonium acetate 0.428 0.158 
Furan, 2-methyl 0.975 0.937 
Benzene 0.299 0.272 
Heptane 0.199 0136 
Urea, ethyl- 0.199 0.004 
3,5-dihydroxybenzamide 0.229 0.028 
Tetrachloroethylene 0.035 0.004 
ß-Methylhistamine 0.428 0.875 
Dimethylsulfoxonium formylmethylide 0.428 0.041 
Maleic anhydride 0.719 0.530 
Oxime-, methoxy-phenyl- 0.082 0.005 
Styrene 0.237 0.638 
Heptanal 0.766 1.000 
Methanesulfonylacetic acid 0.254 0.117 
Tricyclo[2.2.1.0(2,6)] heptane, 1,3,3-trimethyl- 0.111 0.028 
Benzaldehyde 0.558 0.272 
Pentanoic acid 0.309 0.209 
2-vinylfuran 0.178 0.754 
Benzonitrile 0.229 0.583 
Benzofuran 0.021 0.530 
Octanal 0.280 1.000 
3-Carene 0.015 0.182 
o-Cymene 0.517 0.239 
d-Limonene 0.041 0.008 
Benzenemethanamine, N,N-dimethyl- 0.393 0.638 
Acetophenone 0.192 0.071 
Benzene, 4-ethenyl-1,2-dimethyl- 0.766 0.136 
Benzoic acid 0.289 0.424 
1-decen-3-one 0.975 0.638 
Phthalic anhydride 0.339 0.973 
Tetradecane 0.894 0.308 
5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 0.009 0.814 
Phenylmaleic anhydride 0.339 0.814 
Benzophenone 0.043 0.308 
 
p-values <0.05 are highlighted in grey. 
Chapter 6 – Bronchial challenge testing in asthma: the effect of mannitol dry 




Acetone and d-limonene show a significant difference pre- and post-challenge on 
both the negative mannitol challenge and the sham bronchial challenges. This would 
suggest that the changes are due to the challenge procedure (repeat spirometry) 
rather than the presence of MDP or release of inflammatory mediators.  
Those compounds where there is a significant differene with the negative mannitol 
challenge but not with the sham suggest the change might be due to the presence  
in the lungs of MDP rather than an inflammatory reaction to it; a non-inflammatory 
pathway such as the suppression of VOC exhalates by the presence of powder; or 
altered breath profiles due to coughing. Alternatively it is possible that these are 
compounds related to inflammation that were present in those negative mannitol 
challenges which were borderline (those which saw some fall in FEV1 but not sufficient 
to meet the threshold for a positive test).  
That there are a number of compounds in which a significant difference occurred with 
the sham challenge but not with the negative mannitol challenges raises questions. 
These may be spurious results or it may be that changes induced by spirometry in 
the sham challenge are obscured or counteracted by changes which occur in the 
presence of inhaled MDP. 
Comparing pre- and post-challenge samples from those who had a positive response 
to the mannitol challenge revealed three compounds exhibiting a significant 
difference – isoprene; urea, ethyl-; and 5,9-undecadien-2-one, 6,10-dimethyl-, (E). 
Isoprene did not change significantly in those participants having a sham challenge 
nor those who experienced a negative mannitol challenge; the difference in observed 
levels may therefore be due to inflammatory changes induced by the positive 
mannitol challenge. That urea, ethyl- exhibited a significant change in the sham 
challenge, throws into doubt its utility as a marker of inflammatory activity. 5,9-
undecadien-2-one, 6,10-dimethyl-, (E) exhibited a significant change in the negative 
mannitol challenge however this was in the opposing direction (see table 35); this 
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Table 35 – ABC study: pre vs post-positive mannitol challenge samples - list of VOC 
which differed significantly (before the application of FDR) 
Compound Direction of change in 
positive mannitol challenge 
Sham or negative challenge 
Isoprene Decreased post-challenge No significant change 
 









6.2.3.3 Differentiating between positive and negative post-challenge breath samples 
 
6.2.3.3.1 Boxplots 
The following box plots (figure 18) compare the post-challenge breath samples from 
two groups - those who exhibited a positive mannitol challenge and those with a 
negative one.  


























Post-challenge samples categorised 
according to their challenge result 
Positive  
Negative  
Figure 18 – ABC study box plots: a comparison of post-challenge samples categorised according to their challenge result (positive vs negative). For the 
majority of compounds there is little apparent difference in median VOC levels or distribution across the two groups. 
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There appears to be relatively little difference between the two groups for the 
majority of VOC; an observation borne out by the lack of significant values produced 
by the Mann Whitney test conducted (see table 36). 
6.2.3.3.2 Mann Whitney test 
 
Table 36 – ABC study VOC results: positive vs negative post challenge samples 
(Mann Whitney test). 
Compound p-value 
Sulfur dioxide 0.134 
Acetone 0.890 
Isoprene 0.189 
Dimethyl selenide 0.420 
Ammonium acetate 0.764 
Furan, 2-methyl 0.059 
Benzene 0.695 
Heptane 0.580 




Dimethylsulfoxonium formylmethylide 0.310 
Maleic anhydride 0.818 
Oxime-, methoxy-phenyl- 0.189 
Styrene 0.872 
Heptanal 0.628 
Methanesulfonylacetic acid 0.926 
Tricyclo[2.2.1.0(2,6)] heptane, 1,3,3-trimethyl- 0.258 
Benzaldehyde 0.460 








Benzenemethanamine, N,N-dimethyl- 0.159 
Acetophenone 0.645 
Benzene, 4-ethenyl-1,2-dimethyl- 0.393 
Benzoic acid 0.773 
1-decen-3-one 0.612 
Phthalic anhydride 0.729 
Tetradecane 0.926 
5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 0.205 
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The Mann Whitney p-value for Furan 2-methyl was 0.004 when comparing baseline 
(pre-challenge) samples of positive and negative mannitol challenge groups; and was 
0.059 when comparing the post-challenge samples of those same groups. However, 
the Wilcoxon-signed ranks p-value for this compound was 0.605 in a paired-samples 
analysis comparing pre- with post-positive mannitol challenge samples.  This might 
suggest that Furan 2-methyl is a product of an underlying mechanism related to 
positive mannitol response but that it in itself does not change during the release of 
inflammatory mediators triggered by the mannitol challenge. 
Isoprene was the only VOC which differed significantly between the pre- and post-
positive mannitol challenge samples and did not also differ in pre- and post- 
comparisons for negative or sham challenges 
6.2.3.3.3 Logistic regression analysis 
 
A logistic regression was performed (see table 37) to ascertain the effects of VOC on 
the likelihood that participant breath samples were from a positive mannitol 
challenge. The logistic regression model was not statistically significant. The model 
explained 6% (Nagelkerke R2) of the variance in bronchial challenge response. 
Isoprene was the compound more closely associated with an increased likelihood of 
a positive challenge but at 0.187 fell short of significance. The model correctly 
classified 65% of cases but - with a large number of false negatives - had a sensitivity 
of only 13%. 
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6.2.4 Analysis without background correction 
 
6.2.4.1 Per compound analysis 
 
Given the contention regarding the best way of dealing with exogenous VOC and 
background samples; further analysis was conducted with uncorrected data. 
Compounds were not excluded based on the level present in background samples 
however exclusions based on reliability (ICC and SD) were still enforced. Data was 
normalised by the internal standard and sample volume without any correction for 
VOC found in the background air or filtered air samples. The logged geometric mean 
of replicates was used and the following analyses applied: 
A) Baseline (pre-challenge) samples were categorised into those which had a 
positive result to mannitol challenge and those which were negative. A Mann 
Whitney test was performed. 
 
B) All baseline (pre-challenge) samples were compared to post-positive 
challenge samples. A Mann Whitney test was performed. 
 
C) Post-challenge samples were categorised into those from a positive challenge 
and those from a negative challenge. A Mann Whitney test was performed. 
 
D) Baseline (pre-challenge) samples were compared to post-mannitol challenge 
samples. A paired analysis was conducted using samples from those 
participants who experienced a positive bronchial challenge only. A Wilcoxon 
signed rank test was conducted. 
 
The results are outlined in table 38. 
 








Mann Whitney test 
p-value 
Wilcoxon Signed Rank test p-value  
A 
Pre-challenge samples: 












Pre- vs post-challenge 
(positive only) 
E 
Paired analysis  




patient VOC in 
>50% of samples 
Log sulfur dioxide 0.159 0.537 0.122 0.717 0.339  
Log acetone 0.504 0.537 0.800 0.679 0.010  
Log isoprene 0.112 0.282 0.174 0.501 0.339  
Log dimethyl selenide 0.047 0.212 0.146 0.679 0.043  
Log ammonium acetate 0.268 0.386 0.181 0.756 0.017  
Log furan, 2-methyl 0.174 0.439 0.222 0.717 0.829  
Log 1,3,5-trifluorobenzene 0.549 0.555 0.854 0.717 0.213 Y 
Log benzene 0.181 0.958 0.489 0.196 0.544  
Log heptane 0.268 0.864 0.344 1.000 0.299  
Log trichloroethylene 0.628 0.684 0.174 0.044 0.000 Y 
Log urea, ethyl- 0.764 0.969 0.963 0.278 0.016  
Log 3,5-
dihydroxybenzamide 
0.533 0.325 0.489 0.015 0.063  
Log toluene 0.381 0.990 0.230 0.379 0.030 Y 
Log hexanal 0.174 0.854 0.580 0.163 0.959 Y 
Log tetrachloroethylene 1.000 0.854 0.564 0.163 0.005  
Log ß-Methylhistamine 0.393 0.344 0.213 0.234 0.141  
Log dimethylsulfoxonium 
formylmethylide 
0.112 0.618 0.289 0.049 0.943  
Log maleic anhydride 0.818 0.655 0.475 0.469 0.992  
Log ethylbenzene 0.518 0.338 0.249 0.756 0.781 Y 
Log benzene, 1,3-dimethyl- 0.122 0.834 0.258 0.049 0.329 Y 
Log phenylethyne 0.645 0.763 0.800 0.023 0.090 Y 
Log oxime-, methoxy-
phenyl- 
0.299 0.854 0.310 0.020 0.009  




Log styrene 0.420 0.358 0.278 0.148 0.544  
Log heptanal 0.344 0.694 0.800 0.756 0.111  
Log methanesulfonylacetic 
acid 
0.764 0.763 0.982 0.098 0.026  
Log tricyclo [2.2.1.0(2,6) 
]heptane, 1,3,3-trimethyl- 
0.580 0.783 0.278 0.215 0.020  
Log benzaldehyde 0.549 0.393 0.299 0.642 0.673  
Log pentanoic acid 0.645 0.937 0.764 0.959 0.057  
Log 2-vinylfuran 0.278 0.145 0.166 0.215 0.147  
Log benzonitrile 0.333 0.121 0.072 0.326 0.221  
Log heptane, 2,2,4,6,6-
pentamethyl- 
0.084 0.093 0.053 0.063 0.028 Y 
Log benzofuran 0.533 0.431 0.747 0.070 0.020  
Log decane 0.628 0.050 0.065 0.001 0.185 Y 
Log octanal 0.645 0.478 0.645 0.679 0.043  
Log 3-Carene 0.092 0.958 0.518 0.044 0.614 N 
Log o-Cymene 0.764 0.823 0.872 0.642 0.229  
Log d-Limonene 0.393 0.783 0.504 0.109 0.006  
Log benzenemethanamine, 
N,N-dimethyl- 
0.289 0.462 0.289 0.569 0.734  
Log benzene, 
(methoxymethyl)- 
0.433 0.416 0.356 0.278 0.318 Y 
Log acetophenone 0.368 0.294 0.344 0.163 0.037  
Log benzene, 4-ethenyl-
1,2-dimethyl- 
0.533 0.237 0.222 0.679 0.943  
Log benzene, 
(bromomethyl)- 
0.982 0.684 0.406 0.877 0.318 Y 
Log nonanal 0.213 0.834 0.890 0.049 0.057 Y 
Log benzoic acid 0.426 0.365 0.963 0.776 0.048  
Log 1-decen-3-one 0.420 0.823 0.205 0.918 0.478  
Log decanal 0.963 0.674 0.612 0.326 0.041 Y 
Log phthalic anhydride 0.166 0.180 0.134 0.796 0.082  
Log tetradecane 0.854 0.288 0.356 0.352 0.178  




Log  5,9-undecadien-2-one, 
6,10-dimethyl-, (E)- 
0.368 0.906 0.433 0.196 0.006  
Log phenylmaleic 
anhydride 
0.153 0.160 0.213 0.918 0.045  
Log benzophenone 0.368 0.264 0.166 0.535 0.012  
p-values <0.05 are highlighted in grey 
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The data with background correction applied revealed three compounds which 
differed significantly (prior to the application of an FDR calculation) between pre- and 
post-positive mannitol challenge - isoprene; urea, ethyl-; and 5,9-undecadien-2-one, 
6,10-dimethyl-, (E)-). In contrast, the uncorrected data revealed nine compounds; a 
list in which none of the above three feature. Of the nine compounds reported to 
significantly differ, five were excluded from the previous analysis due to background 
VOC exceeding exhaled VOC in more than 50% of samples. The remaining four 
compounds were not excluded from the previous analysis, but were not found to be 
significant when background correction was applied.  
Comparisons A and B - comparing positive with negative challenges in both baseline 
and post-challenge samples – identified two compounds which differed significantly; 
dimethyl selenide and decane; neither of which featured significantly in the results 
of the background-corrected analyses.  
None of the results from the uncorrected-data analyses were found to be significant 
after applying a Benjamini-Hochberg FDR calculation (threshold of 0.05). 
Table 39 – ABC study results: pre vs post-challenge samples - statistically significant 
results using uncorrected data (without FDR) 
Compound Direction of change in 
response to challenge 
Negative challenge 
Trichloroethylene Decrease Decrease 
3,5-dihydroxybenzamide Increase No significant change 
Dimethylsulfoxonium 
formylmethylide 
Increase No significant change 
Benzene, 1,3-dimethyl- Decrease No significant change 
Phenylethyne Increase No significant change 
Oxime-, methoxy-phenyl- Increase Increase 
Decane Decrease No significant change 
3-Carene Decrease No significant change 
Nonanal Decrease No significant change 
 
Table 40 – ABC study results: positive vs negative pre-challenge samples - 
statistically significant results using uncorrected data (without FDR) 
 
Baseline positive vs baseline negative 
 
Dimethyl selenide Lower in those who went on to have a 
positive challenge 
Decane Lower in those who went on to have a 
positive challenge 
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9.2.4.2 Logistic regression analysis 
 
Logistic regression analysis was attempted for both pre- and post-challenge 
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6.3 GC-MS results – untargeted approach  
 
Untargeted deconvolution using the eRah package (283) within R Studio was conducted by MW 
at the MIB. The data proved problematic to deconvolve; integrations for the internal standard 
peak did not seem to accurately reflect what was present and there was a high likelihood of 
phantom peaks where background ‘noise’ had been integrated. A plot of the masshunter peak 
area (x axis) against the eRah peak area (y axis) (see figure 19) shows 40 samples for which the 
integration was poor. With further work the data may prove possible to deconvolve in a more 
reliable fashion however this has not proved possible within the timeframe of this thesis. 
 
Figure 19 – ABC study: a correlation plot displaying problematic deconvolution of untargeted 
data. When examining the internal standard it is clear that for a number of samples there is a 
poor correlation between the relative abundance suggested by the mass hunter intensity 












Mass hunter peak area 
Key  
The raw data used for the analysis was comprised of intensity counts with the area under the peak 
reflecting the relative abundance of the compound. The X-axis represents that generated by Mass 
Hunter, while the Y-axis represents that produced after untargeted data deconvolution using ERAH.  
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6.4 Power calculation 
Powering future studies appropriately is of paramount importance. For this purpose 
acetone and isoprene were selected – two compounds identified both in this study 
and previously published research, and absent from the list of contaminants related 
to tygon tubing (see chapter 4). Using the compound intensity data normalised by 
the internal standard and sample volume, the mean and standard deviation for pre 
and post-challenge were calculated (see table 41).   
 
Table 41 – ABC study results: Acetone & isoprene - intensity counts 
  Acetone Isoprene 
Positive challenge 
samples 
Baseline 0.0110 (mean)  
0.0051 (SD) 
0.0044 (mean)  
0.0028 (SD) 
Post challenge 0.0116 (mean)  
0.0044 (SD) 




Baseline 0.0128 (mean)  
0.0063 (SD) 
0.0062 (mean)  
0.0037 (SD) 
Post challenge 0.0112 (mean) 
0.0042 (SD) 
0.0060 (mean)  
0.0031 (SD) 
 
These were used to conduct a power calculation for detecting a significant difference 
between positive and negative mannitol challenge samples at a threshold of 0.05 
with 80% power (see table 42).  
 
  
Table 42 – Power calculations based on acetone & isoprene 
 Number of participants required 
 Acetone Isoprene 
Baseline samples 256 76 
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6.5 Discussion  
 
The methods used in this study captured data on several VOC previously identified 
as significant in asthma breathomic studies, and indicators of sampling reliability 
were positive for the majority of VOC recorded. On initial inspection of distribution 
histograms, the majority of compounds were skewed and kurtosed despite log-
transformation, however this is not uncommon in breathomic data. The following 
compounds appeared to have a bimodal distribution - dimethyl selenide; ammonium 
acetate; heptane, 2,2,4,6,6-pentamethyl-, and nonanal. While this could reflect 
differing levels of the compound in pre- and post-bronchial challenge samples none 
of these were found to be significantly different when paired analysis of samples was 
conducted. A total of twelve VOC were identified as differing significantly after a 
positive mannitol challenge. However, the VOC differed depending on whether the 
dataset used an alveolar gradient. This is not entirely surprising given that levels of 
exogenous VOC in the background samples were high; frequently rivalling or 
exceeding that found in patient samples. That this occurred despite using filtered air 
is surprising particularly given that common contaminants were excluded from the 
target compound list. The clean air filter was used as per manufacturer’s instructions 
using tygon tubing to connect to the ReCIVA sampling device. It is worth noting that 
twelve of the contaminants thought to be related to the use of tygon tubing (see 
chapter 4) also feature in the target compound list for this study. However, high 
levels of tygon contaminants were not found at the higher flow rates used for this 
study; moreover, high VOC levels in filtered air were reported for the majority of the 
58 target compounds and not limited to those 12 linked to tygon. It is therefore not 
thought likely that the tubing played a critical role in generating contaminants.  
Numerous studies have examined VOC in exhaled breath and their potential as 
markers of respiratory disease; these studies have been the subject of several 
reviews (159, 171) the conclusions of which suggest metabolomic profiles have a 
high discriminative ability for asthma identification. The evidence regarding their 
ability to differentiate between disease control states is less clear (168), however, a 
recent longitudinal, medication withdrawal study by Brinkman et al (185) reported 
classification accuracies of 68% (GC-MS) and 95% (eNose) when comparing baseline 
breath profiles with loss of control. Despite powering the study for paired analyses 
based on prior research, and for PCA using a metabolomics sample size calculator - 
it is likely that the study was underpowered. Significant differences noted on 
univariate analysis were not sustained after the application of a FDR calculation.  
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Nevertheless, the results highlight those compounds which might be prioritised in 
future biomarker research - changing in response to a positive mannitol challenge 
but failing to exceed the threshold set when accounting for false discoveries. 
Powering future studies appropriately is of paramount importance; sample size based 
on the power calculation reported in section 6.4 is significantly higher than that 
reported in previous studies; unpaired analyses such as these require a greater 
sample size than paired analyses. While the results of the paired analyses highlight 
markers that could be prioritised in the search for biomarkers; the results of unpaired 
analyses are likely to be of greater clinical utility – for example the ability differentiate 
between VOC samples generated in the presence inflammatory mediators and those 
without.  The reliability of this sample size calculation is compromised by the 

















Chapter 7 – Exhaled Breath Biomarkers in Acute Asthma: a 
Feasibility Study  
 
7.1 Primary Objective – feasibility assessment 
7.1.1 Study participation 
7.1.1.1 Screening and recruitment 
7.1.1.1.1 Outpatient arm  
 
There were 1,095 independent screening episodes – in which paper or electronic 
notes were screened for suitability – of 764 patients; the difference being due to 
repeat or duplicate screening. 565 patients were excluded on screening electronic 
records. Information was sent or given to the remaining 199 patients. A further 23 
were excluded after disclosures made in response to receiving information or on being 
approached in clinic.  
In total, 588 (77%) of the 764 screened patients were excluded. Of the 176 patients 
who were eligible or potentially eligible for inclusion, 59 were missed in clinic and did 
not otherwise respond to the invitation – either they did not attend their appointment, 
there was no available room in which to see the patient, the researcher was unable 
to attend the clinic or the researcher was with another patient. Of those who were 
invited to participate and who were seen in clinic 42 declined to participate, while 75 
were recruited (64% of those who were approached (95% CI (55,77), and 43% of 
those who were potentially eligible (95% CI (36, 50)). 
Reasons for exclusions were as follows: comorbidity (n=103); receiving maintenance 
oral corticosteroids (OCS) or biologic medication (n=37); smoker (n=58); greater 
than a 10 pack year smoking history (n=67); either diagnosis other than asthma or 
no diagnosis yet made (n=301); no asthma attack/exacerbation within the preceding 
12 months (n=33); other (n=43).  The category ‘other’ includes those for whom 
there were no clinic letters available to screen; those who were pregnant; under 18 
years of age; non-English speaker; and those already approached via the acute arm 
of the study. The number of reasons for exclusion totals more than the 588 persons 
excluded as many patients met more than one exclusion criteria.  





During the period in which the researcher was working full time on the project and recruitment 
was open (1st March 2017 to the 3rd November 2017) 64 participants were recruited; this represents 










































(n = 1,095) 
Records after duplicates removed 
(n = 764) 
Invitations sent 
(n = 199) 
Excluded on screening 
(n = 565) 
Potentially eligible 
(n = 176) 
Excluded on approach in 
clinic 
(n = 23) 
Recruited  
(n = 75) 
No response  
(n = 59) 
Declined  
(n = 42) 
Figure 20 - ABBA study screening and recruitment diagram  (outpatient arm). The screening of 
764 patient records resulted 75 participants recruited. 




7.1.1.1.2 Acute arm  
Acute screening – there were 192 patients screened a total of 205 times; 11 were 
recruited into the acute study arm. Of the 192 who were screened, 138 (72%) were 
excluded while 54 (28%) were potentially eligible. Eleven were recruited (6% of those 
screened); 12 declined, of whom two subsequently joined the outpatient study arm.  
Of the 138 patients who were excluded, 56 were excluded due to a comorbidity; 13 
were on maintenance oral corticosteroids or a biologic medication; 24 were current 
smokers; 16 were ex-smokers with a history in excess of 10 pack years; 31 did not 
have asthma, or had asthma but were not presenting with an asthma attack; 15 were 
‘other’. The ‘other’ category included inability to offer informed consent, pregnancy, 
being in critical care, living out of area (in the region on holiday), and/or being 
distressed. 
Of the 54 potentially eligible patients, 31 (57%) were ‘missed’ or not approached for 
the study; these participants were discharged prior to being approached, or were 
either identified outside of the 24 hours-of-presentation period or with insufficient 
time for them to consider participation and complete the assessment process within 
the 24 hour period. Other reasons included the researcher being occupied recruiting 
another participant or the patient being too poorly to approach when first identified 
and either remaining too poorly to approach or being improved and discharged before 
being re-approached.  
Of the 23 patients who were potentially eligible and approached, 11 (48%) agreed 
to participate. 
Recruitment rate 
During the period in which the researcher was working full time on the project and 
recruitment was open (1st March 2017 to the 3rd November 2017) eight participants 























































(n = 205) 
Records after duplicates removed 
(n = 192) 
Excluded on screening 
(n = 138) 
Potentially eligible 
(n = 54) 
Approached  
(n = 23) 
Declined  
(n = 12) 
Recruited  
(n = 11) 
Missed  
(n = 31) 
Figure 21 - ABBA study screening and recruitment diagram  (acute arm). The screening of 
192 patient records resulted in 11 participants recruited. 




Accident and Emergency 
An audit of patients presenting to A&E between the 6th March 2016 and the 5th 
October 2017 was conducted identifying those for whom ‘asthma attack’ was listed 
as a possible, probable or confirmed diagnosis. There were a total of 1,521 patient 
presentations during this period (including paediatric cases); the number of patients 
– as opposed to presentations - may have been lower than this figure due to repeat 
presentations. Difficulty breathing was the most commonly recorded presenting 
complaint to which an asthma diagnosis was attached, however, others listed 
included the following - unwell, abdominal pain, unspecified chest pain, collapse, 
smoke inhalation, re-attendance, requesting prescription, inhalation of chemical, 
chest pain likely to be cardiac, sepsis, injury to face, unspecified bleeding, injury to 
elbow, accidental ingestion of tablets, back pain, injury to ribs, cardiac arrest, rash, 
request to see doctor, painful lower leg, headache, personal problem, post-operative 
problem, and pleuritic chest pain.  
899 (59%) of these patients were discharged home; 10 went to critical care; 4 did 
not wait; 219 (14%) were paediatric patients; 323 (21%) were transferred to AMU; 
16 were admitted directly onto respiratory wards.  
Acute Medical Unit 
An audit of patients presenting to the acute medical unit between 6th March 2016 and 
the 5th October 2017 revealed 459 patients for whom ‘asthma’ was listed as the 
presenting complaint. Of these 459 patients, 342 were admitted, while 116 were 
discharged home. Of those admitted, two went to critical care and 200 were admitted 
onto respiratory wards. 
Acute screening considerations 
Taking into account those patients admitted from A&E onto AMU, the two audits 
identify a total of 1,657 patients presenting to secondary care in the above time 
frame. Of these, 1,015 (61%) were discharged home. As can be seen by the variety 
of ‘presenting complaint’ labels with which asthma patients were initially recorded on 
the acute care IT systems, it is difficult to identify acute asthma exacerbations within 
the hospital on presentation. A diagnosis was typically added at the point of 
admission/discharge, this meant that for 1,015 potential patients, by the time an 
asthma diagnosis appeared on the system they were in the process of being 
discharged and leaving the hospital.  The alternative would be to screen every patient 
presenting with ‘difficulty breathing’ as their presenting complaint, this would 
necessitate an almost constant presence in the acute hospital departments; while 
also resulting in a huge number of unsuitable patients (for example breathing 
difficulties due to other lung disease, infection or cardiac causes). 




Furthermore it would not identify all asthma patients as many other alternative 
presenting complaints were associated with a later asthma diagnosis. It was not 
possible for the researcher to take this approach, however, for a future study with 
sufficient staffing and resources this might be a fruitful – if inefficient - method of 
recruiting.   
7.1.1.2 Consent 
7.1.1.2.1 Acute arm 
Of the 11 participants, three (27%) had questions about the study after reading the 
participant information sheet. These were 1) whether it was compulsory to continue 
on in the outpatient arm of the study after completing the inpatient arm; 2) whether 
the blood test was compulsory  (this question was asked by two patients); and 3) 
whether there was any flexibility regarding the date/time of the follow-up study 
appointment. 
All participants agreed that they had been given sufficient time in which to 
contemplate study participation. Time taken to consider participation and complete 
the consent process was a mean 98 minutes (median 72).  
7.1.1.2.2 Outpatient arm 
Of the 75 participants recruited at stage 2 (in the outpatient clinic), 11 (15%) had 
questions about participation.  
Questions were as follows: 
- The amount of time and number of visits involved 
- Whether a blood test is absolutely necessary for participation 
- How long the study lasts for 
- How much and what sort of information study participants will receive on 
completion of the study and publication of results  
- Further detail on the anonymization process and measures to ensure 
confidentiality 
- Whether it is permissible – in the event of an asthma attack - to take 
antibiotics or steroids prior to undertaking the study assessment. 
- Whether infective exacerbations of asthma were included in the study 
definition of asthma attack 
- Whether the hospital / GP would be informed if the experimental breath tests 
(VOC, EBC) revealed anything of interest or unusual 
- More information on the aims of the study and what we hope to discover 
The proportion of participants asking questions was lower than that in the acute arm; 
the reasons for which may be speculated upon.  




The participants in the outpatient arm commonly had the information posted to them 
in advance of their clinic appointment allowing a greater time to read and digest the 
material; however, it was the researchers impression that outpatient recruits were 
not necessarily better informed; during the consent process it was frequently 
necessary to discuss the study in some detail again. This impression is supported by 
the fact that many of the questions were already covered in the participant 
information sheet. Those questions above which were not covered by the PIS would 
warrant inclusion in the PIS of a future study.  
The average time to complete consent and recruitment in the outpatient arm was a 
mean 19 minutes (median 14).  
7.1.1.2.3 Focus group 
Four participants were recruited to a focus group in which the study methods were 
discussed in detail; three were recruited from the outpatient arm and one from the 
acute. All those from the outpatient arm had experienced an asthma attack, 
contacted the researcher and attended a study assessment.  
Initially it had been planned to undertake thematic analysis of the focus group data, 
however, despite invitations being sent to all study participants there were only four 
who were willing and able to attend on the dates / times available. Thematic analysis 
of such a small group was deemed inappropriate; instead a combination of summary 
and vignettes is used. 
Focus group participants were asked how they felt about being approached in the 
two different settings (acute and outpatient), whether they thought it was 
appropriate and whether they felt that they’d been put on the spot by being asked. 
Responses were:  
- P1 - No not at all 
- P2 -  No 
- P3 - No. I was a bit intrigued about why you [the patient] were picked… what 
knowledge was gone before… somebody approached you.  
- P4 - Well I just thought that was part of it [usual clinical care] to begin with 
until you said about it [research project]  
P3’s comment suggests uncertainty about how participants are identified and the 
extent to which their medical records are examined. The letter of invitation to the 
study came from a respiratory consultant at the participant’s hospital, however, it 
may have been a name with which they were unfamiliar.  




In the participant information sheet was a section entitled ‘why have I been chosen’ 
in which it was explained that those with asthma who had experienced an 
exacerbation within the previous 12 months were being invited. However, it could be 
made clear during the consent process that – outside of their asthma status - their 
general medical history had not been scrutinised. 
Next, the focus group were asked if they felt they had been given sufficient 
information on which to base a decision about whether to participate. As part of the 
consent process participants were asked if they felt that they’d had sufficient time to 
consider participation. However, asking this question of the focus group participants 
allowed them to answer this question after completing the assessments and having 
had time to reflect.  
- P1 - Yes definitely 
- P2 - I think people who have got asthma quite badly could always be keen to 
do something that will help, improve don’t you? you’re so used to it and it 
goes on but any little thing that looks as if it’s going to improve life, go for it. 
- P3 - Yes  
- P4 - Yes 
Participants were also asked whether they thought it was appropriate being 
approached and asked to do undertake breath sampling while having an acute 
asthma attack. 
- P1- Yes, true readings isn’t it? (P2 - yes, P4 – yes) 
- P2 - I thought it was very interesting; makes you think 
- P4 - Can’t do it unless you’re ill can you? the whole point of it is to do it then 
and you were quite, it was quite plain that should it cause you discomfort or 
you found all of a sudden you could not do it that you could stop; it wasn’t 
that you’ve got to have this on you know; and you said how much more you’ve 
got to put up with it. 
 
7.1.1.3 Study participation 
7.1.1.3.1 Acute arm 
Assessment of acute exacerbation while an inpatient - time from completion-of-
consent to completion-of-assessment - took a mean 137 minutes (median 116). 
Follow-up controlled assessments - undertaken as an outpatient - took a mean 59 
minutes (median 60). This information may inform the participant information sheet 
for any future study.  




However, this time does not include that required for the researcher to process 
samples (including centrifuging blood samples and freezing samples) or to clean and 
tidy facilities and equipment. These would need to be factored in when planning 
staffing and resources.  
Time between exacerbation and follow-up assessment was a mean 65 days (median 
28). Seven out of the eight patients had their follow-up within 6 weeks of their 
exacerbation; with the earliest follow-up being just 15 days after their exacerbation 
(this participant was still uncontrolled at the time of their outpatient appointment and 
so was invited to return for a further, stage 3, study-specific assessment 
appointment). 
One of the 11 participants recruited at stage one withdrew their consent, declining 
follow-up. All ten of the remaining participants attended their follow-up outpatient 
appointment in the respiratory clinic. However, two had to be excluded - one was put 
forward for a biologic while the other was diagnosed with a comorbidity. Of the 
remaining eight participants who completed a follow-up, five reported feeling back to 
‘normal’ but only three had an ACQ score of less than 1.25 (which would indicate 
good control). This does throw into doubt the feasibility of using the routine post-
admission outpatient appointment as an opportunity for obtaining a controlled follow-
up sample. It was planned that - for those not controlled at their follow-up 
appointment - a second study-specific follow-up would be undertaken once they had 
regained disease control. This was not possible for the five participants who remained 
uncontrolled at their outpatient appointment; reasons were as follows – diagnosis of 
a comorbidity; failure to return any contact; commencement of a biologic; and did 
not wish to re-attend solely for a study visit. It was possible to arrange an additional 
follow-up assessment for one participant but their ACQ score remained greater than 
1.25.   
Nine (82%) of the 11 acute recruits agreed to continue in the outpatient arm of the 
study. Two patients who declined participation when approached at stage one 
indicated that they would be happy to consider participation in the outpatient arm; 
these were approached in outpatient clinic and consented to participation. 
Prior to their exacerbation six of the participants were being treated at level-4 of the 
BTS treatment guidelines, four at level-3, and one at level-1. All but one participant 
had experienced an exacerbation in the previous 12 months; with the mean number 
being six prior exacerbations (median four). 
 




Based on the earliest peak expiratory flow recorded in the hospital notes, two 
participants were in the ‘life-threatening’ category when they first presented to the 
hospital (due to a PEF of less than 33% predicted). Four were severe (33-50%) and 
five were moderate (PEF 50-75%). See table 43. 
Table 43 – ABBA study: exacerbation severity (inpatient arm) 
Severity of attack on 
initial presentation 






7.1.1.3.2 Outpatient arm 
There were 84 participants in total – 75 participants recruited in outpatient clinics, 
and nine recruited from the acute study arm.  
Post-study questionnaires were sent to 84 participants, 20 (24%) were received 
back, of which 14 (70%) reported having experienced an exacerbation during the 
course of the study (two (14%) of those reporting an exacerbation in their exit 
questionnaire had attended a study assessment). 
Including returned questionnaires and participant contact during the course of the 
study, exacerbations were reported by 34 participants in the outpatient arm. The 
total number of exacerbations reported was 82; this figure was contributed to by one 
outlier who reported 26 attacks; the mean number of attacks reported to have 
occurred during the study duration was two (median one).  
Outpatient exacerbation assessment was undertaken in 18 participants, this was 21% 
of the 84 participants, and 53% of those participants who reported an exacerbation. 
The researcher was unable to assess while still symptomatic four patients who made 
contact; it was not possible to offer a convenient appointment in a sufficiently timely 
manner. The other exacerbations which were not assessed were those reported after 
the event by way of the 3-monthly follow-up enquiry letter or by completing the exit 
questionnaire. 
Method of contact for those 18 participants for whom it was possible to arrange an 
assessment was as follows: email (n=3); telephone (n=12); exacerbation noted at 
outpatient clinic visit (n=1); hospital admission noted on symphony (n=2); and in 
one case a follow-up visit for a stage 1 acute exacerbation was used as outpatient 
exacerbation due to the participant remaining uncontrolled (n=1).  




On two occasions the participant did not contact us but they were detected when 
screening acute asthma admissions for the acute study arm; when approached these 
participants were happy to participate. One participant underwent acute assessment 
twice (for two separate exacerbations). 
Of the 14 participants reporting an exacerbation in their exit questionnaire, seven 
stated that they’d managed the exacerbation themselves, three that they managed 
it via primary care only, two that they’d managed it via secondary care only; and 
four that they’d been managed by both primary and secondary care. Of the 20 
questionnaires returned, none reported starting a biologic but two reported having 
commenced maintenance oral corticosteroids. None reported a change in their 
asthma diagnosis. Eighteen reported returning to baseline or obtaining full control at 
some point during the study. 
The range of severity of exacerbations amongst those who attended for assessment 
in the outpatient arm ranged from mild/early to severe (see table 44). The severe 
attacks were from those patients noted on acute screening (n=2) or under 
management at asthma outpatient clinic appointment (n=1). The other two had a 
respiratory rate of 25 (meeting the criteria for a severe asthma attack) but had PEF 
rates of greater 90% predicted and no other features of severe attack.   
 
Table 44 – ABBA study: exacerbation severity (outpatient arm) 
Severity of asthma attack Number of 
participants 
Mild / early  






Participants in the outpatient arm reported their exacerbation to have started a 
median 8 days prior to assessment, with symptoms peaking 4 days prior to 
assessment (both mean and median 4). Eight participants were receiving oral 
steroids at the time of assessment. 
 




Of the 18 exacerbations captured from the 17 participants who were recruited in the 
outpatient arm the time between exacerbation and follow-up assessment was a 
median 67 days. All but one of the follow-up assessments were conducted within 6 
weeks of the exacerbation assessment.   
7.1.1.3.3 Acute and outpatient arms 
 
Table 45 – ABBA study: patient characteristics - Inpatient vs outpatient arm 
  Acute arm 
 
Outpatient arm 









Participants controlled (ACQ 








Days between onset of 
symptoms and exacerbation 
assessment 
 
Mean (+ SD) 
Median (IQR) 
10.2 (+ 8.3) 
7 (11) 
24.3 (+ 27.8) 
8 (40) 






[data missing on three] 
9  
(64%) 
[data missing on 
five] 










In the outpatient arm, all but one of the 14 participants who attended follow-up 
assessment reported feeling back to normal again, but only five (36%) gained a score 













































































 P = 0.202 
 
There was a significant difference in ACQ score, PEF percent predicted, respiratory 
rate, and heart rate between acute and follow-up assessments. While there appears 
to be a difference between acute and follow-up FeNO scores this did not reach 
significance; the mean difference between the two visits was 31ppb but the 95% 
confidence interval for this figure was -20 to +82. Similarly, the mean difference in 
PEF between the two visits was -102 but the 95% confidence interval for this figure 










































P = 0.000  


































 P = 0.887 
 
 
As in the acute arm, there was a significant difference in ACQ score and PEF percent 
predicted between the acute / exacerbated state and the follow-up assessment. Like 
the acute arm there was no significant difference between the two assessments in 
FeNO. In contrast to the acute arm, there was no significant difference in respiratory 
rate or heart rate; this may be a reflection of the less severe nature of the 
exacerbations being captured. Unlike the acute arm, there was a significant difference 
in the raw PEF rate between the two assessments. 
 
A more flexible follow-up schedule - not tied to the post-admission clinic appointment 
- might lead to a greater number of samples from participants in a controlled state. 
However, this did not prove to be the case in the outpatient arm of which only five 
scored under 1.25 on the ACQ at follow-up. That the majority reported a return to 
full control scored despite this score throws some doubt on the ability to use the 
results of the exit questionnaire as an indicator of the number of participants from 
whom it would - theoretically - be possible to obtain a controlled sample. 
In the acute arm two participants became ineligible and were excluded from follow-
up (one commenced a biologic while the other was diagnosed with a comorbidity). 
This compared with 13 participants in the outpatient arm. Of these 13, nine had not 
contacted us for an exacerbation or assessment; three completed both an 
exacerbation assessment and follow-up before becoming ineligible; and one 
completed an exacerbation assessment but was excluded before follow-up.  
 




7.1.1.3.4 Adverse Events 
Only one study-related adverse event occurred. This was in the acute study arm 
during assessment of an exacerbation. While using the Niox Vero to undertake a 
measurement of FeNO the participant developed a cough which necessitated the use 
of their salbutamol inhaler. The participant was using their inhaler frequently for 
symptomatic relief; the causality with the study assessment was not clearly 
established but nonetheless was reported as an adverse event in the study end report 
to the study site (NNUH) and REC. The cough rapidly settled and the participant was 
comfortable for the remainder of the study visit. This was documented in the patient’s 




Across both acute and outpatient arms of the study there were 86 participants, from 
whom 30 acute asthma exacerbations were sampled. These 30 exacerbations were 
captured from 27 study participants (35%, 95% CI (26, 45)); three participants 
provided samples during two separate exacerbations; 11 exacerbations were 
captured in the acute arm of the study and 19 in the outpatient arm of the study.  
Follow-up samples were obtained for 20 of the 27 participants; reasons for loss to 
follow-up were: 
- Development of exclusion criteria; this affected three participants (one 
commenced a biologic medication, while two were diagnosed with a 
comorbidity) 
- Three participants dropped out (one withdrew of consent, one failed to return 
any contact, while a third did not attend appointments) 
- Insufficient time to complete follow-up before study end 
94% of participants managed to complete all three breath assessments (ReCVA, Niox 
Vero and RTube) at each assessment.  All participants, irrespective of the severity of 
their asthma attack were able to provide an exhaled breath sample using the ReCIVA. 
During an attack 90% of participants managed the Niox Vero, compared with 100% 
when assessed in a more controlled state at follow-up. Sampling issues were as 
follows: 
7.1.1.4.1 Acute arm  
RTube – Five of those who attempted a sample needed to remove the nose 
clip before completing the test. One participant was not able to provide a 
sample of EBC; they were unable to tolerate breathing through the tube.  




At the follow-up assessment all participants were able to complete the test 
but one attempt yielded no condensate (query manufacturing fault with tube). 
Niox Vero – all participants were able to complete a least one successful 
attempt on the Niox Vero bar one; this patient was unable generate sufficient 
exhalatory effort to complete the test. The aim was to undertake three 
readings in order to assess reliability within the acute setting. Two patients 
took six and seven attempts in the course of their assessment and stopped 
before managing to obtain all three readings. At follow-up all participants 
managed to complete the test (with the exception of one participant for whom 
the test was not attempted due to practical / resourcing reasons). 
7.1.1.4.2 Outpatient arm  
RTube – all participants completed the test when attempted during their 
exacerbation, although eight (27%) had to remove their nose clips during the 
test. In two cases there was very little sample collected (one was too small to 
pipette). There was also an equipment failure with one tube – a sample had 
been collected but leaked during the harvesting process. At follow-up all 
participants completed the test and only three (15%) had to remove their 
nose clips part way through. 
Niox Vero – During asthma exacerbation, two patients were unable to 
complete the test. One was unable to sustain their exhalation for the sufficient 
length of time, the other was already familiar with the test and declined to 
attempt it such was her certainty that she would not be able to manage it. At 
follow-up all completed the test successfully. 
 
Table 48 – ABBA study: sampling method success 
SAMPLING METHOD ACUTE AND OUTPATIENT ARMS COMBINED:  
NUMBER OF PARTICIPANTS PROVIDING A SAMPLE 
Acute exacerbations 
n = 30 
Follow-up 
n = 20 
VOC SAMPLE 30 (100%) 20 (100%) 
EBC SAMPLE 27 (90%) 19 (95%) 
FENO RESULT 27 (90%) 19 (95%) 
SPUTUM SAMPLE 11 (37%) 3 (15%) 
SERUM SAMPLE 22 (73%) 16 (80%) 
FBC 26 (87%) 15 (75%) 
 




A serum sample was obtained in 73% of exacerbations. Reasons for a lack of serum 
sample and absence of FBC include failed phlebotomy attempts, needle phobia or 
patient declining this aspect of study participation (for example due to having had 
multiple blood tests or cannula insertion as part of their standard clinical care). The 
figure for FBC is slightly higher than that for serum due to those participants who 
had phlebotomy as part of their standard care but declined further phlebotomy for 
the study. 
Sputum samples were obtained at only 37% of exacerbation assessments and 15% 
of follow-ups. A low yield of spontaneously expectorated sputum samples at the 
follow-up visits is not entirely surprising given that participants’ asthma was largely 
controlled at this point. Reasons for a lack of sample in the exacerbated state included 
an inability to produce a sample but also patients declining to attempt active cycle 
breathing techniques in pursuit of a sample. 
7.1.1.4.3 Sampling considerations 
Sputum and the metabolomics of respiratory infection 
One potential application of exhaled breath metabolomics in asthma might be the 
identification of infectious exacerbations; in particular identifying those with a 
bacterial infection whom antibiotics would benefit. Based on the current study design 
this would be challenging and would require large participant numbers in order to 
generate sufficient sample numbers. There are a number of modifications which 
might address this. Yield at the follow-up visit might be increased by undertaking 
induced sputum sampling. This method requires the inhalation of nebulised saline to 
provoke cough and increase mucous clearance. This could be undertaken for those 
participants who were successful in producing a sample during the acute stage. 
However, it would be necessary to first ascertain whether spontaneous sputum 
samples differ from induced sputum samples in terms of identification of infection, 
and also whether the induced sputum process has any effect upon exhaled breath 
VOC. A study looking at infection would not necessarily need to be longitudinal; a 
cross-sectional design might be more appropriate in which case the question would 
be how to increase the number of sputum samples in the acute stage. One option 
would be to use induced sputum sampling during asthma attack, this could be done 
only for those who were not able to provide a sample (in which case differences 
between induced and spontaneous sputum would need to be taken into account in 
addition to the effect – if any – upon exhaled VOC). Undertaking induced sputum 
sampling during asthma exacerbation may be challenging; patient recruitment might 
be negatively impacted; and it may not be appropriate for those experiencing a more 
severe asthma attack.  




It may be that with multiple breath assessments patient effort was diluted and 
participants were less motivated to provide a sputum sample. If the study was 
designed solely with infection in mind and the participant understood this from the 
patient information sheet and consent process a larger number of participants might 
be willing to go through the active cycle breathing techniques and provide maximum 
effort in attempting to provide such a sample. That this would increase the 
percentage of participants providing a sputum sample is speculation. 
Exhaled breath condensate 
The European Asthma research and Innovation Partnership (EARIP) reached similar 
conclusions to those in chapter 2 of this thesis; they state that although EBC methods 
have the potential for use in asthma diagnosis / monitoring there needs to be 
increased standardisation in both sample collection and analysis (101). While the EBC 
analysis of 8-isoprostane has not proceeded, other potential markers could be 
sought. Moreover, a metabolomics approach such as that which is being applied to 
the exhaled breath gases could also be applied to EBC (or serum) by way of LC-MS; 
such analyses have differentiated between samples from healthy controls and those 
with asthma (101). Ibrahim et al used EBC as a biomedium for a metabolomics 
analysis; their feasibility study suggests it would be possible to collect both 
simultaneously for use in a systems biology approach, to study the whole of the 
exhaled breath metabolome (both volatile and non-volatile) (354). 





Table 49 – ABBA study: sampling success rates 
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The RTube collection period was a standardised 10 minutes; it took a mean seven minutes to obtain a breath VOC sample of 500ml using 
the ReCIVA; while it took a mean three minutes and two attempts to obtain a successful reading using the Niox Vero.  




It took a mean 49 minutes to get EBC samples into the -80oC freezer. This time was 
comprised of the remainder of the study assessment; saying goodbye to the 
participant; completing paperwork; cleaning the room / equipment; preparing it for 
transport; and transporting the sample to the freezer room. This time would likely be 
reduced if a future study was taking fewer other samples or could be reduced to 
approximately 5 minutes were additional staff available for the transport and 
processing of samples. Based on the current processes, selection of a target analyte 
for EBC sample analysis would have to take into account the sampling-to-freezing 
time; a time during which biochemical processes would continue (for example 
oxidisation). Similarly, if the samples from this study are to be analysed the analyte 
would need to be stable in storage for the period which has elapsed since the first 
samples were collected. 
7.1.1.5 Data extraction 
Data extraction relating to PEF during admissions was frequently incomplete. It was 
hoped that it would be possible to use inpatient peak flow charts to track when the 
patient achieved 75% of predicted or previous best PEF. This could potentially be 
used in an analysis of VOC or EBC marker; looking for a correlation between an 
exhaled breath compound and the length of time required to regain lung function. 
However, it was frequently difficult to find peak flow charts in the patient notes and 
when present these tended not to be completed with a frequency that would permit 
identification of this moment with any accuracy. Data extraction conducted 
retrospectively was frequently challenging due to the size, complexity and 
organisation of some patient records. If the study were to be repeated, even though 
it is frequently difficult (due to time, demands on the paperwork from other 
professionals, and a lack of physical resources such as desk space) it would be 
prudent to undertake the fullest possible data extraction at the initial visit, and return 
to extract data from the notes over the course of the participant’s admission rather 
than relying on requesting notes post-discharge. 
7.1.1.6 Sample processing 
7.1.1.6.1 Exhaled breath condensate 
The planned analysis of EBC samples from the ABBA study was not conducted due to 
the equivocal findings of the systematic review of EBC 8-isoprostane (see chapter 2) 
and the inability to detect 8-isoprostane using a commercially available ELISA kit 
(see chapter 4); a result which the review findings suggest is perhaps not uncommon. 
The samples remain in storage at -80oC pending the establishment of a reliable and 
sensitive method of 8-isoprostane detection or selection of alternative biomarker. 
Unless it were to be established that there is little inter-and intra-individual variation 
in EBC dilution a method of sample dilution calculation is required.  




Whether sample conductivity can be used will depend on the stability of the marker 
of choice when the sample is subjected to lyophilisation. An alternative method of 
sample dilution calculation (such as serum albumin) could be used as the majority of 
participants have contemporaneous blood results. Given the duration of storage, the 
marker of choice would need to be stable for extended duration at -80oC. 
7.1.1.6.2 Volatile organic compounds 
Isoprene is ubiquitous in exhaled breath samples and was used as an indicator of 
successful sampling. Similarly it was anticipated that breath humidity would result in 
water retention; the presence of water was therefore used as another indicator of 
successful sampling (with a threshold of 1.0mg used). Mean water retention was 
2.7mg (SD 1.45mg).  
Three tubes were not effectively dry purged and retained too much water for 
successful GC-MS analysis. Eleven samples had water quantities < 1.0mg; while 
seven samples were associated with low or absent levels of isoprene. Three of the 
seven had both low isoprene and low water retention levels. These levels may be a 
reflection of a wide distribution of isoprene concentration and water retention across 
the data set, alternatively they may indicate an issue with sampling. Table 50 
presents those samples which failed to meet the above thresholds. As a percentage 
of the total patient samples taken these make up 15%. 
 





Table 50 – ABBA study: sampling and analysis issues 




Water retention < 
1.0mg 
Low or absent 
isoprene levels 
PIN 28  
Acute exacerbation 
 No issues noted at time of sampling. 
No device data available 







No issues noted at time of sampling 
Device data suggests sampling successful 
 PIN 17 
Acute exacerbation 
 PID 36 
Acute exacerbation 
No issues noted at time of sampling 







 No issues noted at time of sampling 
Device data suggests sampling successful 
 PIN 60 
Acute exacerbation 
 
 PIN 17 
Controlled follow-up 
Patient had low isoprene levels in their previous visit; this is a consistent result across study visits. 
No comments made by researcher but device data shows sample volume of just 220ml. 
 PIN 17 
Controlled follow-up 
PIN 56 
Controlled follow-up  
PIN 56 
Controlled follow-up 
No issues noted at time of sampling 
Device data suggests sampling successful 
PIN 68 
Acute exacerbation 
 No issues noted at time of sampling 
Device data suggests sampling successful  
PIN 73 
Controlled follow-up 
 No issues noted at time of sampling 
Device data suggests sampling successful 






 Only 20% of the sample volume / 180ml collected in the 10 minute sampling window. Reason unclear - fit of mask and 
head strap adjusted (good seal achieved); slower breathing encouraged in order to improve tracking and sample 
gating. Patient was bearded. There is a mis-match in respiratory rate with the researcher recording 24-30 and the 
device data suggesting 12. 
PIN 80 
Acute exacerbation 
 Sample capture was slow, took the full 10 minute sampling window.  
The respiratory rate as recorded by the researcher was 24 breath per minute and shallow. 
In contrast to this, device data reports a respiratory rate of 13 and a 540ml sample taken. 
 
 
When undertaking sampling the ReCIVA allows parameters such as sampling volume and collection rate to be modified, it then reports when the specified 
sample volume has been collected and the time taken to do so. All other data recorded by the ReCIVA during sampling is saved in a proprietary format 
and is not displayed by the user interface on the laptop. MW from the MIB developed a programme using R to read these files. While the use of such a 
programme might have alerted to the researcher to certain sampling issues, in the majority of cases above the device data appears to suggest that 
sampling was successful.   In two cases the respiratory rate as recorded by the researcher was at odds with that recorded by the device. The rate recorded 
by the researcher was simply a snapshot of respiratory rate at a midway point in collection whereas the rate presented by the device represents an 
average over the collection period. The latter should be more accurate but a mismatch between the two could indicate difficulties in detecting the 
respiratory rate and a subsequent sample-gating issue. Of note is the fact that only 3 of the 10 samples where issues were noted occurred in the controlled 
/ follow-up assessment, with the majority occurring during the acute assessment. This might suggest that the frequently rapid breathing rate of the acute 
patient poses problems for sample gating. 
 




7.1.2 Acceptability of study methods 
 
The acceptability of the three breath capture devices used in the study was assessed 
by way of a visual analogue scale (VAS) and the assessment of acceptability 
questionnaire (AAQ); a participant focus group was used to explore feelings about 
study participation more generally.  
The VAS was presented with a range of 0 (‘very acceptable’) to 10 (‘not at all 
acceptable’). The AAQ was scored in the same direction with a higher AAQ score 
indicating increased unacceptability of the device. Possible scores range from 7 (most 
acceptable) to 40 (most unacceptable). 
Across both the acute and outpatient study arms, the AAQ and VAS were completed 
153 times. VAS scores ranged from 0 to 9; while AAQ scores ranged from 7 to 27. 
Results are summarised in table 51. The average VAS score was less than three for 




















Table 51 – ABBA study: acceptability of breath capture devices 
 RECIVA Niox Vero RTUBE RECIVA Niox Vero RTUBE 
 Total across visits  
 
Exacerbation Follow-up Exacerbation Follow-up Exacerbation Follow-up 
VAS SCORE 









































































The ReCIVA and the Niox Vero appear to be similarly acceptable, with the RTube 
the least acceptable of the three devices used.  
Whether considering the VAS score or the AAQ-R, the Niox Vero was deemed 
marginally more acceptable when the measurement was undertaken at the 
controlled, follow-up appointment than when it was undertaken during acute 
exacerbation. In contrast the ReCIVA was deemed slightly less acceptable at 
follow-up when compared to the acute setting. Acceptability of the RTube was 
consistent across both settings. The difference in scores between the assessment 
settings were not found to be statistically significant when assessed using a paired 
samples t-test. 
Although the differences between assessment settings were not found to be 
significant it is interesting to note that the results of the VAS score also differed; 
and although the direction in which the AAQ-R score differed was different for the 
ReCIVA (less acceptable at follow-up) and the Niox Vero (more acceptable at 
follow-up), the VAS score differences were also in the same directions. If the 
setting did indeed have some small effect on attitudes towards acceptability, it is 
not clear why this would be in opposite directions for the two devices.  
The AAQ-R, like the VAS score, does not have an established threshold for whether 
a device should be used in a study; it is merely data to inform the decision making 
process of researchers. Despite grading a device as poor in terms of acceptability 
a participant may nonetheless be very happy to participate in research; deeming 
the discomfort (or whatever the reason for a low acceptability level) worthwhile 
for the stated research aim. The results may also inform the design of a future 
participant information sheet. The acceptability scores may give some indication 
of the number of participants likely to say yes to study participation, likely to 
complete the assessment, or likely to drop-out if asked for a repeat measurement. 
However, given that the study has generated these actual figures – the number 
declining participation; the number dropping out – attempting to imply this from 
acceptability data adds little value. It may help to make informed decisions about 
device design, and whether a device, if rolled out for - for example for home use 










Table 52 – ABBA study: focus group feedback on device acceptability 
 Focus group 
comments in grey 
 CRF comments in 
white 
RTube Niox Vero 
(frequently referred to by patients during the focus group 
as ‘the cloud’) 
ReCIVA 
P1 I struggled with that one and the 
nose clips. 
That one is my worst.  
Dried my throat out a little bit. 
Probably wouldn’t do it at home. 
Those two [ReCIVA and RTube] are 
kind of almost like, not suffocating 
but… it’s covering my face and I feel 
a bit claustrophobic. 
I found that one [RTube]… because 
your nose is blocked and then you’re 
dry as well and it’s almost like you’re 
afraid to swallow because everything 
is dry, and that kind of puts a … well, 
a slight panic. I wouldn’t panic while I 
was doing it but it can make you feel 
a bit uncomfortable. 
 
I love it. 
The cloud is my favourite. 
I’d do the cloud at home, I probably wouldn’t do the others. 
That one is just blowing into a machine and playing around 
with a cloud which is fun, plus I don’t feel so claustrophobic. 
I love technical things, I love gadgets and stuff so that [the 
Niox Vero] I really like 
Probably wouldn’t do at home. 
Facilitator: anything at home where 
you had to wear a mask - even if it 
was say for 10 minutes - that might 
put you off? Yeah I think so 
Those two [ReCIVA and RTube] are 
kind of almost like, not suffocating 
but… it’s covering my face and I feel 
a bit claustrophobic. 
Least favourite. 
Would do it at GP surgery if asked 
[and in preference to the RTube] 
 
P1  Fun and easy to use The device was comfortable and easy 
to use 
P2 No real preference [between RTube 
and the Niox Vero] 
Agreed with the following statement 
from another participant - because 
your nose is blocked and then you’re 
I still have trouble with it 
just keeping it at that level, and to keep it there. 
I say ‘not the cloud, not the cloud’ 
The cloud and I didn’t get on very well. 
Would do it at GP surgery if asked 




dry as well and it’s almost like you’re 
afraid to swallow because everything 
is dry, and that kind of puts…well a 
slight panic  
Would do it at GP surgery if asked 
I remember being cross with myself because I couldn’t get it 
to work. 
No real preference [between RTube and the Niox Vero] 
I’d probably get to grips and I’d argue with myself until I got 
it right. If you were doing it yourself that would probably be 
the easiest one to cope with. 
I’d prefer to do that [the Niox Vero, when compared with 
ReCIVA or something with a mask] if you could get to grips 
with it and got practices at it 
Yes, once you’d got to grips with it 
P2 I don't know if some people would 
be able to use the device 
Once you get the hang of it then OK If this device will give accurate 
information it could be a good thing. 
P3 I didn’t mind the clip [nose clip] and 
doing that [RTube]. 
Now I tolerated that and that one 
but when I’ve had anaesthetic I can’t 
have a mask over me 
Would do it at GP surgery if asked 
I had great difficulty a couple of months ago trying to do 
that.  
I can’t, I haven’t got much ‘out’, I can breathe in but it’s the 
‘out’. 
No the cloud and I didn’t get on very well. 
It didn’t really matter but I was annoyed with myself that I 
couldn’t do that. 
You’d have to practice with it. 
I think this was the hardest thing. 
Would do it at GP surgery if asked 
P3 Seemed a long time; nose clip a little 
uncomfortable, but still very useful. 
All OK; found it fun to watch Did not find it unpleasant at all 
P4 Agreed with the following statement 
from P1 - Those two [ReCIVA and 
RTube] are kind of almost like, not 
suffocating but… it’s covering my 
face and I feel a bit claustrophobic  
Cloud is my favourite 
I couldn’t quite grasp what I was meant to be doing with 
the cloud to start with, it took two goes to actually realise 
what it was about. 
 
That one is my worst 
Agreed with the following statement 
from P1 - Those two [ReCIVA and 
RTube] are kind of almost like, not 
suffocating but… it’s covering my 
face and I feel a bit claustrophobic 
 




7.1.3 Acceptability of Assessment Questionnaire  
7.1.3.1 Evaluation 
As discussed in chapter four (developing a methodology) the AAQ-R was designed 
with the following eight criteria in mind - appropriateness; acceptability; 
feasibility; interpretability, precision, reliability, validity and responsiveness (296, 
300).  
7.1.3.1.1 Appropriateness  
Is the instrument content appropriate to the questions which the application 
seeks to address  
Both appropriateness (is the instrument content appropriate to the questions) and 
face validity (does the instrument measure what it claims to measure) were 
assessed during the questionnaire design stage through the input of health 
professional colleagues and the AUKCAR PPI group.   
7.1.3.1.2 Acceptability  
Is the instrument acceptable to patients? 
Feedback from members of the PPI suggested that its use would be acceptable to 
them. The time taken to complete the questionnaire - a mean 2.7 minutes (median 
2.0) - seems likely to be an acceptably small amount of time, adding little to the 
study burden for either participant or researcher. Furthermore, the absence of 
incomplete or not attempted questionnaires again suggests a level of acceptability 
to participants.  
Four study participants attended a focus group; among the topics discussed were 
their opinions on the AAQ-R. Little usable feedback was generated with regards to 
the AAQ-R – one participant stated that the questions were really clear and that 
they thought it was good; another expressed an aversion to questionnaires in 
general but observed that the use of statements accompanied by a range of 
emoticons such as are used on pain scales (smiley face to grimace) might simplify 
the format and make it more accessible, particularly to those with a language 
barrier or learning difficulty. This would not however address the fact that the 
questionnaire relies on statements to elicit a reaction on acceptability. 
7.1.3.1.3. Feasibility 
Is the instrument easy to administer and process? 
The experience of the researcher was that the questionnaire was easy to 
administer. The only issue noted was that the direction of scoring for the VAS was 
opposite to that of the participants expectations – in one or two cases the score 
on the VAS was in sharp contrast to the participants other responses and apparent 




experience, on questioning they stated that they had made an error and had not 
read the scoring instructions.  
It is possible that other errors in this question went unnoticed and that the 
correlation between VAS score and AAQ would have been stronger had the scoring 
on the VAS scale been reversed in its orientation. Data entry and processing was 
straight-forward.  
7.1.3.1.4 Interpretability and precision 
How interpretable and how precise are the scores of the instrument? 
Scores on the AAQ-R can range from a minimum of 7 (very happy with use, very 
comfortable, and suitable for use during any severity of asthma attack) to a 
maximum of 40 (very uncomfortable, very unhappy to use, and not suitable for 
use during even a mild attack).  
Most questions having a range of 1-5 allows for a degree of precision; should the 
researcher wish to look at any individual question, a five point scale is large 
enough to capture meaningful differentiation. However, an overall score of 7-40 
results in a large data range; the question can be asked as to what the minimum 
clinically significant or meaningful difference in score might be (whether a score 
of 27 is significantly less happy with the device than a score of 25; and whether 
this is likely to translate into any clinically significant action such as cessation of 
device usage). Without a gold standard to compare against it is challenging to 
quantify the precision of the instrument scores. The question posed by the Oxford 
University Patient Reported Outcomes Measurement group (300) is whether the 
questionnaire results in usable data that can be statistically analysed with 
meaningful outcomes. The data has certainly shown that the RTube was deemed 
less acceptable to participants than either of the other devices. In and of itself this 
does not tell us any more than the VAS results; however, the AAQ allows us to 
see what elements contributed to this unacceptability.  
Participant scores on the VAS ranged from 0 to 9; while AAQ-R scores ranged from 
7 to 27. It is interesting to note that participants were happy to score a 9 on the 
VAS (the 2nd highest possible score for unacceptability), whereas the maximum 
score on the AAQ-R was 27 out of 40, some way short of the maximum score for 
unacceptability. This suggests that the AAQ-R is a more discriminative test and is 
capturing some elements of the device which the patient deems to be acceptable. 
 
 




7.1.3.1.5 Reliability  
Does the instrument produce results that are reproducible and internally consistent?  
Across both the acute and outpatient study arms, the AAQ-R was completed 153 times.  
It is possible that the perceived acceptability of a device might change depending 
on the context in which a patient is asked. Asking whether a device might be 
suitable to use during a severe attack may elicit a different answer if the question 
is asked during such an attack as compared to when it is being posed as a 
hypothetical question during a period of control. While the average scores in the 
exacerbated and controlled states do differ, the direction of difference is not 
consistent (for example, at follow-up the ReCIVA scores more highly than during 
an exacerbation, whereas the Niox Vero scores slightly lower). The difference is 
however small; it was not found to be statistically significant when tested using a 
paired samples t-test; and there is little-to-no difference in scores for the RTube 
across settings. This would suggest an encouraging degree of reproducibility in 
test results.  
7.1.3.1.6 Responsiveness 
Does the instrument detect changes over time that matter to patients? 
This question is perhaps less relevant to the AAQ-R. The acceptability of a device 
depends not only on the device related factors such as comfort, time required to 
complete the assessment but also perhaps upon contextual factors such as the 
location of assessment, familiarity with the device (likely to improve if enters 
clinical practice), current health status and belief in the potential benefit of using 
the device. One might anticipate attitudes towards the acceptability of a device to 
depend upon on the severity of a patient’s condition and the potential benefit a 
device might offer. Moreover, attitudes to self-care, and the wider patient-disease 
relationship in chronic conditions may be subject to change over time; change in 
these broader health attitudes may result in a change in the threshold of what an 
individual might consider acceptable. Without having undertaken 
contemporaneous assessment of broader health attitudes it is not possible to 
comment on the extent to which the AAQ-R is sensitive to such changes over time.  
The more pertinent questionnaire for the AAQ-R is not whether it detects change 
over time but whether it detects difference between devices. As can be seen from 
table 51 the results of the AAQ-R suggest there is a difference in acceptability 
between the RTube and other devices. This result is corroborated both by the VAS 
score and the researchers own experience of conducting the tests – informal 
feedback from participants on the RTube (primarily the use of the nose clips) was 
more consistently negative than that of the other devices.   





Does the instrument measure what it claims to measure? 
Face validity was established through feedback from health professionals and the 
Asthma UK PPI group.  
The is no gold standard PROM against which to compare the results of this study, 
however, the degree of correlation between AAQ result and VAS score was 
calculated using Pearsons correlation co-efficient; r=0.732, p=0.00 suggesting a 
strong positive correlation. The relationship can be seen in the scattergraph below 
(figure 22), which exhibits a linear relationship between the two measures of 
acceptability.  
 
Figure 22 – ABBA study scattergraph of VAS versus AAQ score indicating a linear 
relationship between the two. The coefficient of determination (R2) = 0.54 
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Table 53 shows comments from the free text section of the AAQ-R and the overall 
score they gave to the device (comments are taken from all study stages and all 
devices). It can be seen that the overtly negative comments are generally 
associated with a higher score and vice versa. This subjective assessment does 
appear to lend support to the questionnaire validity; scores appear to represent 
patients overall views on device acceptability.  Table 54 presents a summary of 
focus group participants’ views on the assessment devices alongside their scores 




Table 53 – ABBA study: comments and AAQ-R scores 
Comment Score 
I like the design, it's a fun way to get a constant breath at an appropriate rate 7 
All OK 7 
The device was very comfortable and did not make me feel claustrophobic like some do. Also it was much 
quieter. I would say that I felt relaxed. 
7 
Very simple piece of kit; comfortable and easy to use 7 
I am able to use this machine quite easily 7 
Did not find it unpleasant at all 8 
Unsure if this device could be used during a major attack, for the timescale it would be used. Other than 
this, very comfy to use 
8 
Happy to use while in hospital during a severe attack but not at home alone 8 
Mouthpiece a little uncomfortable on the lips 8 
The device was comfortable and easy to use 8 
The equipment may need to be simplified for home use. My lips touched the tubes. Maybe remember to 
say if patient may shut mouth and breathe through the nose during the test. Fine. 
8 
Absolutely fine 8 
The headset is comfy and easy to use, I just needed to hold the nose area of the mask to get a good seal. 9 
It would be helpful if we had one at home for when symptoms are worse, to be able to compare / 
monitor. I always feel comfortable with this test. 
9 
I have no worries about the device but do think that an old person might feel a bit anxious  10 
All fine 10 
Easy to do, so long as you can breathe at the beginning of the test 11 
If the device was made to operate easier by myself I would be comfortable to use it at home. I found the 
whole experience very acceptable  
11 
Only thing with the test is the fact of wearing a nose clip, really hampers breathing. 12 
More difficult to use as I am a natural nose-breather; left me feeling a little dizzy at the end. 12 
Feel much better 14 
The mask could feel a little claustrophobic when having a moderate-to-severe asthma attack; having 
anything over ones face can be quite upsetting. The airflow made my mouth dry. 
14 
Nose plug always slightly uncomfortable, generally easy to use though if I was having a flare up I feel it 
may aggravate things. 
14 
Found it fun to watch 15 




Having had some difficult exacerbations this week as an inpatient I was a little bit hesitant to accept the 
test, however I found it went very well 
15 
A little hard to draw breath but, all told, very good 17 
Seemed a long time; nose clip a little uncomfortable, but still very useful. 18 
OK once you get the hang of it 18 
I felt the nose clip uncomfortable as I realised I couldn't breathe out very well; overall easy to use. 19 
Main issue that bothered me was the feeling of an almost inability to get a breath in. As a whole relatively 
comfortable and straight forward 
19 
I don't know if some people would be able to use the device 19 
Very hard to keep the flow rate up 20 
I found this very difficult to do however my asthma is pretty bad; it would be much easier if I could 
breathe 
20 
Fix the noisy valve! 21 
Just one flaw, it feels more difficult to breathe. Harder to get breath in. All in all not overly comfortable.  22 
Would not be able to use this whilst having an attack, made me feel breathless today 23 
I just couldn't breathe 24 
I did struggle on this test needing a few breaks 25 









Table 54 – ABBA study: focus group summaries and acceptability scores 
Participant Summary of focus group transcript VAS score 
 
AAQ-R scores 
RTube Niox Vero ReCIVA RTube Niox Vero ReCIVA 
P1 Niox Vero was a clear favourite.  
Stated that the RTube was the least 
favourite.   
 
0 + 0  
 
0 + 0 
 
0 + 0 
 
11 + 12 
 
7 + 8 
 
8 + 10 
VAS score failed to differentiate; 
correlation with AAQ score. 
P2 Reported struggling with the Niox 
Vero but also stated that if able to 
practice and get the hang of it, this 
would the preferred device. 
 
3 + 3 
 
6 + 3 
 
4 + 3 
 
19 + 20 
 
18 + 23 
 
17 + 19 
No consistent pattern 
P3 Slight preference for the RTube; 
reported struggling with the Niox 
Vero and not liking the face mask 
with the ReCIVA 
 
 
1 + 0 
 
0 + 0 
 
0 + 0 
 
12 + 18 
 
7 + 15 
 
8 + 10 
Does not correlate with AAQ scores 
P4 Niox Vero was clear favourite; 
ReCIVA the least preferred. 
 
 
4 + 2 
 
1 + 1 
 
1 + 1 
 
20 + 24 
 
12 + 13 
 
14 + 15 
VAS and AAQ scores correlate; AAQ 
score in agreement with focus group 
comments on Niox Vero but not 
ReCIVA. 




The focus group transcript excerpts (see table 52) and the comments made 
contemporaneously with sampling (see table 53) were at odds with one another in 
the case of one participant. At the time of assessment they reported the RTube to be 
slightly uncomfortable and taking a long time, whereas the ReCIVA was not 
unpleasant at all. In the focus group the opinions were reversed with the ReCIVA 
being reported as the hardest of the three devices. This may have to do with the 
length of time between undertaking the assessment and participating in the focus 
group; and the perception of a problem (e.g. wearing a mask) looming large in the 
participants mind when in actuality - in the clinical environment with close supervision 
and support - it had not bothered the patient.  The scores on the AAQ-R support the 
comments made at the time of the assessment, and conflict with the opinions 
expressed as the time of the focus group. In future, focus groups should be 
undertaken in a more timely manner.  
In the focus group one participant expressed a very strong preference for the Niox 
Vero “I love it… the cloud is my favourite” scoring the device 7 and 8 in their two 
visits; however, despite describing the RTube as their worst they scored this  11 and 
12 offering only a relatively small score difference between the two devices. One 
participant expressed a strong opinion that the RTube was the least acceptable device 
to them; they scored this device 20 and 24 in their two visits, compared to 12 and 
13 for their favourite, the Niox Vero. Another participant expressed no preference 
between the Niox Vero and the RTube; the scores from the AAQ were roughly in 
agreement - 18 & 23 for the Niox and 19 & 20 for the RTube. This limited and 
subjective assessment - linking qualitative statements with the AAQ score – does 
nonetheless supports the notion that the questionnaire is measuring what it sets out 
to measure. 
  




7.1.3.2 AAQ-R Discussion 
The key question is whether the AAQ-R offers any benefit over and above a simple 
VAS.  
Because acceptability is a subjective construct any measure is going to have limited 
value in comparing between people – for example one participant might never score 
something at the positive extreme of a VAS whereas another person might score 
everything there unless really awful. It is therefore difficult to establish a threshold 
score for acceptability as this may differ between individuals. Moreover, if such a 
score were established it would need to be validated in terms of clinical impact – 
whether the score correlated with, for example, device adherence. More useful might 
be the minimum clinically significant difference; this would be useful in determining 
preference between devices, or determining improvement in acceptability with design 
refinement. The advantage this offers over a VAS is that the researcher can look at 
the individual domains, digging into the reason behind the score. Moreover, 
participants tended to use a very limited spread of scores on the VAS; the focus 
group participant P1 (see table 54) gave all devices a score of 0 on the VAS, whereas 
in the focus group expressed clear preferences which were captured in their 
responses on the AAQ. 
One member of the PPI group who offered feedback on the draft AAQ-R listed the 
time taken to complete the test as one of their concerns when considering any new 
device for the assessment of asthma. Having conducted the research with 
participants, it became apparent that the pleasantness / unpleasantness of the test 
was often magnified by the time required to complete it (particularly the case for 
those participants bothered by the nose clip). This emerged in some of the focus 
group comments with some participants suggesting that they’d prefer the test they 
struggled to complete – the Niox Vero – because, with practice, they could imagine 
being able to complete it more easily, and they would prefer this quick test (with no 
face mask or nose clip) to one of the more time consuming devices. Future 
modification of the questionnaire might directly assess the acceptability of time taken 
to complete the test. 
Although face validity of the questionnaire was considered by the research team and 
members of the AUKCAR PPI group, an assessment of content validity was not 
undertaken. This refers to the extent to which the elements of an assessment tool 
reflect the domain and operational definition of a construct. To be done properly 
Almanasreh et al (355) state that a panel of experts is required to evaluate the 
instrument; their judgements being quantified in a content validity ratio.  




This process lies outside the scope of this thesis but would form an important part of 
validation were the questionnaire to be developed for use in a future study. 
7.2 Secondary objectives - VOC analysis 
The analysis of targeted VOC data from the ABC study (see chapter 6) was shown to 
have levels of background contaminants despite the use of a clean air filter; and the 
untargeted deconvolution of ABC data revealed poor sample integration. Given the 
degree of background contamination and lack of a consensus method for dealing with 
such; the conflicting results yielded when comparing results from background 
corrected and non-corrected data; and the lack of significant results after the 
application of a post-hoc false discovery rate – and having achieved the primary study 
objectives – it was decided that the pursuit of the ABBA study’s secondary objectives 
through VOC analysis was not warranted. 
7.3 Conclusion 
The primary study objective was to determine the feasibility of conducting a study of 
exhaled breath biomarkers in patients with acute asthma.  
What is the best method of recruiting patients into a definitive study?  
 
Both the acute and outpatient arms were successful in recruiting participants while 
falling short of the initial target. The outpatient arm succeeded in capturing a greater 
number of exacerbations however only the acute arm captured participants who had 
experienced a life-threatening attack. With the exception of those participants with 
missing data, all those in the acute arm were receiving oral corticosteroids at the 
time of their assessment compared with 65% of those in the outpatient arm. 
Depending on the research question and the population of interest, these two factors 
may be important considerations when determining the recruitment method of any 
future study. 
Are patients both prepared and able to provide EBC, VOC and other samples in the acute asthma 
setting? Are patients prepared to perform repeated measures / multiple assessments? 
 
In the acute arm, 67% of patients screened were excluded; of those who were 
approached regarding the study 48% agreed to participate. Two participants were 
lost to follow-up, one from each study arm (acute and outpatient). Two participants 
withdrew their consent - again one from each study arm - constituting 2.3% of the 
total participants.  
 




The outpatient who dropped-out moved out of the area, stating that they would not 
be able to travel the required distance to be assessed should they experience an 
exacerbation. The acute recruit did not give a reason; they completed an acute 
assessment but when later offered a follow-up appointment declined. This acute 
drop-out constitutes 3.3% of those who underwent exacerbation assessments (in 
either study arm) or 9% of acute arm participants.  
Are patients both willing and able to contact the research team and return for assessment when 
experiencing an exacerbation? 
Including those identified by the exit questionnaire, a total of 34 participants reported 
having an exacerbation during the course of the study. Of these, 21 (62%) made 
contact to arrange an exacerbation assessment (95% CI (45, 76); 17 participants 
attended providing 18 acute samples. With staffing and availability of rooms being 
no object a greater number of assessments would have been possible. Furthermore, 
with greater resources study reminders could have been undertaken by phone, email, 
text in addition to by post which may have increased awareness and numbers of 
contact. 
Are researchers able to perform the initial assessment of hospital patients early during the acute 
exacerbation?  
No; this will be discussed further in chapter 10 (discussion) but the study failed to 
identify and recruit participants in A&E prior to their admission; 59% of patients 
presenting to A&E with asthma listed as a possible, probable or confirmed diagnosis 
were discharged home. The vast majority of these patients were not approached for 
study participation as coding of their complaint with ‘asthma’ was done at the point 
of discharge. This resulted in the systematic exclusion of those patients who were 
not admitted to hospital. Of those who were admitted and for whom a full data-set 
exists, 100% had received oral corticosteroids prior to assessment; it did not prove 
possible to recruit and assess patients in the acute arm before this had occurred. 
Is it possible to assess patients who are in receipt of supplementary oxygen?  
Chapter 4 (developing a methodology) details the work undertaken to make this 
possible. However, surprisingly, only one participant was on supplementary oxygen 
during their assessment. There were no adverse events reported in this assessment 
and a sample was successfully collected. 
 




How does collection of EBC & VOC compare with more established measurements (such as FeNO) 
in terms of acceptability to patients? 
There is relatively little difference in acceptability between the three devices. The 
RTube was perhaps the least preferred but this seemed to be largely due to the 
wearing of nose clips. This was done in accordance with EBC sampling guidelines 
however the necessity of this measure may depend on the biomarker of interest and 
whether nasal contamination could act as a confounder. The ReCIVA was least 
favoured by some due to the use of a face mask. Some participants expressed real 
fondness for the Niox Vero while others were more frustrated by it; however, 
irrespective of preference, three participants were not able to manage the breath 
control required to generate a result on the Niox Vero when in the acute stage; all 
managed it at their follow-up appointment. Only one participant was unable to 
tolerate the RTube, this was in the acute stage. All participants managed to tolerate 
the ReCIVA and complete the sampling process, irrespective of stage. 
Is it possible to obtain exploratory data comparing controlled and exacerbated states to power a 
definitive study?  
The recruitment rate in the acute arm was one patient per month and in the 
outpatient arm seven per month. Recruitment percentage was 64% of those 
approached in the outpatient arm and 48% of those approached in the acute arm.  
These figures will help inform the planning of future acute studies. However, in terms 
of sample size, a definitive study will be one with adequate power to assess pre-
specified outcome measurements. To conduct such a power calculation requires 
knowledge of the anticipated difference in the biomarker of interest. It was not 
possible to provide this information; EBC sample analysis was not conducted due 
equivocal results in a review of the proposed analyte and lack of success in the 
analytical process; while the reliability of VOC data was negatively affected by 
methodological issues and difficulties with data deconvolution. 
What percentage of patients experiencing an acute exacerbation have a bacterial trigger?  
It was not possible to answer this question due to the lack of spontaneous sputum 
samples provided by study participants. Any future study would likely require induced 
sputum to be part of the research protocol. Nasal swabs identified only four viral 
respiratory infections in the exacerbation assessment (representing 13% of all 
exacerbations) and two at follow-up. It is not clear whether this represents the true 
number of viral exacerbations or whether throat swab or cough swab might have 
reliably identified a greater number of infections.  





This chapter has reported on the feasibility outcomes from the ABBA study. The 
qualitative data may be useful in the design of future acute asthma studies using 
breath capture devices; while the quantitative data may be used to help in study 
design and recruitment calculations. The following chapter discusses the results 
reflecting on their implications for future research.  




Chapter 8 – Discussion 
8.1 Introduction 
The work presented in this thesis has illustrated the complex, heterogeneous nature 
of asthma and the need for biomarkers to improve both diagnosis and management; 
it has reviewed the literature on two different approaches to exhaled breath analysis; 
undertaken research to determine whether changes induced by indirect bronchial 
challenge are detectable using exhaled VOC; and undertaken research to determine 
the feasibility of conducting exhaled breath studies in the acute setting. This chapter 
concludes the thesis by considering the implications of the results presented and 
discussing study limitations.  
 
8.2 ABC study 
8.2.1 A summary of results 
Results were presented on the effect of indirect bronchial challenge testing on VOC 
profiles in patients with asthma; identifying those VOC whose intensity changed after 
positive mannitol challenge; and comparing these results with those from negative 
and sham challenges. In addition, those compounds exhibiting significant differences 
- at baseline or in the post-challenge samples - between those who tested positive 
and those who tested negative were identified. With the exception of those 
compounds excluded due to a lack of reliability, 15 significant differences were 
identified in 14 compounds (see table 55; further detail can be found in chapter 6 














Table 55 – ABC study: compounds identified as statistically significant (before 
application of FDR calculation) across all analyses  
Compound Analysis in which significant difference 
was noted 
Background corrected data 
Furan, 2-methyl Baseline, pre-challenge samples 
Significant difference between those who 
went on to have a positive challenge and 
those with a negative challenge 
Isoprene  
Significant difference between pre- and 
post-challenge samples in those 
experiencing a positive bronchial challenge 
Urea, ethyl- 
5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 
Uncorrected data 
Trichloroethylene  
Significant difference between pre- and 
post-challenge samples in those 








Decane Significant difference between pre- and 
post-challenge samples in those 
experiencing a positive bronchial challenge 
+ 
Significant difference in baseline samples 
between those who went on to have a 
positive challenge and those with a negative 
challenge 
Dimethyl selenide Baseline, pre-challenge samples 
Significant difference between those who 
went on to have a positive challenge and 
those with a negative challenge 
 
Of these compounds, five have been previously reported in the adult asthma 
literature (see chapter three, table 16) - Furan 2-methyl; Isoprene; Benzene, 
Decane; and Nonanal. Furthermore, evidence of 5,9-undecadien-2-one, 6,10-
dimethyl-, (E)- has been published in the paediatric (356) and adult asthma literature 
(357) since the completion of this thesis.  




The fact that several previously identified compounds featured in the results serves 
to validate the methodology used (to a limited extent). These compounds may be 
considered to be potential biomarkers warranting further investigation; possible 
targets for the future development of point of care tests; and markers of a metabolic, 
pathophysiological pathway worthy of elucidation.   
Although statistically significant results are reported for pairwise comparisons of 
individual VOC before and after mannitol challenge, these results were not found to 
be significant once a FDR calculation (Benjamini Hochberg) was applied.  
Differentiating positive from negative samples - being able to identify breathprints 
associated with the release of inflammatory mediators - has potential use in disease 
monitoring. Unpaired analysis comparing samples from the positive mannitol 
challenge group with those of the negative challenge group revealed three 
statistically significant results in the comparison of pre-challenge samples. These 
were furan 2-methyl (in the background corrected data), and dimethyl selenide and 
decane (in the uncorrected data). These results were not found to be significant once 
a FDR calculation (Benjamini Hochberg) was applied. 
The compounds identified in these analysis varied depending on whether the data 
used accounted for background contaminants; and for both data sets the statistical 
significance was not maintained after application of a FDR calculation. Similarly, 
binary logistic regression analysis failed to reveal any results of statistical significance 
and the resultant model displayed a high number of false negatives, indicating poor 
sensitivity.  
The paired-sample analysis was powered based on the limited prior results available, 
but the study was not powered appropriately for non-paired analyses. A sample size 
calculation for independent samples was conducted; for this purpose acetone and 
isoprene were selected - compounds found by systematic review (chapter 3) to be 
the most frequently named as significant in asthma breathomic studies. In the case 
of isoprene, a sample size in the region of 80 participants would be required to have 
sufficient power to detect significant differences in either baseline or post-challenge 
samples between those who tested positive and those who tested negative. In the 
case of acetone a much larger samples size – 260 – would be required. For any future 
study investigating this subject such a sample size would lend additional weight to 
the paired analysis. Given that the size of difference across clinical groups for many 
compounds has not been reported, larger samples sizes are likely required, 
particularly for those studies taking an untargeted inductive approach to analysis.  




While the values produced by this study may help researchers to plan sample size in 
future studies (depending on the compound of interest and clinical question), it 
should be stressed that the calculations are dependent on the accuracy and reliability 
of the data upon which they were based.  
Before further studies are undertaken methodological issues need to be addressed in 
order to improve reliability. On analysis of the clean air supply used in the study, 
exogenous VOC were detected in similar quantities to those found in the unfiltered 
background air; quantities which frequently rivalled or exceeded the levels found in 
patient breath samples. Methods for addressing background contaminants suggest 
that compounds with such high levels in background air should be excluded from 
analysis. The results of the analyses conducted in this thesis point to the importance 
of addressing this issue – those compounds identified as significant when analysing 
data uncorrected data set differed from those identified when using the background-
corrected data-set with exclusions based on contaminant levels.    
8.2.2 Compounds of interest 
Furan 2-methyl 
Exposure to environmental 2-methyl furan - which is released by the degradation of 
biomatter including the combustion of fossil fuels - has been linked to occupational 
asthma (358). However, it has also been found in the faeces, urine, exhaled breath, 
and skin of healthy individuals (359); a ubiquity which may be advantageous in a 
potential biomarker. Furans have been studied and reported most frequently in the 
context of smoking where they have been consistently found to be elevated in the 
exhaled breath of smokers (360, 361). In an asthmatic population Caruso et al (362) 
reported significantly higher levels of 2-methyl furan in ex-smokers when compared 
to never-smokers, suggesting it may be a product of long term airway changes 
associated with past smoke exposure. In a non-smoking population, Brinkman et al 
(198) reported a significant correlation between exhaled 2-methyl furan and asthma 
control test scores; and van Vliet et al produced a seven-compound model predictive 
of asthma exacerbation (356) which included 2-methyl furan. Waqar et al (363) point 
out that such findings might be due to epiphenomena such as differences in diet or 
exposome. However, Zanella et al (364) stimulated lung inflammation in vitro using 
epithelial cells exposed to oxidative stress (using hydrogen peroxide) and biological 
stress (sputum supernatant from patients with asthma). They report increased 2-
methyl furan production in response to both stressors.  
Mochalski et al (365) suggest that one possible endogenous source of furans might 
be the degradation of isoprene by alkoxy radicals in a pro-oxidant state. With 




previous studies reporting an association with asthma; in vitro  evidence suggesting 
endogenous production; and the identification of a possible biological production 
pathway, 2-methyl furan warrants further investigation as a potential asthma 
biomarker. It is clear however that smoking status / history is a potential confounder 
which will need to be controlled for.  
Isoprene 
An unsaturated hydrocarbon, isoprene is produced in large quantities by plant matter 
(366). It is also a by-product of cholesterol synthesis and one of the most abundant 
VOC found in exhaled breath. Although part of the mevalonate pathway, its exact 
biochemical origin and physiological actions are not yet fully understood (367). 
Studies have reported isoprene to be elevated in asthma when compared to healthy 
controls (174, 181) and it is one of five VOC in van der Schee et al’s (181) model for 
the differentiation of asthma and healthy control samples. Isoprene has also been 
shown to have a circadian rhythm in asthma that is absent in health (368). However, 
exhaled isoprene has been found to be elevated in other inflammatory states 
including myocardial infarctions, post-cardiac surgery, and high cardiac indices (369). 
In a study monitoring ozone exposure (370) it was found that FeNO was inversely 
associated with isoprene leading to the suggestion that endogenous isoprene may 
play a protective, ozone-scavenging, antioxidant role. In particular it may react with 
H2O2 and peroxynitrite (products of the oxidation of nitric oxide) in the lungs. This, 
they suggest, may explain the correlation between exhaled isoprene and acute 
inflammation or inflammatory states. 
The ubiquity of isoprene in exhaled breath samples; its typically positive alveolar 
gradient (272); and its reporting in previous asthma studies suggest it warrants 
further investigation as a potential biomarker. However, highly variable levels in the 
breath - influenced by age, gender, ventilatory effort and respiratory effort (371-
373) – and a lack of specificity to asthma are likely to complicate efforts to confirm 
its utility.  
Urea, ethyl- 
Urea is both the name of a compound and a functional group (which may be found 
as a part of other compounds). While the compound urea has been used in EBC 
studies as a maker of sample dilution, ethylurea does not feature in the existing 
breathomics literature.  
 




5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 
5,9-undecadien-2-one, 6,10-dimethyl-, (E)- is a ketone. These are typically produced 
by lipolysis in the liver, with production being increased during fasting or prolonged 
exercise. Similar compounds are produced as a result of the peroxidation of 
unsaturated fatty acids (374) however detail of an endogenous production pathway 
for this particular ketone could not be found in the literature.  
van Vliet et al (356) report that exhaled 5,9-undecadien-2-one, 6,10-dimethyl-, (E)- 
levels differed significantly between exacerbated and non-exacerbated asthma states 
in a paediatric population; while Stefanuto et al (375) developed a 10 compound 
model (which included 5,9-undecadien-2-one, 6,10-dimethyl) for the differentiation 
of eosinophilic asthma from other phenotypes. Although its biogenesis and relation 
to asthma is unclear, given its recurrence in asthma breathomic studies this 
compounds warrants further investigation.    
Trichloroethylene 
A halocarbon and industrial pollutant, the effect of exogenous trichloroethylene 
exposure on asthma and bronchial hyperreactivity has been studied (376, 377) but 
it does not feature in the asthma breathomics literature and little information is 
available regarding endogenous production pathways. 
3,5-dihydroxybenzamide 
An aromatic compound previously unreported in breathomics literature. 
Dimethylsulfoxonium formylmethylide 
An organosulfur, Paudel et al (378) posit possible antimicrobial properties for this 
compound which is present in some plant-based traditional Chinese medicines. It is 
absent from the breathomics literature and an understanding of endogenous 
metabolic pathways is lacking. 
Benzene, 1,3-dimethyl- 
An aromatic compound. While benzene occurs in the asthma literature with some 
frequency (70, 177, 379) 1,3-dimethyl-benzene is absent. Benzene was included in 
several breathomic models; these include the differentiation of asthma and controls 
(70, 177) and the prediction of exacerbation (376). It is a common environmental 
(carcinogenic) contaminant and its use as a biomarker could stem from the way in 
which asthma differentially affects the metabolism of inhaled, ambient benzene 
rather than its endogenous production.  




Refinement of the approach for dealing with negative alveolar gradients may 
therefore be required to successfully evaluate the utility of this compound.    
Phenylethyne 
An aromatic hydrocarbon. Such compounds in particulate matter / pollution have 
been examined in terms of their relation to asthma severity and exacerbation but 
they are absent from the breathomics literature.  
Oxime-, methoxy-phenyl- 
The origin of many methoxy esters is not known (359). Methoxy-phenyl-oxime has 
been found to be associated with the ulcerative colitis (380), and to be decreased in 
those with severe pulmonary arterial hypertension when compared to healthy 
controls (381). Significant differences in both lung and inflammatory conditions 
suggest this marker might warrant further investigation however it is absent from 
the asthma breathomics literature to-date. 
3-Carene 
3-carene is a terpenoid, a group which have been found to have anti-inflammatory 
effects - inhibiting the production of reactive oxygen species; increasing anti-oxidant 
enzyme production; and stimulating autophagy (382). 3-carene itself is a common 
exogenous VOC being emitted by both living and dried wood. Like other terpenoids 
anti-inflammatory effects have been reported (382-384), however, it may also be an 
irritant (385) and has been found to cause bronchoconstriction on inhalation (386). 
While the biotransformation of exogenous 3-carene has been elucidated (387) little 
has been published on endogenous production (386). It was identified in exhaled 
breath samples by Ibrahim et al (70) and formed part of their model differentiating 
eosinophilic from non-eosinophilic asthma.  
Nonanal 
A saturated aldehyde, nonanal is one of many products formed in the oxidisation of 
arachidonic acid (388). It has previously been reported to differ between exacerbated 
and non-exacerbated asthma (356); between allergic asthma and healthy controls 
(389); and between neutrophilic and eosinophilic phenotypes (390). It has also been 
found to be elevated in lung cancer (391). These observations are lent further 
credence by Zanella et al (364) who found nonanal to be under-expressed following 
chemically induced oxidative stress but over-expressed following inflammatory 
stress.  The frequency of its occurrence in asthma breathomic studies coupled with a 
known endogenous production pathway and in vitro evidence makes nonanal a good 
candidate for further study. 





Decane was one of six alkanes reported by Caldeira et al (389) in a model 
differentiating paediatric asthma from healthy controls. They describe leukocyte 
activation in asthma leading to the release of inflammatory mediators and free 
radicals, with alkanes subsequently being produced through the lipid peroxidation of 
fats (389). Other alkanes were also reported as significant by Ibrahim et al (70) and 
Meyer et al (177) in the differentiation of asthma from controls. Zanella et al (364) 
report numerous alkanes differentially expressed as a result of exposure to 
inflammatory or oxidative stress; with decane altered by both. Decane was found in 
all exhaled breath samples in a study by Jalali et al (392) but was significantly higher 
in those exposed to crystalline silica dust – a cause of oxidative stress and silicosis. 
The prevalence of decane in breath samples; the frequency with which it is reported 
in asthma breathomics; and its plausibility as a marker of both inflammation and 
oxidative stress marks this as a potential candidate for further investigation   
Dimethyl selenide 
An organoselenium which can be found in the exhaled breath of healthy volunteers 
(393) originating from the metabolism of ingested selenium and responsible for a 
garlic-like breath odour. Associations have been drawn between exhaled dimethyl 
selenide and liver disease (394); it is not clear if or how dimethyl selenide might 
relate to the pathophysiology of asthma.  
A summary of compounds 
Alkanes, aldehydes, and ketones have all come up frequently in the asthma 
literature; these are identified as being associated with inflammation and oxidative 
stress via lipid peroxidation (363). Aromatic hydrocarbons have been studied in terms 
of exogenous sources and their potential to trigger exacerbation, rather than as 
markers of disease. The in vitro study by Zanella et al also reported altered levels of 
aldehydes, alkanes and ketone (364) in response to inflammatory sputum 
supernatant and/or hydrogen peroxide, lending support to the notion that the altered 
levels of these compounds in asthma breathomic studies are the result of 
inflammatory cell activity and oxidative stress. 
Many of the compounds identified above also feature as significant compounds in the 
identification of other disease, for example nonanal and dimethylbenzene in 
colorectal cancer (395); decane in lung cancer (396); dimethyl selenide in liver 
disease (397) and furan 2-methyl in COPD (398, 399) and lung cancer (398).  




This provides further impetus to the argument that biomarker panels rather than 
individual compounds will be required to produce accurate diagnostic or phenotyping 
performance.  
 
8.2.3 Secondary study objectives 
  
The first of the secondary objectives for the ABC study was to determine whether 
VOC profiles could predict bronchial challenge response. The ability to predict a 
positive mannitol challenge - to identify bronchial hyperreactivity from baseline 
samples – would save the time and unpleasantness of undertaking a mannitol 
challenge. However, upon viewing the results; noting the lack of compounds 
identified as significant in the non-paired analysis; and performing a post-hoc power 
calculation; it was clear that modelling the data in this way was not appropriate. A 
further secondary objective related to variability in breath VOC; when analysed on a 
per VOC basis, the variance between participants (standard deviation from the mean) 
was compared with the standard deviation within participants (between replicate 
samples); for only seven of the 58 compounds was the between-replicates difference 
greater than that between participants. Coupled with a low intraclass correlation 
coefficient this suggests reliability in the sampling process. 
In summary, the results fell short of significance once a false discovery rate was 
applied; a larger sample size will be required to tackle research questions based on 
differentiating between positive and negative challenges. While a power calculation 
was completed for the paired analysis, given the scarcity of data on the size of 
difference which might be expected, it is not possible to say with certainty that the 
lack of significant results (after FDR) is a robust conclusion. Future studies powered 
according to the size of difference reported in this and other studies - for the 
compound/s of interest - will be required to confirm the absence of any significant 
differences. However, before this can be undertaken methods need to be refined in 
order to address the issue of background contaminants. 
8.2.2 ABC study design strengths  
One of the strengths of this study is the control of confounders. Attempts to capture 
a breath sample during an acute exacerbation and then at a future, controlled time 
suffer potential confounding from changes in treatment introduced as a result of the 
exacerbation (whether a change of medication or simply increased adherence); 
exogenous VOC exposure; changes in sampling environment; and changes in the 
participants’ general health. Similar confounders are present in medication 
withdrawal studies.  




By taking samples before and after a bronchial challenge such confounders are kept 
to a minimum. Furthermore, if looking solely at changes occurring in a positive 
mannitol challenge the certainty of diagnosis (frequently an issue in studies of 
asthma) is confirmed in the process of participation. The key limitation of this study 
design is that a bronchial challenge is being used to provoke an inflammatory 
response and the extent to which this might differ - in terms of inflammatory 
pathways and VOC produced – to that which might occur ‘naturally’ has not been 
established. Alongside other asthma breathomic studies this approach does however 
provides an important means of verifying findings. 
8.2.4 ABC study limitations 
8.2.4.1 Study design  
A randomised cross-over study design would typically be considered for this type of 
study and indeed this was the initial approach used. However, it was decided to 
conduct mannitol challenges first and invite only those with a positive mannitol 
challenge to return for a placebo challenge. Had a cross-over design been maintained, 
some participants would have had a placebo challenge first, returned, and 
experienced a negative mannitol challenge. This would, in effect, have given us two 
‘control’ results and resulted in a number of unnecessary challenges. Furthermore, 
in attempting to account for the effect of the challenge process, it is necessary to 
match the number of inhalatory efforts and spirometries conducted in the sham 
challenge with that conducted in the positive challenge. This would not be possible if 
some participants were randomised to have the sham challenge first. A non-
randomised, sequential design was deemed acceptable due to the transient effect of 
mannitol; the lengthy washout period used; and the use of FeNO and other measures 
of disease activity to ascertain whether any carry-over effect was occurring. 
It was not possible to blind the researcher or participant due to the ease of detecting 
the presence or absence of mannitol during the test procedure. When undertaking 
spirometry, normality of the flow volume loop trace, good peak expiratory flow rates 
and maximum apparent effort was looked for in order to safeguard against any 
participant bias in spirometric effort. Laboratory staff processing the samples were 
blinded in order to prevent any bias in application of processing procedures such as 
time-to-dry purging. 
As discussed in section 8.2 the mannitol challenge was used as a proxy for real 
exacerbation. Given the mechanism of action, the pathophysiological activity and 
resultant VOC profile may be comparable to that of an exercise induced-asthma 
attack, however, the extent to which is might serve as a proxy for other types of 
exacerbation such as viral or allergy triggered exacerbation is not clear.  




Results may be limited to those asthma phenotypes which are associated with a 
positive mannitol challenge; given the high number of false negatives associated with 
mannitol challenge this may limit the wider applicability of results.  
The initial sample size calculation (see chapter 5) was necessarily imprecise. It had 
been hoped to obtain samples totalling 19 in each group (positive and negative); 
however there were only 16 positive challenges and a resultant excess of negative 
challenges. It is possible that the paired (pre- and post-) analyses were 
underpowered to detect statistically significant differences, nevertheless the results 
provide target compounds for future investigation.  
A number of participants showed some reaction to the MDP – dropping their FEV1 by 
10-14.9% - but did not meet the threshold for a positive challenge. In order to 
maximise the difference between positive and negative challenges in an initial 
analysis such participants could be excluded; however, the sample size used was not 
sufficiently large to permit such an exclusion of data. Future studies might consider 
this when calculating sample size. 
 
8.2.4.2 Disease activity 
Several participants who believed themselves to have mild, well-controlled asthma 
had elevated FeNO results and/or poor spirometry. Upon being informed of this some 
participants engaged with their asthma management plan, became more adherent in 
their use of preventative medication and returned with a lowered FeNO and improved 
ACT score. This has the potential to affect comparisons of pre-challenge or post-
challenge samples across the two study visits. 
The mannitol challenge has high specificity but relatively poor sensitivity for asthma; 
this may be due, in part, to its inherent inability to provoke non-inflammatory asthma 
phenotypes. It is nonetheless likely that some of those with a negative mannitol 
challenge did not in fact have asthma. An attempt was made to ascertain the 
diagnostic certainty by extracting data from participants’ primary care notes. Due to 
the low negative predictive value of mannitol challenge (333) a negative mannitol 
challenge cannot be used to identify those with a misdiagnosis of asthma. Moreover, 
several participants failed to abstain from caffeine or exercise prior to the challenge. 
The bronchodilator effect of caffeine has been established (400) but evidence 
regarding its or bronchoprotective effect and confounding of bronchial challenge tests 
is equivocal for methacholine (401) and unstudied for mannitol. It is likely that - in 
comparisons between the positive and negative challenge groups – the negative 
challenge group is likely to include a mixture of those with and without asthma.  




That some participants had a low likelihood of asthma when assessed according to 
BTS/SIGN guidelines is likely to be relatively unimportant. These participants had 
negative bronchial challenge tests and their data was used to account for the changes 
in breath profile induced by repeated spirometry and mannitol inhalation only. There 
is, however, a possibility that even in a negative challenge, the changes which occur 
in exhaled VOC profiles after spirometry may differ between those with asthma and 
those without. 
8.2.4.3 Sample processing factors 
The most significant limitation was the high degree of background contamination 
present in the filtered air samples. Key to breathomic studies is reducing the impact 
of exogenous compounds on exhaled breath results.  
This is typically tackled in two ways – reducing the inhaled VOC by supplying filtered 
air and accounting for those contaminants present through the calculation of alveolar 
concentration gradients or eliminating from analysis those compounds present at 
high levels. The high levels of contaminants present in the filtered air supply impacted 
on both of these elements of sampling and analytical rigour.  
8.2.4.4 Methodological Recommendations  
A reliable clean air supply needs to be established and monitored during any future 
study. Given the growing number of published studies of both targeted and 
untargeted approaches, future studies should aim to validate previous findings with 
studies powered according to reported compound differences. 
8.3 ABBA study 
 
The primary objective was to determine the feasibility of a study to evaluate the 
utility of exhaled breath biomarkers in patients with acute asthma. It was established 
that patients are able and willing to provide breath samples using multiple collection 
methods in the acute setting taking a mean of approximately two hours for a study 
visit; it was found that outpatients are willing to contact researchers and attend for 
a study visit when experiencing an exacerbation. While falling short of the overall 
recruitment target, both the inpatient and outpatient study arms were successful in 
recruiting and sampling suggesting either method is possible for future studies. The 
shortfall in recruitment is discussed further in section 8.4.1 and will have implications 
for the resourcing of any future study. A method was devised for sampling patients 
in receipt of oxygen permitting the assessment of those more acute patients in receipt 
of such treatment. It was established that assessing patients before receiving 
systemic steroids in the acute population was not possible; while this may frustrate 




the study of certain research questions it is reassuring and in keeping with clinical 
guidelines that acutely unwell asthma patients are receiving systemic steroids at the 
earliest possible juncture. The collection of both EBC and VOC was deemed 
acceptable by patients; although EBC was less favourably reviewed – likely due to 
the closing off of the nasal airways with a nose clip.  
Performing FeNO proved challenging for some acutely unwell patients; and while 
some patients in the focus group expressed a degree of exasperation with the test, 
they also expressed confidence in it and a belief that once they’d practiced the 
technique it was an acceptable device. It was not possible to establish with certainty 
the percentage of participants with a bacterial trigger due to the limited number of 
participants found capable of producing a sputum sample.  
This could be addressed through the use of induced sputum sampling – a process 
which is not contra-indicated in the acute population - however it would first be 
necessary to establish how many patients in an acute setting would be willing to 
undergo this process. It was not possible to obtain reliable exploratory data from the 
ABBA study for assessing the secondary study objectives and powering a future VOC 
study; the current methodology resulted in a high level of background contaminants 
and reliable figures could not be obtained.  
8.3.1 ABBA study strengths 
The ABBA study captured data on real-life acute asthma exacerbations in patients 
receiving usual care; it did not rely upon an exacerbation proxy (such as bronchial 
challenge), nor a medication withdrawal design. As such the results can be 
generalised more readily to real asthma populations. The acute study setting is 
appropriate to tests of diagnostic accuracy (for exacerbation phenotyping) or to 
attempts to validate findings from controlled settings in a real life clinical 
environment. In trialling two different recruitment approaches it was possible to 
provide data on both methods allowing future researchers to determine which might 
be more appropriate to the clinical question under investigation and estimate 
recruitment rates accordingly.  
8.3.2 ABBA study limitations 
8.3.2.1 Clinical factors  
Patients approached in the acute arm tended to be recruited towards the end of the 
24 hour window. This was either due to their having been admitted in the afternoon 
/ evening and not being approached until the following day, or due to declining the 
initial invitation and requesting the researcher return later when they felt better. This 
will have led to an increased exposure to the hospital environment and increased 
treatment duration.  




Exhaled VOC have been reported to be capable of identifying those asthma patients 
in which oral corticosteroid and salbutamol urinary metabolites were present (200); 
a possible confounder. Known drug metabolites could be excluded from analysis and 
the use of filtered air and alveolar gradients aim to minimise the impact of the 
exposome but – as previously discussed – this is an imperfect solution; particularly 
given the apparently limited filtration achieved with the current equipment. 
The initial intention had been to capture breath samples during an acute exacerbation 
and then again at a future time-point when the patient was controlled and stable. 
This was often not the case; although participants frequently returned to their prior 
‘normal’ state this could not necessarily be called stable and controlled; this can be 
seen from ACQ scores.  
A comparison can therefore be made between acute attack and a less acute state but 
it cannot be claimed that the comparison is with that of a controlled condition. In a 
steroid withdrawal study Fens et al (205) reported that VOC present in the breath at 
the point of loss of control often had not returned to baseline values by the time of 
recovery (four weeks after completing a course of steroids).  
This does raise concerns as to whether follow-up appointments at a post-
exacerbation asthma clinic would represent a true baseline. 
Although diagnosed with an acute asthma attack the diagnosis in many cases was 
unclear and potentially confounded. Seven participants were removed before study 
completion due to a change of diagnosis or diagnosis of a comorbidity; these included 
sarcoidosis, tachycardia, heart failure, atelectasis and bronchiectasis. The extent to 
which new diagnoses were considered to have replaced the prior diagnosis (asthma) 
varied, in some cases the new diagnosis did not alter the view that the presentation 
was an acute asthma attack; in other cases the prior diagnosis was considered to 
have been a misdiagnosis. In any future study an a priori decision as to how such 
samples will be used in the analysis should be made, and a decision tool for the 
process leading to sample exclusion detailed. 
A surprising (to the researcher) number of patients admitted with acute asthma 
attack were current or recent smokers. This reduced opportunities for recruitment 
but in addition suggests that future studies of diagnostic test accuracy or biomarker 
use would need to include smokers if the equipment is to be clinically useful.  
There were a number of incomplete data sets; the reasons included recruitment late 
in the study with insufficient time for follow-up; subsequent diagnosis leading to 
exclusion; lack of recovery and commencement on a biologic; withdrawal of consent; 




and moving out of area. Relatively few participants were willing or able to provide a 
spontaneous sputum sample thereby limiting the ability to identify bacterially 
triggered exacerbation. 
8.3.2.2 Processing factors 
Due to the location of facilities within the hospital and the researcher working alone, 
the time between obtaining EBC samples and their freezing was longer than desirable 
(a mean of 49 min). The extent to which this might affect samples will depend upon 
the analyte being examined. The time between the first samples being obtained and 
the end of the study meant EBC samples were frozen for up to 18 months; the extent 
to which this might compromise any subsequent analysis will again depend to some 
extent on the analyte in question.  
A future study of similar design would need to balance the twin issues of processing 
samples in batches within a timeframe designed to minimise sample degradation, 
and accounting for possible batch difference. The analyte under consideration will 
also determine whether any chemical additive is required – for example the 
antioxidant butylated hydroxytoluene (BHT) is suggested for the storage of EBC prior 
to analysis of 8-isoprostane.  
The equivocal results of the systematic review of 8-isoprostane in EBC (chapter 2), 
coupled with the lack of success in analysing previously obtained EBC samples for 8-
isoprostane (chapter 4) led to abandonment of the planned analysis of EBC samples 
for 8-isoprostane. Having commenced the collection of EBC samples from study 
participants this was continued in order to obtain data on the feasibility of obtaining 
such samples in the acute setting and of participants undergoing multiple sampling 
methods at one acute visit. Data was also obtained on the acceptability of such 
devices with the use of the RTube providing useful contrast to the ReCIVA. It is a 
limitation of this thesis that no alternative analyte was identified in order to permit 
swift processing and analysis of samples upon study completion.    
Sample transport, processing and tracking was improved for the ABC study but was 
not optimised for the ABBA study. The unpredictable nature of the study design 
meant that sampling tubes which were prepared by MIB were shipped to the UEA and 
stored until use, with the period between preparation and usage being variable. 
Conducting study visits for inpatients proved to be time consuming and frequently 
disrupted. On occasion participants had completed a nebulized therapy just prior to 
a study visit; moved wards part way through an assessment; or received other 
medications or a meal part way through the assessment.  




While this may not have affected the VOC sampling process it did mean that – on 
occasion - there was a time delay between for example completing FeNO sampling 
and undertaking VOC sampling. 
Samples were stored for up to 2 weeks before they were shipped to MIB. In the case 
of one sample insufficient purging resulted in excess humidity and an inability to 
analyse the sample. For three participants sampling appeared to be slow and in ten 
minutes less than the target 0.5L was collected; in two of the cases this occurred 
during the acute exacerbation sampling rather than the controlled follow-up. The 
reasons for this under-sampling are unclear – none of the participants complained of 
air leak nor was there any audible indicator of air egress; and the respiratory rates 
of the participants varied.  
In one case there was a significant deficit with only 180ml collected; in this case the 
participant had a beard and on the CRF was recorded as breathing rapidly (24-30 
breaths per minute) when using the ReCIVA. On the sampling log subsequently 
obtained from the ReCIVA data files, the respiratory rate was recorded at 12 – a 
significant mismatch between observed and recorded breath rate. It is likely that 
there was a gating issue. The MIB breathomics group used R to create a file reader 
capable of presenting the data files created by the ReCIVA in a user-friendly format. 
This allowed sampling volumes to be checked on completion of the sampling process 
rather than at a later date.  While this provides useful data it would not allow 
resolution of gating problems such as those experienced on this occasion. Gating 
settings are modifiable but would require input from the manufacturer to develop a 
troubleshooting guide. This would also require goodwill and additional time from the 
participant to repeat sampling processes. 
While pre-study tests were conducted to determine the presence of contaminants in 
the hospital oxygen supply and to determine the contribution of tygon tubing to 
contaminants, a direct comparison wasn’t made between contaminants in room air 
and filtered air; nor was a comparison made between VOC in the filtered air supply 
and those in exhaled breath.  
This was largely because there was no a priori target compound list and also because 
the GC-MS analysis was not being conducted in-house. The external processing of 
samples and pre-processing of sample data proved lengthy, with the first data set 
not available until a significant time after study-completion. In-house GC-MS analysis 
might facilitate more timely analysis of data and permit interim quality control 
analysis; alternatively commercial agreement with agreed timescales for sample 
processing including quality assurance procedures might be explored.  




8.3.2.3 Organisation factors  
It is likely that those experiencing milder asthma attacks or those which were more 
responsive to treatment will have been excluded from the acute arm of recruitment. 
For patients presenting to the emergency department, ‘shortness of breath’ or ‘chest 
pain’ were frequently recorded. Of these, patients with asthma were a minority; 
cardiac and other respiratory conditions such as infection and COPD exacerbation 
were commonly recorded under these codes. It tended to be only be at the point of 
either admitting the patient or discharging them that a diagnosis – for example 
asthma - would be entered onto the IT system.  Screening all patients presenting 
with chest symptoms would have given a relatively low yield of suitable patients and 
would have required a permanent presence in the emergency department; this was 
not possible.  
Screening for an asthma diagnosis tended to yield patients who had been or were in 
the process of being discharged (and did not want to stay an additional 2 hours for 
study participation) or who had been or were in the process of being admitted. The 
NNUH has launched a 12-month pilot project in which an asthma specialist nurse is 
based in A&E; a referral pathway has been established and the asthma service is 
being contacted with the details of asthma presentations soon after admission.  
Were the study to run now it is likely that this group of patients would not be 
excluded. However, the feasibility outcomes may differ – given the mean time taken 
to complete an assessment with multiple methods of breath assessment, it is not a 
surety that the participation rate and number of participants completing the 
assessment would be the same. It is likely that a shorter, more focussed study visit 
would be required to assess such a patient group. 
Extracting data relating to inhaler use was difficult; patients were often – 
understandably - unclear as to what treatments they had received when, so patient 
reports of time-since-last-inhaler/nebuliser were often unclear.  
Closer contact with study participants might have resulted in a greater number of 
stage four (outpatient exacerbation) visits. Collection of email addresses - along with 
the appropriate consent - could have been used to issue a newsletter; this could have 
contained short articles on asthma research along with a reminder on how to 
participate and when to contact us. Alternatively text reminders or a WhatsApp group 
could be used. In a similar vein, a greater number of staff trained on the study 
protocol would have resulted in greater flexibility in offering convenient appointments 
for those contacting the study team for sampling during an exacerbation. 




8.3.2.4 Methodological recommendations  
Future studies investigating acute asthma exacerbation and capturing data on 
triggers - including infection - will need to improve the number of sputum samples 
yielded. It is conceivable that an experienced respiratory physiotherapist coaching 
participants through active cycle breathing could increase the yield; also a study 
focussed more specifically on infective markers might exclude those participants not 
willing to provide a sample and/or reduce the number declining to attempt sputum 
production. Induced sputum is not contra-indicated in this population but including 
this in a study protocol might reduce participation. Given the growing number of 
published studies of both targeted and untargeted approaches, future studies should 
aim to validate previous findings with studies powered according to reported 
compound differences. 
8.4 Common limitations – contaminants 
In preparing for the studies, the levels of contaminants present in hospital oxygen 
and air supplies was measured and the effect of the tubing used upon contaminant 
levels examined. It was determined that contaminants with the hospital oxygen 
supply were low and consistent however this proved not to be pertinent to the study 
outcome as it did not prove possible to recruit and assess participants early in their 
admission while still in receipt of oxygen.  
Hospital air could not be used as it was not supplied at sufficient flow rates to power 
the ReCIVA breath capture device and was not available in all clinical areas. A CASPER 
clean air supply device was purchased; this contains Desotec activated carbon pellets 
in a cylindrical chamber. With the CASPER in commercial use and used by the MIB 
breath research group we did not conduct tests to ascertain its filtration efficacy. 
Moreover, such efforts are challenging to perform in advance; until patient samples 
are analysed; a target list of compounds generated; and chromatograms 
deconvolved, it is not possible to determine the compounds of interest and the levels 
of such within filtered air. Moreover, the absolute level is less important than the 
concentration relative to patient samples; the range of which may not be known in 
advance. This provides a salutary lesson; if undertaking a targeted analysis 
compounds of interest should be identified a priori and filtration systems assessed 
with regard to these compounds; alternatively if undertaking an inductive analysis 
checks should be undertaken at the earliest opportunity to determine possible 
compounds, their levels within patient samples and their levels in filtered air.  
Future research will need to assess clean air filtration systems and their performance 
particularly on compounds of interest in order to determine the best clean air source 
for breathomic studies.  




Additionally, predictive models based on data generated by different approaches 
(alveolar gradient; exclusions; correction according to retention indices) might be 
tested in clinical settings to evaluate their validity.  
8.5 Difficulties in study completion – organisational difficulties 
 
The study was the result of a matched funding bid between the UEA and AUKCAR. 
Initially the study author was the UEA funded candidate; the funding stream was 
later switched to that of AUKCAR; this had the unintended effect of making the 
project eligible for registration on the NIHR clinical portfolio. That this happened at a 
late stage meant that the author was not able to take advantage of all the benefits 
this entailed and did not receive any staffing support.  
Running the two studies single-handedly was challenging but gave the author a good 
appreciation of all aspects of research work from study design, through recruitment 
and assessment to data analysis.  
The progress of the study was hampered by an inter-organisation debate on the 
definition of ‘direct patient care’ status.  Although the researcher’s role – as outlined 
in the study protocol and ethics application – was presented to and approved by the 
study sponsor (UEA), research site (NNUH), research ethics committee (REC), and 
Health Research Authority (HRA) the question arose as to whether the researcher 
was eligible to screen hospital records for potential participants. Continued 
recruitment would have been a possible protocol breach so the study was placed on 
hold while the study sponsor and research site reached an agreement. This process 
took four months to complete.  
In order to minimise the potential impact of this 4 month hiatus and offer participants 
an appropriate length follow-up period the PhD was converted to a part-time 
programme (50% full time equivalent). At the same time the researcher was 
attempting to launch the ABC study. The reduced hours available to run all aspects 
of both studies necessarily impacted on activities such as screening; recruitment; 
assessment of those experiencing an asthma attack; and keeping in touch with 
participants in the outpatient arm. The veracity of the feasibility conclusions must be 
tempered by this fact. While the intended numbers of participant recruits was not 
achieved, the feasibility data gives a good indication of what might be possible with 
increased resourcing. An assessment of organisational capacity is required to ensure 
successful delivery with particular reference being paid to staffing and the nature of 
employment contracts. 
 






In conclusion, this thesis has demonstrated that an acute asthma breath study is 
feasible but methods are not yet fully established and further developmental work is 
required. That statistically significant changes in VOC levels after a positive mannitol 
challenge were detectable, and that these included some of the compounds identified 
by previous studies is encouraging. However, the reliability of the data is 
compromised by the high exogenous VOC levels present in background samples; and 
the statistical significance of the results is undermined by the results of FDR 
calculations. Results of the ABC study should therefore be interpreted with caution.  
While the ABBA study is concerned with feasibility, the ABC study can best be 
characterised as a phase one, pre-clinical exploratory study identifying compounds 
with potential relevance to asthma for prioritisation in future research. A more 
appropriately powered study may determine whether there are any baseline markers 
predictive of response to mannitol challenge, while also validating those compounds 
highlighted by the pairwise analysis as potential markers of early inflammatory 
activity. Based on the two most frequently identified VOC in asthma breathomics a 
future trial would need to enrol approximately 80 participants to have sufficient power 
to detect significant differences in isoprene between positive and negative bronchial 
challenges (in either baseline or post-challenge samples). If acetone were the focus 
then a much larger sample size - running into hundreds or even thousands of 
participants - might be needed. While these numbers may be helpful, it is clear that 
making such results available from other breathomic studies would aid the design of 
appropriately powered studies for alternative compounds of interest.  
The implication for future research is that sample size needs to be much greater if 
untargeted analysis or targeted analysis with a large compound list is attempted. 
While a large study with untargeted methods is perfectly appropriate, given the 
number of research papers published on asthma, and the range of clinical questions 
these have addressed, targeted studies validating previously published results is 
perhaps the next step. Isoprene is amongst the compounds most frequently reported 
in the literature; it was found to differ in this study as a result of a positive bronchial 
challenge and should be at the front of any list of compounds to be validated as 
potential asthma biomarkers.  
 
 




For industry - those developing equipment to capture and analyse VOC - there are 
major issues about technical performance and the ability to monitor this over time. 
Addressing issues such as contaminants will be more easily achieved when analysing 
a limited number of compounds, however, attempts to deal with this in inductive 
studies with large data sets are required; along with methods for monitoring the 
success of any such attempts.  
Cost and resources have not been explicitly considered in this thesis but conducting 
breath research is an expensive undertaking. The RTube is relatively cheap to 
purchase but processing the samples requires technical expertise and access to 
laboratory equipment. The ReCIVA, CASPER clean air filter, and sorbent tubes used 
for sample capture are more expensive and again require specialised equipment and 
expert staff to undertake sample analysis. Furthermore, data obtained from such 
analysis requires pre-processing which is a time consuming and specialised 
undertaking. As such these methods are unlikely to be widely available to clinicians 
in their current form. However, using these methods to identify and subsequently 
validate disease biomarkers would narrow the number of target compounds opening 
the way for more focussed methods of analysis appropriate to online or point of care 
testing. The development of point of care tests measuring markers of disease activity 
would provide opportunities for the development of personalised medicine and the 
targeted use of therapeutics.  
 
In summary, this thesis has found that disease heterogeneity is well matched by 
heterogeneity in approaches to breath analysis and compounds identified as potential 
biomarkers. VOC analysis has been the methodology of choice in recent years; it is 
well suited to identifying panels of markers reflective of multiple underlying disease 
processes. The researcher has shown that such a study is possible in the acute 
setting, although there are a number of major limitations in the research presented 
herein. Methodological refinement is essential, not least clean air filtering and it’s 
monitoring; and an appropriately tolerated method for obtaining sputum samples in 
the acute setting. Changes in exhaled VOC as a result of mannitol challenge are 
detectable but determining their significance relies upon the generation of reliable 
data. While VOC analysis holds great promise it still has a long way to go before it 
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Bronchial Challenge Tests in Asthma:  
Their Effect on Volatile Organic Compounds in Exhaled Breath 
Asthma Bronchial Challenge – The ABC Study  
 
Patient Information Leaflet 
We would like to invite you to take part in a research study looking at markers of 
inflammation in the breath of patients with asthma. 
Before you decide whether you would like to take part, it is important for you to 
know why this study is being done and what it would involve for you if you do 
take part. Please take time to read this information and to discuss it with others 
if you wish. Please talk to us if anything is unclear or if you would like more 
information. 
What is the purpose of this study? 
Every time a person exhales, they breathe out water vapour and various gases.  
These contain many different substances that come from the lining of the airways. 
We hope that by capturing and examining these we can discover which ones 
provide the most reliable and useful information about asthma and airways 
inflammation. 
Measuring inflammation might give us useful information about how severe an 
attack is (or how severe it might become) and what treatments might be most 
effective.  
Bronchial challenge tests – commonly used in the assessment of difficult-to-
diagnose asthma – cause the cells responsible for inflammation to release 
chemical messages. By capturing exhaled breath samples before and after such 
tests we can assess our ability to detect subtle inflammatory changes.  
Why me? 
We are seeking participants with asthma which is controlled without the need for 
oral steroid tablets.  Participants may use reliever and preventer inhalers and 
other asthma medications. Participants must be non-smokers (this includes 





Do I have to take part? 
No. The decision to take part is entirely up to you. If you decide that you would 
like to take part in the study you remain free to withdraw at any time. You do not 
need to give a reason if you decide to withdraw. If you decide to withdraw from 
the study or that you do not wish to take part, it will not affect the standard of 
care that you receive. 
What will happen to me if I take part? 
We would invite you to attend a study appointment at the hospital. We will answer 
any questions you might have before seeking your consent for participation. We 
will then ask some questions to ensure you are eligible for the study and complete 
an asthma control questionnaire. We will ask permission to contact your GP to 
inform them of your participation and to ask for details of how your asthma was 
diagnosed.  
We may be able to undertake the first study assessment at this visit. If, however, 
we need you to withhold any medications prior to the tests we will invite you back 
at a future date with adequate time for preparation.  
During the study assessment we would ask you to complete an asthma control 
questionnaire and to provide a breath sample using the ReCIVA Breath Analyser. 
This requires you to wear a face mask and breathe normally for 10-15 minutes. 
The machine captures the gases you breathe out which can then be analysed. 
After this we would undertake spirometry and measure FeNO - both routine 
breathing tests commonly used in asthma clinics – and take a sample of blood 
(less than 10ml or two teaspoons). 
The ReCIVA Breath Analyser 
Note: people with severe 
claustrophobia may have difficulty 
using the device. 
 
 
We would then perform a bronchial challenge test. This involves inhaling 
increasing concentrations of mannitol, a substance delivered as a powder from 
an inhaler device. We would perform regular spirometry as you undertake the 
test. The test finishes as soon as you experience a fall in your spirometry readings 
or once you have completed all the inhalations. You may experience some chest 
tightness or coughing. Other less common side effects of the test may include 
light-headedness, dizziness, headache, breathlessness, wheezing, runny nose, 




If you do experience a side-effect these are only temporary and should stop 
before you leave the appointment.  
We would ask you to bring a reliever inhaler and spacer with you for use after 
the test (although these will be provided if you do not have them). 
Following this we would ask you to provide another breath sample, taking 10-15 
minutes. There would be nothing further at this visit. The whole process should 
take 60-90 minutes in total.  
If you have a positive result in the bronchial challenge test (ie if your lungs react 
to the mannitol) then we would invite you back for a second assessment visit. 
This would consist of the same tests as the first except that the bronchial 
challenge would be a placebo / ‘mock’ challenge in which the challenge ingredient 
– Mannitol - is left out.  
In some cases it may be possible to undertake the first assessment at the 
recruitment visit.  
In order to undertake the test successfully you would need to withhold certain 
medications before the assessment including any preventer (steroid) inhaler for 
12 hours; short-acting reliever inhaler for 8 hours; long acting reliever inhaler for 
24 hours and antihistamines for 72 hours. The bronchial challenge test (including 
the withholding of medications) is recommended by both national and 
international asthma management guidelines and is considered safe. Nonetheless 
there is the possibility of experiencing an asthma attack during the period in 
which medications are withheld. In the event of you experiencing any asthma 
symptoms we would ask you to ignore these instructions, take your medications 
as usual and inform the study team.    
What do I have to do? 
If you agree to take part in this trial we will ask you to: 
1. Complete the consent and recruitment process 
2. Attend the hospital for assessment  
3. Perform the breathing tests as part of this assessment 
4. Return for a follow-up assessment 
What is the investigation being tested? 
Collecting exhaled breath gas is a way of measuring substances which tell us 
about conditions within the lung.  We would like to know whether these tests can 
detect changes taking place during bronchial challenge testing and predict the 






What happens to my samples? 
The exhaled breath and other samples will be used exclusively for research and 
will be treated as a gift. They will be stored anonymously and labelled with a 
unique code i.e. not your name or personal details. Breath gas samples will be 
analysed by the University of Manchester. Please see section Will my taking part 
in the study be kept confidential? below for more details.  
What are the possible disadvantages of taking part? 
We will ask you to attend a consent visit and two study assessment visits 
(although it may be possible to conduct the first assessment at the consent visit). 
We will reimburse your transport costs for these visits but they are additional 
appointments which you would not normally have as part of ‘usual care’. The 
bronchial challenge tests can cause coughing and chest tightness; this can be 
relieved by using a reliever inhaler on completion of the assessment. 
What are the potential benefits of taking part? 
The results from this study may help us to develop better ways of assessing and 
monitoring asthma, and better ways of directing treatment.  
There is no payment for participation however we will provide you with a £20 gift 
voucher by way of a thank you at the two study assessment visits. 
What happens when the research study stops? 
Once the data has been collected from all participants the results will be compiled. 
We will send you a copy of these results so that you know what the outcome of 
the study was. 
What if there is a problem? 
The contact details for the research team are shown at the end of this sheet. If 
you have any concerns please contact the research team. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
mechanisms. Contact details can be obtained from the Patient Advice and Liaison 
Service (PALS) 01603 289036. 
What will happen if I don’t want to carry on in the study? 
You have the right to withdraw your consent at any time. If you wish to withdraw 
from the study you do not have to give a reason for this. Withdrawing from this 
study will not affect your present or future treatment in any way.  
Once data has been entered onto the database it is not be possible to remove it; 




once your results have been included in our database we cannot remove this 
data. 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled with the strictest confidence. All information which is collected about you 
during the research will be held securely in accordance with the Data Protection 
Act.  It will be kept for 10 years after which it will be disposed of securely. All of 
your data (your questionnaire information, samples and clinical details) will be 
labelled by a code and will not have your name or any other details about you on 
it. We refer to this as linked anonymised data as, although your sample is 
anonymous, it can be linked to you by a code. The code will only be known by 
members of the research team. It will be kept securely.  
Other third party researchers may wish to access anonymised data from this 
study in the future (anonymised data does not include names, addresses or dates 
of birth, and it is not possible to identify individual participants from anonymised 
data).  If this is the case, the Chief Investigator will ensure that the other 
researchers comply with legal, data protection and ethical guidelines. 
If you join the study, the data collected for the study, together with any relevant 
medical records, may be looked at by authorised persons from Norwich Medical 
School, the Research and Development department of the Norfolk & Norwich 
hospital and the Regulatory Authorities to check that the study is being carried 
out correctly. They all have a duty of confidentiality to you as a research 
participant.  
Informing your General Practitioner (GP) 
We would inform your GP of your participation in this study by writing; we are 
happy for you to discuss the study with them, including showing them this 
information sheet. We would ask your GP for details from your medical notes 
regarding your asthma diagnosis and we would write to them with your test 
results. 
What will happen to the results of this study? 
Once all the data from study participants has been collected it will be analysed; 
the results will be shown to the medical team at the Norfolk and Norwich 
University hospital, and may be published in a medical journal. No identifiable 






Who is organising this study? 
The research study is designed and managed by Adam Peel, a PhD student at the 
Norwich Medical School (UEA). The study is funded by the Asthma UK Centre for 
Applied Research, sponsored by the University of East Anglia, and hosted by the 
Norfolk and Norwich University Hospital. 
Who has reviewed this study? 
This study has been reviewed by a research ethics committee to ensure that the 
project is delivered in accordance with all legal and ethical guidelines. This study 
received a favourable outcome from the Cambridge South Research Ethics 
Committee.  
Contact details for further information 
Thank you for considering participation in this study. If you have any further 
questions please ask. If you choose to participate please retain this information 
sheet for future reference; contact details for the respiratory research group are 
below:    
   Mr Adam Peel   Email: 
Norwich Medical School  respiratory.research@nnuh.nhs.uk 
University of East Anglia Telephone: 01603 289876 
Norwich Research Park,  (24 hour answerphone) 





























Bronchial Challenge Tests in Asthma: Their Effect on Volatile 
Organic Compounds in Exhaled Breath 
Asthma Bronchial Challenge – The ABC Study  
 
PREPARING FOR YOUR STUDY VISIT 
 
Withholding medications 
 Preventer inhaler (corticosteroids): 12 hours 
e.g.  beclometasone  
 budenoside 
 fluticasone  
 
 Reliever inhaler (short acting beta-agonists): 8 hours 
e.g.  salbutamol 
 terbutaline 
 
 Long acting reliever inhaler (long acting beta-agonist): 24 hours 
e.g.  salmeterol 
 formoterol 
 
 Combination inhaler (corticosteroids and long acting beta agonist): 24hrs 
e.g. fluticasone/salmeterol or budesonide/formoterol 
 
 Inhaled NSAIDs (non-steroidal anti-inflammatory drugs): 8 hours 
e.g.  sodium cromoglycate 
 nedocromil sodium 
 
 Ipatropium Bromide: 12 hours 
 
 Theophylline: 24 hours 
 






 Antihistamines: 72 hours 




 Leukotriene recepetor antagonists: 4 days 
e.g.  montelukast sodium 
 
Other advice 
On the day of the test:  
 Avoid any caffeine e.g. tea, coffee, cola, chocolate 
 Avoid vigorous exercise 
 Please remember to bring your reliever inhaler (Ventolin/Salbutamol) and 
spacer (if you use one) to the study visit. 
 
Note: if you experience any asthma symptoms please take your medications as 
usual and inform the study team. We would urge you to follow your personalised 
asthma plan and to prioritise your own care over study participation.  
If you have any concerns over withholding your medication you may wish to 
arrange for a friend or family member to remain with you during this period.    
Please contact us using the details below should you have any questions or if it 
has not been possible to withhold medications.  
 
Mr Adam Peel 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 








Telephone: 01603 289876  





















Participant identification number 
 
British Thoracic Society – Asthma Diagnostic Guidelines  
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Biomarkers in the management of acute asthma: a feasibility study 
The ABBA Study: Asthma Breath Biomarker Assessment 
Patient Information Leaflet 
We would like to invite you to take part in a research study looking at markers of 
inflammation in the breath of patients with asthma. 
Before you decide whether you would like to take part it is important for you to 
know why this study is being done and what it would involve for you if you do 
decide to take part. Please take time to read this information and to discuss it 
with others if you wish. Please talk to us if anything is unclear or if you would like 
more information. 
What is the purpose of this study? 
Existing ways of assessing asthma - such as peak flow meters - tell us about lung 
function and how well people are breathing but they don’t actually tell us how 
inflamed their airways are. Measuring inflammation might give us useful 
information about how severe an attack is (or how severe it might become) and 
what treatments might be most effective. We also lack quick and easy tests to 
tell us whether bacteria are involved in triggering someone’s asthma attack. A 
reliable bedside test for this might allow doctors to target their use of antibiotics 
more selectively. 
Every time a person exhales, they breathe out water vapour and various gases.  
These contain many different substances that come from the lining of the airways. 
We hope that by capturing and examining these during an asthma attack we can 
discover which ones provide the most reliable and useful information about 
airway inflammation and infection.  
We will be using three different devices - all of which have been used in studies 
before – to collect these substances for analysis. In the future these tests may 
have a place in the standard monitoring of patients with asthma so we also want 
to discover what patients think about the collection devices.  
Why have I been chosen? 
We have asked you to participate in this trial because you have been diagnosed 
with an asthma attack. We are approaching people attending the Norfolk and 




This will allow us to see if there is a relationship between the substances being 
measured in the breath and asthma attacks. 
Do I have to take part? 
No. The decision to take part is entirely up to you. If you decide that you would 
like to take part in the study you remain free to withdraw at any time. You do not 
need to give a reason if you decide to withdraw. If you decide to withdraw from 
the study or that you do not wish to take part, it will not affect the standard of 
care that you receive. 
What will happen to me if I take part? 
You will be asked to use the following three devices 
a) The RTube – this requires you to breath normally into a chilled plastic tube 
for about 10 minutes. This causes moisture in the breath to collect on the 
sides of the tube; we can then sample this liquid. 
b) The Niox Mino – this requires you to breathe into a machine in controlled 
manner for 6 to 10 seconds. This records the amount of nitric oxide (gas) 
that you exhale. 
c) The ReCIVA Breath Analyser - this requires you to wear a face mask and 
breathe normally for less than 10 minutes. The machine captures the gases 
you breathe out, which can then be analysed. If you are stable and 
comfortable but still in hospital after 8 hours, we may ask you if you’d be 
willing to provide more breath samples (four) using this machine. 
After using each device you will be asked to fill out a brief questionnaire telling 
us what you think of it. We will also ask you to fill out a questionnaire about your 
asthma control and perform a peak expiratory flow test; we will ask your 
permission to take a nasal swab and to provide us with a spit sample. The whole 
process should take approximately 60-80 minutes.   
We will also ask to take a blood sample. At this visit it will be one tube of 5ml or 
less. At any subsequent visit it would be two tubes totalling 10ml or less. 
We will ask your permission to use details from your medical notes; this will 
include details of your medical history, height and weight, and results of any tests 
that you might have had done as part of your normal hospital care. After you 
have performed the tests and completed the questionnaires there will be nothing 
further at this visit (although we will continue to monitor your hospital records in 






With your permission we would repeat these tests: 
1. At your follow-up outpatient appointment at the asthma clinic (in 
approximately 6 weeks).  
2. If your asthma is not fully controlled at the time of your follow-up 
appointment we may invite you to attend at a future date when your 
asthma is stable and controlled. 
3. In the event of you experiencing another asthma attack or deterioration of 
symptoms before the study end date (December 2018). If this were to 
happen we would ask you to contact the research team – if convenient - 
and attend the hospital for assessment. 
We would also contact you every three months to enquire about any asthma 
attacks you might have had. 
What do I have to do? 
If you agree to take part in this trial we will ask you to: 
1. Perform the breathing tests. 
2. After each test provide us with feedback on it (by filling out a brief 
questionnaire). 
3. Complete an asthma control questionnaire and provide any other samples. 
4. Return for the follow-up assessments. 
5. Contact us and attend the hospital for assessment if you experience another 
asthma attack or deterioration in your symptoms. 
What is the investigation being tested? 
Collecting exhaled breath condensate and exhaled breath gas is a way of 
measuring substances which tell us about conditions within the lung.  We would 
like to know whether these tests can predict things such as the frequency or 
severity of attacks or response to treatment. We would also like to know what 
patients think of these tests and of using them during an attack.    
What happens to my samples? 
The exhaled breath and other samples will be used exclusively for research and 
will be treated as a gift. Breath gas samples will be analysed by the University of 
Manchester. All samples will be stored anonymously and labelled with a unique 
code i.e. not your name or personal details. Please see section Will my taking 
part in the study be kept confidential? below for more details.  
If any of the samples remain unused at the end of this research project these will 
be stored, in a linked-anonymised form (as described in Will my taking part in 
the study be kept confidential? below), by the Norfolk and Norwich University 




approved research projects including by third parties. Samples will be stored in 
this way for up to 10 years before being destroyed. 
What are the possible disadvantages of taking part? 
In addition to participating in the tests now, we would be asking you to undertake 
tests at your routine follow-up appointment. This would add approximately 1 hour 
to the length of your follow-up appointment and involve a blood test. We might 
also ask you to come in for another assessment when your asthma is stable and 
controlled. We would reimburse your transport costs for this visit but it is an 
additional appointment which you would not normally have. Finally, we would be 
asking you to contact us - and attend for an assessment - in the event of 
experiencing another asthma attack or worsening of your symptoms. Again, we 
would reimburse your travel costs but this is an appointment and a blood test 
which you would not normally have as part of ‘usual care’.  
What are the potential benefits of taking part? 
The results from this study may help us to develop better ways of assessing and 
monitoring asthma, and better ways of directing treatment.  Your views on how 
acceptable the tests are are also important. In the future these tests may have a 
place in the standard monitoring of patients with asthma and it is important to 
know whether patients would be happy to perform the tests and under what 
circumstances. 
What happens when the research study stops? 
Once you have performed the follow-up assessment/s you will have completed 
the study – unless you experience another asthma attack within the remaining 
study period. Once the data has been collected from all participants the results 
will be compiled. We will send you a copy of these results so that you know what 
the outcome of the study was.  We will invite a sample of patients to participate 
in a focus group where they can discuss the study and provide us with feedback. 
What if there is a problem? 
The contact details for the research team are shown at the end of this sheet. If 
you have any concerns please contact the research team. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
mechanisms (or Private Institution).  Contact details can be obtained from the 
Patient Advice and Liaison Service (PALS) 01603 289036. 
 
 




You have the right to withdraw your consent at any time. If you wish to withdraw 
from the study you do not have to give a reason for this. Withdrawing from this 
study will not affect your present or future treatment in any way.  
Once data has been entered onto the database it is not be possible to remove it; 
this means that although you are free to withdraw from the study at any point, 
once your results have been included in our database we cannot remove this 
data. 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled with the strictest confidence. All information which is collected about you 
during the research will be held securely in accordance with the Data Protection 
Act.  It will be kept for 10 years after which it will be disposed of securely. All of 
your data (your questionnaire information, samples and clinical details) will be 
labelled by a code and will not have your name or any other details about you on 
it. We refer to this as linked anonymised data as although your sample is 
anonymous it can be linked to you by a code. The code will only be known by 
your hospital doctors and members of the research team. It will be kept securely.  
Other third party researchers may wish to access anonymised data from this 
study in the future (anonymised data does not include names, addresses or dates 
of birth, and it is not possible to identify individual participants from anonymised 
data).  If this is the case, the Chief Investigator will ensure that the other 
researchers comply with legal, data protection and ethical guidelines. 
If you join the study, the data collected for the study, together with any relevant 
medical records, may be looked at by authorised persons from Norwich Medical 
School, the Research and Development department of Norfolk & Norwich Hospital 
and the Regulatory Authorities to check that the study is being carried out 
correctly. They all will have a duty of confidentiality to you as a research 
participant.  
Informing your General Practitioner (GP) 
We would inform your GP of your participation in this study by writing; we are 









What will happen to the results of this study? 
Once all the data from study participants has been collected it will be analysed; 
the results will be shown to the medical team at the Norfolk and Norwich 
University hospital, and may be published in a medical journal. No identifiable 
individual data will be published at any time. 
Who is organising this study? 
The research study is being organised by the respiratory research group, which 
is based at the Norfolk and Norwich University hospital and Norwich Medical 
School (part of the University of East Anglia). The study is also being supported 
by the Asthma UK Centre for Applied Research. 
Who has reviewed this study? 
This study has been reviewed by a research ethics committee to ensure that the 
project is delivered in accordance with all legal and ethical guidelines. This study 
received a favourable outcome from the London-Fulham Research Ethics 
Committee. 
Contact details for further information 
Thank you for considering participation in this study. If you have any further 
questions please ask. If you choose to participate please retain this information 
sheet for future reference; contact details for the respiratory research group are 
below: 
 
Mr Adam Peel 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 


















Biomarkers in the management of acute asthma: a feasibility study 
The ABBA Study: Asthma Breath Biomarker Assessment 
Patient Information Leaflet 
We would like to invite you to take part in a research study looking at markers of 
inflammation in the breath of patients with asthma. 
Before you decide whether you would like to take part it is important for you to 
know why this study is being done and what it would involve for you if you do 
decide to take part. Please take time to read this information and to discuss it 
with others if you wish. Please talk to us if anything is unclear or if you would like 
more information. 
What is the purpose of this study? 
Existing ways of assessing asthma - such as peak flow meters - tell us about lung 
function and how well people are breathing but they don’t actually tell us how 
inflamed their airways are. Measuring inflammation might give us useful 
information about how severe an attack is (or how severe it might become) and 
what treatments might be most effective. We also lack quick and easy tests to 
tell us whether bacteria are involved in triggering someone’s asthma attack. A 
reliable bedside test for this might allow doctors to target their use of antibiotics 
more selectively. 
Every time a person exhales, they breathe out water vapour and various gases.  
These contain many different substances that come from the lining of the airways. 
We hope that by capturing and examining these during an asthma attack we can 
discover which ones provide the most reliable and useful information about 
airway inflammation and infection.  
We will be using three different devices - all of which have been used in studies 
before – to collect these substances for analysis. In the future these tests may 
have a place in the standard monitoring of patients with asthma so we also want 








Why have I been chosen? 
We have asked you to participate in this trial because you have been diagnosed 
with asthma and have experienced an attack within the last 12 months. We are 
approaching people who attend the Norfolk and Norwich Hospital for asthma and 
we aim to recruit 100 patients to the study.  This will allow us to see if there is a 
relationship between the substances being measured in the breath and asthma 
attacks. 
Do I have to take part? 
No. The decision to take part is entirely up to you. If you decide that you would 
like to take part in the study you remain free to withdraw from the trial at any 
time. You do not need to give a reason if you decide to withdraw. If you decide 
to withdraw from the study or that you do not wish to take part, it will not affect 
the standard of care that you receive. 
What will happen to me if I take part? 
We will arrange an appointment at the Norfolk & Norwich Hospital in order to 
discuss the study, answer any questions you might have, and seek your consent 
for participation. Alternatively, if you have an outpatient appointment scheduled 
at the respiratory clinic we will arrange to see you before/after your appointment. 
If you participate we will ask permission to use details from your medical notes; 
this will include details of your medical history, height and weight, and results of 
any tests that you might have had done as part of your normal hospital care.  
There would be nothing further at this appointment. We would, however, ask you 
to contact the research team and attend the hospital for an assessment if you 
experienced a worsening of symptoms or asthma attack any time between now 
and December 31st 2018 (the study end date). During this assessment you would 
be asked to use the following three devices: 
 The RTube – this requires you to breath normally into a chilled plastic tube 
for about 10 minutes. This causes the moisture in the breath to collect on 
the sides of the tube; we can then sample this liquid. 
 The Niox Mino – this requires you to breathe into a machine in a controlled 
manner for 6 to 10 seconds. This records the amount of nitric oxide (gas) 
that you exhale. 
 The ReCIVA Breath Analyser - this requires you to wear a face mask and 
breathe normally for less than 10 minutes. The machine captures the gases 
you breathe out which can then be analysed. 
After using each device you will be asked to fill out a brief questionnaire telling 
us what you think of it. We would also ask you to fill out a questionnaire about 




(two tubes totalling 10ml or less). In addition we would ask permission to take a 
nasal swab and to provide us with a spit sample. 
The whole process should take 60 – 80 minutes in total. With your permission we 
would repeat these tests during a follow-up appointment at a time when your 
asthma was stable and controlled.  
We would also contact you every three months to enquire about any asthma 
attacks you might have had. 
What do I have to do? 
If you agree to take part in this trial we will ask you to: 
1. Contact us and attend the hospital for assessment if you experience an 
asthma attack or deterioration in your symptoms 
2. Perform the breathing tests as part of this assessment 
3. After each test provide us with feedback on it (by filling out a brief 
questionnaire) 
4. Complete an asthma control questionnaire and provide any other samples 
(including a blood sample). 
5. Return for a follow-up assessment. 
What is the investigation being tested? 
Collecting exhaled breath condensate and exhaled breath gas is a way of 
measuring substances which tell us about conditions within the lung.  We would 
like to know whether these tests can predict things such as the frequency or 
severity of attacks or response to treatment. We would also like to know what 
patients think of these tests and of using them during an attack.    
What happens to my samples? 
The exhaled breath and other samples will be used exclusively for research and 
will be treated as a gift. Breath gas samples will be analysed by the University of 
Manchester. They will be stored anonymously and labelled with a unique code i.e. 
not your name or personal details. Please see section Will my taking part in the 
study be kept confidential? below for more details. If any of the samples remain 
unused at the end of this research project these will be stored, in a linked-
anonymised form (as described in Will my taking part in the study be kept 
confidential? below), by the Norfolk and Norwich University Hospital NHS 
Foundation trust so that they might be used in future ethically approved research 
projects including by third parties. Samples will be stored in this way for up to 10 





What are the possible disadvantages of taking part? 
Enrolment in the study will add time to your outpatient appointment (<30 
minutes). We will ask you to contact us - and attend for an assessment - in the 
event of experiencing an asthma attack or worsening of your symptoms. This 
assessment would last approximately 1 hour and involve a blood test as well as 
the breathing tests. We would also ask you to come in for a follow-up assessment 
when your asthma was stable and controlled. We would reimburse your transport 
costs for these visits but they are additional appointments which you would not 
normally have as part of ‘usual care’. 
What are the potential benefits of taking part? 
The results from this study may help us to develop better ways of assessing and 
monitoring asthma, and better ways of directing treatment.  Your views on how 
acceptable the tests are are also important. In the future these tests may have a 
place in the standard monitoring of patients with asthma and it is important to 
know whether patients would be happy to perform the tests and under what 
circumstances. 
What happens when the research study stops? 
Once you have performed the follow-up assessment you will have completed the 
study – unless you experience another asthma attack within the remaining study 
period. Once the data has been collected from all participants the results will be 
compiled. We will send you a copy of these results so that you know what the 
outcome of the study was.  We will invite a sample of patients to participate in a 
focus group where they can discuss the study and provide us with feedback. 
What if there is a problem? 
The contact details for the research team are shown at the end of this sheet. If 
you have any concerns please contact the research team. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
mechanisms (or Private Institution).  Contact details can be obtained from the 
Patient Advice and Liaison Service (PALS) 01603 289036. 
What will happen if I don’t want to carry on in the study? 
You have the right to withdraw your consent at any time. If you wish to withdraw 
from the study you do not have to give a reason for this. Withdrawing from this 
study will not affect your present or future treatment in any way. Once data has 
been entered onto the database it is not be possible to remove it; this means 
that although you are free to withdraw from the study at any point, once your 




Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled with the strictest confidence. All information which is collected about you 
during the research will be held securely in accordance with the Data Protection 
Act.  It will be kept for 10 years after which it will be disposed of securely. All of 
your data (your questionnaire information, samples and clinical details) will be 
labelled by a code and will not have your name or any other details about you on 
it. We refer to this as linked anonymised data as although your sample is 
anonymous it can be linked to you by a code. The code will only be known by 
your hospital doctors and members of the research team. It will be kept securely.  
Other third party researchers may wish to access anonymised data from this 
study in the future (anonymised data does not include names, addresses or dates 
of birth, and it is not possible to identify individual participants from anonymised 
data).  If this is the case, the Chief Investigator will ensure that the other 
researchers comply with legal, data protection and ethical guidelines. 
If you join the study, the data collected for the study, together with any relevant 
medical records, may be looked at by authorised persons from Norwich Medical 
School, the Research and Development department of the Norfolk & Norwich 
hospital and the Regulatory Authorities to check that the study is being carried 
out correctly. They all will have a duty of confidentiality to you as a research 
participant.  
Informing your General Practitioner (GP) 
We would inform your GP of your participation in this study by writing; we are 
happy for you to discuss the study with them, including showing them this 
information sheet. 
What will happen to the results of this study? 
Once all the data from study participants has been collected it will be analysed; 
the results will be shown to the medical team at the Norfolk and Norwich 
University hospital, and may be published in a medical journal. No identifiable 









Who is organising this study? 
The research study is being organised by the respiratory research group, which 
is based at the Norfolk and Norwich University hospital and Norwich Medical 
School (part of the University of East Anglia). The study is also being supported 
by the Asthma UK Centre for Applied Research. 
Who has reviewed this study? 
This study has been reviewed by a research ethics committee to ensure that the 
project is delivered in accordance with all legal and ethical guidelines. This study 
received a favourable outcome from the London-Fulham Research Ethics 
Committee.  
Contact details for further information 
Thank you for considering participation in this study. If you have any further 
questions please ask. If you choose to participate please retain this information 
sheet for future reference; contact details for the respiratory research group are 
below: 
 
Mr Adam Peel 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
Norwich, NR4 7TJ 
Email: 
respiratory.research@nnuh.nhs.uk 





















Biomarkers in the management of acute asthma: a feasibility study. 
The ABBA Study: Asthma Breath Biomarkers Assessment 
 
                  Yes            No   Don’t know 
During the period in which you were enrolled on the study, would you     
say that you had experienced an asthma attack? 
If yes, how many?      
 
Thinking about the most severe of these asthma attacks did you:   
Manage it on your own / without medical assistance    (please tick as many boxes as  
Contact primary care (GP or walk-in centre)     appropriate) 
Contact secondary care (e.g. attend A&E) 
Receive a course of oral steroid tablets (e.g. prednisolone) 
Receive a course of antibiotics 
Not applicable (did not experience an asthma attack)    
 
During the period in which you were enrolled on the study, did you experience any of the 
following? 
                     Yes            No   Don’t know
        
- Decreased peak flow (>20% decline) for 2 days or more  
 
- Decreased peak flow of > 30% at any time? 
 
- Waking at night and needing a reliever inhaler (> 2 consecutive nights) 
 
- Increased reliever inhaler (4 puffs a day more than usual) 
 
- Increased use of steroid / combination inhaler 
 
- Starting oral steroid tablets 
 








       Yes            No    Don’t know 
Did you feel that your asthma was back to ‘baseline’ or back to your  
usual level of control at any point during the study? 
 
Did you feel that your asthma was fully controlled at any point during  
the study? 
 
During the course of the study was your diagnosis of asthma changed  
to something different? 
 
Did you receive any new medical diagnoses during the study?  
 




         
During the course of the study were your asthma medications   
changed? 
  
During the course of the study did you start an injectable ‘biologic’  
drug such as Omalizumab or Mepolizumab? 
  
During the course of the study did you start a long-term maintenance 






















Invitation to focus group 
We would like to invite you to participate in a focus group (group discussion) about the ABBA 
study.  This would be a meeting of 6 – 8 participants from the study.  The purpose is to gather 
the opinions of study participants, both on the breathing devices which were used and the 
study methods more generally.  
The group will meet at the University of East Anglia and the meeting will last no longer than 
one hour. Refreshments will be provided and travel costs reimbursed. The discussion will be 
recorded (audio, not video); any contributions made to the discussion will be anonymised; 
and names will not be used when converting the audio recording to a typed manuscript. One 
or more member of the respiratory research team will be present to chair the meeting.   
This is a valuable stage in the research process, allowing us to gather the thoughts and 
opinions of participants in a more in-depth fashion than a questionnaire would allow. 
If you would like to participate, please tick this box  
If you would like further information, please could you let us know by calling us on 01603 






Focus Group Questions 
Open / Generic 
- How did you find participation in the study?  What did you think of the study? 
- Was there anything you particularly liked or disliked about the study? Or the way in which it was run? 
- Did you have any concerns about the study? Was there anything you questioned during your participation (why am I doing 
this)? 
- What do you think the strengths or weaknesses of the study were? 
Recruitment strategy 
- Why did you agree to participate? 
- Was there anything that made you think twice about taking part? 
- Can you think of any reasons why you might have said no to participation in the study?  Why do think people might not want 
to take part? 
- How might we recruit more patients? 
- Why do you think people might have dropped out? Did you consider dropping out at any point, and if so why? 
Ethics 
- How did you feel about being approached about the research while you were in hospital?  
- What did you think of the information you were given about the study (when deciding whether to participate)? Did you feel like 
you had sufficient information on which did base a decision about participation? 
- Did you feel like you were given sufficient time to consider your participation? 
Measurements in the acute exacerbation & hospital settings 
- How did you feel about being asked to contact the team / come in for assessment during an exacerbation? 
- How easy or difficult was it to contact the team? to book an assessment?  to come to the hospital and attend for assessment? 
- What do you think of the assessments we were asking you to perform? 
- Do you think they were appropriate given the symptoms you were experiencing? How did you feel about performing the 
assessments while experiencing an exacerbation?  
Device specific questions – devices present as reminder / prompt 
- What did you think of using the Niox Vero? Did you have any difficulty using the Niox Vero? 




- What did you think of the VOC breath analyser? Did you have any difficulty using the VOC breath analyser? 
- Was any one of them more user-friendly / easier / more comfortable to use than the others? 
Questionnaire assessment 
- What did you think of the AAQ(R)? Did you think it adequately captured how you felt about the acceptability of devices? Is there 
anything you would want to add? Anything you felt but couldn’t express in the questionnaire? 
 
Measurements in the outpatient setting 
- As above 
- For those who attended a stage 3 assessment - How did you feel about coming in for the follow-up assessment visit? 
- Can you imagine doing any of the tests at home?  
- How would you feel about doing any of these tests at your GP practice? 
Barriers to undertaking a larger study: 
- What do you think might be the problems with doing a study like this on a larger scale? 
Facilitators to undertaking a larger study: 
- Is there anything you can think of that would make this study easier to run? 
- Is there anything you can think of to make this study easier for patients to do? 
Dissemination of findings: 
- How would you like to find out the results of this study? 
- What would be the best way of disseminating the findings of this study to the public? 
Others: 
- What do you think of personal asthma action plans? (If you have a personal management plan, do you use it? how useful do 
you find it? what triggers you to take your medication?  
- What do you think of peak expiratory flow meters? (do you pay more attention to changes in symptoms or to peak flow? 
how regularly do you do them? do they tell you anything that you don’t already know?) 
- How would you feel about your treatment being guided by the results of a test such as this? (how would you feel about a 
personal asthma action plan that required you to use another device? Do you feel like you need more information on your lungs 





- Would you recommend participating in a research study to friends or family? (Would you recommend participating in this 







Appendix 5 – Documents relating to the development of the AAQ-R 
questionnaire 
 
Dear member of the AUKCAR Patient Advisory Group (PAG), 
 
Thank you very much for taking the time to read this letter and for your help 
in designing this questionnaire.  
 
Background: 
I am a PhD student at the University of East Anglia (UEA) in the process of 
designing a study looking at markers of inflammation.  By doing this we hope 
to aid the development of new methods to assess the severity of attacks and 
guide treatment. As part of this study we will be using two or more devices 
to identify and measure markers found in the exhaled breath of people with 
asthma. One of the devices has been used a lot in research but is not used in 
general practice, the other is in more widespread use. However, there is no 
information on what patients think of these devices, particularly what they 
think of using them when having an asthma attack. In addition to gathering 
data on the exhaled breath markers themselves we also want to find out how 
acceptable the devices are to patients.  When deciding whether a device is 
useful in clinical practice it is crucial to understand whether patients think it 
is an acceptable test. This questionnaire has been designed as a way of 
assessing this; it would be given to study participants (aged 18+) after using 














How you can help: 
The questionnaire has been designed with input from respiratory doctors but 
we would really like your opinion to help determine whether the questionnaire 
is fit for purpose. We want to make sure if someone with asthma was asked 
to fill in the questionnaire after using a breathing device, that it would really 





Below is a draft copy of the questionnaire that will be used to gather study 
participants’ views and also a feedback sheet. If you choose to help, please 
read the questionnaire (you do not need to fill this out) and then complete 
the feedback sheet, answering as many or as few of the questions as you 
wish. There may well be things that you consider important that we have not 
mentioned so please add any comments you might have.  
 
Thank you for taking the time to get involved; any feedback would be greatly 
appreciated. The study is being organised by the UEA respiratory research 
group, which is based at the Norfolk and Norwich University Hospital and 
Norwich Medical School (part of the UEA). The results of this feedback 
exercise will be incorporated into the questionnaire design. If you have any 
further questions or if you would rather arrange to give your feedback by 






















Mr Adam Peel 
School of Medicine 
University of East Anglia 












Question Response from PPI Summary Amendments 
made 
If several similar 
breathing devices 
were available for 
monitoring 
asthma, what sort 
of things would 
you use to decide 
between them? 
A) My primary concern regarding the 
test relates to the status of the 
patients asthma at the time of any 
test. Where the patient is 
experiencing difficulty breathing 
then any test will result in difficulties 
for the individual and may impact 
negatively on the results. 
 
B) Ease of use, ability to understand 
what information the devices give 
 
 
C) What size and shape they are and 
how large they are. And how easy 
they might be to use. 














C) Ease of use 
None required – the 
AAQ  captures ease 
of use and suitability 
for setting 
What sort of 
concerns (if any) 
might you have 




A) Impact on breathing! Need for 
continuous exhaling! Confidence in 
accuracy of results! Not being use as 





B) I would be concerned that 
doctors, etc, would rely completely 
on the device and not take patients' 
symptoms into account.  But if it's 
clear to everyone that the device is 
one more tool to help manage 
patients' asthma I think it could be 
very helpful. 
C) That it would not take too much 
time to use. 
D) Most patients would find the 2nd 
device easier to use than the first 
one - may find it difficult when 
having a more severe attack - 
knowing asthmatics - relief is the 
only important word - so co-
operation might just be limited 
during one 

















C) Time it 
takes 
The AAQ captures 
concerns about 
potential impact on 
breathing in the 
question ‘do you 
think it would make 
your symptoms 
worse’; it addresses 




The AAQ does not 
capture the time 
taken to do test or 
the time to get 
results. Time taken 
to do the test / use 
the device is partly 
captured under ease 







Do the options for 
responding seem 
appropriate (e.g. 
very easy, easy, 
difficult, very 
difficult)?  
Do you think 
there should be, 
for example more 
or fewer options? 
A) Where seeking guidance on scale, 
it may be better to ask the patient to 
score the issue on a scale lying 
between 1 and 10 rather than 
placing a mark on a line. Probably 
will result in higher accuracy and 
easier for patients to understand. 
 
B) The options seem appropriate, 
but somehow on my copy they were 
rather mixed up.  There were also 
long strings of numbers which may 
have had to do with images, but 
anyway were rather confusing.  
 
C) The options for responding are ok 
but I find them frustrating in that 
they do not allow people to express 
what they actually think or feel, so I 
think there should be boxes below 
quite a number of them to allow for 
further comment. That way you 
would receive more detailed 
information. 
D) The questionnaire looks very 
good but too many different options 
in answering the questions - people 
would probably waver over making a 
decision when there are multiple 
answer questions - me included. 
(They) will lose interested and waver 
over the answers - result this is 
going to take too long - and he will 
end up with not getting a true 
picture because of the length - hope 
this makes sense to him - needs to 
make less options. 
The options seem appropriate, but 
somehow on my copy they were 
rather mixed up.  There were also 
long strings of numbers which may 
have had to do with images, but 
anyway were rather confusing.  
 
The options for responding are ok 
but I find them frustrating in that 
they do not allow people to express 
what they actually think or feel, so I 
think there should be boxes below 
quite a number of them to allow for 
A) Dislike of 











































Changed blank VAS 








but changing to 3-
point Likert would 
give insufficient 
discrimination in the 




disagree that it is 








The PPI group 
member who 
reported ‘long 
strings of numbers’ 
uses equipment to 
assist with reading 
due to sight 
impairment so the 
formatting may 
have been an issue. 
It depends on 
whether the 
questionnaire will be 
given electronically 
as to whether or not 
this would matters 
for the study.) 
 
Insufficient space 
for free type box 
after every question 
but added one to the 








further comment. That way you 
would receive more detailed 
information. 
the questions as a 
prompt for 
comments. 
Is the length of 
time it would take 
to complete the 
questionnaire 
acceptable? 
A) Filling the form will take very little 
time but explanation will have to be 
very clear to assist an understanding 
of what is required. 
 
B) Questionnaire is rather long but it 
could be a necessity to get a 
complete picture but this needs to be 
a simple and easily understood - 
otherwise you will not get co-
operation 
C) Yes, even if someone is helping 
the patient, such as reading out the 
questions for those with reading 
difficulties.  It would still not take 
very long to do. 
 
D) Yes, it is brief and to the point. 
 
A) Yes, won’t 












C) Yes, won’t 







versus 1 on being 
too long therefore 
no changes made. 




pointless? If so 
which ones and 
how could we 
improve them? 
A) A clearer explanation of the 
devices to be used, their benefits to 
asthma sufferers and resulting 
improvement to care may 





C) Not that I’m aware of. 
A) N/A – they 










Are we missing 
any key 
questions? If so 
what? 
A) Those who complete the 
questionnaire may wish to complete 
it on-line. Is that the proposed 
route? If so the patient may wish to 
view the test results, will you 
facilitate access via a URL link? 
 











Do you have any 
other comments? 






Initials    Study ID No            Name of device 
    
   
Assessment of Acceptability Questionnaire   
 
How easy/difficult did you find it to use the device?  
 
   Very easy                 Easy                  Neither easy                  Difficult                  Very 
                                                            nor difficult                                              difficult 
     
 
How comfortable/uncomfortable did you find the test?  
 
    Very                    Comfortable      Neither comfortable       Uncomfortable            Very 
comfortable                                      nor uncomfortable                                   uncomfortable 
     
 
How bothered/embarrassed were you by the test? 
 
               Very                   Moderately                     Slightly                  Not at all 
                           
 
How willing would you be to have your asthma monitored using this device in the 
future? 
 
   Very                   Somewhat                  Neither happy            Unhappy                 Very 
  happy                     happy                      nor unhappy                                        unhappy 
     
 
This device would be appropriate for use in the following situations: 
(please mark either yes or no for each situation)                                                                               
                                                                                  Yes, suitable       No, not suitable 
 During a mild attack/exacerbation?  
 During a moderate attack/exacerbation? 
 During a severe attack/exacerbation?  
 
This device would be appropriate for home use 
 
   Strongly              Somewhat               Neither agree                  Disagree               Strongly 
    agree                    agree                   nor disagree                                               disagree 




How likely do you think it is that using this device might make your symptoms worse? 
 
   Very                  Somewhat                  Neither likely                 Unlikely               Very 
   likely                     likely                       nor unlikely                                          unlikely 
     
 
How believable is it that this device could give useful information? 
 
   Very             Somewhat           Neither believable         Somewhat difficult       Unbelievable       
believable         believable            nor unbelievable               to believe 
     
 
Overall, how acceptable did you find the use of the assessment device? 
(please circle a number) 
 
0          1           2           3            4           5          6            7            8           9         10 













We value your opinion and experience; please feel free to add other comments.  
(these may be positive or negative) 
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